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Abstract
Properties of prion protein (PrP) conformational variation can be obtained by
analysis of PrPSc by Western blotting. PrPSc is closely associated with infectivity and
pathology in transmissible spongiform encephalopathies (TSE), such as Creutzfeldt-
Jakob disease (CJD) and Bovine spongiform encephalopathy (BSE). PrPSc is notably
insoluble and treatment with proteinase K produces a truncated protease resistant
core; this form of the protein is termed PrPres. It has been hypothesised that
distinctive conformations and glycoform ratio properties (relative levels of the three
possible glycoforms) of PrPres are 'markers' or a diagnostic indicator of TSE strains.
These banding patterns can be classified according to the molecular weight of the
unglycosylated fonn of PrPies, the relative glycoform ratio and correlated with the
aetiology (sporadic, variant, iatrogenic and familial), codon 129 genotype,
neuropathological features and clinical signs. A large scale study of PrPres isotypes
present in the cerebral cortex of suspected or confirmed human prion disease patients
was carried out to investigate the consistency of these isotypes between different
genotypic/aetiological subgroups, to determine the potentially distinguishing nature of
PrP,cs strain patterns.
Cases from different subgroups have been investigated to identify any
anatomically specific features of PrPICS or strain consistency. The results show that all
possible PrP isotype/codon 129 genotype combinations are represented in sporadic
CJD (sCJD), albeit at differing frequencies. The consistency between and within
genotypic/aetiological subgroups is, however, at odds with the findings of regional
PrPres isotype heterogeneity within the brains of some sCJD and iatrogenic CJD
(iCJD) cases. In contrast the PrPres isotype associated with variant CJD (vCJD)
appears stereotyped both between cases and within the brains of individual cases.
These results are consistent with the differing aetiologies associated with these
diseases: one possibly involving stochastic events (sCJD) the other resulting from the
infection of susceptible individuals by a single strain of agent (vCJD). The molecular
strain hypothesis was further tested by the analysis of transmitted TSE samples
(including mice and a marmoset) and a case each of BSE, natural scrapie and Feline
Spongiform Encephalopathy (FSE).
The candidate confirms that the work submitted is his own and that appropriate credit
has been given where reference has been made to the work of others.
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Transmissible spongiform encephalopathies (TSEs) are rare fatal
neurodegenerative disorders. They can be both genetic and transmissible, which
distinguishes them from other diseases (Aguzzi and Weissmann, 1996). They also
have long incubation periods (Liberski and Gajdusek, 1997) and are known to afflict
both humans and animals (Prusiner, 1991, Weissmann, 1994, Prusiner, 1995, 1998).
They include Creutzfeldt-Jakob disease (CJD), Kuru, bovine spongiform
encephalopathy (BSE) and scrapie.
The term spongiform encephalopathy (SE) derives from the characteristic
neuropathology of vacuoles seen in the brains of affected individuals, which may be
accompanied by neuronal loss, astrocytic gliosis and protein plaques (Budka et al,
1995, Jeffrey et al, 1995, Ironside and Bell, 1997, Ironside, 1998). Spongiform
change is a result of focal dilation of neuronal processes and cell bodies by
intracellular vacuoles in the grey matter which arise from the cisternae of neuronal
smooth endoplasmic reticulum (Clinton et al, 1993, Levine et al, 1996). The
transmissible nature of these diseases was demonstrated by the intraocular inoculation
of scrapie infected spinal cord into a ewe by Cuille and Chelle in 1936, hence the term
TSE. The TSEs are often referred to as prion diseases. Stanley Prusiner coined the
term prion, which stands for proteinaceous infectious particle. The prion protein
(PrP) forms the basis of the protein only hypothesis, proposed to explain the
molecular mechanism involved in the pathology of the TSEs (Prusiner, 1982). The
infective agent, termed a prion, is largely if not exclusively composed of PrPsc (PrP
scrapie), an abnormal isoform of the normal prion protein found in all mammals,
termed PrPc (PrP cellular). The findings to date support the protein only hypothesis
and thus the role of the prion protein as the causative agent of the TSEs (Aguzzi and
Weissmann, 1997). Despite this, in disease pathogenesis the precise molecular
mechanisms involved in prion replication or PrP conversion are still to be determined.
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1732 First documented case of scrapie (M'Gowan, 1914).
1920s Creutzfeldt and Jakob described neurological disease akin to TSEs.
1922 Spielmeyer "status spongiosis" CJD (this term is not specific to prion diseases).
1936 Gerstmann, Straussler and Scheinker describe a familial human TSE.
1936 Cuille and Chelle demonstrated the first transmission of scrapie.
1957 Gadjusek and Zigas reported kuru in the Fore tribe of Papua New Guinea.
1959 Hadlow reported the similarities between scrapie, Kuru and CJD.
1961 Chandler reported scrapie transmission to mice.
1966 Gadjusek et al, first transmission of human TSE (kuru) to primate (chimp).
1968 Gibbs et al, reported transmission ofCJD to a chimpanzee.
1974 Duffy et al, first report of iCJD (due to corneal transplant).
1983 Masters et al, first transmission ofGSS. Thus infective-genetic paradox.
• 27 30
1985 Chromosomal gene cloned from amino acid sequencing ofPrP " .
1986 Lugaresi et al, first report of fatal familial insomnia (FFI).
1986 PRNP sequenced.
1987 Wells et al, identified Bovine Spongiform Encephalopathy (BSE).
1989 Hsiao et al, GSS genetic abnormality identified.
1990 CJD surveillance was re-instated in the UK.
1990 First case ofFSE reported in a domestic Siamese cat in the UK.
1992 FFI genetic abnormality identified.
1993 PrP structures determined.
1995 Tateishi et al and Collinge et al, transmitted FFI to rodents.
1996 Will et al, A new variant ofCJD (nvCJD) was reported.
2001 Saborio et al, developed high yield PrPsc amplification method.
A brief history of CJD and TSEs
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1.2 The role of PrP
1.2.1 The transmissible agent
The agent responsible for TSEs is smaller than conventional pathogens
(Prusiner, 1982). It can withstand treatments that inactivate more commonly
encountered pathogens such as parasites, bacteria and fungi, including ionising and
ultraviolet radiation which damage or destroy nucleic acids (Prusiner, 1982).
However, infectivity is reduced by procedures which denature protein (Brown et al,
1986b). It is postulated that there is no requirement for nucleic acids in TSE
infections, based on the infective resistance of the causative agent i.e. the ability of
the causative agent to withstand treatments that would inactivate any other known
transmissible pathogens. Protein as the agent responsible for TSEs was first
postulated in 1967 (Alper et al, 1967) and the protein only hypothesis was outlined by
Griffith (Griffith, 1967). Since that time the theory has been modified, most famously
by Stanley Prusiner, to give the prion hypothesis (Prusiner, 1982). Other
modifications have been made to the theory to take into account new findings, such as
seeding/template assistance, nucleation polymerisation and physiological dimer
models (Warwicker, 1997, Kelly, 1998). Other causative agents have been proposed
from acetinobacter (Tiwana et al, 1999) to slow viruses (Gajdusek, 1977, Manuelidis
et al, 1995). However, the evidence for other agents are lacking and there is very
persuasive evidence against the presence of any of these agents. There is also
evidence that there is another mechanism operating. This involves the 27-30 kDa
protein (PrPsc) which remains after limited Proteinase K (Raymond et al, 2000)
digestion of infected brain homogenates (aka protease resistant PrP; PrPres) and
associates with infectivity (Aguzzi and Weissmann, 1997).
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1.2.2 Structural properties of PrP
The transmissible properties of prions have become well recognised (Brown et
al, 1994b), however it was the discovery that the prion protein was host encoded that
opened up a whole new field of research. Using partial sequences of PrP and
complementary DNA (cDNA) it was possible to clone the gene responsible (Oesch et
al, 1985, Prusiner, 1991). Using this cDNA as a probe it was discovered that it
corresponded to a host gene. PRNP is highly conserved and found on the short arm of
chromosome 20 in humans and codes for the PrP° protein. The same gene is found on
chromosome 2 in mice and is termed prn-p (Sparkes et al, 1986). PRNP structure
consists of a promoter, a single uninterrupted open reading frame (ORF) and two
additional exons (Puckett et al, 1991, Lee et al, 1998). The human form of PrP
contains 253 residues (Silvestrini et al, 1997), that is subsequently post-translationally
amino (NH3) and carboxyl (COOH) terminally truncated to 209 residues (figure 1)
(Shyng et al, 1993, Kelly, 1998). It has two asparginine (Asn/N)-linked
oligosaccharide chains (Haraguchi et al, 1989) potentially forming at least 30
different glycoforms (Stimson et al, 1999), a glycosylphosphatidylinositol (GPI)
anchor and a single disulphide bridge (Stahl et al, 1987, Caughey and Raymond,
O-i- ^ I ^ I ^ I
1991). Divalent cations (Zn , Mn and Ni ) particularly copper (Cu ) are capable
of binding histidines, residing in the octapeptide repeat region (Homshaw et al, 1995,
Brown et al, 1997b) and a possible second upstream site found before the structured
regions, with high affinity (dissociation constants of 10"13 to 10"14 M) (Manolakou et
al, 2001). Several polymorphisms have been identified in PRNP the most extensively
investigated ofwhich is at codon 129 where the presence ofmethionine (M) or valine
(V) maybe homozygotic or heterozygotic. In familial cases there is generally a wild
type (wt) and a mutated copy (mt).
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Figure 1. The life and death of PrP.
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PrPc and PrPsc differ in their structural conformation, not their primary amino
acid sequences, thus making them isomers or conformers of the same protein (Stahl et
al, 1993). PrPsc which displays resistance to the relatively non-specific protease,
Proteinase K, has a different structure to PrPc. Partial and complete structures of the
C-terminal globular domain have been determined from Nuclear Magnetic Resonance
(NMR) studies of recombinant mouse, hamster, bovine and human PrP (Riek et al,
1996, Korth et al, 1997, Liu et al, 1999, Calzolai et al, 2000, Zahn et al, 2000). This
region corresponds to the infectious fragment (Prusiner et al, 1993, Nguyen et al,
1995) and contains the majority of ordered secondary structure and modifications.
The results are supported by Fourier-transformation infrared (FTIR) spectroscopy and
circular dichromism (CD) studies of purified hamster PrPc and PrPsc (Pan et al, 1993).
The structures of bovine and human PrPc have been reported to be almost
identical (Lopez Garcia et al, 2000). PrPc is largely a-helical, approximately 42% (3
a helices comprising residues 144-154, 173-194 and 200-228), and contains only
approximately 3% P-pleated sheet (a short anti-parallel P-sheet either side of the first
helix, residues 128-131 and 161-164). In contrast, the PrPsc p-sheet content is
predicted to be approximately 40% and the a-helical content approximately 30% (2
p-pleated sheets and 2 a-helices) (Riek et al, 1996). The organised structural portions
of PrPc (a-helices and P-pleated sheet) are found at the carboxy-terminal end. The
amino-terminal is composed of a random coil of amino acids in PrPc, that take on an
ordered structure only in the presence of copper (Brown et al, 1997b) when
hydroxylation forms a poly(L-proline) II (PPII) helix (Gill et al, 2000). PrPc is 30-35
kDa while the 27-30 kDa fraction is the protease resistant part of PrPsc and
corresponds to the helical regions of PrPc (residues 90-228). It is postulated that the
amino-terminal region and the conserved hydrophobic domain between codons 113
and 126, take on a p-sheet structure in the conversion from PrPc to PrPsc. This region
does not contain the a-helical motifs, but the formation of the P-sheets results in an
unstructured loop in place of the first hydrophilic a-helix (Morrissey and
Shakhnovich, 1999). It is this p-sheet conformation that makes PrPsc very stable and
resistant to protease digestion (Pan et al, 1993, Peretz et al, 1997, Jackson et al,
1999a, Jackson et al, 1999b). This protein can therefore adopt 2 quite different
conformations, both ofwhich are very stable (Korth et al, 1997) (figure 2).
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Prion Protein Properties
Number ofPRNP copies 2
Promoter Guanine (G) cytosine (C) rich promoter.
Conserved sequence 5 tandem repeats of 8 or 9 amino acids near the NH3 terminal.
Metal ion binding Copper binding sites in the octapeptide repeat region.
Polymorphisms
Methionine or valine at codon 129, glutamic acid or lysine at
codon 219.
Length 209 amino acid residues.
Disulphide bridge
A disulphide bond between two cysteine (Cys) residues at
codons 179 and 214.
Glycosylation
2 asparagine (Asn) glycosylation sites (residues 181 and 197),
N-linked with heterogeneous oligosaccharides.
GPI anchor
A GPI membrane anchor linked to the C terminal region via
serine 231.
Table 1. Features of Human PrPc.







The conversion of PrPc to PrPsc may occur ifPRNP is mutated or if PrPc comes
into contact with PrPsc. Wild type and mutated PrP have been reported to be insoluble
in fCJD carrying the E200K (Gabizon et al, 1996) though other studies have found
only the mutant PrP to be insoluble and resistant to PK digestion in Al 17V patients
(Tagliavini et al, 1995) or cell culture expressing mutant PrP (Lehmann et al, 1997).
Both copies (wt and mt) in D178N CJD are found to be both insoluble and protease
resistant (Chen et al, 1997). It is assumed that a two step process occurs; mutant PrP
conversion to PrPsc and subsequent conversion and accumulation of both mt and wt
alleles.
The pH of the surrounding mileu and reduction of the disulphide bond
reversibly alters the a-helical and P-sheet structure of recombinant PrP (Swietnicki et
al, 1997, Jackson et al, 1999a, Jackson et al, 1999b). Binding of the NH3-terminal to
vesicle membranes has also been reported at acidic pH (Morillas et al, 1999). The
conversion process occurs via a rapid unfolding and refolding process (Post et al,
1998) which at acidic pH (such as the internal mileu of lysosomes) features an
intermediate conformational state. CD spectroscopy of recPrP91-231 indicates that
the intermediate structure is predominantly P-sheet, prone to fibril aggregation and
possesses a degree ofPK resistance, however lack of the disulphide bond and suitable
redox potential is required to induce these properties in PrP (Jackson et al, 1999a).
Synthetic PrP peptides in p-sheet conformation can impose a P-sheet structure
on helical PrP peptides (Kaneko et al, 1995, Kaneko et al, 1997a). Implying this is a
conversion process, not a replication process. PrPsc molecules link together to form
stable protease resistant chains or rods, PrPsc then accumulate intracerebrally in
cytoplasmic vesicles (Caughey et al, 1991, McKinley et al, 1991, Arnold et al, 1995).
This accumulation of protein may compromise cell function. Findings suggest that
acquisition of protease resistance, detergent insolubility or P-sheet structure and fibril
formation by PrP in vitro is insufficient for propagation of infectivity (Hill et al,
1999a). Conversely, the entire PrP molecule is not required to support prion
propagation, the PrP27"30 fragment is infectious and cell based studies have found that
lack of the GPI anchor and oligosaccharide chains does not prevent formation of
PrPres (Lehmann and Harris, 1997). Transgenic mice carrying deletions of large
portions of PrP, including the unstructured NH3-terminal (residues 23-88), the second
P-sheet as well as the first a-helix and part of the second (residues 141-176)
(Muramoto et al, 1997, Supattapone et al, 1999, Baskakov et al, 2000) can be infected
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and subsequently transmit disease. It is also not required to induce neurotoxicity in
cell culture with the 106-126 portion alone capable of forming P-sheets, amyloid
structure (Rymer and Good, 2000) and inducing cell death (Brown, 1999, Rymer and
Good, 2000).
1.2.3 PrPc expression
PrP mRNA levels are unchanged in normal and scrapie-infected tissue
(Sakaguchi et al, 1995). However, PrPsc accumulates from one hundred to one
thousand times the PrPc levels (Prusiner, 1982) measured by sarkosyl purification of
scrapie infected and uninfected mouse brain. PrPc is expressed in numerous tissues
including nervous, lymphoid, immune, haematological (lymphocytes, monocytes, but
predominantly platelets) (Bendheim et al, 1992, Perini et al, 1996, Mabbott et al,
1997, Jimenez-Huete et al, 1998, Brown, 1999), epithelial (Pammer et al, 1999) and
even germ line cells (Shaked et al, 1999b). PrPc is constitutively expressed in the
brain of adults, particularly the olfactory bulb. Developmental specific expression is
seen during synaptogenesis (Sales et al, 1998). In the nervous system expression is
found in astrocytes and in neurons, particularly at the synaptic membranes (Brown,
1999, Herms et al, 1999).
Nascent PrPc is translocated into the lumen of the ER where the GPI anchor
and glycan chains containing a high proportion of mannose are attached (Caughey,
1991). As the PrPc is transported through the Golgi apparatus the sugar chains are
trimmed (Caughey et al, 1989). PrPc is primarily anchored in the plasma membrane
via the GPI anchor, though a variety of topological forms have been described (Hegde
et al, 1998) and there is evidence some is released as a secretory form (Borchelt et al,
1993). PrPsc in contrast to PrPc is not released from the plasma membrane (PM) by
cleavage of the GPI anchor with phosphatidylinositol-specific phospholipase C
(PIPLC) or trypsin (Borchelt et al, 1990, Stahl et al, 1990a, Stahl et al, 1990b). On
the membrane PrPc has been localised to caveolae-like domains (Vey et al, 1996).
The membrane bound form is routinely taken back up into the cell either in
association with these domains or by clathrin-coated pits (Pauly and Harris, 1998),
though most of it returns from the ER to the surface (Shyng et al, 1993). PrPc is
degraded in endolysosomes and lysosomes (Caughey et al, 1991), where acidic
conditions may alter the conformation of PrPc and protease activity prior to digestion
of the mid region (Shyng et al, 1993). PrPc is cleaved between residues 110/111 and
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112 in the toxic 106-126 domain, possibly by the protease ADAM10 (a disintegrin
and metalloprotease) (Silvestrini et al, 1997) releasing a fragment termed N1 which
may have neuroprotective properties and leaving a longer carboxyl-terminal fragment
termed C2 (Chen et al, 1995). PrPsc is found intracellularly (late-endosome-like
organelles or lysosomes) (Taraboulos et al, 1990b, Borchelt et al, 1992, Arnold et al,
1995) extracellularly (Jeffrey et al, 1994) and at the cell surface (DeArmond et al,
1997a), dependant upon the cell under investigation, which implies that the
processing of this isoform is different.
1.2.4 PrPc function and pathology
The physiological function of PrPc is currently unknown and attempts to
elucidate the role it plays have been hampered by the relatively healthy phenotype of
transgenic PRNP null mice. Developmental compensation for this loss of function
has been proposed to account for the lack of an overt pathological phenotype. The
function has been postulated, based on the loss of function phenotype of PRNP null
mice in some studies (altered circadian activity rhythms, sleep patterns, motor co¬
ordination and long term potentiation [LTP]) (Collinge et al, 1994, Sakaguchi et al,
1996, Tobler et al, 1996, Katamine et al, 1998). Brain pathology and infectivity have
been detected in the presence of low levels of PrPres (Budka et al, 1997, Lasmezas et
al, 1997) suggesting a loss of function as opposed to an accumulation of
misfunctioning PrPc. A gain of function has also been postulated in transgenic mice
carrying truncated PRNP genes (display ataxia and neuronal loss in the cerebellum)
(Shmerling et al, 1998) suggesting competition with a PrPc ligand. Cellular studies
(Pauly and Harris, 1998, Caughey et al, 1999) indicate a role as a receptor for an
extracellular ligand possibly involving intemalisation. The potential interaction of
PrPc with Bcl-2, Hsp60 (Edenhofer et al, 1996), Hsp70 (Kenward et al, 1996)
Hspl04, GroEL (DebBurman et al, 1997), the laminin receptor (Rieger et al, 1997)
and plasminogen (Fischer et al, 2000), has been observed and may be a result of non¬
specific binding or may hold a clue to the normal function of PrPc (Prusiner et al,
1998). Of particular interest either as a binding partner or even a functionally
comparable protein is the homologous downstream protein Doppel (Dpi) encoded by
PRND (Lu et al, 2000). Dpi is a GPI anchored, N-glycosylated protein of 179
residues with ~20% homology to PrP (Silverman et al, 2000). Developmental studies
of PrPc expression, neural localisation, synaptic activity and neuropathological
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degeneration studies indicate a role in embryogenesis, synaptogenesis or synaptic
function (Manson et al, 1992, Clinton et al, 1993, Sales et al, 1998, Herms et al,
1999). Expression of PrPc has been reported to coincide with a time in early
development when synaptic contacts form and the neural tissue required for LTP in
the hippocampus is generated (Sales et al, 1998) prior to any possible loss of function
in the adult. However, PrPc has been found in limbic-associated structures and in the
striato-nigral complex (Sales et al, 1998). Loss of functional ability in these regions
may explain reported y-aminobutyric acid (GABAa) deficiency (Collinge et al, 1994)
as well as thalamic (FFI neuropathology and PET scans and CJD MRI), putamen and
hippocampal (memory impairment and dementia) involvement in the pathology.
Cu2+ binding and the oxidation of methionine residues (Wong et al, 1999) indicate
antioxidant properties (Levine et al, 1996) and there is evidence for superoxide
dismutase (SOD) activity (Brown et al, 1999a) which maybe related to the synaptic
localisation. A function as a copper transporter and role in metal ion homeostasis is
suggested by overall levels of metal ions in the brains of null mice, sCJD patients
(Brown et al, 1997b, Wong et al, 2001a, Wong et al, 2001b, Wong et al, 2001c) and
intracellular Ca2+ (Kristensson et al, 1993, Wong et al, 1996, Brown et al, 1997a,
Herms et al, 2000, Kawahara et al, 2000). Dpi does not have the octapeptide repeat
copper binding region of PrPc and is thus unlikely to compensate for PrPc in this
respect. Defining the function of PrPc is of great importance in understanding how
TSE pathology arises, as conversion to PrPSL may result in a loss of normal function or
gain of pathological function.
The central nervous system is the primary site of pathological changes in prion
diseases (Bell and Ironside, 1993b). There are no indications of inflammation in the
brain, though immune responses have been detected. Inflamatory mediators such as
cytokines (Williams et al, 1994b), microglial involvement (Barcikowska et al, 1993,
Ironside et al, 1993a) and activation detected by their expression of MHC class II
molecules (Williams et al, 1994a, Gray et al, 1999) as well as T-lymphocyte
recruitment in lab mediated scrapie have been reported (Betmouni et al, 1996). PrPc
is expressed in many periphal tissues and is required for transport of PrPsc from the
periphery to the CNS (Blattler et al, 1997, Brown et al, 1999b). PrPsc and PrPrcs have
been detected in many non-nervous system tissues, yet do not seem to generally cause
pathological changes in situ (Groschup et al, 1996, Hill et al, 1997c, Hilton et al,
1998). There is growing evidence of peripheral nervous system involvement in the
11
TSEs (Groschup et al, 1999, Hainfellner and Budka, 1999, McBride and Beekes,
1999). This raises the question of the mechanism of tissue suceptibility to TSEs.
The pathological process involved is also poorly understood and incompletely
resolved. It could be a result of loss of function of PrPc, however this is unlikely
based on experiments with PrP null mice which have some deficiencies; altered
circadian rhythms (Tobler et al, 1996), synaptic degeneration (Clinton et al, 1993)
involving inhibitory postsynaptic currents (IPSC) (Collinge et al, 1994) and slow
after-hyperpolarisations (Herms et al, 1999), impaired long term potentiation,
defective GABAa receptor-mediated fast inhibition (Collinge et al, 1994), impaired
motor co-ordination and loss of cerebellar purkinje cells (Sakaguchi et al, 1996,
Katamine et al, 1998). Yet they show none of the symptoms or neuropathology of
scrapie infected mice and develop normally (Bueler et al, 1992).
Or it could be due to a toxic gain of function e.g. aggregative properties.
Directly toxic effects as a result of build up of large PrPsc aggregates are the most
plausible explanation, however amyloid PrP deposits are not always detected in TSEs.
Cleavage of the NIC-terminal at the cell surface to yield an extracellular neurotoxic
peptide is feasible, based on the toxic effects of PrP peptide fragments observed in
cell culture studies (Brown et al, 1996), which need only stretch from codon 106 to
126 (Rymer and Good, 2000). However, in grafting experiments with PrP null mice
and over expressing PrPc tissue, intracellular toxicity as a result of PrPsc build up
seems more likely, due to the survival of the surrounding 'null' tissue. Triggering of
signalling pathways such as the apoptotic pathway (Kuwahara et al, 1999) could
initiate cell death and this may involve release of cytokines, nitric oxide (NO) or
production of oxygen free radicals by microglia (Ironside et al, 1992a, Ironside et al,
1992b, Ironside et al, 1993a, Williams et al, 1994a, Williams et al, 1994b, Brown et
al, 1996, Brown et al, 1997c, Choi et al, 1998) while glutamate or copper mediated
pathways may be activated (Gray et al, 1999). High levels of ubiquitination in
response to PrPsc accumulation (Ironside et al, 1993b) may occur, while ion transport,
homeostasis (Ca2+, Cu2+ and Zn2+) and membrane fluidity (Wong et al, 1995, Wong et
al, 1996) may be disrupted. The CNS is not the only human tissue shown to display
prion deposits. The use of tonsil tissue to aid in the diagnosis of vCJD has been
undertaken (Hill et al, 1997c) with PrP localisation to germinal centres and PrP
immunoreactivity has been detected in follicular dendritic cells of the appendix
(Hilton et al, 1998). Oral and supposed meat and bone meal (MBM) exposure
infection of primates presents evidence of PrPsc in the gut, lymph tissue, tonsil and
12
spleen (Baker et al, 1993, Beekes et al, 1995, Bons et al, 1999) suggesting a route of
infection. These findings have not been replicated in sporadic or familial CJD cases
(Kawashima et al, 1997). The spread of prions possibly follows neuroanatomical
pathways in the CNS (Taraboulos et al, 1994, Betmouni et al, 1996). Peripheral
transport appears to involve the immune system including B cells (Klein et al, 1997),
follicular dendritic cells (FDCs) and the spleen, according to severe combined
immunodeficient (SCID) mouse resistance to peripheral prion infection, grafting and
surgical studies (pronounced incubation period in mice peripherally infected after
splenectomy). PrPc is found on the surface of platelets (Ghetti et al, 1996) which
presents a possible transfusion route of infection based on the transferal of GPI
anchored proteins from the PM of one cell to another (Ilangumaran et al, 1996) and
likewise peyers patches in the gastrointestinal (GI) and afferent nerves could provide
vectors for prion neuroinvasion into the spinal cord.
1.3 Glycosylation
There are two forms of glycan adddition in the ER, N-linked and O-linked.
Transfer of an N-acetylglucosamine, mannose, glucose chain to the NH2 group of
asparagine residues is termed N-linked glycosylation reviewed in (Sears and Wong,
1998). The preformed oligosaccharide chain (consisting of 2 N-acetylglucosmines, 9
mannose and 3 glucose residues) is transferred from the membrane bound lipid
dolichol to asparagines in the sequence Asn-X-Ser or Asn-X-Thr (X representing any
amino acid except proline). This is carried out in a single step catalysed by
oligosaccharyltransferase (OST) as proteins are translocated into the lumen of the ER.
While still in the ER the glucose residues and one mannose are removed. High-
mannose oligosaccharides receive little additional modification, usually just removal
of further mannose residues. Trimming of chains is carried out by specific
glycosidases. Complex oligosaccharide chains, after trimming, are extended by
addition of monosaccharides (galactose, sialic acid and fucose) in the trans Golgi,
catalysed by glycosyltransferases using specific sugar-nucleotide donors. Once the
core oligosaccharide chain is fonned, prior to elongation, the bond between the N-
acetylglucosamines becomes resistant to the highly specific endoglycosidase, Endo H,
and is often used as a marker of complex oligosaccharides in the Golgi.
O-linked glycosylation occurs in the Golgi apparatus and involves the transfer
of oligosaccharide chains to the COOH group of serine, threonine or hydroxylysine
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residues. This form ofmodification is less common than N-linked glycosylation. The
core glycan xylose is added to the serine residue and subsequently large
glycosaminoglycan polymer chains can be added to yield a proteoglycan.
Glycosylation of proteins can alter their properties in a variety of ways
including physical properties such as stability and solubility, as well as folding
(Imperiali and Rickert, 1995), activity and cellular localisation. Of significance in
relation to PrP is the ability for glycosylation to confer resistance to proteolysis and
direct protein folding into more compact conformations. Influencing the correct
glycosylation of proteins are a wide range of factors including; regulation of
glycosyltransferases, substrate availabilty in the Golgi, competition between glycan
processing enzymes as well as epigenetic and environmental factors (Dennis et al,
2~b
1999). The glycosyltransferases require divalent cations to function, usually Mn
and the correct pH, which must be maintained as a gradient across the Golgi. The
protein itself can also influence glycosylation through local structure at the glycan
addition sites.
1.4 The prion hypothesis
The prion hypothesis is based on a protein only theory (Prusiner, 1982) that
purports there is no nucleic acid portion to the causative infectious agent and that the
conversion of PrPc secondary structure arises by direct homodimerisation with PrPSL
to bring about the observed pathology. The evidence from studies on the nature of the
infective agent, co-purification of PrPres and infectivity, transmission of familial
TSEs, linkage ofPRNP sequence and TSE disease, and in vitro conversion of PrPc to
PrPsc, support a protein only hypothesis, however no definitive experiment has yet
been carried out (see table 2). This thesis is following a line of investigation that is in
accordance with the prion hypothesis.
The prion hypothesis centres on the prion protein or PrPsc (Prion Protein
scrapie) which is also referred to as the infectious particle and is defined as a modified
form of PrPc that readily forms protease-resistant aggregates after treatment with
detergent. PrPsc may convert PrPc or a PrPc precursor via post-translational, chemical
or conformational modification to PrPsc. It is thought that once PrPc is converted into
PrPsc there is an autocatalytic propagation which results in the build up of PrPsc as a
consequence of resistance to endogenous protease mediated catabolic breakdown
down by the normal protein recycling mechanisms of neurons.
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1.4.1 Template assistance model
The template assistance model involves extremely slow conversion in the
absence of PrPst. The template molecule directs the refolding and confers its own
properties on the PrPc (Aguzzi and Brandner, 1999). It may therefore require a third
party known as protein X, which has been suggested might be a chaperone (Telling et
al, 1996c). Binding of protein X appears to occur in the carboxyl-terminal a-helical
region, to a discontinuous epitope formed with residues 214, 218 (in the helix) and
residues 167 and 171 (Kaneko et al, 1997b) based on transgenic substitution
experiments. The conversion step may occur on a membrane through direct contact
between the two forms of the protein, to bring about the conversion of endogenous
protein from one conformation to another. Transgenic, human molecular genetic and
in vitro conversion studies support direct interaction between PrPc and PrPsc and an
autocatalytic process which is most efficient when the proteins are of identical





1.4.2 Nuclear polymerisation model
The conversion step on its own may not be sufficient and PrP aggregates may
be required for infectivity (Shaked et al, 1999a). There is most probably more than
one step in the conversion process (Prusiner et al, 1998, Shaked et al, 1999a). The
nucleation polymerisation model hypothesises that a 'seed' of aggregated PrPsc is
required to facilitate conversion (Raeber et al, 1992). In this model the conversion of
PrPc to PrPsc is relatively fast in the presence of a large aggregate of PrPsc. However,
in the absence of a PrPsc aggregate the PrPc conformation is favoured.
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Investigation
1. Linkage of scrapie incubation times to the PrP gene (Carlson et al, 1986).
2.
Infective resistance to procedures which would 'neutralise or inactivate' conventional
pathogens (Prusiner, 1991).
3.
Co-purification of PrP 27-30 and scrapie infectivity by biochemical and immunoaffinity
chromatography (Prusiner, 1991).
4. Neutralisation of infectivity by a-PrP antisera (Prusiner, 1991).
5.
NMR structure studies predict different conformations in the form of a greater level of (3-
pleated sheet in PrPsc (Korth et al, 1997).
6.
Synthetic PrP peptides can induce PrPc to fold into (3-pleated sheets, develop PK resistance
and aggregate into amyloid fibrils (Kaneko et al, 1995, Kaneko et al, 1997a, Pillot et al,
1997).
7.
Mixing of the two isoforms can bring about in vitro conversion of PrPc to PrPsc (Kocisko et
al, 1994, Bessen et al, 1995, Kocisko et al, 1995, Raymond et al, 1997, Caughey, 1999,
Saborio et al, 2001).
8.
Transgenic studies involving genetically engineered mice with point mutations that
spontaneously develop TSEs (Hsiao and Prusiner, 1990, Palmer et al, 1991, Hsiao et al,
1994, Telling et al, 1996a).
9.
Resistance of PrP-knockout mice to transmission of TSEs (Bueler et al, 1993, Brandner et
al, 1996a, Brandner et al, 1996b, Blattler et al, 1997).
10.
Susceptibility of PrPc expressing grafts in PrP null mice (Brandner et al, 1996a, Brown et al,
1999b).
11.
Genetic linkage of human PrP gene mutations and development of familial TSEs (Hsiao et
al, 1989, Goldfarb et al, 1991, Medori et al, 1992).
12.
Transmission of familial TSEs to experimental animals (Brown et al, 1994b. Collinge et al,
1995, Tateishi et al, 1995, Tateishi et al, 1996).
Table 2. Evidence for the protein only hypothesis.
The discovery of PrPc and the host gene PRNP, which encodes the protein,
made it possible to propose a mechanism of infection. However until the structure of
PrPc was determined a molecular explanation could not be suggested, though self
propagating transcription (Griffith, 1967) and alternatively spliced mRNA had been
postulated. Despite these breakthroughs, the molecular mechanism of conversion
(possibly involving some or all of the following; unfolding, refolding, dimerisation,
oligomer formation, non-covalent interactions, associated protein interactions and
membrane interactions) remains undetermined.
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Post-translational modification suggests that conversion of PrPc occurs at
some point during protein processing in the ER, while present on the surface of the
cell or following endocytosis. The post-translational modifications of PrPc and PrPsc
are the same (Pan et al, 1993) and the disulphide bond remains intact following
conversion (Muramoto et al, 1997). Glycosylation affects the rate of the conversion
process and increased glycosylation may confer protective effects (Caughey, 1999)
which may have implications for the spectrum of glycoform ratios observed
throughout the human prion diseases (see page 23). The conversion step is thus a
conformational change that could be a result of a dysfunctional transport step or
folding process prior to cell surface expression or a deficiency in the proteolytic
machinery required to degrade or metabolise PrPc. However, this does not allow for
interaction between the two different isoforms and it has been shown that PrPsc is not
formed when PrPc migration to the cell surface is inhibited. It is thus more likely the
conversion would occur at either the cell surface, where dimerisation of the two
different isoforms may be more feasible because of exposure to extracellular PrPsc and
orientation of the two isoforms in the membrane could facilitate protein interaction, or
following endocytosis (Caughey et al, 1991, Arnold et al, 1995).
Spontaneous conversion is unlikely (Swietnicki et al, 1998). PrPsc is more
stable than PrPc but conversion is kinetically unfavourable (Prusiner et al, 1998) and
intermediate conformations do not constitute significant amounts with rapid folding
and unfolding (Wildegger et al, 1999). Therefore conversion may require extensive
unfolding and refolding of PrPc under the direction of PrPsc. This could possibly be
mediated by another protein (protein X), but would require a source of energy to drive
the conversion process. If so, this would explain why conversion in vitro can only be
achieved in mixing experiments with large amounts of PrPsc (Raymond et al, 1997).
However, a method has been described recently that yields significant quantities of
PrPres from small amounts of PrPsc template via a sonication induced protein-
misfolding cyclical amplification (PMCA) method (Saborio et al, 2001). Familial
mutations of PRNP occur in or close to regions of ordered secondary structure and
may destabilise the PrPc structure (Prusiner, 1998). The conformation of both PrPc
and PrPsc is also dependent on Cu2+ binding (Brown et al, 1997b, McKenzie et al,
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Secondary structure Predominantly a-helical a-helical and (3-sheet
Table 3. The differences between PrPc and PrPs\
Adapted from Prusiner, 1991.
1.5 TSE Strains
Only pathogens containing nucleic acid display the characteristics of multiple
strains (Bruce and Dickinson, 1987). If this were true, then the pathogen responsible
for TSEs could not solely consist of protein, reviewed in (Ridley and Baker, 1997).
One apparent flaw in the prion hypothesis seems to be the existence of strains
(Farquhar et al, 1998). Strains of scrapie have been isolated which produce different
clinicopathological patterns in the same host and retain their strain characteristics
between hosts upon passage, even after transmission into intermediate species with
different PrP primary structure and reisolation (Fraser et al, 1994). Strain
characteristics are demonstrated with isolates of scrapie infected brain that can be
passaged in an inbred panel of mice with consistent incubation times (Westaway et al,
1987) and neuropathological features (Bruce et al, 1989, Hecker et al, 1992,
DeArmond et al, 1993). They can even be passaged from different regions of brain
tissue (Carp et al, 1997). Thus they are not the result of differences in PrP primary
sequence. Numerous different strains have been isolated from distinct cases of
scrapie (Fraser et al, 1994) and multiple strains can even be isolated from the same
source of natural scrapie (Kimberlin and Walker, 1978). The 2 different strain types
in transmissible mink encephalopathy (TME), termed hyper (HY) and drowsy (DY)
on the basis of the clinical symptoms, correlate with different PrPres banding patterns,
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when analysed by Western blotting following PK treatment (Bessen and Marsh,
1994). The HY strain has a short incubation period featuring hyperexcitability,
tremors, inco-ordination and cerebellar ataxia and accumulates PrPres with a
nonglycosylated band of 21 kDa, in contrast the DY strain produces progressive
lethargy with a longer incubation period and accumulates a nonglycosylated PrPres
band of 19 kDa. Therefore the source of this strain variation may be differences in
the protein conformation (Telling et al, 1996b). These confomers might then alter the
binding or conversion kinetics and hence the time course of the disease, or the cell
specificities, which may result in different symptoms and brain pathology.
Differences in conformation need to be conferred (i.e. heritable) onto the host PrP to
retain the strain properties of the agent. As well as conformation the degree of
protease resistance has been shown to differ between different strains (Buschmann et
al, 1998). Mutation of glycosylation sites affects the expression of PrPc and the
neuropathological profiles of PrPsc deposition in transgenic mice (DeArmond et al,
1997b). Glycosylation is not required for PrPres formation in transgenic mice
(DeArmond, 1999), cell culture (Taraboulos et al, 1990a) or cell-free conversion
assays (Kocisko et al, 1994).
1.6 The species barrier
Another hurdle for the prion hypothesis has been the existence of the species
barrier. When transmissions are carried out from one species to another there is often
a lack of success or increased incubation times, which decrease as the number of
passages in the new species are carried out (Kimberlin and Walker, 1978, Fraser et al,
1994). It appears that the greater the similarity between the 1 ° structure of PrPSL and
PrPc, the more likely it is that the new host will acquire the disease (Bartz et al, 1994).
Transgenic mice with both their own and a Syrian hamster PrP gene, when inoculated
with PrPsc from either other mice or Syrian hamsters, specifically accumulated PrPsc
of the same species (Prusiner et al, 1990).
1.7 CJD
CJD is a fatal neurodegenerative TSE disorder that affects humans. It can be
subdivided into a number of classes, depending on the aetiology (idiopathic, inherited
or acquired) and the resultant clinical and pathological features. It is a rare disease
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with the incidence being approximately 0.7 case per million per annum worldwide
(Will etal, 1998).
Sporadic CJD (sCJD) is the most common form of CJD and makes up
approximately 87% of cases (Will et al, 1998). The cause of sCJD is not currently
known, but is assumed to be due to somatic PRNP mutation or spontaneous
conversion of PrPc to PrPsc as a rare stochastic event rather than environmental
exposure to prions.
Familial CJD (fCJD) (along with other inherited prion diseases such as
Gerstmann-Straussler-Scheinker syndrome [GSS] and fatal familial insomnia [FFI])
are linked to autosomal dominantly inherited mutations in the PrP gene and account
for approximately 8% of the human prion diseases (Will et al, 1998).
Iatrogenic CJD (iCJD) occurs only in those individuals who have been
exposed to contaminated tissues, tissue products or surgical instruments and only
accounts for 5% of CJD cases (Will et al, 1998). The time and route of infection in
iatrogenic CJD can de defined and indicates that the route of infection influences both
the incubation period and spread of the disease (Turner and Ironside, 1998).
Variant CJD (vCJD) is thought to result from the consumption of BSE
contaminated meat products, based on epidemiological, clinical and neuropathological
findings (see section 1.8), transmission studies and molecular strain typing with
Western blotting (Collinge et al, 1996, Bruce et al, 1997, Hill et al, 1997a).
1.7.1 Clinical features of CJD
The symptoms of prion diseases generally involve neurological dysfunction
that corresponds to global CNS impairment i.e. cerebellar, pyramidal and
extrapyramidal signs. Abnormalities arising from damage to other organs and tissues
outwith the central nervous system (CNS) have not been noted.
Sporadic CJD has characteristic clinical features; it generally affects older
individuals with a mean age at onset of 65 years and has a rapidly progressive
prodrome (duration of approximately 2-6 months) and profound presenile dementia
which presents with either loss of memory, behavioural changes or 'higher cortical
functioning deficits' e.g. dysphasia or dyslexia (Ironside, 1998). Deterioration to a
demented state occurs along with visual disturbances, a lack of co-ordination, rigidity
and involuntary movements e.g. myoclonic jerks, ataxia. This progresses to a
terminal rigid state, featuring cortical blindness, akinetic mutism and dysphagia, with
death often resulting from inhalation pneumonia. The disturbance noted in the
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putamen on magnetic resonance imaging (MRI) may relate to obstruction of
procedural actions involving movement. Electroencephalogram (Lemstra et al, 2000)
triphasic sharp wave spike complexes occur in conjunction with these clinical features
(Brown, 1996).
The age at onset and duration of disease due to iCJD exposure is dependent
upon the route of infection (Allan and Tuft, 1997). Peripheral infection such as
growth hormone therapy (GHT) can take ~15 years from adolescent treatment to
present (Huillard et al, 1999), but cranial surgery or corneal transplants may be
carried out on a wide age range and presents quickly (~18 months). The symptoms of
iCJD are variable depending on the route of transmission. There is primarily
progressive cerebellar ataxia and myoclonus in cases of peripheral infection, whereas
dementia occurs in central inoculation. The presence of dementia in both centrally
infected iCJD and sCJD patients suggests that sCJD arises in the brain and not from
contact with an exogenous source. In iatrogenic disease the route of infection
influences the development of pathology as demonstrated by the clinical symptoms
reviewed in (Brown et al, 1992).
One of the most distinguishing initial features of vCJD was the occurrence in
young individuals (Will et al, 1996) mean age 26. Variant CJD has certain clinical
features that distinguish it from other forms of CJD. The presenting symptoms are
usually psychiatric and sensory (Will et al, 1996, Zeidler et al, 1997a). Patients
generally develop ataxia early in the course of the disease. All patients suffer from
progressive dementia, but in only a few is memory impairment part of the initial
clinical presentation. Some develop myoclonus, though often late in the course of the
disease. A slower progression occurs with the mean duration being 13 months (range
6 to 39) in comparison to 2-6 months for sCJD, a lack of classical triphasic short wave
complexes seen on EEG (Ironside, 1998). The similar symptoms of ataxia in
peripheral iCJD, vCJD and kuru may relate to the peripheral route of infection, while
sensory symptoms may relate to thalamic involvement (Zeidler et al, 1997a).
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Phenotypic feature Sporadic CJD Variant CJD
Mean age at onset
(range)
65 (14-90) 26 (12-74)
















Codon 129 genotype MM, MV, VV MM
PrPsc molecular typing 1 or 2A 2B
MRI
Signal change in basal
ganglia, putamen, posterior
thalamus.
High signals in posterior
thalamus in some cases.




PrP plaques Present in MV Present in all cases
Tissue distribution CNS CNS, PNS, LRS
Table 4. Differential features of sporadic and variant CJD.
1.7.2 Diagnostic criteria (from www.cjd.ed.ac.uk):
CLASSIFICATION
Suspect cases are classified according to the criteria below by a neurologist
from the CJDSU. This is an on-going process, being constantly up-dated as more
information is ascertained. The date of any change of classification and the reason for
that change is recorded. In addition, the classification is recorded at the following key
stages:
At notification;
When the suspect case was first seen in life by a neurologist from the CJDSU;
The highest classification on the basis of clinical information alone (ie. not including
neuropathological information); and when review by the CJDSU is complete (ie.
when the case-file is 'closed').
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CLASSIFICATION CRITERIA:
SPORADIC CJD (Rotterdam 1998)
I Rapidly progressive dementia
II A Myoclonus
B Visual or cerebellar problems






I, 2 symptoms of II and III OR possible sCJD and positive 14-3-3.
POSSIBLE SPORADIC CJD
I, 2 symptoms of II and duration < 2 years.
IATROGENIC CJD
Progressive cerebellar syndrome in a pituitary honnone recipient
OR sporadic CJD with a recognised exposure risk, eg. dura mater
transplant.
FAMILIAL CJD
Definite or probable CJD plus definite or probable CJD in a first
degree relative OR neuropsychiatric disorder plus
disease-specific PRNP mutation.
VARIANT CJD (UK, 2000)
I A Progressive neuropsychiatric disorder.
B Duration of illness > 6 months.
C Routine investigations do not suggest an alternative diagnosis.
D No history of potential iatrogenic exposure.
II A Early psychiatric symptoms*
B Persistent painful sensory symptoms**
C Ataxia.
D Myoclonus or chorea or dystonia.
E Dementia.
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III A EEG does not show the typical appearance of classical CJD
(after review by CJDSU staff)***
OR no EEG performed.
B Posterior thalamic high signal on MRI scan
(after review by CJDSU staff).
IV A Positive tonsil biopsy.
DEFINITE VARIANT CJD
IA and neuropathological confirmation of vCJD****
PROBABLE VARIANT CJD




I and 4 or 5 symptoms of II and IIIA
* depression, anxiety, apathy, withdrawal, delusions.2
** including both frank pain and/ or unpleasant dysaesthesia.
*** generalised triphasic periodic complexes at approximately one per second.
**** spongiform change and extensive PrP deposition with florid plaques,
throughout the cerebrum and cerebellum.
In addition, there are three additional sub-categories for those referrals that do not
meet the criteria of possible CJD, which are:
Diagnosis unclear- when the diagnostic criteria for possible, probable or
definite CJD are not met nor is there a reasonable alternative diagnosis and, therefore,
CJD remains a possibility;
CJD thought unlikely- when information indicates that a clinical diagnosis of
CJD is very unlikely because of atypical disease features, and/or an atypical course,
and/or atypical clinical investigation results, and/or a reasonable alternative diagnosis
is made, but is not confirmed. This category includes cases which improve clinically
without another firm diagnosis being made; and
Definitely not CJD- when information indicates that CJD is not the diagnosis
and there is another definite diagnosis proven by clinical examination, clinical
investigations or pathology.
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1.7.3 Neuropathology of CJD
The neuropathology observed in the brain of sporadic, iatrogenic and familial
CJD patients consists of spongiform change in one or all of the following grey matter
regions of the brain, cerebrum, cerebellar cortex and subcortical, detected by
conventional haemotoxylin and eosin (H&E) staining (Bell and Ironside, 1993b).
Neuronal loss occurs as a result of apoptosis (Dorandeu et al, 1998, Gray et al, 1999),
along with astrocytic and microglial proliferation and activation (Williams et al,
1994a, Betmouni et al, 1996). This is accompanied by PrPsc accumulation as plaques
in the neuropil, a diffuse synaptic PrPsc pattern of perivascular PrP accumulation as
detected by PrP immunocytochemistry (Bell and Ironside, 1993b), recrudescence of
synaptic contacts (Clinton et al, 1993) and axonal damage (Gray et al, 1999). These
features display considerable variation between cases and between brain regions in
individuals (Ironside et al, 1996).
The spongiform change and amyloid plaque formation is largely dependent on
PRNP genotype in sCJD. Individuals homozygous for methionine at codon 129 of
PRNP show cerebral cortical spongiform change and synaptic or perivacuolar PrP1"
accumulation, however, individuals homozygous for valine show corpus striatum and
cerebellum spongiform change but PrPies plaque-like structures in the cerebellum,
thalamus and basal ganglia. MV genotypes have a varied neuropathology that can
resemble either of the homozygote patterns (Parchi et al, 1995a, Ironside, 1998,
Parchi et al, 1998b) and the PrPres isotype determines the formation of plaques (type 1
patients) or kuru type plaques (type 2). Amyloid plaques also occur in familial prion
diseases, particularly in GSS where multi-centric cerebellar plaques are characteristic.
Variant CJD has a distinct neuropathology. Multiple "florid" amyloid plaques have
been seen in the cerebrum and cerebellum as well as typical plaques and deposits
(Ironside and Bell, 1997). Florid plaques are seen very rarely, most commonly in
cases of kuru and experimental Icelandic scrapie, aside from vCJD. Florid plaques
are fibrillary PrPres plaques surrounded by a halo of spongiform vacuoles. They are
also seen in the brain stem and spinal cord. Overall, PrP'es staining in the form of
clusters ofmultiple small plaques and amorphous deposits around neurones and blood
vessels is most intense in the cerebellar cortex molecular and granular layers and
occipital lobe. Punctate PrPres staining is seen in the pontine nuclei. The basal
ganglia shows perineuronal and linear periaxonal deposits. Spongiform change is
seen in the basal ganglia and there is a marked thalamic gliosis and neuronal loss
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involving dorsomedial and posterior nuclei (Ironside, 1998) but no confluent
spongiform change or status spongiosis.
1.8 Kuru
Kuru was first reported in 1957 by Gadjusek and Zigas, in the Fore tribe
residing in the Eastern Highlands of Papua New Guinea. The suggestion that it was a
TSE akin to scrapie and CJD was made in 1960 by Hadlow and in 1966 the first
transmission of a human TSE to a primate was reported by Gadjusek et al. The
disease is thought to be transmitted by cannibalistic funerary practices and since the
cessation of these events the incidence of the disease has diminished (Liberski and
Gajdusek, 1997).
The presumed oral route of infection has provided a comparative model of
human TSE infection with vCJD. Kuru patients homozygous for methionine at codon
129 display a earlier age at onset and shorter disease duration (Cervenakova et al,
1999). The clinical signs of kuru (the native tenned used to describe the pronounced
tremors) involve progressive cerebellar ataxia. Comparison of kuru and vCJD
neuropathology have found spongifonn change in the putamen, caudate nucleus and
thalamus as well as involvement of both the granular and molecular cerebellum cell
layer with gliosis and PrPsc deposition (McLean et al, 1998). Prion plaque formation
in kuru is seen in reasonably well preserved regions and forms proper plaques that in
some cases are multicentric. The neuropathology of kuru cases show PrPres plaques,
only in individuals with at least one allele carrying methionine at codon 129, thus the
MM vCJD cases noted to date may not be representative of all individuals exposed to
BSE (Cervenakova et al, 1999). However, this has been contradicted in a number of
other studies (Hainfellner et al, 1997, Lantos et al, 1997, McLean et al, 1998). The
levels of PrP in vCJD brain are far higher and overall the pathology of these two
diseases differs, suggesting that the strain of agent plays a greater role than the route
of infection in determining the clinico-pathological phenotype (McLean et al, 1998).
1.9 Genetics
There is continued identification of variant PRNP genotypes in humans and
animals and the influence they have on both the spontaneous development of inherited
TSEs and the susceptibility to developing TSEs on exposure to PrPsc (Hsiao and
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Prusiner, 1990, Goldfarb et al, 1994, Ikeda et al, 1995, Pickering-Brown et al, 1995,
Goldmann et al, 1998, Lee et al, 1998, Wopfner et al, 1999, Gilch et al, 2000).
Familial forms of human spongiform encephalopathies are tightly linked to certain
mutations in PRNP. The familial forms are passed on in an autosomal-dominant
fashion (Baker et al, 1985, Collinge et al, 1992). Families carrying these mutations
are sometimes related to certain ethnic groups such as Libyan or Sephardic Jews or
Slovakians carrying the E200K mutation (Lee et al, 1999). Carriers of the E200K
mutation may be heterozygous or rarely homozygous for the mutation, with the latter
presenting a little earlier and having a longer disease duration, but otherwise a similar
clinical phenotype (Simon et al, 2000). The influence of other host factors in the
development of human TSE disease is most clearly demonstrated by a large pedigree
containing 47 affected members carrying a 144 base pair insertion of six octapeptide
repeats in the octapeptide motif (Collinge et al, 1992).
There are over 20 different non-conservative substitution and insertion
mutations in the human PRNP gene which can bring about inherited prion diseases
(Goldfarb et al, 1991, Bosque et al, 1992, Medori et al, 1992, Gabizon et al, 1994,
Campbell et al, 1996, Windl et al, 1996, Lee et al, 1999, Collins et al, 2000, Nixon et
al, 2000, Peoc et al, 2000) and are associated with the familial forms of human TSE.
All of the known substitutions occur in the 4 putative a-helices of PrPc or at their
borders (Riek et al, 1996). At least 13 different mutations are present in fCJD and
GSS, including point mutations and insertions of various lengths, which are found
around the octapeptide repeat-coding region (Silvestrini et al, 1997). These mutations
may result in inappropriate amino acids at critical sites in the PrP required for three
dimensional conformational stability which may be lost and destabilise the a-helix
conformation therefore increasing the likelihood of (3-sheet refolding. Thus mutation
may facilitate or enhance the rate of PrPc conversion, whether it is PrPsc or
spontaneously driven. The phenotype of the disease varies according to the specific
mutation. It is possible that some of the mutations in familial forms of human TSE
result in pathology through mechanisms not involving PrP conversion or
accumulation, such as protein processing problems. This could explain a lack of PrP
plaques or spongiform degeneration and the uncharacteristic banding patterns in
forms of GSS (Collinge et al, 1990, Piccardo et al, 1998) and possibly FFI. This
would be consistent with a protein only hypothesis.
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1.10 Effects of polymorphisms
In addition to inherited cases, there are sporadic cases and acquired cases of
CJD. Genetic factors that predispose, protect or alter the outcome of infection or
exposure to infected tissues have been studied. Thus far the most important variations
appear to be the polymorphisms at codon 129 of PRNP. The incubation period of
iCJD and kuru can be influenced by the PRNP codon 129 genotype, with
heterozygotes in some studies presenting later and at a much lower incidence than
homozygotes for either amino acid (Deslys et al, 1998, Shibuya et al, 1998,
Cervenakova et al, 1999). Furthermore, the susceptibility to sCJD, iCJD and kuru
appears to be influenced by this polymorphism (Palmer et al, 1991, Deslys et al,
1998). Homozygosity for either methionine or valine at codon 129 is present in
approximately 49% of the normal population (Palmer et al, 1991). In contrast
individuals with sCJD or iCJD are found to be homozygous in approximately 71%
(Windl et al, 1996, Will et al, 1998, Alperovitch et al, 1999) and 80% of cases
respectively (Brown et al, 2000). The age at onset in patients with sCJD is
influenced by the codon 129 genotype with greater numbers of methionine
homozygotes over 49 years of age than under, while greater numbers of the valine
homozygotes were under 50 years of age than over (Alperovitch et al, 1999). In
iCJD acquired from growth hormone treatments, valine homozygotes are more
common (Bendheim et al, 1992, Alperovitch et al, 1999). This polymorphic effect
could be influenced by the potential oxidation of methionine in PrP (Wong et al,
1999) or the propensity for p-sheet conformation of valine (Jackson et al, 1999b).
The possibility that this polymorphism influences dimer formation and aggregation
due to allelic homology is unlikely because PrPsc aggregates are found to contain both
the methionine and valine alleles (Chen et al, 1997).
The homozygosity at codon 129 predisposes to sCJD and so far all cases of
vCJD have been homozygous for methionine. This would imply that a similar
mechanism is in operation in these two subtypes of CJD. However, the differences in
Western blotting banding patterns of PrPres imply a different 'strain' ofTSE is causing
the appearance of the new CJD subtype. In the initial report of vCJD the PrP
genotypes for 8 cases were analysed and all were methionine homozygotes at codon
129 ofPRNP (Will et al, 1996). Variant CJD occurring in an individual with a valine
allele is yet to be reported among the 132 cases of definite or probable vCJD as of the
3rd ofMarch 2003 (http://www.cjd.ed.ac.uk/figures.htm).
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There is also an inherited susceptibility to CJD in human carriers of the
D178N mutation, dependent on M or V at codon 129 (129M linked to FFI, 129V
linked to fCJD). While the D178N mutation induces development of the TSE, the
codon 129 genotype affects the form of the disease (Parchi et al, 1995a, Parchi et al,
1995b, Parchi et al, 1998b, Parchi et al, 1998c). The clinical and pathological
features of these two diseases differ markedly. FFI features a prominent insomnia and
thalamic atrophy, but fCJD displays prominent spongiform degeneration of the
cerebral cortex. When FFI patients with differing codon 129 polymorphisms on the
unmutated allele are compared, significant differences in disease duration are noticed,
the MM cases were found to have a mean duration of 9.1 months and the MV cases
30.8 months (Montagna et al, 1998). The 144 base pair (bp) insertion in one kindred,
co-segregating with M, has different age at death depending on M or V on the normal
allele. The latter, displaying later age at death (Baker et al, 1991). The P102L
mutation as well as four or five repeat inserts can cosegregate with methionine or
valine, resulting in different neuropathology and clinical signs (Baker et al, 1991,
Young et al, 1997). This difference in disease duration presumably arises due to
differential allelic homology and is proposed to account for the differences in
neuropathology and clinical signs. Cases of fCJD with the E200K mutation are
usually in conjunction with methionine at codon 129 and homozygous for methionine.
This is due in part to the large Libyan Jewish kindred that is primarily MM
(Rosenmann et al, 1997).
1.11 Evidence that vCJD is a result of BSE exposure
BSE was first reported in 1987 in the UK (Wells et al, 1987). From
November 1986 to May 1995 there were 150,00 reported cases (Anderson et al,
1996). As little as 1 gram of BSE infected bovine brain tissue is transmissible to a
wide range of animals by peripheral injection and oral infection (Collee, 1996). It is
postulated to represent a distinct strain and has been reported to be consistent among,
BSE, vCJD, zoo animals (Kirkwood et al, 1993), macaques, marmosets (Baker et al,
1993), FSE in domestic cats (Aldhous, 1990, Pearson et al, 1991, Pearson et al, 1992,
Wells and Wilesmith, 1997) and captive wild cats (Willoughby et al, 1992, Baron et
al, 1997). The neuropathology is concordant with other TSEs as well as being
reproducible on transmission to cattle, primates (Baker et al, 1993, Lasmezas et al,
1996b) mice (Bruce et al, 1994, Lasmezas et al, 1996a, Bruce et al, 1997, Hill et al,
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1997a, Raymond et al, 1997, Ironside, 1998) cheviot sheep, goats and pigs (Foster et
al, 1993, Foster et al, 1996, Ryder et al, 2000). Suspected cases arising from BSE
such as feline spongiform encephalopathy (FSE) or BSE in greater kudu, nyala have
also been transmitted to mice (Bruce et al, 1994, Fraser et al, 1994). BSE was
initially identified in 3 domestic cats with FSE (Aldhous, 1990, Leggett et al, 1990,
Wyatt et al, 1990, Pearson et al, 1991, Wyatt et al, 1991, Pearson et al, 1992), a prion
disease which appeared in 1990 in the UK. Since then numerous captive and
domestic (85) cases (Wells and Wilesmith, 1997) have been reported.
The source of the epidemic was traced to food supplements including the
MBM from dead sheep and cows. This has been given to cows since the 1920s but the
important solvent extraction step in the processing of sheep carcasses was excluded in
the early 1980s and the temperature of the procedure was changed. PrPsc is solvent
sensitive, therefore it has been proposed scrapie PrPsc was deactivated in this step and
without it the PrPsc remained infectious (Prusiner, 1997). BSE may represent a cattle
adapted strain of scrapie or a propogated case of either familial or sporadic BSE, the
original cause as in kuru is unknown. The identification of a single strain would
support the potential for de novo initiation of a new strain. The epidemic was
amplified by recycling of infected cattle that commenced in 1984, and led to a marked
increase in incidence of BSE in 1989.
Variant CJD is a subtype of CJD unidentified previous to 1996 (Will et al,
1996). It has a number of characteristics that distinguish it from other forms of CJD.
A very distinctive neuropathology and atypical clinical symptoms, along with the very
noticeable incidence of the disease in young people, in comparison to sCJD, which
generally afflicts individuals between the ages of 50 and 70. The occurrence of these
cases following the BSE epidemic and the distinctive features provide circumstantial
evidence of a link. While transmission studies (Bruce et al, 1997, Hill et al, 1997a,
Raymond et al, 1997, Ironside, 1998, Bruce et al, 1999) provide experimental results
to back up the association between the two outbreaks. The most important evidence
with relevence to this study is the consistent identification by Western blotting of a
distinctive PrPlcs banding pattern (Collinge et al, 1996, Parchi et al, 1997).
1.12 PrPsc biochemistry
Studies on PrPSL biochemistry include in vitro mixing experiments (Raymond
et al, 1997), the production of synthetic peptides (Kaneko et al, 1995), structural
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studies (Riek et al, 1996, Korth et al, 1997) and electrophoresis studies (Brown et al,
1986a, Bessen and Marsh, 1992, 1994, Collinge et al, 1996, Parchi et al, 1996,
Castellani et al, 1997, Hill et al, 1998). Electrophoresis studies have included
investigations into the protease resistance, relative molecular mass, glycosylation
profdes, tissue distributions and the investigation of the biochemical basis of strain
variation of PrPres (Prusiner et al, 1983, Bockman et al, 1985, Hope et al, 1986,
Brown et al, 1995, Telling et al, 1996b). Protease resistance of the pathological
isoform of PrP was observed in 1985 by Oesch et al (Oesch et al, 1985) and by Meyer
et al in 1986 (Meyer et al, 1986). The purification of PrP can be carried out by
detergent extractions, enzymatic digestions, differential centrifugations (separating
out membrane fractions) and discontinuous sucrose gradient sedimentation as used by
Prusiner et al, in 1983 (Prusiner et al, 1983). PrPc migrates to 33-35 kDa, but PrPres is
found at 27-30 kDa (Beekes et al, 1995) due to NH3-terminal proteolytic cleavage
(Hope et al, 1986). The first indication of molecular weight differences in CJD
derived PrP,es were made in 1985 (Bockman et al, 1985) and in the same year
differences in the relative amounts of SAF immunoreactive bands, dependent upon
host and scrapie strains, were observed (Bode et al, 1985). The SAFs were found to
be composed of a low molecular weight glycosylated protein in the same year
(Multhaup et al, 1985). PrP was then found to co-purify and appear at a similar
molecular weight to the SAF protein (Hope et al, 1986). The heterogeneity in the
molecular weights of the banding pattern observed is a result of N-linked
glycosylation (Somerville and Ritchie, 1990). Electrophoresis studies are proving
increasingly important for strain typing and diagnosis. The molecular analysis of
human TSEs may allow the identification of distinct strains of prion disease, based on
PrPres conformation differences elucidated through partial Proteinase K digestion
(Bessen and Marsh, 1992, 1994). The incubation period or clinical signs may be
related to different protease sensitivity. At present distinct banding pattern types are
being equated with strains in human SEs, however there is little data on the repeated
passage of these 'strains' in mice (Bartz et al, 1994, Bartz et al, 1998) and on passage
in humans (el Hachimi et al, 1997). Pattison isolated brain from two separate groups
of goats with scrapie (Pattison, 1966). The passage of these extracts into Chandler
mice resulted in different symptoms, one made animals drowsy (DY), the other
hyperactive (HY). Transmissible mink encephalopathy (TME) likewise has two
strains which produce excitable and drowsy symptoms, as stated previously, (Bessen
and Marsh, 1992). Similarly the banding patterns observed in human TSEs may
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represent phenotypic strain differences. The isoform differences are represented by
different PrP,e:> fragments after PK digestion and degrees of glycosylation. There are
a number of problems in investigating and diagnosing CJD. One of these has been the
need to carry out post mortem investigations to accurately diagnose the disease. PrPsc
biochemistry may allow prenecropsy and preclinical tests to be carried out by brain or
tonsil biopsy (Castellani et al, 1996, Castellani et al, 1997, Hill et al, 1997c).
1.13 Interpretation of banding patterns
Cases of CJD can be readily distinguished upon Proteinase K treatment. Only
the abnormal form of PrP is partially resistant to this protease and non-TSE diseases
do not display the characteristic banding pattern. Western blots of PrPres from CJD
cases results in 3 bands, 2 glycosylated bands which correspond to a greater molecular
mass and 1 nonglycosylated band which is of lower molecular mass (figure 3). The
relative molecular weights and glycosylation ratios vary and the classification systems









Figure 3. Schematic diagram of the PrP Western analysis of TSE samples.
The distinct mobilities are due to different degrees of PK cleavage of the
amino-terminal portion of PrPsc, possibly due to different conformations of PrPres
(Bessen and Marsh, 1994). Individual fragments (bands) may correlate to the mutated
allele, spongiform changes or multi-centric amyloid plaques (Parchi et al, 1998a).
The size of cleavage fragments are retained after transmission of fCJD and FFI
(Telling et al, 1996b) and it is postulated that this is a strain specific characteristic
(Bessen and Marsh, 1992).
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1.13.1 Collinge et a/, 1996
The banding patterns observed by Collinge et al, (Collinge et al, 1996) in
sCJD case are termed type 1 and type 2. Type 1 forms the majority of cases with the
codon 129 genotype always being methionine homozygous (MM) and the
deglycosylated PrPres band being found at approximately 21 kDa. The type 2
nonglycosylated PrP'es band is found at approximately 20 kDa in a few MM genotype
individuals, heterozygote (MV) and valine homozygote (VV) individuals. A type 3
banding pattern has been described, with a decreased apparent molecular weight of 2-
3 kDa in comaprison to type 2, in MV and VV cases of sCJD and pituitary derived
iCJD (Collinge et al, 1996, Wadsworth et al, 1999b, Jackson and Collinge, 2001).
There appears to be some degree of variation in the glycoform ratios of sCJD, this
was first indicated by a slight difference between types 1 and 2. Type 1 and 2 have
different clinicopathological phenotypes in the sCJD. Type 2 has a greater middle
band intensity than type 1. When type 3 was compared with either type 1 or type 2
the intensity of the bands and their ratios were not significantly different (Collinge et
al, 1996). Some MM iCJD cases have the type 1 or 2 pattern, growth hormone
derived in the former and dura mater derived in the latter. Type 3 iCJD
(peripheral/intramuscular injection of human cadaveric hormones) presents with a
distinct clinicopathological phenotype (cerebellar ataxia and psychiatric disturbance)
to iCJD resulting from CNS exposure (dura mater grafting) and resembles classical
sporadic CJD. All of these banding patterns, after Proteinase K treatment, have
similar but not identical glycofonn ratios. They are differentiated on the basis of their
fragment size (Hill et al, 1997a).
All patients with vCJD are MM and have banding patterns significantly
different to types 1,2 and 3 in terms of high-relative molecular mass, proteolytic
cleavage site and glycosylation ratio. The banding patterns seen in cases of vCJD are
different to types 1 and 2. The mobility of the bands are the same as that seen in type
2 or 3 cases, however the glycoform ratios differ from that seen in sporadic cases of
CJD. Deglycosylation with PNGase F gave a single band that may be consistent with
a single proteolytic cleavage site. The glycoform with the higher relative molecular
mass is the most abundant judging by band intensity while there is relatively little of
the mono and nonglycosylated bands which implies that unlike types 1, 2 and 3, type
4 is a distinct CJD subtype (Collinge et al, 1996). Variant CJD has a glycoform
signature similar to transmitted BSE; experimental murine (wt FVB mice and C57BL
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mice) BSE (Bruce et al, 1997), naturally transmitted domestic cat BSE and
experimental macaque BSE (Lasmezas et al, 1996a) which supports the proposition
that vCJD has occurred as a result of infected material from BSE afflicted cattle
entering the human food chain.
The consistency of molecular strain typing was supported by the fact that
CJD transmission to wt FVB mice resulted in banding patterns that resembled the
inoculum (Collinge et al, 1996). The murine PrPres apparent mobility and glycoforms
were the same as those seen in humans. However, transgenic mice (homozygous for
human PRNP codon 129 valine, null for murine PRNP) inoculated with type 1 sCJD
produced type 2 PrPres, and transmission of vCJD to the same strains of mice lead to
production of a type 5 pattern (PrPres with a type 2 relative mobility and prominent
diglycosylation).
PrPres has only been detected in the CNS in cases of sCJD (Hill et al, 1999b).
In tissues outside the nervous system it has been reported that there is a different
glycosylation pattern to that reported in the CNS of the same host. The banding
pattern observed in tonsil tissue taken from patients with vCJD has shown a far
greater proportion of the diglycosylated band than in the brain and this has been
designated 4t (Hill et al, 1997c). Types 6 and 7 have also been reported, characterised
by prominence of the nonglycosylated band and higher molecular weight than type 1
respectively (Collinge et al, 1996, Hill, 1998).
1.13.2 Parchi etal
In contrast to Collinge's findings Parchi et al, 1996 and 1997, report that
immunoblot analysis of SDS-PAGE PrPies shows only two mobility variants. Type 1
has a Mr of approximately 21 kDa, which corresponds to types 1 and 2 of Collinge et
al, yet type 2 has a Mr of approximately 19 kDa (Parchi et al, 1997) and corresponds
to types 3 and 4 of Collinge et al. The study included a case of kuru and it was found
that the vCJD, kuru, one case of iCJD (VV homozygous at codon 129) and the 88
cases of sCJD were type 2. The type 1 pattern was composed primarily of sCJD cases
and iCJD (MM homozygous at codon 129), though Tranchant et al, have reported
MV cases in this group (Tranchant et al, 1999). Type 1 and 2 have different
clinicopathological phenotypes in the sCJD cases (Parchi et al, 1996). There is
further classification of banding types by Parchi et al, based on glycosylation patterns,
though vCJD was still found to be highly diglycosylated and designated type 2B.
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However there was reported variability of the type 1 Mr and only one kuru and one
vCJD case were investigated.
The banding pattern as well as clinical symptoms and neuropathology are
affected by the codon 129 genotype, with fCJD D178N-129VV showing type 1
mobility while FFI D178N-129 MM or MV showing type 2 mobility (Monari et al,
1994, Parchi et al, 1998c). The glycofonn ratios of fCJD D178N and FFI differ,
however within each group they do not differ in relation to the unmutated allele
(Monari et al, 1994). Iatrogenic CJD displays different mobilities according to route
of infection yet like sCJD it shows the opposite effect of the codon 129
polymorphism, with valine predisposing to generation of type 2 PrPIcs. The formation
of particular PrPres banding patterns is constrained by host PRNP codon 129 genotype.
This finding is supported by conversion of type 1 to type 2 when passaged into
transgenic mice with the human PrP gene (Telling et al, 1996b). When material was
transmitted from FFI patients to mice the 19 kDa fragment was retained yet when
material from fCJD or sCJD was used the PrPICS migrated to 21 kDa (Telling et al,
1996b) implying strain dominance over host genotype. Cell free conversion reactions
have also provided evidence for the maintenance of strain specific conformations as
defined by PK cleavage (Bessen et al, 1995).
A high proportion of the diglycosylated banding has been reported in familial
cases, (GSS P102L and E200K) that have type 1 migration patterns (Parchi et al,
1998a, Cardone et al, 1999), while FFI displays type 2 mobility (Gambetti et al, 1995,
Parchi et al, 1995b, Parchi et al, 1998c, Rossi et al, 1998) and on transmission of
Chronic Wasting Disease (CWD) to ferrets (Bartz et al, 1998) and TME to hamsters
(Bessen and Marsh, 1992). Thus the characteristic glycoform feature of vCJD is not
unique. Though vCJD, GSS P102L and FFI cases with this feature are almost
completely restricted to the methionine carrying population, aside from fCJD E200K
valine homozygotes. However, it may be a feature of first passage with crossing of
the species barrier selecting for the diglycosylated form of PrPc.
The banding patterns of other human prion diseases (kuru, fCJD V210I and
GSS) have been investigated and they also migrate to 21 or 19 kDas in some cases,
though there are many more fragments of PrPres after PK treatment. A 37 kDa band
was observed prior to PK treatment in patients with insertional mutations that
corresponds to the extended mutant allele (Capellari et al, 1997). The production of
small molecular weight fragments and their subsequent detection is dependent upon
the accesibility PK has to cleavage sites and the presence of the respective epitope to
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allow binding of antibody to the fragments. Cases of FFI have type 2 mobility, while
cases of GSS show 7-8, 11 and 21 kDa fragments (Tagliavini et al, 1991, Parchi et al,
1998a). As well as having a more varied production of fragments the relative
proportions of the different glycoforms can be more extreme and may correlate to
spongiosis (Piccardo et al, 1998). Fragments have also been detected in sCJD
designated CI and C2 (Chen et al, 1995). The identification of sporadic cases of fatal
insomnia (sFI) based on spongiform changes, reactive astrogliosis and PrPsc
deposition (Mastrianni et al, 1999), with type 2 mobility, as in FFI suggests that the








etalDiagnosis / Codon 129
Sporadic CJD MM 1 1,2,7
Sporadic CJD VV 1 2
Sporadic CJD MV 1 2,6
Variant CJD MM 2B 4




Iatrogenic CJD GHT MM - 1
Familial CJD E200KM< 1 -
Familial CJD E200K VV< 2 -
Familial CJD D178N VV 1 -
FFID178N MM/MV 2 -
Sporadic FI MM 2 -
GSS P102L 1, + 8 kDa -
GSS F198S D202N 2, ±8 kDa -
GSS Q217R - 27-29 kDa
Kuru 2A 2,3
Table 5. Comparative isotype classification.
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1.14 Investigative frontiers
The main problem facing researchers in this area is the still disputed nature of
the causative agent. There is a reasonable amount of agreement that the infectious
agent is a protein even though the prion hypothesis is still unproven, however at
present this does not help in the management or treatment of TSEs. They are fatal
diseases with no cure as yet. The risks from TSEs are limited by the banning of offal,
meat on the bone and cattle over 30 months for consumption as well as blood
transfusions or organ donations by infected individuals or affected families. Prion
replication in spleen and other lymphoreticular tissues makes it possible to detect the
PrPsc 27-30 molecular marker for prion infection in tonsil or lymph node biopsy in
scrapie (Roels et al, 1999) and vCJD. Elowever, the risks of transmission from
lymphoid and haematological tissues remains undetermined (Turner and Ironside,
1998). The transmission of BSE to humans was thought to be unlikely due to the
species barrier, however, the host range of a TSE agent can broaden upon passage
(Bartz et al, 1998). It is possible that a large proportion of the population are
incubating vCJD, which might be transmitted iatrogenically (Hill et al, 1999b, Hill et
al, 2000) (secondary transmission). Thus continued surveillance is necessary to
manage the wider health care implications (recommendations of the Southwood
Committee). The possible transmission of vCJD by blood transfusion and use of
preclinical tonsil biopsy tests for vCJD, represent some of issues that need to be
discussed by groups other than scientists and clinicians. Similar issues concern those
families who have offspring bom to mothers with vCJD, a group of people who may
well increase as more cases of vCJD arise.
The possible routes and spread of infection need to be determined to allow
proper risk assessments of primary and secondary transmission of BSE, which might
be further elucidated by the detection of PrPsc immunoreactivity and molecular
markers of vCJD in peripheral tissues. The risks of oral transmission in terms of
doses also need to be better determined for an increased sensitivity in determining the
risks to humans of eating food products such as meat on the bone. This will most
likely be resolved through transmission studies involving transgenic mice. Studies
with scrapie suggest the lymphoreticular system (LRS) is involved. Exactly how
genetics affect the outcome of TSE exposure is important and may play a significant
role in determining the likely size of the epidemic.
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PrPres typing is important for epidemiological studies, especially if BSE
transmission to different genotypic, age or ethnic groups has occurred that does not
present itself in a similar manner to vCJD. Investigating unusual cases of sCJD is
prudent to establish the range of pheontypic presentation and identifying vCJD cases
found to be MV or VV at codon 129 could help to identify more closely the
relationship between the disease phenotype, genotype and PrPlcs banding patterns
(Zeidler et al, 1997b). Investigations of peripheral iCJD infection will help establish
the pathological mechanisms of peripheral TSE infection. Typing of various animals
may also prove useful considering the possibility of BSE having infected sheep.
Identification of BSE in sheep, which may seem to be affected by "scrapie" is
important and would pose a significant hindrance to eradication of the disease (Foster
et al, 1993, Raymond et al, 1997, Hill et al, 1998, Baron et al, 1999, Hope et al, 1999,
Baron and Biacabe, 2001).
1.15 Hypothesis
The current dogma regarding the different PrPres banding patterns observed in
TSEs is that differences in molecular weight correspond to differences in
conformation and these differences in conformation represent a molecular marker of
prion strains (i.e. strain characteristics are enciphered by protein conformation).
Furthermore, this molecular marker can be used reliably and consistently to determine
TSE aetiology and differentiate between CJD subgroups. To test this hypothesis two
approaches will be adopted:
1. The comparison of a large cohort of CJD cases and analysis of multiple
brain regions, to determine the consistency of PrP'es banding patterns. These banding
patterns can be compared with clinical, genetic and neuropathological data to
determine if the clinico-pathological phenotype correlates to a molecular strain of
agent. Comparison of neuropathological data and PrPies will allow a greater
understanding of the relationship between the pathological process and the prion
protein.
2. The use of Western blotting as a tool for differential diagnosis of CJD
subgroups and aetiologies will also be examined. This study will focus on CJD for
two main reasons; CJD is the most common form of human spongiform
encephalopathy and presents with a variety of different phenotypes. Also the
differential diagnosis of sCJD and vCJD may be possible based on the unique
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Western blotting isotype but this needs to be confirmed and analysis extended to a
larger cohort of patients. Being based at the UK National CJD Surveillance Unit
provides an unparalleled resource of tissues obtained by biopsy and at autopsy from
CJD patients. This will allow analysis of the PrPres presentation of CJD cases in the
UK and identification of epidemiological or chronological changes. It will also allow




2.1 Collection of material in the National CJD Surveillance Unit
Tissues were obtained with consent from cases referred to the Unit, with no
preselection. Referral bias cannot therefore be excluded and the cases were initially
examined "blind" to the clinical and pathological data. Investigations were approved
by the Lothian Regional Ethics Committee. Cases were assigned a laboratory
identification number (RU#year/case) to maintain confidentiality and will be referred
to where individual cases are discussed. The Unit has an impressive record on
autopsy achievement rates, with 70% of clinically suspected cases examined, which is
in contrast to the typical rate of 10% in UK hospitals (Ironside et al, 1998).
To carry out SDS-PAGE, frozen material was required. Samples that were
frozen at -70°C shortly after autopsy provided the most suitable tissue preparations
for recovering and detecting proteins by Western blotting. The autopsy protocol for
frozen tissue sampling is included in the appendix. Limitations in terms of local
facilities available for tissue handling and storage may influence studies on protease
resistant PrP deposition in different brain regions (Bell and Ironside, 1993b, a, 1997).
The tissues available range from small portions of undefined brain tissue or spinal
cord, to complete half hemispheres frozen as a whole. A range of cases were










Table 6. Cases investigated.
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There were also a small number of tissues obtained from outside the UK.
Tissues from Alzheimer's disease, lewy body dementia and non-CNS disease patients
were analysed as controls. In addition, animal tissues have been investigated; mice
inoculated with vCJD, natural scrapie in a sheep, BSE in a cow, FSE in a domestic cat
(presumed to be ofBSE aetiology) and a marmoset experimentally infected with BSE.
2.2 Sample storage and handling
The frozen tissues were stored at -80°C in a level 3* containment facility.
After tissue sampling and homogenisation, samples were stored at -20°C in safe-lock
eppendorf tubes. The handling of material, decontamination and safety procedures
were carried out in accordance with the Advisory Committee on Dangerous
Pathogens, Spongiform Encephalopathy Advisory Committee, "Transmissible
Spongiform Encephalopathy Agents: Safe Working and the Prevention of Infection."
guide 1999. All work with frozen material not denatured in SDS, was carried out in a
Class 1 bio-safety containment hood. Exposure of wrapped nitrocellulose or
polyvinyl diflouride (PVDF) membranes and enhanced chemiluminescence (ECL)
reagents to Hyperfilm was carried out in a level 2 containment dark room.
2.3 Brain sampling
The frozen tissues were transported from the brain store to neuropathology
laboratory using a designated box as secondary containment. Samples were taken
observing the full safety procedures for category hazard 3* laboratories. Tissues were
sampled in a class 1 bio-safety hood. Work was carried out in pairs as a 'clean/dirty
team'. Dissection instruments were provided and notes taken by the 'clean'
individual. The 'dirty' individual carried out tissue dissection. Both participants
wore chain-mail gloves between two pairs of surgical gloves to safeguard against
accidents with disposable scalpels. Dissection was carried out on a cut resistant
surface to minimise contamination of the dissection area. Approximately 100 mg
pieces of CNS material enriched for grey matter were excised for each sample.
Frontal cortex material was routinely analysed whenever possible. Samples taken
when a frozen half brain was available for detailed neuroanatomical investigation are
detailed in table 7.
When samples were taken from a half brain stored at -70°C, it was left to
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warm to approximately -20°C before sampling. This allowed better identification of
anatomical features and easier excision. The samples were transferred to 2 ml safe-
lock Eppendorf tubes, pre-weighed, labelled and held in a -20°C freeze block in a
dedicated transport box (IsoTherm-system 3880, Eppendorf). This secondary



















Table 7. Brain regions sampled.
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2.4 Western blotting
PrP was analysed by Western blotting as described by Collinge et al, (Collinge
et al, 1996), with modifications as follows.
2.4.1 Western blot sample preparation
2.4.1.1 Homogenisation
Tissues were weighed and homogenised in NPD buffer (Tris buffered saline
[TBS] pH 7.6 containing 0.5% Nonidet P40 [NP-40] and 0.5% sodium deoxycholate)
to give a 10% w/v (weight/volume) brain homogenate. Homogenisation was carried
out in a safe locked Eppendorf tube using a disposable micro-pestle and cleared by
centrifugation. Samples were centrifuged at 2000 rpm (420 g) at 4°C for 5 minutes
(Centrifuge 5417C/R, Eppendorf). The cell debris pellet was retained and the
postnuclear supernatant removed to a separate Eppendorf. Loading and unloading of
the centrifuge rotor was carried out in the hood and an opening tool used on the
Eppendorf tubes to limit the risk of spillage and minimise contact with samples.
2.4.1.2 Metal ion chelation and addition
EDTA (500 mM) was added to the NPD buffer of various samples prior to
standard PK treatment (outlined below) to chelate metal ions. These samples were
not included in routine analysis and their isotyping is discussed in Chapter 6. Control
postnuclear supernatant samples (Alzheimer's disease and Lewy body dementia) were
incubated overnight at 4°C, 20°C and 37°C with excess MnCl (100 mM) in NPD
buffer prior to standard PK treatment. This was carried out to assess the ability of
manganese to induce PrPres formation.
2.4.1.3 Experimental proteolytic degradation
Aliquots of the cleared 10% brain homogenates were subjected to limited
proteolysis by digestion with Proteinase K (BDH, UK) at a final concentration of 50
pg/ml for 1 hour at 37°C in a heat block (QBT1 block heater, Grant Instruments
[Cambridge] Ltd). Proteinase K is a widely used relatively non-specific protease
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classified as a serine endopeptidase and isolated from the filtrate of the fungus
Tritirachium album limber. It cleaves peptide bonds adjacent to the carboxylic group
of aliphatic, aromatic or hydrophobic amino acids. The reaction was terminated by
addition of Pefabloc SC (4-[2-Aminoethyl]-benzenesulfonyl flouride hydrochloride)
to a final concentration of 1 mM. Pefabloc SC (Boehringer Mannheim/Roche,
Germany) is an irreversible inhibitor of serine proteases.
2.4.1.4 Centrifugal concentration of PrPres
Increased yields of PrPres was obtained with the following method; 100 pi of
PK digested supernatant and an equal volume of MeOH was spun in a safe lock
Eppendorf tube at 14,000 rpm (21,000 g) (Centrifuge 5417C/R, Eppendorf) for 1 hour
at 4°C. The supernatant was then aspirated and discarded. The remaining pellet was
dissolved in 20 pi 2X SDS-PAGE dissociation buffer (outlined below 2.4.2) by
vortexing and heating to 100°C for 10 minutes.
2.4.1.5 Enzymatic deglycosylation
PrPres was deglycosylated using PNGaseF (peptide-N4-[acetyl-P-
glucosaminyl] asparagine amidase) Peptide N-glycosidase (New England Biolabs)
purified from Flavobacterium meningosepticum, under the manufacturers'





Ri = N and C substitution
R2 = H or the rest of the oligosaccharide
R3 = al-6 fucose
Denaturation solution (10X, supplied in conjunction with PNGaseF,
containing 5% SDS and 10% 2-Mercaptoethanol) was mixed with 12 fold aliquots of
PK treated sample and heated at 100°C for 10 minutes in a heat block to denature and
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reduce the samples. Deionised H20 was added at 10% and buffered with 10X G7
buffer (0.5 M sodium phosphate, pH 7.5, supplied with PNGaseF) at 10%,
supplemented with 1% NP-40 (supplied with PNGaseF) and a final concentration of
500 ET/pl of PNGaseF made and incubated at 37°C for 2 hours in a heat block. The
proteins were precipitated by addition of 4 volumes ice cold methanol (MeOH) (160
pi) and centrifugation at 14,000 rpm for 10 minutes at 4°C. 25 pi of homogenisation
buffer was added and dissolved by boiling for less than 10 minutes.
This removes, intact, the oligosaccharide chains attached to PrP at the two
consensus sequence sites at Asn codons 181 and 197. The asparagine residue is
deaminated to aspartic acid. This removes heterogeneity and allows easier resolution
of types. It enables the mobility of unglycosylated PrP to be established and helps
confirm that the top two bands seen are glycosylated fonns ofPrP.
2.4.2 Denaturation.
Treatment of the samples in preparation for SDS-PAGE involves boiling
samples in Laemlli sample buffer i.e. Dissociation/denaturation buffer (2X) an
aqueous solution containing, 125 mM Tris (BDH/Merck), 5% SDS (BDH/Merck),
0.02% bromophenol blue (BDH/Merck) and 20% glycerol (BDH/Merck) in a heat




Mini-PROTEAN® II Dual cell gel (Bio-Rad Laboratories) system was used
according to the manufacturers' instructions;
SDS gels were hand-cast at a thickness of 0.75 mm with a 10 well comb.
Denatured samples were spun at 2,000 rpm for 5 minutes. Initial screening involved
loading 14 pi of denatured samples, as this was found to give a well-resolved signal
after X-ray film exposure of between 30 seconds and 3 minutes. Samples were
equalised in their loading by addition of homogenisation buffer and dissociation
buffer was added to unoccupied wells to prevent distortion of the bands. The buffers
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used were based on Laemmlis' method (Laemmli, 1970). Approximately 300 ml of
SDS-PAGE running buffer was added to the upper and lower tanks and air bubbles
flushed from below the resolving gel with a pasteur pipette. The bromophenol dye
front was run close to the bottom of the gel to enhance separation but not run off to
minimise contamination of the lower tank. Re-usable components in contact with
sample, such as glass plates and spacers, were decontaminated in 2 M NaOH for 1
hour.
Mini-gels reduce electrophoretic run time and reagent usage, thus minimising
decontamination. The gel was cast between glass plates separated by spacers, held in
a casting assembly. A 12%T (final total monomer concentration) (1%C) (crosslinking
monomer concentration) acrylamide SDS-PAGE mini-gel was routinely run (see
appendices). Hand-cast gels were overlayed with dH20 and left to polymerise
overnight. The stacking gel (3%T) was overlayed onto the first gel the following day.
Electrophoresis was carried out with a Bio-Rad PowerPac 300. Electrophoresis was
run on a 0.75 mm 12%T gel at a constant 200 volts for 45 minutes.
Alternative Conditions
Gel thickness was determined by spacers. Gel thickness as well as acrylamide
concentration affects the electrophoretic run time and transfer conditions required (see
below), the electrophoresis run time was longer with thicker gels. 1.5 mm thick gels
allowed the addition of more sample to the wells and produced sharper resolution.
16%T gels were made by altering the constituents according to the formula (see
appendices). 16%T gel was run for 1 hour and a 12%T 1.5 mm gel for 40 minutes.
The electrophoretic run time must be increased to 1 hour for 16% T gels. Combs
forming 12 or 15 well gels were also used.
Bio-Rad precast mini-protean II gels; Tris-Tricine 8 cm x 10 cm (WxH) 1 mm
thick with 10-20%T acrylamide, based on Schagger & von Jagow formulation
(Schagger and von Jagow, 1987) were used to aid identification of mobility in
chelated PrPres samples. Proprietary dissociation buffer (containing 1 M Tris-HCL,
pH 6.8, glycerol, 10% SDS, P-mercaptoethanol, 0.5% coomasie G-250) and run
buffer (Tris, Tricine, SDS) were used in conjunction with Tris-Tricine precast gels.
The electrophoresis was run at 100 volts constant current (approximately 65 mA) for
100 minutes according to manufacturers' instructions. The transfer conditions were
the same as hand-cast gels.
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Criterion Cell Precast system (Bio-Rad Laboratories) was used as instructed
by the manufacturers. A range of different resolving gels including 12%T, 15%T and
8-16% gradient gels, utilising an SDS-ffee Tris-HCl system were employed. The
electrophoretic run time was 55 minutes at a constant 200 volts. Transfer times were
altered to account for the larger size of the gels (13.5 by 8.5 cm) from 18 to 25
minutes at 192 mA/gel. The increased size requires longer to run (as outlined in the
appendix, A3) and involves diposal of more contaminated waste but it allows a
greater number of samples to be loaded (12 as opposed to 10 lanes).
2.4.4 Markers
The molecular weight of PrPres was estimated by reference to biotinylated
enhanced chemiluminescence (ECL) (Amersham Pharmacia Biotech) molecular
weight markers (1 pi per lane). ECL markers were visualised by the inclusion of
streptavidin peroxidase (Amersham Pharmacia Biotech) at a dilution of 1:1500 in the
secondary incubation. These markers contain Phosphorylase b (97,400 Da), Bovine
serum albumin (68,000 Da), Ovalbumin (46,000 Da), Carbonic anhydrase (31,000
Da), Trypsin inhibitor (20,100 Da) and Lysozyme (14,400 Da) to produce a molecular
weight ladder. Benchmark™ prestained protein ladder (Gibco BRL Life
Technologies or Bio-Rad Laboratories) (7 pi per lane) and Kaleidoscope markers
(Bio-Rad Laboratories) (7 pi per lane) were used to monitor the electrophoretic run
and transfer steps. These markers were mixed with dissociation buffer prior to
loading on the gel. They contained either one or a range of coloured markers
allowing easy identification. BFAV (federal research centre for virus diseases of
animals) markers were kindly supplied by Dr Martin Groschup. These markers were
dihydrofolate reductase (DHFR) constructs ranging in molecular weight from 16.2-21
kDa 6xHis and mab P4 tagged and use the QIAexpress detection system (Qiagen).
2.4.5 Semi-dry transfer
Proteins were routinely transferred to Hybond-P PVDF membranes
(Amersham Pannacia Biotech). Transfer was carried out using a semi-dry transfer
apparatus (Sammy-Dry, Schleicher and Schuell) following the method outlined by
Towbin et al, (Towbin et al, 1979) using a Pharmacia EPS 600 power supply.
Twenty pieces of blotting paper (3MM) and two pieces of PVDF were required (5.5
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by 9 cm). The PVDF was first wet in MeOH, then equilibrated in dH20 for 15
minutes followed by transfer buffer (192 mM Glycine, 50 mM Tris in dH20) for 15
minutes. The SDS page gel was equilibrated in transfer buffer for 5 minutes. The
transfer apparatus was setup with 5 sheets of blotting paper laid on the anode with a
membrane on top followed by the gel and then another 5 sheets of blotting paper. Air
bubbles were expelled by rolling a Universal relatively firmly over the upper layer of
blotting sheets before the lid was placed on top. Transfer occurs downwards from the
cathode to the anode (graphite electrodes) at 140 mA per gel, 18 minutes for 0.75 mm
or 25 minutes for 1.5 mm and 25 minutes for 16%T gels (calculations are outlined in
the appendix). After transfer the blotting sheets and gels were disposed of in 2 M
NaOH and the transfer assembly was wiped down with paper towels also disposed of
in 2 M NaOH. The size of molecules and gel thickness determine the rate of sample
migration out of the gels onto the membrane, thus affecting quantitation.
2.4.6 Wet transfer
Novex Xcell II™ blot module (Novex) was used according to the
manufacturers' instructions with precast Tris-Tricine gels (Novex) based on Schagger
& von Jagow, (Schagger and von Jagow, 1987) formulation. Transfer was carried out
at a constant 25 volts (~100 mA) for 1-2 hours.
2.4.7 Gel and Membrane staining
Proteins were visualised nonspecifically on PVDF membranes with Ponceau S
or in polyacrylamide gels with Coomassie Blue dye to confirm complete transfer of
proteins from the gel to the membrane. Ponceau S staining was carried out with 0.5%
Ponceau S in 1% acetic acid incubated for 5-10 minutes with agitation before washing
in dH20 for 2 minutes. Coomassie staining was carried out with 0.1% Coomassie
Blue R-250 in an aqueous solution of 7% volume/volume (v/v) acetic acid and 50%
v/v MeOH and incubated for 15 minutes. The destaining was carried out in two
consecutive 10 minute washes with 7% v/v acetic acid and 50% v/v MeOH.
49
2.4.8 Western blotting
Western blotting was used for specific identification of PrPres. The use of
specific antibody binding and secondary detection systems enabled semi-quantitative
results to be obtained with a high degree of confidence in the identity of the protein.
After transfer to PVDF or nitrocellulose the membrane was first washed in
TBS-T (20 mM Tris Buffered Saline 137 mM NaCl, 0.1% Tween-20 pH 7.6) for 2 x 5
minutes. The membrane was then washed in 20 ml blocking buffer (5% w/v dried
skimmed milk [Safeway] in TBS-T) for 1 hour at room temperature with agitation or
overnight at 4°C. The membrane was rinsed and washed in TBS-T (3x5 minutes).
Then the membrane was incubated with primary antibody for 1 hour at room
temperature with agitation or overnight at 4°C. The membrane was washed again in
TBS-T (3x5 minutes) before being incubated in secondary horse radish peroxidase
(HRP) conjugated sheep anti-mouse IgG antibody 1:1000 for 1 hour at room
temperature with agitation (kindly provided by Diagnostics Scotland). Streptavidin
peroxidase where ECL markers were used was added at 1:1500. A final wash in
TBS-T was carried out (4x5 minutes).
Antibody concentrations required may differ depending on the source (1:1,000
Dako, 1:10,000 Senetek). The anti-PrP monoclonal antibody 3F4 (Senetek or Dako)
was used at a final concentration of 100 ng/ml IgG for 1 hour on human samples. The
antibody was supplied as purified IgG2a kappa of ascites diluted in 0.05 mol/L
Tris/HCl, 15 mmol/L NaN3, pH 7.2, 1% bovine serum albumin (BSA). The 3F4
antibody detects an epitope at amino acid residues 108-111 in humans and hamsters
and was produced from immunisation with hamster scrapie strain 263K (Kascsak et
al, 1987). Alternatively 6H4 (Prionics, Switzerland) was used at dilutions from 1 in
10-20,000 (which detects human amino acid residues 144-152, DYEDRYYRE),
IgGl mouse monoclonal with light chain k subtype, stock 2 mg/ml), final
concentration of 100-200 ng/ml. Some anti-PrP monoclonal antibodies such as KG9
do not work on Westerns, despite being of great use in immunohistochemistry (as
stated earlier). Antibody cross reactivity with PK may occur and was seen on longer
exposures of PrPies negative samples at approximately 28 kDa just above the position
that the diglycosylated band was found in on positive samples.
The incubation steps were routinely carried out using a Western processor
(Bio-Rad laboratories) and occasionally by hand. The Western processor
automatically washes with controlled incubation times and volumes. Reagents were
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aspirated. This minimises the contact with potentially contaminated fluids and
ensures a consistent treatment of all membranes. Rocking speeds were adjusted to
medium (incubations) or fast (washes) settings (15 rpm or 30 rpm). The ISTAR
program number 5 or custom PRP program was followed and matched the steps
described above. A purge cycle was run with 2% bleach to cleanse tubing after each
assay, then rinsed and dried.
2.4.9 PrPres visualisation
PrPres bands can be visualised by a number of different methods. Detection
employed the ECL (Amersham Pharmacia biotech) or ECL Plus™ (Amersham
Pharmacia biotech) reagents and Hyperfilm ECL (Amersham Pharmacia Biotech).
The ECL reagent is converted by the HRP to hydrogen peroxide (H2O2) which in
combination with the oxidation of luminol and the enhancer produces light. There
was a final wash in TBS-T before the development reagents were added to the
membrane. The ECL kit reagents were mixed in equal amounts (2 ml of reagent A
and 2 ml of reagent B), spotted onto the membrane and incubated for 1 minute. ECL
plus was mixed with 4 ml reagent A and 100 pi reagent B. The membranes were
wrapped in cling film (Saran) and ECL Plus™ was left to incubate for 5 minutes
before disposable of excess reagents. ECL Plus™ reagent Lumigen® PS-3 (2,6-
diflourophenylA-methylacridan-9-carboxylate) reacts with HRP and peroxide to
produce acridinium ester intermediates that react with peroxide to produce light with a
maximum emission at 430 nm (Akhavan-Tafti, 1995). A series of exposures were
made with hyperfilm. The film was then developed using an X-Ray film
Hyperprocessor (Amersham Pharmacia Biotech). Developing and fixative solutions
were obtained from X-ograph imaging systems.
2.5 Prionics Kit
Animal samples were assessed by both standard procedures and the use of a
commercially available kit designed for detection of disease specific prion protein in
cattle and sheep. The Prionics kit procedure was similar; a 10% brain homogenate
was produced, treated with PK, boiled in dissociation buffer and electrophoresed on a
12%T gel. Proteins were transferred to Hybond-P membranes, and the membranes
were incubated with 6H4 and a secondary goat anti-mouse IgG alkaline phosphatase
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(AP) conjugated antibody, before being detected with CDP-Star (1, 2-dioxetane), an
alkaline phosphatase substrate in a proprietary buffer (Tropix buffer). AP
dephosphorylates the substrate to yield an anion with a relatively long half life leading
to light emission for hours to days. It is ideal in conjunction with PVDF and emits
light at 461 nm. This kit has been validated for use in the diagnosis of BSE (Schaller
etal, 1999).
2.6 Total protein concentration
A modified Lowry assay (Lowry et al, 1951) suitable for samples in buffer
containing detergent was used following the manufacturers' instructions (DC Protein
Assay, Bio-Rad Laboratories). The assay is compatible with Tris and NP-40.
A standard dilution curve was generated from stock BSA (1.4 mg/ml) to give
the following concentrations; 0.2, 0.4, 0.8, 1.2, 1.4 mg/ml, in homogenisation buffer.
A standard or sample volume of 37.5 pi was added to 187.5 pi of working reagent (20
pi of reagent S per ml reagent A [alkaline copper tartrate solution]) and vortexed. 1.5
ml reagent B (dilute Folin reagent) was then added and incubated for 15 minutes. The
absorbance of samples in a disposable 1cm path length cuvette was read at 750 nm up
to 1 hr later with an Ultrospec 3000 spectrophotometer (Pharmacia).
2.7 Isotype and glycotype analysis
The banding patterns were classified alongside standard samples according to
mobility and relative glycoform ratios as stated in the introduction.
2.8 Densitometry
Glycoform analysis was performed using a GS-700 imaging densitometer and
Quantity One 4.1 software (Bio-Rad Laboratories). X-ray films were chosen based on
the quality of the exposures. Those with high background, distorted lanes, transfer
bubbles, under or over exposed, or other assorted experimental artifacts such as
smudges, specks or spots were eliminated. X-ray films were scanned into the
densitometer and compared to a grey scale calibration template. A standard protocol
was established and applied to all the results (detailed in the appendix A5).
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2.9 Quantitation
With the use of a densitometer with sophisticated image manipulation
software, strict control over image quality and analysis of multiple exposures, values
within the linear range can often be obtained with confidence. Bands were defined
manually as l/3rd of the width of a lane, background was removed and a base line
intensity determined. The procedure is detailed in the appendix. The linear range was
determined based on dilution curves of sCJD and vCJD cases. It corresponded to
optical densities (OD) between 0.7 and 7 or 0.8 and 8 (see appendix A5). The
variance that can arise due to repeat exposure times or repeated analysis of the same
sample (intra-assay error) has been quantified (see appendix).
2.10 Storm™ ImageQuant Densitometry
PVDF membranes were incubated for 5 minutes with ECLPlus™, following
Western blotting. The Storm 860 (Molecular Dynamics™) was set to detect
chemiluminescence (Fluorescence mode Red [635 nm] / 650 LP 800 volts) and scans
performed at normal and high sensitivity with a resolution of 50 dots per cm. A
protocol of image manipulation is detailed in the appendix.
2.11 Statistics and presentation of the data
Glycoforms were determined by separation of the three bands, within the
linear range (see appendix), as percentages. The mean percentages for each band
were determined along with the standard deviation and standard error. Values are
expressed as means ± standard error of the mean. Glycoforms were displayed as
histograms. The glycofonn ratio means for each patient were displayed on
scattergraphs with the diglycosylated and monoglycosolated values input onto the x
and y-axis respectively. This results in the nonglycosylated band being taken as the
remaining percentage of 100 and emphasises the need to characterise the banding
patterns as a total of 100% lane density. Statistical analysis was carried out with
SPSS version 11. Independent two tailed t tests and one way ANOVA analysis was
performed to compare the mean di, mono and nonglycosylated bands of cases. Paired
two tailed t tests were performed on EDTA treated samples. One sample two tailed t
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tests were carried out to compare the animal samples with vCJD cases. All significant
results were within a 95% confidence interval.
2.12 Genetics
The results of genetic analysis of blood taken from the patients while alive
was provided by CJD Surveillance Unit staff, including both codon 129 and
mutational data. This invaluable resource enabled the subgrouping of the cases.
Retrospective analysis of cases in which there was only frozen brain tissue (n=45)
were analysed as follows:
2.12.1 DNA Extraction
DNA extraction was carried out primarily on frozen tissues, preferably tissues
containing high levels of nuclei but low infectivity, i.e. liver as opposed to CNS,
wherever possible. Extraction was carried out in a Category 3* laboratory in a Class
1 bio-safety containment hood. The QIAamp DNA mini kit was used (Qiagen) and
the manufacturers' frozen tissue or paraffin embedded protocol followed where
appropriate. Buffer reagents were prepared according to the manufacturers'
instructions and the reagents were equilibrated to room temperature. Spins were
carried out with an Eppendorf Centrifuge 5417C/R.
Samples were analysed alongside 1 co-processed negative per 5-6 samples.
Tissues were weighed with the addition of 80pl phosphate buffered saline (PBS) per
25 mg, homogenisation, followed by addition of a detergent buffer (ATL). Proteinase
K (20 mg/ml, final concentration 2 mg/ml) was added at 20 pi per 25 mg of tissue and
the samples vortexed prior to overnight incubation at 56°C in a heat block. The PK
was added in excess to remove protein contaminants. Proprietary wash buffer (AL)
was added and vortexed for 15 seconds, incubated at 70°C for 10 minutes followed by
a brief centrifugation. Ethanol (96-100%) was added at a volume of 200 pi per 25 mg
of original tissue sample, vortexed for 15 seconds, followed by another brief
centrifugation. Samples were transferred to QIAamp spin columns (with 2 ml
collection Eppendorf) including any white precipitate. The spin columns were
centrifuged at 6000 g (8000 rpm) for 1 minute. The filtrate collection tube and
contents were discarded and the spin columns were placed in a fresh collection tube.
Proprietary wash buffer (AW1) was added to the spin columns and centrifuged at
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6000 g for 1 minute. The filtrate was discarded and AW2 buffer was added to the
spin columns for a further wash and centrifuged at 20,000 g for 3 minutes. The
filtrate was discarded and the spin columns placed in a clean-labelled 1.5 ml
microcentrifuge tube. Proprietary elution buffer (AE) or distilled water was added
and incubated at room temperature for 1 minute then centrifuged at 6000 g for 1
minute. The elution was carried out twice and the two eluates were combined and
stored at -20°C.
2.12.2 Polymerase chain reaction
The first two steps were carried out in a class II hood using dedicated
equipment and stored separately to other pipettes tubes and racks to prevent cross
contamination of polymerase chain reaction (PCR) product. The Qiagen
HotStarTaq™ PCR kit was used following the manufacturers' guidelines. Reagents
in the stated volumes were added to each tube in the hood in the following order;
Qiagen PCR buffer (TrisHCl containing KC1, [NH4]2S04 and 15 mM MgCl2, pH
8.7) 10 pi, Qiagen MgCl2 (25 mM, final concentration 3 mM) 6pl, Promega dNTPs
(10 mM) 2pl, primers A2/A3 (0.1-0.5 pM) 1 pi, HotStarTaq (5 units/pl, 1 unit per
reaction) 0.2 pi, dH20 78.8 pi. Taq is sensitive to agitation so was carefully mixed
and briefly centrifuged, prior to aliquoting 98 pi per tube. Extracted DNA templates
were thawed, mixed and pulsed down. 2 pi of extracted DNA was added to each tube
with a positive displacement tip. 2 pi of dH20 was added to the reagent negative in
place of a template. A2 primer (forward) TGA TAC CAT TGC TAT GCA CTC ATT
C, A3 primer (reverse) GAC ACC ACC ACT AAA AGG GCT GCA G. Samples
were then incubated using the Peltier Thermal Cycler-200 DNA engine (MJ-
Research), and run on program PrPA2A3, featuring the following cycles of
denaturation (steps 2 and 6), step down annealing temperatures annealing (steps 3 and
7) and elongation (steps 4, 8 and 10) with an initial HotStarTaq DNA polymerase
activation step.
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1. 95°C 15 minutes
2. 94°C 1 minute
3. 65°C 1 minute (decrease 0.5°C per cycle)
4. 72°C 2 minutes
5. Repeat steps 2-4 10 times.
6. 94°C 45 seconds
7. 60°C 30 seconds
8. 72°C 1 minute
9. Repeat steps 6-8 30 times.
10. 72°C 15 minutes
11. 4°C forever
12. END
PCR products were then stored at 4°C.
2.12.3 PRNP codon 129 restriction digest assay
PCR products were cleaved with the restriction enzyme Nspl to generate
DNA fragment lengths specific to the polymorphism at codon 129 (Zimmermann et
al, 1999). Nspl from Nostoc species is cloned and expressed in E. coli. The Nspl
restriction site cuts at the following sequence encoding methionine;
5'-Pu CATG ^ Py-3'
3'-Py j GTAC Pu-5'
The following reagents were mixed in the stated volumes, NEB buffer 2, 1 pi, BSA
100 pg/pl (NEB), 0.1 pi, Nspl 5 U/pl (NEB) 0.2 pi and dPEO 3.7pl and pulsed down.
5 pi of reagent mix and 5 pi of DNA (PCR product) was added to each tube and
mixed well. Samples were once again run on the DNA Engine, program
37DEG1 DIG (37°C, 5 hours).
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2.12.4 Agarose gel electrophoresis
To give a 1.5% agarose gel 2.25 g of agarose (Merck) was mixed with 150 ml
IX 89 mM Tris-boric acid, 2 mM disodium EDTA, dihydrate pH 8.3 (TBE) and
heated until the agarose melted and the solution was clear. Once cooled sufficiently
to be handled, Ethidium Bromide (10 mg/ml) was added (to give 0.33 pg/ml) and
gently mixed. The gel was then poured into a gel assembly and allowed to set for 30
minutes. TBE (IX) was added to the gel tank to equilibrate with the gel for 5
minutes. Bromophenol Blue loading dye was mixed with an equal volume of Nspl
digested PCR product. A 100 bp ladder was added to the first lane and the samples
added subsequently. Electrophoresis using a power pack at 75-100 Volts for
approximately 1 hour, until there was migration of the dye front by ~5 cm to ensure
good band separation. The gel was orientated so that the samples migrated to the
anode. Gels were photographed under UV.
2.13 Histology
The PrP immunohistochemistry and haemotoxylin and eosin (H&E)
information was obtained from autopsy reports and detailed investigative studies
(Kovacs et al, 2000, Kovacs et al, 2002). The findings were described in terms of
typical features of the disease, spongiform vacuolation, neuronal loss and amyloid
deposits identifiable on H&E sections. Astrocytic gliosis was identified by glial
fibrillary acidic protein (GFAP) immunostaining and PrP deposits identified by
immunostaining with numerous anti-PrP antibodies, primarily 3F4 and KG9. The PrP
immunoreactive staining was subclassified into four main patterns by Kovacs, G.;
vacuolar, diffuse/synaptic, neuronal or granular deposits and plaques. Vacuolar
deposits were found around areas of confluent spongiform vacuolation in a sparse
granular pattern. Diffuse staining was a nondescript pattern found in the neuropil
with small granular deposits. Neuronal staining was in either intracellular or
pericellular punctate form with granular deposits surrounding an unstained region
around the nucleus (the perikarya). Finally granular deposits were found in
association with plaques fonning a dense centre that was only detected on
immunostaining.
The wide array of subjects and ancillary information enables a detailed
definition of subgroups and correlations to be drawn between PrPies and other
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phenotypic features. Those involved in obtaining and providing the data are duly
acknowledged.
2.14 Transmission procedure
The transmission procedure was as outlined in Nature (Bruce et al, 1997).
Samples were taken from each of three vCJD patients in the category 3* diagnostic
laboratory facilities of the National CJD Surveillance Unit. The sampling was from
areas showing the maximum pathology, whenever possible and stored at -80°C before
transport to the IAH Neuropathogenesis Unit (Edinburgh, Scotland). They were
homogenised at 10% (w/v) concentration in sterile physiological saline and stored at -
20°C. The samples were thawed and resuspended by being drawn repeatedly through
a series of graded needles. Control samples consisted of saline passed through the
homogeniser and glassware prior to infected samples, also frozen at -20°C. The
samples were inoculated into mice under halothane anaesthesia by intracerebral (20
pi) and intraperitoneal (100 pi) injection. Three inbred mouse strains were used;
C57BL and RIII (both of the Sincs7 or Prn-pa genotype) and VM (Sincf7 or Prn-pb
genotype). Two controls per mouse strain were inoculated and each of the vCJD
patients' samples was inoculated into two mice of each strain i.e. vCJD patient 1
inoculated into two C57BL mice. Mice were coded, examined daily throughout their
lifespan, and formally scored for signs of neurological disease from 250 days after
injection. Mice showing definite signs for two consecutive weeks were killed and
incubation periods calculated as the interval between injection and this standard
clinical endpoint. All other mice were maintained to full life span. Post-mortem, a
lateral third of each mouse brain was dissected aseptically and frozen at -20°C. The
samples were then transported to the CJD surveillance unit, handled in the same way
as potential human TSE material was and stored at -20°C. They were thawed and
homogenised in the category 3* facilities of the protein laboratory prior to Western
blotting in exactly the same manner as for human CNS material, as stated above.
Samples were obtained with a blind ID number from 1 to 32, 24 samples in all. The
samples were then amalgamated into the protein lab sample records and assigned
extract numbers 00.516 to 00.539 (year.chronological number). The samples were
homogenised, PK treated and run on 12% SDS-polyacrylamide gels, followed by
semi-dry transfer onto PVDF membrane and Western blotting with 6H4 primary
monoclonal antibody. Detection was carried out with ECL Plus reagents. Stonn
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chemiluminescence analysis and X-ray film records were made where possible. The
samples were run alongside previously classified human CNS CJD standards and
consensually 'typed' according to our classification nomenclature (Ironside et al,
2000) when PrPres could be detected.
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Results
CHAPTER 3: PrPrcs isotyping.
3.1 Classification
The study started as a retrospective analysis of definite CJD cases. A
comprehensive group of cases were investigated, including a range of human TSE
cases and a few pertinent animal TSEs. Along with these were cases of non-TSE
neurodegenerative disease used as controls. This constitutes the largest study of the
PrP biochemistry of prion disease cases conducted in the UK so far and the largest
reported cohort of vCJD and iCJD cases. By increasing the sample size (n) of studies
and attempting to correlate Western blotting banding patterns with genetic, clinical
and histological data, a better understanding of the phenotypes of disease can be
established, allowing anomalous cases to be further investigated. Continued
surveillance of CJD cases, especially unusual cases e.g. those of long duration or in
young people is essential to potentially identify vCJD PRNP codon 129 MV or VV
genotypes which may or may not have recognisable neuropathology or banding
patterns. Therefore, is there a relationship between the PrP1^ banding pattern and
either the aetiology, codon 129 polymorphism, age at onset, disease duration,
neuropathology or clinical features?
Cases referred to the UK CJD surveillance unit were ordered into aetiological
subgroups (sCJD, fCJD, iCJD, vCJD) according to final diagnosis. Further
classification was then carried out to take into account codon 129 genotype (MM,
MV, and VV) to determine the relative contribution of this well-defined host factor to
the disease phenotype.
Western blot analysis of PrP from CJD frontal cortex (figure 4) shows three
bands in the low molecular weight range. These correspond to di, mono and
nonglycosylated PrP (Haraguchi et al, 1989, Bessen and Marsh, 1992).
Deglycosylation of PrP with PNGaseF results in a single PrP glycoform with a Mr of
around 20 kDa. Experimental PrP constructs and familial forms of CJD incapable of
N-linked glycosylation (discussed in chapter 7) as well as treatment of PrP expressing
cultured cells with tunicamycin (glycosylation inhibitor) have demonstrated the nature
of this characteristic banding pattern. Treatment with the non-specific serine
protease, Proteinase K (PK) is a standard test of TSE and results in NFE-terminal
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truncation of the three glycoforms and the appearance of three bands of increased Mr,
termed PrPies (Caughey et al, 1991). This isotyping study focussed on the use of the
banding pattern as a molecular marker for diagnosing TSEs and investigated the scope
of variation within this pattern.
3.2 Non-prion diseases
Non-prion CNS/neurodegenerative diseased tissues were tested. Neurological
diseases, e.g. Alzheimer's, Lewy Body Dementia (LBD), corticobasal ganglionic
degeneration and murine brain tissue from mice inoculated with saline were chosen as
suitable negative control cases. PK (50 pg/ml) treatment of all these cases lead to a
complete loss of PrP specific signal (figure 4). 10% brain tissue homogenates treated
with PK were loaded at the same levels as PrPres positive controls. Concentration of
samples 15 fold as detailed in the Materials and Methods and over exposure of X-ray
film failed to detect PrP,es. PK treated control samples have a lack of bands being
indicative of susceptibility of host PrP to PK treatment and thus a lack of the disease
associated PrPies. The detection of PrPies under the standard protocol in conjunction
with clinical and neuropathological findings was therefore deemed sufficient to
declare samples TSE negative. It should be noted that PK itself has a molecular
weight of 28.9 kDa and can sometimes be observed as a sharp band due to cross-
reactivity in concentrated samples and should not be misinterpreted as a PrP band
(Jany and Mayer, 1985).
vCJD vCJD Alz Alz
+ - + PK
Figure 4. Proteinase K treatment ofCJD and Alzheimer's. 10% w/v brain
homogenates of variant CJD and Alzheimer's disease before (PK-) and after
proteinase K digestion (PK+). Lane 1 and 2, vCJD postnuclear supernatant, lane 3
and 4, Alzheimer's postnuclear supernatant.
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3.3 Prion disease classification
3.3.1 Standard isotyping
Samples were loaded at equivalent levels for primary screening (14 pi) as
stated in the materials and methods. PrPres was invariably detected when loaded at
this level by X-ray exposures of 30 seconds to 3 minutes. The consistency of PrPres
levels in screened samples aided rapid positive identification of TSE disease. PrPres
banding intensity after PK treatment did not correlate to overall protein levels either
prior to or after PK digestion e.g. if the banding intensity seen on X-ray film was high
there was not necessarily a high overall protein content. Relative signals as compared
to positive standards were a more useful guide than total protein content in assessing
molecular weight and glycoform ratio.
The first stage of the study involved analysing a wide range of samples,
blinded to diagnosis, codon 129 genotype and all other patient information (blind
study 1 n = 59, blind study 2 n = 52) and comparing their banding patterns. The
resultant molecular weights and glycofonn patterns were compared with
classifications of a limited number of samples analysed previously by Collinge et al,
and the classification systems applied by Collinge et al, 1996 and Parchi et al, 1996.
Two molecular weight groups of samples were identified in all but two cases and two
glycoform patterns (figure 5). The molecular weights were termed types 1 and 2 as
described by Parchi et al, 1996 with type 1 having a nonglycosylated band of 21 kDa
and type 2 having a nonglycosylated band of 19 kDa. Consistent correlation with
samples analysed by Collinge et al, 1996 could not be made. Glycoforms were
classified A or B, with A representing a prominent monoglycosylated content and B
representing a prominent diglycosylation. In no cases was prominent
nonglycosylation seen, though some cases had nonglycosylated bands of similar
intensity to the monoglycosylated band (discussed further in chapter 4). All
subsequent investigations were classified according to these isotypes and in total 213
human TSE cases were investigated.
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Figure 5. PrPres isotypes. PK treated brain tissue from sporadic and variant CJD
analysed on a 12% polyacrylamide gel with the anti-PrP monoclonal antibody 3F4,
demonstrating types 1, 2A and 2B. Lane 1, sCJD MM type 1, lane 2, sCJD VV type
2A, lane 3, vCJD MM type 2B. Markers are indicated by horizontal bars and their















Figure 6. PRNP primer and restriction digest map.
A2 and A3 represent the corresponding primer sequences.
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3.3.2 Codon 129 determination
Restriction fragment length polymorphic (RFLP) digestion of purified and
amplified DNA with Nspl, results in three PRNP fragments (figure 6). The three
banding patterns seen on agarose gel electrophoresis resemble the three possible
polymorphic subgroups MM, MV, VV (figure 7). This is a result of the different
specificity for DNA cleavage of Nspl at codon 129 of PRNP. Nspl also cuts at
codon 155 of the PRNP ORF but only cuts at codon 129 if a methionine is present
(figure 6). The uncut DNA migrates at 956 bps and an internal control band of 389
bps is generated from cleavage at codon 155 in all samples. The distinguishing bands
are at 567 bps (the valine encoding gene uncleaved by Nspl) and at 492 bps (the
cleaved methionine encoding gene), both ofwhich can be seen in heterozygotes.
Figure 7. PRNP codon 129 analysis by agarose gel electrophoresis of RFLP digest
fragments of PCR products. Lane 1, 100 bp DNA ladder, lane 2, VV patient, lane 3,
MV patient, lane 4, MM patient.
3.3.3 Subgroup classification
The PrP isotype classification was considered in combination with the final
diagnosis of sCJD, vCJD, iCJD, fCJD and the methionine/valine polymorphism at
codon 129 of the PRNP gene e.g. sCJD MM 1.
Typical examples of the three isotypes (1 MM, 2A VV and 2B MM), shown in
figure 5, were selected and used throughout the study as positive control standards
against which the isotype of new samples were determined. Repeated sampling of
brain tissue from these standard cases gave consistent mobility (vCJD n=25, sCJD
MM 1 n=9, sCJD VV 2A n=17). Prior to proteinase K digestion, PrP in brain
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homogenates showed no obvious difference in Mr (figure 4). Proteinase K digestion
produces an increase in the mobility of each glycoform in all three samples, enhances
the resolution of the bands and removes background protein staining/signal.
The foregoing classification ofCJD cases was made on the basis of analysis of
PrPres found in the cortex, usually frontal cortex. Western blot analysis of CNS tissue
from a total of 213 cases of CJD showed the presence of two predominant PrPres
conformations either 21 kDa (type 1) (n=84) or 19 kDa (type 2) (n=48)
nonglycosylated PrP,es. There were a few cases of sCJD, iCJD (GHT) and 1 case of
fCJD (GSS) that could not be classified as types 1 or 2 (table 8). The glycoform
ratios were broadly of type A (predominantly monoglycosylated) or type B
(predominantly diglycosylated), though once again there were exceptions to the rule
and a range of glycoform ratios were detected. A non-quantitative approach to
isotyping can be determined visually, however, a quantitative assessment will be
covered in chapter 4. Cases with type 2 mobility in which the diglycosylated PrPres
glycoform predominates were termed type 2B (Parchi et al, 1997). So far this pattern
is distinct and specific to vCJD.
3.3.4 Intermediates
A number of cases did not fit conveniently into the classification system
adopted. A limited number of cases had nonglycosylated PrPres with a mobility
intermediate (INT) between type 1 and type 2. This was clearly seen in two cases of
sCJD during the initial characterisation exercise, both of which were methionine
homozygotes (RU#96/060 and RU#96/128) (figure 8). These two cases were 68 and
82 years old at onset of symptoms and their disease duration was 9 and 3 months
respectively. These values are more akin to the sCJD MM 1 subgroup than the MM
2A subgroup. Repeated sampling gave a consistent mobility. Subsequently, one
other case of sCJD (valine homozygote), three cases of iCJD GHT (two VV
RU#92/019, RU#95/055 and one MV RU#97/013) and one GSS case (RU#94/007),
failed to conform to the above classification system and displayed an intermediate
mobility.
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1 Int 2A Int 1
Figure 8. Intermediate mobility type in sCJD MM patients. Lane 1, sCJD MM type
1. lane 2, sCJD MM type INT, lane 3, sCJD VV type 2A, lane 4, sCJD MM type INT,
lane 5, sCJD MM type 1.
The biochemical basis of this intermediate type mobility may represent type 1
PrPrcs isolated in a metal-depleted form. This could represent the in vivo state of the
PrPres, isolated, as metal ion chelators are omitted from our extraction procedure or
could be an experimental anomaly due to the removal of metal ions prior to PK
cleavage (for results see chapter 6).


















































































































Total 97 7 58 51 213
Table 8. Isotype/genotype classes in sCJD, vCJD, iCJD and fCJD.
• includes 1 case in which type 2 PrP"^ was subsequently detected, ■ includes 2 cases
in which type 1 PrP1^ was also detected. * includes 3 cases in which type 1 PrPres
was subsequently detected. A includes one case displaying predominantly type 2
PrPres with some type 1. Values in brackets represent percentages of each codon 129
genotype in each isotype subgrouping.
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3.4 Sporadic CJD
Sporadic CJD was found to be heterogeneous in terms of isotype and
genotype. All six possible isotype / genotype combinations (MM 1, MM 2A, MV 1,
MV 2A, VV 1, VV 2A) were represented but there was a clear difference in the
number of cases in each subgroup (table 9). Overall type 1 (63.9%) was more
frequently observed than type 2 (36.1%) and within the type 1 group, methionine
homozygotes were most abundant (81%). Within the type 2 group the genotypes
were more evenly represented but with a slight preponderance of valine carriers
(72.3%). The over representation of MM individuals with sCJD (61.8%) in
comparison to the general population -40% (Palmer et al, 1991, Alperovitch et al,
1999) extends to isotyping. The distribution of codon 129 genotypes in isotyped
cases (61.8% MM: 19.9% MV: 18.3%VV) reflects that seen for sCJD cases analysed
at the CJD unit since 1990 (69% MM: 15% MV: 17% VV) (National UK CJD
Surveillance Unit, 10th annual report, 2001). The greater numbers of type 1
individuals may be due to type 1 PrP1^ being formed by MM patients or alternatively
type 1 PrPres may afflict MM individuals to a greater degree. Whether the codon 129
is a susceptibility or determining host factor is therefore not apparent based merely on














1 68 44/56 65.3 (42-86) 4.7 (1-21)
2A 13 54/46 54 (37-72) 19.1 (8-38)
MV
1 12 55/45 60.3 (15-79) 12.2(2-54)
2A 15 36/64 64.5 (50-78) 18.3 (3-52)
VV
1 4 50/50 46.5 (25-78) 16.5 (8-29)
2A 20 45/55 62.7 (46-79) 5.5 (2-11)
MM 2B 50 56/44 27 (12-53) 15.3 (7-39)
Table 9. Sporadic and Variant CJD subgroups. Gender, age at onset and duration.
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The sCJD MM 1 subgroup constitutes the majority of sporadic cases (51.1%)
with a mean age at onset of 65.3 years (range 42-86) and a mean disease duration of
4.7 months (range 1-21). This subgroup contains two cases with deletions of 24 bps,
found in a small proportion of the population (Bosque et al, 1992) not shown to cause
familial TSE and classified as sCJD. The sCJD MM 2A subgroup (9.8% of total
cases) constitutes cases with a mean age at onset of 54 years (range 37-72) and mean
disease duration of 19.1 months (range 8-38). The age at onset (p < 0.000, unpaired
two tailed t test) and disease duration (p < 0.000, unpaired two tailed t test) is
significantly different for these two subgroups. Sporadic CJD MM cases, as a whole,
have a mean age at onset of 63.6 years and a disease duration of 6.9 months. The
MM 2A subgroup has a younger age at onset and significantly longer duration than
the MM 1 subgroup. These features, along with the same codon 129 genotype, are in
common with some vCJD cases especially considering the occurrence of vCJD in
older individuals. The separation of the MM 1 and MM 2A two codon 129 sCJD
subgroups would not be possible without Western blotting analysis and suggests that
there is a correlation between clinical features and PrP'es conformation.
Chronological analysis of MM 2A cases shows the identification of only one case
prior to 1996, in 1991. There are similarities between MM 2A cases and vCJD
particularly in terms of the duration, though to some extent also the younger age at
onset. However, this does not suggest that these cases classified as sCJD are a result
of BSE exposure and their identification is most likely the result of improved
ascertainment. This highlights the usefulness of the glycoform pattern in
distinguishing the two aetiological groups. Importantly, these cases are still clinically
and neuropathologically distinct from vCJD.
The sCJD MV 1 subgroup (9% of total cases) constitutes a minority of
sporadic cases with a mean age at onset of 60.3 years (range 15-79) and a mean
disease duration of 12.2 months (range 2-54). As seen with the MM 2A subgroup,
chronological analysis only shows two cases prior to 1997, in 1991 and 1992, once
again long disease duration may be a factor in this or the relative rarity of cases falling
within this subgroup. The sCJD MV 2A subgroup (10.5% of total cases) constitutes
cases with a mean age at onset of 64.5 years (range 50-78) and a mean disease
duration of 18.3 months (range 3-52). The disease duration is not significantly
different between the two MV subgroups (p = 0.316, unpaired two tailed t test). Most
noticeable is the gender difference within this subgroup (36% male: 64% female).
Interestingly the disease duration in the heterozygotes patients is not notably
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prolonged in comparison to MM 2A or VV 1 patients and in the MV 1 group aside
from one case with a very long 54 month duration (RU#97/292) is actually more in
keeping with the MM 1 subgroup (4.25 months, excluding RU#97/292). The wide
range of age and duration along with intermediate mean values, implies that
individual cases may be atypical, but as a group heterozygosity tempers the extremes
of codon 129 influence. This subgroup includes a case carrying a deletion suspected
to be 24 bps in the octapeptide repeat region that will be discussed in more detail in
the next chapter.
Cases making up the sCJD VV 1 subgroup (3% of total cases) are the rarest
and have a young mean age at onset of 46.5 years (range 25-78) and prolonged mean
disease duration of 16.5 months (range 8-29). The sCJD VV 2A subgroup is the
second most prevalent subgroup (15% of total cases) constituting cases with a mean
age at onset of 62.7 years (range 46-79) and a mean disease duration of 5.5 months
(range 2-11). The age at onset (p = 0.027, unpaired two tailed t test) and disease
duration is significantly different between these two subgroups (p < 0.0001, unpaired
two tailed t test). A detailed analysis of 12 cases falling within the VV subgroup is
detailed in Kovacs et al, 2000 (see appendix). Referred to as CJD1, CJD2 to CJD12,
five of these cases (CJD2 RU#96/011, CJD4 RU#92/046, CJD7 RU#93/014, CJD10
RU#94/083, and CJD12 RU#94/136) isotyped from frozen frontal cortex material are
from the VV 2A subgroup and their clinical and neuropathological features suggest all
12 cases would have type 2 PrP'es. The average age at death of 63.6 years (range 49-
80) and duration of illness, 6 months (range 4-17) are in line with the VV 2A
subgroup. The patients presented with unsteady gait and half suffered memory loss,
they all became demented and exhibited myoclonus, before akinetic mutism and
death. No CSF findings or EEG triphasic complexes indicated CJD.
Neuropathological findings were obtained (with kind permission) from Kovacs et al,
(Kovacs et al, 2000). The histopathology of these cases represents an in depth
examination of VV sCJD cases and provides a good description of the VV 2A
subgroup. Spongiosis is common as are PrP plaque-like structures in cortical, basal
ganglia, parahippocampal gyrus, thalamus, hypothalamus and cerebellum, sometimes
also present in the subcortical white matter and hippocampus and diffuse/synaptic PrP
staining.
With all these cases the availability of frozen tissue implies further
investigation was warranted and this may be due to either doubt over the diagnosis of
possible CJD or similarity to vCJD. For this reason the age and duration data may be
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more similar to vCJD than for sCJD subgroups as designated by codon 129 data
alone. Differences in gender are marginally over represented by females in the larger
sCJD cohorts (MM 1, MV 2A and VV 2A) (table 9).
3.5 Variant CJD
All cases (n=50) with a final diagnosis of vCJD appeared relatively
homogeneous and quite distinct from sCJD. All cases showed a type 2B isotype and
occurred in methionine homozygotes. In addition, the cases all had a prominent
diglycosylated PrPres band in stark contrast to all the sCJD cases that displayed
predominant monoglycosylated or more rarely nonglycosylated PrPrcs. This confirms
earlier observations (Collinge et al, 1996, Hill et al, 1997a, Ironside et al, 2000,
Parchi et al, 2000b, Head, 2001) and reaffirms this discriminating feature as a means
of distinguishing between sporadic and variant CJD. Western blotting is thus a
reliable ancillary diagnostic test for vCJD.
The vCJD cases continued to display a consistent isotype throughout the
study, distinct from any sporadic cases, despite a changing range in age at onset since
the first reported cohort in 1996, with a mean age at onset of 26.8 years and range
(Will et al, 1996). Recent figures show a mean age at onset of 26 years but a range of
12 to 74 years and a mean disease duration of 13 months (range 6-39) (National UK
CJD Surveillance Unit, 10th annual report, 2001). The total number of definite and
probable vCJD cases in the UK up to 31st of January 2002 was 114, 53% male and
47% female (National UK CJD Surveillance Unit, 10th annual report, 2001). The
cases investigated by Western blotting were representative of the cases as a whole
with 56% male and 44% female, mean age at onset of 27 years (range 12-53) and
mean disease duration of 15.5 months (range 7-39). This study is the largest analysis
of vCJD cases, spanning 5 years and enables the establishment of a good baseline
from which changes in the molecular phenotype can be identified. If this coincides
with any other epidemiological, clinical or phenotypic changes in vCJD presentation
an increased understanding of linkage to pathogenesis may be established.
3.6 Iatrogenic CJD
Between 1970 and the end of 2001, 45 cases of CJD in the UK have been
related to surgical procedures or therapeutic treatments. Six cases were in individuals
who received dura mater (DM) grafts, 38 received human-derived growth hormone
and one received human gonadotrophin (National UK CJD Surveillance Unit, 10th
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annual report, 2001). The 18 iCJD cases described here are the largest single cohort
of cases so far reported. They are primarily divided into two major aetiological
subgroups, those caused by dura mater transplants (n=2) and those treated with
pituitary derived growth hormone/gonadotrophin (GHT) (n=16), prior to codon 129
classification. The iCJD GHT cases as a whole had a mean age at death of 29.5 years
(range 20-45) while the dura mater cases were on average 43 years old at death (27
and 59) (National UK CJD Surveillance Unit, 10th annual report, 2001). The two DM
cases with available frozen tissue were both MM type 1 (figure 9), but the age and
disease duration figures were very different; 44 years old with a duration of 5 months
and 24 years old with a duration 33 months. The GHT cases analysed were in
individuals with MV or VV genotypes, 8 of each i.e. 50:50. The mean age at onset
for the GHT cases analysed was 30.7 years (range 37-23) and mean disease duration
is 11 months (range 5-18). The homozygous cases have a younger mean age at onset
(28.8 years) and shorter disease duration (6.5 months) than heterozygotes, 31.9 years
and 13.9 months respectively. The distribution of isotypes within the subgroups
reflected that seen in sCJD with the presence of a valine allele; 56% (9/16)
predisposing to generation of type 2A PrPies. Equal numbers were diagnosed as type
1 or intermediate 18.8% (3/16) and at least one case had an anomalous finding (co¬
existence of types 1+2). As with sCJD, all mobilities were represented (1, 2A and
INT) (table 8). In one case PrPres was hard to detect, only spinal cord tissue was
available in this case and appeared to have an intermediate mobility. The presence of
PrP'cs has been confirmed by immunocytochemistry in this case and reported in other
peripheral iCJD infections (Goodbrand et al, 1995, Sutherland et al, 1996).
W2AGHT W2AGHT MM 1 DM MM 1 DM MV 2A GHT
Figure 9. Iatrogenic CJD cases displaying the aetiological and isotype differences.
Lane 1, GHT VV type 2A case, lane 2 GHT VV type 2A case with low PrPres levels,
lane 3, DM MM type 1, lane 4, DM MM type 1, lane 5, GHT MV type 2A.
Similar proportions of isotypes among the iCJD and sCJD codon 129 groups
were obtained despite the route of infection being an additional factor in the
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pathogenesis. This implies that the codon 129 polymorphism does not influence
peripheral conversion or transport to the CNS. The small sample size makes it
difficult to draw conclusions from the results of this study alone. Type 1 MM cases
were restricted to DM infection, while GHT cases showed a preponderance of type 2
mobility and were either MV or VV.
3.7 Familial CJD, GSS, FFI
Familial CJD, GSS and FFI cases arise as a result of a number of different
PRNP sequence mutations. They do not reflect any route of exposure or interactions
between host and infecting strains, however their phenotypic characteristics are still of
interest and a range of isotypes were identified.
fCJD FFI
1 E200K 2A Basal Ganglia 1 P102L
FC 5 fold loading Thalamus
Figure 10. Comparison of sCJD standards and the three phenotypic familial prion
diseases. The standards are from frontal cortex material and the tissues of the familial
cases are indicated. Lane 1, sCJD MM type 1, lane 2, fCJD MM E200K type IB, lane
3, sCJD VV type 2A, lane 4, FFI MM D178N, lane 5, sCJD MM type 1, lane 6, GSS
MM P102L.
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Figure 11. Comparison of isotype and glycoform differences between sCJD MM
type 1 and vCJD MM 2B standards and fCJD MM patients. Lane 1, sCJD MM type
1, lane 2, fCJD MM E200K type IB, lane 3, vCJD MM type 2B, lane 4, fCJD MM
insert type 1.
fCJD «CJD sCJD SCJD
insert MM 24 bP deletion MM mm 1 W 2A
Figure 12. Comparison of familial CJD case carrying an insert with a case featuring
an uncommon polymorphism classified as sCJD and sporadic CJD standards. Lane 1,
fCJD 4 octapeptide repeat insert MM, lane 2, sCJD MM 24 bp deletion, lane 3, sCJD
MM type 1, lane 4, sCJD VV type 2A.
Familial CJD, FFI and GSS cases were available (n = 6, 1 and 3 respectively).
The fCJD cases included 3 cases carrying the E200K mutation (Lee et al, 1999), 2
with inserts (an undefined insert in one, figure 11, and 4 octapeptide repeats in the
other, figure 12) and one with a rare VI801 mutation (Nixon et al, 2000) (discussed
further in chapter 7). The FFI case had a confirmed D178N mutation coupled with
methionine homozygosity and age at onset of 67 years. The GSS cases were of the
classical P102L variant, one was heterozygotic at codon 129 and displayed a different
isotype (INT) to the two MM cases. The heterozygote patient was unrelated to the
homozygous patients, one of whoms PrPres is shown in figure 10 (Adam et al, 1982,
Baker et al, 1985). Presence of a valine can lead to a greatly different clinical
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presentation (Young et al, 1997). The isotype patterns were diverse and in many
cases quite unlike sCJD and somewhat more similar to vCJD. Cases with a 1B pattern
have been detected but are restricted to fCJD cases (figure 10). The IB classification
was adopted from Cardone et al, 1999, in line with our adoption of the B suffix
denoting glycosylation status. This isotype was present in the cases carrying the
E200K mutation (table 10). Figures 10 and 11 both show case RU#94/097. All the
cases carrying deletion or insertion mutations were type 1 mobility without prominent
diglycosylation. Not all CJD cases carrying deletions are classified as familial (figure
11 shows a CJD case with a 24 bp deletion RU#97/232, classified as sporadic). The
ability to molecularly distinguish the deletion or insertion mutations was not seen
after PK treatment, due to the removal of the NH3-terminus. Analysis of samples
without PK treatment may display a broader mobility due to the decrease or increase
in molecular weight of the mutant PrP in conjunction with the presence of the wt PrP.
The influence of the NH3-terminus on the PK cleavage site will be discussed in
chapter 6, and the ability of PrP mutated at the octapeptide repeats to bind metal ions
may influence the PK cleavage, though the consistency of the mobility does not
suggest that it plays any part in familial disease.









Familial Inserts 2 0 0 0 2
CJD
MM
E200K 2 0 0 0 2
VI801 1 0 0 0 1














FFI MM D178N 0 0 0 1 1
Total 0 0 0 1 1
GSS MM P102L 2 0 0 0 2
MV P102L 0 1 0 0 1
Total 2 I 0 0 3
Total 8 1 0 1 10
Table 10. PrP165 isotyping patterns of patients carrying PRNP mutations.
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Summary
• Cases diagnosed with aetiologies other than TSEs did not display PK resistant
PrP.
• The majority of cases displayed nonglycosylated PrPres bands with molecular
weights of either 21 or 19 kDa and were termed type 1 and type 2 respectively.
• Two banding patterns were observed, either predominantly monoglycosylated or
predominantly diglycosylated.
• A small number of cases displayed a nonglycosylated PrPres band intermediate
between types 1 and 2. Neither aetiology, codon 129 or phenotypic features
distinguished these cases.
• Type 1 MM sCJD cases were the most prevalent.
• Type 2 sCJD cases were more frequently observed in conjunction with a valine
allele at codon 129.
• All vCJD cases displayed a 2B isotype.
• DM iCJD cases were type 1 but the majority ofGHT iCJD cases were type 2.
• Some familial cases displayed a IB isotype and the FFI case displayed an isotype
similar to vCJD.
The findings indicate that two major PrP'es conformations are formed that
differ in their susceptibility to PK cleavage. Both these conformations are found in all
of the TSE aetiologies. Therefore, the conformation of the PrPies does not define the
cause of the disease. The glycoforms were either of the type A or B, with the type A
occurring in sCJD and iCJD, and the type B occurring in vCJD and familial prion
disease. The accumulation of greater levels of diglycosylated PrPres is distinctive of
vCJD so long as the PRNP sequence is taken into account. Conversely, the type A
pattern can occur in familial prion diseases and therefore does not correlate with the
aetiology.
Among the sCJD cases the type 1 conformation was the most common,
however, when the cases were ordered according to the codon 129 genotype it was
seen that the type 2 conformation is more common among cases carrying a valine
allele. The conformation was not restricted between codon 129 subgroups but implies
that there is a relationship between the two factors. The phenotypic features of sCJD
did not correlate with the PrPres pattern, however, MM 1 and VV 2 cases displayed
shorter disease durations and VV 1 cases had a younger age at onset. The restriction
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ofDM iCJD cases to type 1 is most likely due to the prevalence ofMM individuals in
the population. Likewise the prevalence of type 2 in the GHT cases probably arises
due to the prevalence of the valine allele, that is more commonly associated with type
2 in sCJD. Therefore, the PrPres may be a contributing factor in disease presentation
that is modulated by the codon 129 polymorphism.
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CHAPTER 4: PrPres glycoform analysis.
The foregoing classification of CJD cases was made on the basis of analysis of
PrPres found in the cortex, usually frontal cortex. Repeated sampling from the same
cortical region typically gave a consistent isotype. The only feature of PrPres that
allows vCJD to be distinguished from other forms of human TSE is the prominent
diglycosylation. This feature is termed type 2B as discussed in the previous chapter,
however the classification is by eye and requires quantitative testing. To establish the
quantitative difference between vCJD and sCJD the percentage representation of the
three glycoforms were measured. Densitometric analysis of the signal detected from
the three glycoforms was repeated in an identical manner for all experiments (see
appendix A5). Can more accurate quantitation of the PrPres glycoforms identify subtle
differences between the sCJD subgroups and is there any overlap with vCJD cases?
4.1 Quantitation
As in previous studies the 'linear range' (the range over which X-ray film has
a linear response, generally taken as 1 log), of the samples was determined, within
which densitometric readings of the three glycoforms represent their in vivo levels.
The linear range was established by dilution curves of standard samples to determine
the lower and upper levels of density within which the glycoforms were quantitatively
relative to each other (see appendix). There are a few caveats to take into
consideration when interpreting the values obtained in relation to in vivo levels of
PrPres.
Not all samples analysed were within a 1 log scale of relative levels i.e. if the
diglycosylated levels comprised 80% of the total PrPres density yet the
nonglycosylated band comprised less than 8%. In such a situation the X-ray film
results would become saturated with the diglycosylated band before the luminescent
output of the nonglycosylated band reached a quantitative level. This limit of the
experimental technique affected very few human samples, however it presupposes
that all cases produce all three glycofonns of PrPres with levels no greater than 10
times either of the other bands. The use of the STORM™ 860 phosphoimager to
analyse chemiluminescent output of samples was able to increase the linearity limits
to 2 logs (see appendix). This approach was available later in the study and was
primarily used for murine transmission samples. Due to the restrictions in
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interpreting three way ratios on a linear scale, equal levels of all three bands are easily
misinterpreted as reaching saturation, as all three bands tend towards 33% at complete
saturation. Theoretically this artificially excludes a proportion of cases, however, in
very few cases were equal levels seen by eye and these appeared to represent high
PrPres levels. The analysis of all human cases involved the use of 3F4. Non-human
tissues were analysed with 6H4 and the possibility that glycosylated PK resistant
PrPII is measured cannot be discounted. The main aim is to establish a quantitative
molecular differentiation assay for sporadic and variant CJD involving one standard
antibody for ease of interpretation.
The consistency of the technique was assessed upon repeated runs of the same
standard samples used to type the cases and between different samplings of those
cases. Multiple experimental analyses were conducted in the majority of cases
(detailed in the appendix). Statistical analysis was carried out on the standard cases to
detennine the degree of variability in glycoform ratio using the approach detailed in
the appendix. Standard deviations were calculated for multiple linear exposures in
each experiment and between each experiment for each case to identify any variability
within individual cases.
Cases within each subgroup, cases between subgroups and sCJD and vCJD
cases as a whole were compared. The glycoform ratios were established from frontal
cortex material where possible. In some cases this was merely stated as being cortical
on the autopsy report or unavailable, in which case other cortical regions were used.
Rarely other CNS material was used, sometimes only certain regions contained
significant quantities in non-cortical regions; such as FFI in which the use of thalamic
tissue was required. The analysis of glycoform ratios in numerous brain regions will
be covered in the following chapter.
4.2 Sporadic CJD
Glycoform ratios were obtained in the majority of sCJD cases (n=124) and
further analysed. The glycoform ratios of sCJD cases of all genotype / isotype
combinations are most easily displayed as histograms to express the relative levels of
each band. Figure 14 displays the mean ratios for each sCJD subgroup with error bars
representing standard errors of the mean (SE) between cases within the subgroup.
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Figure 13. Composite image showing examples of the range of banding patterns
observed. Lanes 1 and 2, 3 and 4, and 5 to 7 are from separate Western blots. All the
images are from 12% gels detected with 3F4. Lane 1, sCJD MM 1, lane 2, sCJD VV
2A, lanes 3 and 4, sCJD MV 2A, lane 5, vCJD MM 2B, lane 6, sCJD VV 1, lane 7,
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Figure 14. Histogram of sCJD and vCJD subgroup glycoform ratios. Error bars
represent SEs.
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The sCJD MM 1 subgroup is the most prevalent form of sCJD and displays a
strikingly consistent glycoform ratio with prominently monoglycosylated PrPres and a
greater level of nonglycosylated PrPres than diglycosylated (diglycosylated 21.9% ±
0.6: monoglycosylated 47.9% ± 0.6: nonglycosylated 29.3 % ± 0.6).
The sCJD MM 2A subgroup was the first to be closely investigated because
the duration of the clinical signs, codon 129 polymorphism and PrPres mobility could
be taken to resemble vCJD. The small number of cases also allowed data to be
gathered quickly. As with the MM 1 group a prominence of monoglycosylated PrPres
was detected, though the levels of nonglycosylated and diglycosylated PrPres were
similar. The prominence of monoglycosylated PrPres is a consistent feature in sCJD
(figure 14) and the ratios were therefore most easily distinguishable in terms of the
relative levels of diglycosylated to nonglycosylated PrPres (diglycosylated 24.1% ±
1.8: monoglycosylated 43.9% ± 1.7: nonglycosylated 29.9% ± 1.9).
A slight range of di to nonglycosylated ratios was observed from the MM 2A
subgroup to the VV 1/MV 2A groups, with the monoglycosylated band always being
the most abundant (figure 14); VV 1 cases (diglycosylated 20.4% ± 2.5:
monoglycosylated 46.3% ± 1.4: nonglycosylated 32.4% ± 1.4), MV 1 cases
(diglycosylated 22.9% ±1.3: monoglycosylated 46.7% ±1.3: nonglycosylated 30.1%
± 2.3) and MV 2A cases (diglycosylated 21.4% ± 1.9: monoglycosylated 42.8% ± 0.7:
nonglycosylated 35.1% ± 2.2). There was no significant difference in glycoform
ratios between these subgroups as assessed with unpaired two tailed t tests. Cases
displaying the diametrical pattern of pronounced nonglycosylated PrPIL!> are less
common but predominate in sCJD MV (both type 1 and 2) and sCJD VV type 1. The
appearance of these banding patterns was noticeable in some cases as can be seen in
figure 13. Cases with predominantly nonglycosylated PrP have previously been
identified and termed type 6 (Hill, 1998). Though lane 3 of figure 13 appears to be a
type 6 case, densitometry measurements within the linear range did not show greater
levels of the nonglycosylated than the monoglycosylated band (figure 14). It was thus
decided that this appearance is not a true representation of the proportions of the three
bands present. As the type 6 classification does not denote an additional mobility
type and the suffix A already indicates a majority of monoglycosylated PrPres, this
term was not adopted.
Only the VV 2A group has a significantly different glycosylation pattern,
characterised by a greater proportion of the diglycosylated PrPres band than the
nonglycosylated PrPres band (diglycosylated 31.3% ± 0.9: monoglycosylated 45.5% ±
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0.9: nonglycosylated 22.3% ± 1.3). The proportion of the diglycosylated PrPres band
was not more than that of the monoglycosylated PrPres band, or enough to be
indistinguishable from the vCJD glycoform ratio. The limits of the analysis, as
mentioned previously, did not pose a significant problem in assessing any of the sCJD
subgroups as they all displayed all three glycoforms in sufficiently relative levels.
The quantitative results may also be expressed in the form of a scattergraph,
allowing individual cases to be compared between subgroups and clustering of cases
investigated (figure 15). The X:Y bisecting line represents the nonglycosylated axis,
with cases containing higher levels of nonglycosylated PrPres being found closer to the
origin. As can be seen the sCJD subgroups cluster in the same general area.
The VV 2A subgroup stands out clearly due to higher levels of diglycosylated
PrPres (unpaired two tailed t test found a significant difference between the di and
nonglycosylated bands of the MM 1 and VV 2A subgroups, p < 0.000, the
monoglycosylated p = 0.083). The MV cases are more dispersed, which reflects the
range of ages at onset and duration durations seen in these cases. The MV 2A
subgroup is spread out predominantly in the direction of the origin. The level of
monoglycosylated PrPres found in these cases appears to remain fairly consistent.
However, the relative diglycosylated levels vary, most likely due to higher levels of
nonglycosylated PrPres in some cases. This may be due to differences in levels of
glycosylated PrPres present or may be an experimental artifact. Identification of PrPres
species isolated is dependent on the antibodies employed and nonglycosylated PrPres
lacking the 3F4 epitope (PrPII) would not be identified. Some of the cases appear to
be on the X:Y axis, primarily in the VV 2A subgroup, this may be explicable due to















































































































Figure 15. Scattergraphs of the mean glycoform ratios in sCJD cases according to
codon 129/isotype subgroups. The standard deviation range of individuals within a group
is stated in brackets, for the diglycosylated (di) and monoglycosylated (mono) bands.
A. MM 1 (di 0-6.8. mono 0-7.5) B. MM 2A (di 0-5.7, mono 0-10.6)
C. MV 1 (di 0-7.6, mono 0-3.9). D. MV 2A (di 0-3.4, mono 0-5.5). E. VV 1 (di 1.3-6.5,
mono 3.8-6.5. F. VV 2A (di 0-5.7, mono 0-10.3).
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The two sCJD cases displaying intermediate mobility were also quantitatively
analysed and did not have glycoform ratios (diglycosylated 21.1% ± 0.2:
monoglycosylated 46.8% ± 0.2: nonglycosylated 31.3% SD 0.02) that significantly
distinguished them from type 1 (diglycosylated 22.4% ± 0.5: monoglycosylated
47.3% ± 0.5: nonglycosylated 29.5% ± 0.6) or type 2 (diglycosylated 26.3% ±1.1:
monoglycosylated 44.4% ± 0.6: nonglycosylated 28.1% ± 1.3) sCJD cases. The
glycoform ratios of type 1 and type 2 were not significantly different and neither was
the difference seen between the glycoform ratio ofMM (diglycosylated 22.7% ± 0.6:
monoglycosylated 46.9% ± 0.6: nonglycosylated 29.3% ± 0.6) and MV
(diglycosylated 21.6% ± 0.6: monoglycosylated 44.9% ± 0.8: nonglycosylated 33.1%
± 1.6) cases. The di and nonglycosylated bands ofVV patients (diglycosylated 29.3%
+ 1.2: monoglycosylated 45.6% ± 0.8: nonglycosylated 24.1% ± 1.4) differed
significantly from both MM and MV cases as a whole (p < 0.000).
One case (RU#97/257) diagnosed as sCJD and classified as MV 1 displayed a
shift in the 452 bp DNA band after restriction enzyme digest, indicating a 'silent'
(non-pathogenic) deletion (figure 17). However, there was no permission for research
purposes to carry out full sequencing of the ORF to characterise the deletion in detail.
This case stood out from the other cases in the MV 1 subgroup and displayed a greater
degree of diglycosylation (figure 16), akin to that seen in sCJD VV 2A cases (figure
18). The atypical glycoform ratio (diglycosylated 32.3%: monoglycosylated 56.8%:
nonglycosylated 10.6%) and long disease duration (14 months) implies that the
deletion affects the phenotypic presentation. The presence of the deletion on the M
allele (shown by the shift in the middle band) precludes the possibility that this is the
result of intra-allelic interaction between the deletion and the valine present at codon
129. The two sCJD MM type 1 cases with 24 bp deletions of the octapeptide repeat
region did not display glycoform ratios that set them apart from the sCJD MM 1
group as a whole (diglycosylated 25.3%: monoglycosylated 45.8%: nonglycosylated
28.6% and diglycosylated 22.6%: monoglycosylated 45.7%: nonglycosylated 31.9%).
However, disease duration data was available for one of these cases (13 months) and
is in stark contrast to the typically short duration observed in the MM 1 subgroup.
Rare polymorphic deletions in the tandem repeat region of PRNP are carried in ~1%
of the population (Bosque et al, 1992, Windl et al, 1996) and do not appear to affect
the conformation due to metal ion binding as type 1 cases invariably have bound







Figure 16. Western blot of sCJD case with rare polymorphism analysed with 3F4.
Lane 1, sCJD MM 1, lane 2, sCJD MV 1 with a 24 bp deletion, lane 3, sCJD MV 2A.
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Figure 17. Agarose gel electrophoresis of PRNP after RFLP digest with Nsp 1. Lane























Figure 18. Scattergraph sCJD MV 1 cases vs MV 1 silent deletion.
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4.3 Variant CJD
Variant CJD appeared homogeneous by visual inspection, quantitative
analysis confirmed the discreet nature of this group from sCJD. Since the extent of
glycosylation alone distinguishes PrP168 in vCJD from the MM type 2 class of sCJD,
the glycosylation ratios of the first 12 vCJD cases were compared with those of the 12
MM type 2A sCJD cases (figure 19). The sCJD MM 2A subgroup acts as the
differential genotypic/molecular diagnosis, thus the degree of quantitative separation
between the two groups is important to establish. The glycoform ratios of all three
bands were significantly different between the sCJD MM 2A cases and the first 12
vCJD cases (p < 0.000, unpaired two tailed t test). The analysis confirmed the



















Figure 19. Histogram of mean glycoform ratios of 12 sCJD MM 2A cases and the
first 12 vCJD cases with available frozen tissue. Error bars represent SEs.
In total 50 vCJD cases were analysed. This only represents half of the cases
reported during the study and is due to ethical and consent considerations as well as
frozen tissue availability. Glycoform ratios were obtained in 47 cases (diglycosylated
47.3% ± 0.7: monoglycosylated 35% ± 0.4: nonglycosylated 17.1% ± 0.5). There was
a significant glycoform ratio difference between vCJD and all the sCJD cases in all
three bands (p < 0.000, unpaired two tailed t test). The type 2 VV sCJD subgroup,
represents the most similar glycoform pattern to vCJD. However, these cases are
quite distinct from that of vCJD (unpaired two tailed t test found a significant
difference between all three bands p < 0.000 for the di and monoglycosylated band
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and p < 0.001 for the nonglycosylated band). When plotted on a scattergraph with the
sCJD cases (figure 20), distinct clustering is observed without any overlap. The X:Y
axis (X=Y line) separates the two aetiological groups and represents the difference
between the 2B and 2A isotypes.
20 40 60
Diglycosylated (%)
□ MM 1 ■ MM 2A
A MV 1 A MV 2A
O VV 1 • VV 2A
O INT O vCJD
Figure 20. Scattergraph of mean glycoform ratios of sCJD and vCJD cases. Yellow
squares represent sCJD MM 1, red squares represent sCJD MM 2A, yellow circles
represent sCJD MV 1, red circles represent sCJD MV 2A, yellow triangles represent
sCJD VV 1, red triangles represent sCJD VV 2A, yellow diamonds represent sCJD
MM INT and blue circles represent vCJD.
4.4 Iatrogenic CJD
Comparison of DM cases and GHT cases showed a strict codon 129 segregation
as discussed in the previous chapter, however in terms of glycoform ratio the two DM
cases (figure 2IB, white triangle and white diamond) are indistinct from any other
iCJD case. Comparison of MV (circles) and VV (squares) GHT cases in figure 21,
does not clearly divide the two groups though a slight preponderance of the
nonglycosylated portion may be in evidence in the MV cases. Cases displaying the
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diametrical pattern of pronounced nonglycosylated PrPres were less common in sCJD,
but predominate in iCJD MV cases (figure 2IB). The bands were often harder to
resolve and could thus constitute greater levels of PrPies or possibly cases with
multiple isotypes or ragged NH3-terminals. The nature of this appearance thus needs
greater biochemical investigation. As mentioned earlier this pattern was termed type
6 by Hill, 1998, however, a quantitative approach may be more enlightening.
Comparison of the MV type 1 cases (green and yellow filled in circles) with type 2
MV or VV GHT cases also shows evidence of increased nonglycosylation in the two
MV 1 cases. This may represent a similar effect of the VV genotype seen in sCJD
that increases the level of diglycosylated PrPres. A wide range of glycoform ratios
were observed but none with a type 2B pattern. There was no statistically significant
difference in glycoform ratio of PrPres in DM or GHT derived infections. No apparent
correlation of the route of entry or codon 129 genotype with glycoform ratio was
seen.
4.5 Familial CJD, GSS and FFI
The glycoform ratios of the fCJD cases were predominantly classified as
highly diglycosylated (B). However, not all cases were the same and as is well
known with fCJD E200K, fCJD D178N and FFI it can be the mutation or the codon
129 that determines the molecular phenotype both in terms of glycoform ratio and
isotype. The glycoform ratios should thus be considered in respect to the mutation
and codon 129 status. The range of glycofonn ratios can be seen in figure 21C.
Some cases displayed very low levels of PrPres and others had a low proportion of
nonglycosylated PrPres making linear range readings difficult. In such cases single
readings or nearly linear readings were taken with estimates in some cases of the
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Figure 21 A. Scattergraphs of the mean glycoform ratios in vCJD, iCJD and familial
prion diseases. The standard deviation range of individuals within a group is stated in
brackets, for the diglycosylated (di) and monoglycosylated (mono) bands. A. Variant CJD
cases, (di 0-9.7, mono 0-8.3). B. Iatrogenic CJD cases, DM cases are represented by
white triangle and white diamond, GHT MV cases are represented by circles and GHT VV
cases by squares, (di 0-10, mono 0-13.7). C. Familial prion disease. Familial CJD cases
are represented by circles (VI801 represented by the black circle), GSS cases are
represented by triangles and the FFI case by the white diamond, (di 0-9.2, mono 0-6.4).
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Summary
• All sCJD cases had a predominantly monoglycosylated glycoform ratio. In all but
the VV 2A subgroup, the unglycosylated band was found in greater levels than the
diglycosylated ban.
• Aside from sCJD VV 2A cases and a few MV 1 cases, sCJD subgroups could not
be distinguished by their glycoform ratio.
• None of the sCJD glycoform ratios overlapped with vCJD.
• A sCJD MV 1 case carrying an octapeptide repeat deletion had a different
glycoform ratio to the other sCJD MV 1 cases.
• Iatrogenic CJD cases did not have significantly different glycoform ratios from
sCJD cases. The route of entry or codon 129 did not influence the glycoform
ratio.
• Familial CJD cases displayed glycoform ratios in the range of vCJD, however,
these two groups are distinguished by their isotype or PRNP genotype.
The quantitation of PrPres glycoforms clearly distinguished the sCJD and vCJD
cases. The glycoform ratios in sCJD established a greater level of monoglycosylated
than diglycosylated PrPres in all but the VV 2A subgroup. The sCJD subgroups could
not be distinguished by their glycoform ratios. This limits the use of the glycoform
ratio as a diagnostic marker to differentiating sCJD and vCJD. However, even then
care needs to be taken in measuring glycofonn ratios, to ensure that under exposed
sCJD VV 2A cases are not misinterpreted as vCJD. The PRNP sequence must also be
taken into account as familial cases can display a glycoform ratio similar to vCJD.
The glycoform ratio should therefore be considered alongside the isotype, codon 129
polymorphism, PRNP genotype, neuropathology and clinical features in making a
diagnosis.
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CHAPTER 5: Regional studies.
5.1 Rationale
The aim of investigating the banding patterns within and between different
tissues was to determine the reliability of basing molecular diagnosis on biopsies or a
single autopsy sample. Detection of PrPres by Western blotting has been demonstrated
to be reliable in numerous host organisms and tissues in identifying and confirming
TSE disease (Brown et al, 1994b, Moynagh et al, 1999, Oesch et al, 2000,
Wadsworth et al, 2001). The consistency of intra-CNS and inter-tissue isotypes is
essential for the results from one region to be used as representative of the patient in
toto. It is also important to enable the role of PrPres patterns in strain typing to be
established and investigate the possibility ofmultiple strains (Ridley and Baker, 1997,
Bartz et al, 2000). This study focuses on the CNS and in particular poses a number of
questions. 1. Is an isotype constant throughout the CNS in a single individual? 2. Do
isotypes correlate with their location in numerous individuals? 3. Do the brain region
isotype patterns differ from those of the corresponding subgroup? The typing was
blind to all host factors but codon 129 genotype. To identify any phenotypic features
that may correlate with isotyping and factors that would preclude extrapolation of
direct comparisons between cases a cursory comparison of gender, age at onset,
disease duration and neuropathological features were examined where pertinent.
In order to directly test the unifonnity of PrP isotype within individual cases,
17 neuroanatomical regions were sampled from six cases of sCJD (one each
previously classified as MM 1, MM 2A, VV 1, VV 2A and two MV 2A cases), five
cases of vCJD (MM2B), one iCJD case (MV 2A GHT) and two fCJD cases (E200K
MM and MV). Multiple regions were analysed in a number of other cases where
frozen tissue, but not a half hemisphere, was available. In total 276 regions were
analysed, 238 from half hemispheres, five regions (frontal, temporal, parietal and
occipital cortices as well as cerebellum) in an additional vCJD case (RU#98/148),
paired biopsy autopsy tissue from one sCJD case (RU#98/153), 8 cerebellums paired
with frontal cortex (5 sCJD, 3 vCJD), occipital cortex and parietal cortex from one
sCJD case (RU#99/025), 6 regions (frontal cortex, temporal cortex, thalamus, basal
ganglia, brain stem and cerebellum) from a case of FFI (RU#91/017), 3 regions




The isotype/genotype/aetiological subgroup classification along with the
glycoform ratios indicated a fairly consistent pattern within each subgroup. However
while conducting this study a case of suspected vCJD with onset at 42 years and a
final duration of 18 months was investigated that on cortical biopsy displayed type 1
PrPres and was genotyped as W at codon 129. This case also had a glycoform ratio
(diglycosylated 17.2% ± 3.0: monoglycosylated 47.3% ± 1.3: nonglycosylated 33.2%
± 2.5) in keeping with the VV type 1 subgroup (diglycosylated 20.4% ± 2.5:
monoglycosylated 46.3% ± 1.4: nonglycosylated 32.4% ± 1.4). Yet, when the
subsequent autopsy sample from the contra-lateral frontal cortex was analysed the
mobility was type 2 and the glycoform ratio was distinct from that of the biopsy
sample (diglycosylated 45.2% ± 2.8: monoglycosylated 43.6% ± 2.4: nonglycosylated
9.3% ± 0.6) and closely resembling that of vCJD (figures 22 and 23). There was a
significant difference between the proportions of the diglycosylated and
nonglycosylated PrPres in the biopsy and autopsy (p < 0.000, unpaired two tailed t
test) but no significant difference between the monoglycosylated bands (p = 0.324,
unpaired two tailed t test). Such differences might be attributed to regional variation
or to changes associated with disease progression.
Figure 22. Lane 1, sCJD MM 1 standard, lane 2, cortical biopsy type 1, lane 3,
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Figure 23. Histogram glycoform ratio analysis at biopsy and autopsy, n = number of
experimental runs, error bars represent SEs.
This chance finding led to re-examination of the assumption that the molecular
diagnosis based on restricted analysis of cortical material is definitive for the patient
as a whole. The case was given a final diagnosis of sCJD, following careful
assessment of clinical and neuropathological features. The significance of this
diagnosis was important due to the similarities with vCJD cases and the
epidemiology. At present, cases of vCJD occurring outside of the UK are restricted to
France (Chazot et al, 1996, Deslys et al, 1997) and Ireland and since the patient
resided in the Netherlands this would have expanded the epidemiological spread of
vCJD to an otherwise unaffected country.
Glycoform ratio analysis of this sCJD case (VV) with the only other biopsy /
autopsy paired tissues (from a case of vCJD RU#98/137) (MHW) suggested that
change associated with disease progression is not a general rule (ethical guidelines
require retrospective analysis of biopsy material once a diagnosis has already been
made). The possibility of regional variation thus required further investigation into
the fidelity of cortical isotype diagnosis.
In addition to this variability, multiple isotypes were detected in another sCJD
case MM (RU#99/068) during another investigation (Kovacs et al, 2000) (figure 24).
Type 1 was seen in the cerebellum (figure 25) in contrast to the classification of the
case as type 2. This finding suggests that reliance on cerebellar material for isotype
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diagnosis may result in misdiagnosis. Only 3 cases were diagnosed from cerebellar
material in the sCJD MM 1 subgroup, one from 1992 and two from 1999. Only one
of these cases had a long disease duration (10 months) in combination with a young
age at onset (42 years) suggesting it is more comparable to MM type 2A cases.
MM1 MM 2A MM 2A MV 2A MV 2A VV 2A
Figure 24. RU#99/068 showing two types. Sporadic CJD frontal cortex samples,
lane 1, MM 1 standard, lane 2, MM 2A, lane 3, RU#99/068 MM 2A+1, lane 4, MV
2A, lane 5, MV 2A, lane 6, VV 1.
FC FC FC CB FC CB CB
MM1 VV2A MM2A MM1 VV2A VV2A MV1
Figure 25. RU#99/068 showing type 1 in the cerebellum. Tissues are indicated
frontal cortex (FC) and cerebellum (CB). Lane 1, MM 1 standard, lane 2, VV 2A
standard, lane 3, RU#99/068 MM 2A, lane 4, Ru#99/068 MM 1, lane 5, VV 2A, lane
6, VV 2A, lane 7, MV 1.
Based on these findings a neuroanatomically wide spread investigation was
initiated with comprehensive analysis of cortical, deep grey matter and cerebellum
tissues to identify any regional variation (as detailed in the materials and methods).
5.3 Sporadic CJD
The number of cases that could feasibly be investigated in detail was limited,
therefore one case from each isotype/genotype subgroup with an available frozen
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hemisphere was chosen. At least one case from each subgroup was available aside
from the MV 1 cases (table 11), due in part to the relative rarity of this subgroup.
Among the sCJD cases PrF*"* variation was found in three cases.
Diagnosis, Age at onset Disease duration Gender
Codon 129, Isotype (years) (months) (M/F)
Sporadic CJD MM 1 86 4 F
Sporadic CJD VV 1 41 11 M
Sporadic CJD VV 2A 75 4 F
Sporadic CJD MM 2A 61 11 M
Sporadic CJD MV 2Al 62 21 F
Sporadic CJD MV 2A2 61 8 F
Iatrogenic CJD MV 2A 37 9 M
Familial CJD MM IB 57 - M
Familial CJD MV IB 61 - M
Variant CJD MM 2B3 35 15 M
Variant CJD MM 2B4 21 29 F
Variant CJD MM 2B3 30 9 M
Variant CJD MM 2B6 17 18 F
Variant CJD MM 2B7 51 11 F
Variant CJD MM 2B8 19 11 M
Table 11. Age at onset, disease duration of regional studies patients.
1
case RU#98/123, 2 case RU#96/153,3 case RU#98/154, 4 case RU#98/156,5
case RU#96/045, 6 case RU#00/025,7 case RU#99/015,8 case RU#98/148.
The sCJD MM 1 (RU#98/088) (figure 26A and B, figure 27A), VV 1
(RU#96/027) (figure 26C and D, figure 27B), and VV 2A (RU#94/083) (figure 26E
and F, figure 27C) cases were consistent throughout the brain both in terms of isotype
and glycoform ratio. Comparison of the glycoform ratios in brain regions of the sCJD
MM 1 case found no significant differences. When the regions were compared with
the sCJD MM 1 subgroup as a whole none had significant differences aside from the
level of the diglycosylated band in the amygdala (29.2% p = 0.016, One way
ANOVA) being slightly higher than in sCJD MM 1 cases. No significant difference
in glycoform ratio between the brain regions of the VV 1 case or the VV 1 subgroup
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was found. The glycoform ratios of the brain regions in the VV 2A case were only
significant (p = 0.001, one wav ANOVA, dunnett t 2 sided post hoc test) in the
diglycosylated band of the temporal cortex in comparison to the VV 2A subgroup as a
whole. The amount of the diglycosylated band was lower (21.1%) in the temporal
cortex than the VV 2A subgoup, as found in other sCJD cases. Comparison of the
brain regions as a whole found only the temporal cortex diglycosylated band to differ
from other brain regions (p = 0.033 parietal cortex, 0.035 hippocampus, 0.006 basal
ganglia, one way ANOVA, bonferroni post hoc test). This consistency was surprising
in that neither of the VV patients displayed variation similar to that seen in the Dutch
case. It may seem unlikely that PrPres of a certain conformation found at biopsy
would be converted or cleared from the brain before the death of the patient, however
a systematic analysis of regions by biopsy is uncalled for and thus precludes the
testing of such a hypothesis. The VV 1 patient (RU#96/027) investigated had an age
at onset of 41 and disease duration lasting 11 months, similar to that in the Dutch case
(42 years, 18 months). The other two cases within the VV 1 subgroup analysed solely
in the frontal cortex had age at onset and disease duration of 78 years and 8 months
respectively and 25 years and 29 months emphasising the variable features for this
subgroup. The wide range of onset and duration may be due to the small sample size,
however cases in this group may be mistaken for vCJD. The VV 2A patient
(RU#94/083) had an age at onset of 75 years and duration of 4 months. The MM 1
patient (RU#98/088) had an age at onset of 86 years and duration of 4 months similar
to other cases of the subgroup.
There were roughly equivalent levels of PrP'cs in all of the brain regions
(figure 26A and B), of the sCJD MM 1 case (RU#98/088). The glycoform ratios were
also similar in all the brain regions (figure 27A). The autopsy report (JWI or JB)
indicated spongiform change in the cerebral cortex, primarily in the frontal, temporal
and occipital lobes. The frontal cortex displayed marked astrocytosis and neuronal
loss, which was also seen to some extent in the other cortical regions. Spongiform
change, astrocytosis and neuronal loss are also seen in the basal ganglia, thalamus and
molecular layer of the cerebellum. There were no amyloid plaques present and PrP
immunostaining showed a synaptic pattern in the cerebral cortices and in some areas
perivacuolar accumulation and occasional accumulations around pyramidal neurones.
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Figure 26. Sporadic CJD PrPies in different brain regions. A; sCJD MM 1
RU#99/088 lanes 1 to 9, frontal cortex to entorhinal cortex. B; sCJD MM 1
RU#99/088 lanes 1 to 8, hippocampus to cerebellar vermis, lane 9, sCJD MM 1
standard. C; sCJD VV 1 RU#96/027 lanes 1 to 8, frontal cortex to entorhinal cortex,
lane 9, sCJD MM 1 standard. D: sCJD VV 1 RU#96/027 lanes 1 to 5, hippocampus
to posterior thalamus. E; sCJD VV 2A RU#94/083 lanes 1 to 9, frontal cortex to
entorhinal cortex. F; sCJD VV 2A RU#94/083 lanes 1 to 9, hippocampus to
cerebellar vermis.
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Figure 27. Sporadic CJD regional glycoform ratios. Scattergraphs of the mean
glycoform ratios from different brain regions within an individual. The standard
error range of brain regions is stated in brackets, for the diglycosylated (di) and
monoglycosylated (mono) bands. A. MM 2 A (di 0.3-2.2, mono 0.5-1.7).
B. MM 1 (di 0.7-6, mono 0.7-3.3). C. MV 2A case 1 (di 1.4-3.4, mono 1-
2.6). D. MV 2A case 2 (di 2.1-2.9, mono 1.7-2.3). E. VV 1 (di 2.8-3.6, mono
3.3-4.3). F. VV 2A (di 2.8-3.1. mono 0.3-1.9).
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The sCJD VV 1 (RU#96/027) case had no significant differences in glycoform
ratios of any of the neuroanatomical regions (figure 27B). There was extensive
neuronal loss and astrocytic proliferation within the cerebral cortex resulting in status
spongiosis. Spongiform change was also noted in the basal ganglia along with less
prominent neuronal loss and gliosis. The cerebellum displayed spongiform change
most prominent in the vermis, but this region did not display detectable PrPres. Non-
PrP amyloid plaques were absent from the brain as a whole. The immunostaining
displayed weak reactivity in the cerebral cortex, basal ganglia and molecular layer of
the cerebellar cortex. There were no PrP reactive plaques in the brain. The cerebral
cortical regions and deep grey matter regions all displayed PrPres (figure 26C and D).
The neuropathological findings were not dissimilar to the Dutch case with significant
spongifonn change, neuronal loss and diffuse or granular synaptic staining for PrPres.
However, small PrP positive plaque-like structures were noted in this case and may be
an indicator of the type 2B PrPres pattern, as they were not detected on biopsy.
The sCJD VV 2A patient (RU#94/083) also had spongiform change
accompanied by gliosis and neuronal loss, though in this case despite the occipital
cortex being spared, low levels of PrPres were detected in both the occipital and
suboccipital cortices relative to the other brain regions (figure 26E). Perineuronal
deposits of PrP were detected in cerebral cortex with small diffuse deposits and the
occasional PrP positive plaque-like deposits seen in the granular layer. The
hippocampus, basal ganglia and thalamus also displayed spongiform change. The
cerebellum had marked spongifonn degeneration of the molecular layer leading to
cortical atrophy. The neuropathological features do not appear to influence the PrPILS
formation in different brain regions. The plaque-like formation is quite distinct from
vCJD florid plaques, yet may be related to the proportion of diglycosylated PrPres.
Neuropathological findings from a group of 12 sCJD VV cases were obtained
(with kind permission) from Kovacs et al, (Kovacs et al, 2000) and from the autopsy
reports. Five of these comprised of cases classified as part of the VV 2A subgroup
described in chapter 3. PrPres as detected by immunocytochemistry was classified as
one of four types of deposit; vacuolar, diffuse/synaptic, neuronal or granular deposits
and plaques (a more detailed description of these four patterns can be found in the
appendix, A6). The neuropathological findings in these 12 patients included
spongiform change and prion protein immunopositivity most apparent in the
subcortical grey matter and cerebellum. Plaque-like deposits staining for PrP were
evident in all brain regions with laminar PrP deposition in the cerebral cortex and the
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hippocampus. Involvement of the hippocampus is rarely seen in sCJD. The
neuropathological findings of this group of patients is similar to that of case
RU#94/083. The uniform features of these patients as a whole along with the
consistent PrP,es banding pattern and their distinction from other sCJD cases in terms
of hippocampal involvement and the slight increase in diglycosylated PrPres indicates
that this subgroup has a distinct phenotypic spectrum that could be regarded as a
'strain'.
The investigation of a sCJD MM 2A patient (RU#99/014) was of particular
significance in light of case RU#99/068 as already discussed. The age at onset and
duration were 61 years and 11 months respectively, thus unexceptional for the
subgroup as a whole. This case displayed both type 1 and 2 mobilities. The
subffontal cortex was found to be type 1 mobility on initial analysis (figure 28A).
Closer examination of overlying frontal cortex sample clearly showed that although
the majority of nonglycosylated PrPres in the sample was type 2, there was also trace
levels of type 1 PrPres present (figure 28C) and some type 2 could be detected in
subfrontal cortex (figure 28B). Twelve regions displayed type 2 PrPies, but in addition
to the frontal cortex and subfrontal cortex the basal ganglia and cerebellum samples
showed some degree of type 1 PrPres. The glycoform ratios in this case were fairly
consistent though a slight decrease in the proportion of monoglycosylated PrPres was
observed in the frontal cortex relative to the subfrontal cortex possibly due to the extra
band observed (figure 27D). This highlights the dependence of glycoform analysis on
distinct and discrete PrP,es fragments for proportional comparisons. This case had
widespread cerebral cortical spongiform encephalopathy, most severe in the occipital
cortex where confluent spongiform change, severe neuronal loss and astrocytosis
were observed. There is strong positivity to PrP in a synaptic and perivacuolar
pattern, particularly in the occipital cortex. Spongiform change was observed in the
basal ganglia, thalamus and cerebellum. In the thalamus this was patchy and the
molecular layer of the cerebellum only displayed focal spongiform change. Both
synaptic and perivacuolar PrP deposits were seen in the basal ganglia and thalamus,
but in the cerebellum there was merely focal synaptic staining of the molecular and
granular layers. This age at onset and neuropathological features suggest this case
corresponds to the MM 2 cortical subgroup described by Parchi et al. All brain
regions displayed roughly equivalent levels of PrPres (figure 28).
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2A+1 2B 1+2A FC vCJD sFC sCJD
2A+1 2B 1 1
Figure 28. Sporadic CJD brain regions showing multiple isotypes in MM 2A case
RU#99/014. A; Lane 1, frontal cortex, type 2A+1, lane 2, subfrontal cortex , type 1,
lane 3 to 9, parietal cortex to entorhinal cortex, type 2A. B; Lane 1, RU#99/014
frontal cortex, type 2A+1, lane 2, vCJD frontal cortex, type 2B, lane 3, RU#99/014
subfrontal cortex, type 1+2A. C; Lane 1, RU#99/014 frontal cortex, type 2A+1, lane
2, vCJD type 2B standard, lane 3, subfrontal cortex, type 1, lane 4, sCJD MM 1
standard. D; Lane 1, hippocampus, type 2A, lane 2, amygdala, type 2A, lane 3, basal
ganglia, type 2A+1, lane 4, anterior thalamus, type 2A+1, lane 5, posterior thalamus,
type 2A, lane 6, mesencephalon, type 2A, lane 7, cerebellar cortex, type 2A + 1.
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This case was the first to demonstrate both types of PrPrcs in the same sample
(i.e. the same brain region). Since the discovery of this co-occurrence phenomenon
more cases have been identified through ongoing routine testing of new cases,
retrospective analysis of iCJD cases and regional analysis. Co-occurrence has been
observed in 5 sCJD cases (RU#99/014, RU#98/082, RU#00/008, RU#00/017,
RU#97/008), and an iCJD case (RU#99/062), where both type 1 and 2
nonglycosylated bands can be seen in the same brain sample. Different isotypes have
also been identified in separate brain regions of individuals in 3 sCJD cases
(RU#98/153, RU#99/068, RU#96/153) and 2 fCJD cases (RU#92/070 and
RU#94/097). Co-occurrence is not restricted to one region of the brain and cases of
sCJD co-occurrence have been found carrying each of the codon 129 genotypes (table
12). The numbers of cases are small yet there is a preponderance of homozygotes. A
majority of heterozygotes would be expected if there is allele preference for one
conformation over the other, resulting in two isotypes. If the preference for the type 1
conformation of MM cases applied, as suggested by the findings in chapter 3, a
dominant type 1 band with residual type 2 would be expected. The cases in which
this phenomenon was identified were initially classified as type 2A, but were older
and had shorter disease duration than the other MM type 2A cases. In the MM 2A
group as a whole the mean age at onset was 54 years and disease duration was 19
months. The mean age at onset was 65.3 years and 10.3 months in the multiple
isotype cases but single isotype cases were on average 50.2 years old at onset and had
disease duration of 20.2 months. These cases had similar onset and duration to cases
classified as MM type 1 and these may be more indicative of the PrPres conformation.






Sporadic CJD MV 2
VV 3




Table 12. Cases displaying two isotypes and their codon 129 breakdown.
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The first MV 2A case (RU#98/123) investigated had a consistent mobility but
displayed variation in glycoform ratio according to neuroanatomical region. This was
most clearly seen in the comparison of three cortical regions with the basal ganglia
and thalamus, which is more heavily glycosylated (figure 29). Comparison of the
glycoform ratios of this case with the sCJD MV 2A subgroup found there to be
significant differences in the glycoform ratios between the individual regions and the
subgroup as a whole (diglycosylated p < 0.000, monoglycosylated p = 0.005,
nonglycosylated p <0.000, one way ANOVA). Thus analysis of the frontal cortex
alone may not provide an indication of the glycoform ratio throughout the brain. The
regions most significantly different from the MV 2A subgroup for the diglycosylated
levels were the parietal cortex p = 0.016, basal ganglia, anterior thalamus, posterior
thalamus p < 0.000 and cerebellar cortex p = 0.048, dunnett t 2 sided post hoc test).
There was no significant difference between the levels of the monoglycosylated band,
but the same regions were all significantly different in the nonglycosylated band as
well as the subtemporal cortex (parietal cortex p = 0.049, subtemporal cortex p =
0.003, basal ganglia p = 0.007, anterior thalamus p = 0.025, posterior thalamus p <
0.000, cerebellar cortex p = 0.003). There was a significant difference between the
levels of all three bands, when compared as a whole with the vCJD cases
(diglycosylated p<0.000, monoglycosylated p<0.000, nonglycosylated p<0.000).
However, there was no significant difference between the levels of nonglycosylated
PrP in the subfrontal cortex, parietal cortex, temporal cortex, subtemporal cortex,
basal ganglia, anterior thalamus, posterior thalamus, cerebellar cortex and vermis).
Indicating that misclasssification from non-cortical tissue is possible, though unlikely
provided all three bands are considered in conjunction, quantitation of the glycoform
levels is carried out and the tissue being investigated is taken into account. The basal
ganglia and thalamic regions of RU#98/123 did overlap with the glycoform ratios of
some vCJD regions. The overlap of glycotype appearance or glycoform ratios with
vCJD, based on single sampling of deep grey matter regions or cerebellum, raises the
potential for misdiagnosis of sCJD cases if relying solely on the PrPres banding
pattern. It also raises the question of the contribution of an M allele to diglycosylated
PrP'es formation in deep grey matter regions, particularly the thalamus as observed in
FFI.
This glycoform variation was further investigated by resampling twice from
each region and investigating another MV 2A case. Resampling did not show as
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convincing a variation, though this may be due to the limited number of repetitions
performed on the resampled tissue and the second case (RU#96/153) did not display
similar anatomically specific variation in glycoform ratio (figure 27F). However
analysis of the glycoform ratios in comparison with the sCJD MV 2A subgroup as a
whole found the subtemporal, suboccipital and entorhinal cortical regions to have
significantly different monoglycosylated bands (p = 0.017, 0.034, 0.022 respectively,
one way ANOVA, dunnets t 2-sided post hoc). This case was significantly different
to the vCJD cases. The variation of glycoforms may be specific for cortical
neuroanatomical region. As with subgroups of cases, regional analysis can be
quantitated and spatially compared for individuals with differing genotypes and
aetiologies.
The second case (RU#96/153) also displayed both type 1 and 2 mobilities.
Similarly to the MM 2A case a subcortical region, in this case subparietal cortex,
displayed type 1 mobility, other regions had type 2 mobility though some contained






Figure 29. Brain regions in sCJD MV 2A case RU#98/123, showing similarity in
relative mobility and differences in glycoform ratio. A; Differences in glycoform
ratio, lane 1 to 6, frontal cortex to subtemporal cortex at 10 second exposure, lane 7 to
9, occipital cortex to entorhinal cortex from the same western blot at 30 second
exposure. B; Difference in glycoform ratio, lane 1 to lane 9, hippocampus to
cerebellar vermis. C; Most contrasting regions in terms of glycoform ratio, lane 1,
parietal cortex, lane 2, subparietal cortex, lane 3, temporal cortex, lane 4, occipital
cortex, lane 5, basal ganglia, lane 6, anterior thalamus, lane 7, posterior thalamus, lane
8, cerebellar cortex, lane 9, cerebellar vermis.
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Figure 30. Brain regions in sCJD MV 2A case RU#96/153 showing differences in
relative mobility. A; Lane 1 to 9, frontal cortex to entorhinal cortex, type 2A, lane 4,
parietal cortex type 1. B; Lane 1 to 9, entorhinal cortex to cerebellar vermis, type 2A.
C; Difference in relative mobility in comparison to standards. Lane 1, sCJD type 1
standard, lane 2, RU#96/153 frontal cortex, type 2A, lane 3, sCJD type 2A standard,
lane 4, RU#96/153 subparietal cortex, type 1, lane 5, sCJD type 1 standard.
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The first case (RU#98/123) investigated in the MV 2A subgroup had an age at
onset of 62 years and duration of 21 months, but the second case, which had a very
similar age at onset of 61 years, had disease duration of 8 months. The first case
displayed widespread spongiform encephalopathy in the cerebral cortex and basal
ganglia. This was most prominent in the parietal cortex were it was accompanied by
neuronal loss and astrocytosis. Routine staining identified occasional small non-
'florid' amyloid plaques. These plaques were also seen in the hippocampus. PrP
immunostaining identified a strong synaptic pattern of staining. Perineuronal staining
was seen in layer 5 with PrP plaques found in layers 1-4. The basal ganglia displayed
widespread spongiform change, extensive gliosis and neuronal loss. The thalamus
has less severe but widespread spongiform change. The basal ganglia and thalamus
had synaptic PrP deposits but few plaques. The cerebellum suffered spongiform
change in the molecular layer in conjunction with pale staining plaques also observed
on PrP immunostaining and more prevalent in the granular layer. There was also
synaptic staining around the dentate nucleus. The second case (RU#96/153) also
displayed cerebral cortex and cerebellum spongifonn change, most prominently in the
frontal and temporal lobes, and cerebellar cortex. This was less apparent in the basal
ganglia and thalamus. The neuronal loss and astrocytosis were most evident in the
cerebral cortex, but non-PrP plaques were not observed. Immunostaining showed
strong perivacuolar deposits with occasional small plaque-like deposits in the cerebral
cortices, while in the cerebellum a more diffuse pattern with small dense plaques was
seen in the granular layer.
There are no significant neuropathological differences between these two
cases that correspond to the differences observed in mobility or glycofonn ratio of
PrP'c\ The levels of PrPres were fairly similar with only the subfrontal and
suboccipital cortices displaying less PrPres. In both cases neither of these lower levels
corresponded to a greater degree of spongiform change, in fact the first case displayed
greater levels of PrPres in the parietal cortex where there was a high degree of
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Figure 31. Comparison of standards with mixed standard samples. Criterion precast
8-16% gradient gel analysed with 3F4. Lane 1, sCJD MM 1 standard, lane 2, sCJD
VV 2A standard, lane 3, type 1 and 2A standards mixed prior to PK treatment, lane 4,
type 1 and 2A standards mixed after PK digestion.
Mixing of equal amounts of type 1 and 2 PrPres to determine the appearance of
potential sample cross contamination either before PK treatment (i.e. during sample
handling) or after PK treatment (i.e. during sample loading) produced patterns similar
to type 2 PrP'cs with an additional type 1 unglycosylated band (figure 31). This
suggests that type 2 PrP'cs can potentially mask lower levels of type 1 PrPres.
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5.4 Iatrogenic CJD
To assess the possibility of codon 129 heterozygosity giving rise to glycoform
ratio variability independent of aetiology an iatrogenic CJD MV 2A case
(RU#99/111) was investigated. Analysis of a GHT iCJD case was also intended to
establish the possibility of neuroanatomically specific host response presiding over
the glycoform ratio of the infective strain i.e. can different glycoform ratios arise in
the host from the discrete infectious glycoform ratio? Isotyping of cortical tissue
from the iCJD cases revealed a GHT case containing both types 1 and 2 (figure 32)
and an undefined high proportion of nonglycosylated PrPres in other cases. However,
glycoform ratio variability had not been established. The case available had displayed
only type 2A PrPres on analysis of the frontal cortex. The same isotype mobility was
seen in all the brain regions (figure 33). Glycoform ratio data for repeated runs was
established for the frontal and parietal cortices, the corresponding sub cortical regions,
basal ganglia, thalamic regions and cerebellum. There was a similar increase in the
level of diglycosylated PrPres in the basal ganglia and thalamic regions (figure 35F).
This similar spatial distribution of glycoform ratios to the sCJD MV 2A case suggests
there is neuroanatomical specificity to PrP glycosylation.
Figure 32. Multiple isotypes in iatrogenic CJD. Lane 1, sCJD MM 1 standard, lane
2, iCJD MV GHT types 1 and 2, lane 3, vCJD standard.
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Figure 33. Brain regions in iCJD showing consistent isotype pattern. A; Composite
image from different 12% SDS-PAGE western blots analysed with 3F4, to show
similar PrPres levels. Lane 1 to 3, frontal cortex to parietal cortex, 1 minute exposure,
lane 3 to 8, subparietal cortex to suboccipital cortex, 3 minute exposure. B; Lane 1 to
8, hippocampus to cerebellar vermis.
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5.5 Variant CJD
Four cases of vCJD were examined in the stated 17 regions (figure 34), one
case in 15 regions and one case in 5 regions due to the availability of frozen tissues.
In contrast to the sCJD, iCJD and fCJD cases (shown below) the vCJD cases
examined showed a uniform type 2 mobility irrespective of the region tested and a
consistent glycoform ratio (figure 35D). Initially one typical case with age at onset of
35 years and a duration of 15 months was examined (RU#98/154). The consistent
isotype pattern in all regions prompted the investigation of cases with differing ages at
onset and duration to establish if either parameter influenced the isotyping. One case
with a long duration (29 months, age at onset 21 years) (RU#98/156), one with a short
duration (9 months, age at onset 30 years) (RU#96/045) the 2B isotyping standard,
one young case (age at onset 17 years, duration 18 months) (RU#00/025) and one
older case (age at onset 51 years, duration 11 months) (RU#99/015). The final case
was 19 years old at disease onset and had an 11 month duration (RU#98/148). All the
vCJD cases were consistent in mobility and glycoform ratio (figure 34). The
glycoform ratios were plotted on a scattergraph and did display some variability
towards decreased diglycosylation and increased levels of nonglycosylated PrPies
(figure 35D), however the monoglycosylated levels remained very consistent. There
was no statistically significant difference in glycoform ratios between the cases or
among brain regions of individual cases. When plotted on a scattergraph the
glycoform ratios did not overlap with sCJD, iCJD or the majority of fCJD regional
glycoforms. A few samples from the fCJD E200K MV case did overlap with vCJD,
primarily cerebellum and deeper grey matter regions.
The glycoform ratio values were in the region of equal levels of all three
glycoforms for some of the samples i.e. 33% on both the monoglycosylated and
diglycosylated scales (figure 35D). This phenomenon may be related to saturation of
sample loading as the PrPies levels were very high (1-2 pi of a 10% brain homogenate
producing a comparable signal intensity to approximately 15-20 pi of a typical sCJD
homogenate) and shorter X-ray exposures did not compensate. Further dilution of the
samples would likely reduce the effect of high PrPies levels as this was seen to
produce a greater resolution and more pronounced ratio on general analysis. The
levels of PrPres were frequently highest in the basal ganglia and thalamus (figure 34B)
where marked spongiform change, severe neuronal loss and marked gliosis were
detected.
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pattern. Composite image from H A BG AT PT M
12% SDS-PAGE western blots analysed with 3F4 at different exposure periods to
equalise appearance of PrPres, Lane 1, FC 10 second exposure, lane 2 to lane 5, sFC to
TC 3 minute exposure, lane 6, sTC to sOC 30 second exposure, lane 9, EC 3 minute
exposure. A2; Lane 1 to lane 8, H to CV. Bl; vCJD RU#98/154 with typical age at
onset and disease duration. Lane 1 to lane 8, FC to sOC. B2; Lane 1 to lane 8, H to
CV. CI; vCJD RU#98/156. Lane 1 to lane 9, FC to EC. C2; Lane 1 to lane 6, H to
M.
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Figure 34 continued. Dl; vCJD RU#99/015. Lane 1 to lane 9, frontal cortex to
entorhinal cortex. D2; Lane 1 to 8, hippocampus to cerebellar vermis. El; vCJD
RU#00/025. Lane 1 to lane 9, frontal cortex to entorhinal cortex. E2; Lane 1 to lane
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Figure 35. Variant CJD regional glycoform ratios. Scattergraphs of the mean
glycoform ratios from different brain regions within an individual. The standard
deviation range of brain regions is stated in brackets, for the diglycosylated (di)
and monoglycosylated (mono) bands. A. vCJD long duration case (di 0.7-6, mono
0.7-3.3). B. vCJD short duration case (di 1.4-3.4, mono 1-2.6). C. Younger vCJD
case (di 2.1-2.9, mono 1.7-2.3). D. Older vCJD case, (di 2.8-3.6, mono 3.3-4.3).








































































Figure 35 continued. Iatrogenic CJD and fCJD regional glycoform ratios.
Scattergraphs of the mean glycoform ratios from different brain regions within an
individual. The standard deviation range of brain regions is stated in brackets, for
the diglycosylated (di) and monoglycosylated (mono) bands. F. iCJD MV 2A (di
0-4.55, mono 0-5.89) G. fCJD MM case(di 0-9.8, mono 0-7.5) H. fCJD MV case
(di 0-9.26, mono 0-7.25).
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Over the course of these investigations a partial difference in glycoform ratio
was detected and seemed most apparent in the basal ganglia, thalamic regions and in
particular the cerebellar cortex, where a slight increase in monoglycosylation could be
detected but was devoid of significant variance (figure 35). Optimal resolution of the
cerebellar samples identified a greater proportion of monoglycosylated PrPres,
characterised by the prominence of the lower region of the band (figure 36). This
regional specific difference in the mobility ofmonoglycosylated PrPres could be due to
a degree of preferential occupancy of either the 181 or 197 asparagines by N-linked
glycan chains. This was further investigated by the sampling of 26 vCJD
cerebellums, most of which clearly demonstrated this feature of the more diffuse
monoglycosylated band. The apparent decrease in diglycosylated PrPres may actually
be due to an increase in monoglycosylated PrPres causing a relative shift in
proportions of the three bands. This phenomenon emphasises the need for statistical
analysis that can compare all three bands in conjunction so as not to misinterpret
levels of the glycoforms in isolation. Densitometry and improved resolution can aid
in quantitation of this phenomenon. In summary the isotype banding pattern in vCJD
displayed a very minor variability between brain regions, the differences in PrPres
morphological deposits did not show any correlation with different banding patterns
and the prominence of the monoglycosylated band in the cerebellum appears to be
tissue specific as florid PrP plaques are found in the cerebral cortex. Surprisingly
high levels of PrPres deposition in the occipital cortex as observed by
immunocytochemical techniques did not give rise to strong signals on Western blots
and high PrPres levels in fact correlated with spongiform change or astrocytosis.
Examination of sCJD and iCJD cerebellums displayed the same lower
prominence phenomenon of the monoglycosylated band and an apparent greater
relative proportion of monoglycosylated PrPres (figure 37). Eleven sCJD cases were
sampled in addition to the 6 regional cases and 1 iCJD case in additional to the
regional case. In some cases only the cerebellum was available to provide isotyping
data for the patient as a whole (4 of the sCJD cases and the iCJD case). Classification
of patients on the basis of cerebellum material may be misleading due to potential co¬
occurrence of isotypes and glycofonn analysis and may be atypical for the case as a
whole, with a potential apparent increase in both monoglycosylated and
nonglycosylated bands. This phenomenon along with cases RU#98/123 and




Figure 36. Variant CJD MM 2B standard frontal cortex (FC) vs cerebellum (CB) line
density trace.
Figure 37. Sporadic CJD cerebellum (CB) line density trace.
5.6 Familial CJD
Two cases of fCJD carrying the E200K mutation were available for regional
analysis, one case was MM the other MV. Their analysis was pertinent, owing to the
similar glycoform ratio seen in frontal cortex (type IB) and the occurrence of the
disease in MM individuals. Establishing if any regions had the type 2 mobility and
retained the predominant diglycosylation seen in vCJD was therefore important in
terms of determining the exclusive nature of the 2B pattern. Two separate UK
families have been described (Collinge et al, 1993) with average age at onset 55,
rapidly progressive dementia, myoclonus, and pyramidal, cerebellar or extra¬
pyramidal signs, characteristic pseudoperiodoc EEG, histologically typical for CJD
with PrP but no plaques. Establishing both isotype and glycoform ratio proved far
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harder than previous cases due to a distinct lack of nonglycosylated PrPres. Most
regions had roughly equal levels of diglycosylated and monoglycosylated PrPres.
Establishing the mobility required PNGaseF treatment, which along with the high
PrPres levels often lead to intense broad signal, hampering resolution. Multiple
mobility patterns were observed in both cases. In the MM case RU#94/097, who died
at the age of 57 following a rapidly progressive dementia featuring myoclonus and
had abnormal EEG readings, there was significant PrPres accumulation throughout
most of the brain (figure 38). Some regions were clearly shown to contain type 1
nonglycosylated PrPres (cerebellar vermis) though in other regions an intermediate
mobility was observed (parietal cortex and anterior thalamus) (figure 39). In the
posterior thalamus of this case a higher molecular mass pattern was observed
(described as type 7 by Hill, 1998) (figure 39). This was the only case to show three
different mobility types and there were even some regions (entorhinal cortex,
amygdala and hippocampus) that may of displayed a type 2 mobility but were hard to
distinguish from an intermediate mobility. The MV case RU#92/070 that died at the
age of 61 displayed what appeared to be both types 1 and 2 (comparison of sub frontal
and parietal cortices in figure 40A). The glycoform ratios did show some variation,
primarily in the MV case, which had a greater degree of diglycosylation in cerebellar
and deep grey matter regions. These regions overlapped with vCJD but not sCJD.
The ratios in the MM case were different to both sCJD and vCJD in most cases with a
tendency to fall on the X:Y axis reflecting the equivalent levels of diglycosylated and
monoglycosylated PrPres. The cases were subtly distinct from the sCJD VV 2A
subgroup in that they either contained greater levels of diglycosylated PrP,es or to
some degree in all cases less nonglycosylated PrPres. Greater levels of
monoglycosylated PrP'es placed them above the vCJD cases on the scattergraph.
Greater levels of diglycosylated PrPies resulted in a position further over to the right of
the scattergraph while less nonglycosylated PrPres placed them further away from the
origin. The misdiagnosis of fCJD as vCJD based purely on the banding pattern is thus
possible.
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Figure 38. Brain regions of fCJD E200K MM case RU#94/097. A; Lane 1 to 8,
frontal cortex to suboccipital cortex. B; Lane 1 to 9, entorhinal cortex to cerebellar
vermis.
Figure 39. Comparison of brain regions in fCJD E200K MM case RU#94/097 with
sCJD standards. Lane 1, sCJD MM 1 standard, lane 2, parietal cortex, type INT, lane
3, sCJD VV 2A standard, lane 4, anterior thalamus, type INT, lane 5, sCJD MM 1
standard, lane 6, posterior thalamus, type 1+, lane 7, sCJD VV 2A standard, lane 8,
cerebellar vermis, type 1.
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Figure 40. Brain regions in fCJD E200K MV case RU#92/070. A; Lane 1 to 8,
frontal cortex to suboccipital cortex. B; Composite image from 12% SDS-PAGE
western blots analysed with 3F4 at different exposure periods to equalise appearance
of PrP'es. Lane 1 to 3 and lane 7 to 9, entorhinal cortex to amygdala and
mesencephalon to cerebellar vermis, 3minute exposure, lane 4 to 6, basal ganglia to
posterior thalamus, 15 second exposure.
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Summary
• Biopsy and autopsy analysis can yield different PrPres isotypes.
• Multiple isotypes were deteced in sCJD, iCJD and fCJD cases.
• Glycoform ratio variation was seen in sCJD, iCJD and fCJD cases.
• Variant CJD cases were consistent in isotype and glycoform ratio throughout the
brain.
• PrPres of type 1 and type 2 can occur in the same brain and even in the same brain
region. The amounts of each type making up the total PrPres can vary.
• The PrPres glycoform ratio can vary according to specific anatomical regions.
• Cerebellum derived PrP,es displays a more pronounced lower monoglycosylated
band.
The PrPies isotype is not consistent throughout the CNS in individual cases. The
presence of different isotypes in different brain regions and at autopsy as opposed to
biopsy undermines the assumption that the PrPres isotype identified from limited
sampling is representative of the individual as a whole. The presence of multiple
isotypes in the same brain region may complicate the determination of the isotype and
lead to misclassification. In contrast vCJD cases were strikingly consistent in isotype
and due to the novel nature of vCJD may be a feature of the strain of agent. A
correlation between the PrPies conformation and the neuropathology could not be
clearly established but suggests that diffuse staining of PrP or focal and PrP plaques
may relate to type 1 or type 2 PrPres respectively. The relative levels of type 1 or type
2 PrPres suggests that the isotype is a feature of PrP accumulation. Thus the
classification of cases may be more accurate as predominantly type 1 or 2. More
comprehensive analysis of cases may lead to reclassification of some cases and
provide a better differentiation of the sCJD subgroups. Spongiform change may
correlate to increased glycosylation of PrPres but the two are not mutually exclusive.
The anatomical specificity of the glycoforms is a contributing factor, but the lack of
difference in vCJD and some sCJD cases indicates the disease process is dominant.
The consistency of the monoglycosylated PrP'es prominence in the cerebellum
suggests that there is a strong pressure influencing PrP glycosylation in the
cerebellum.
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CHAPTER 6: Divalent cation chelation studies.
6.1 Metal ion status of isotype standards
PrPres was extracted in a native form from patients, using an EDTA free
buffer. The concentrations of EDTA and the pH in commonly used lysis or
homogenisation buffers are not sufficient to significantly chelate ions from PrP. The
concentration of copper or zinc required to maintain PrPres conformation is similar to
physiological levels (25 pM). During this study it was reported that removal of bound
metal ions from PrPres with divalent metal ion chelators or washing in buffer and
subsequent proteinase K treatment, led to an increase in relative mobility of samples.
This increased mobility was tenned 2" and was observed in types 1 and 2 of sCJD
according to the nomenclature of Collinge et al (Wadsworth et al, 1999a). Treatment
of samples primarily with the broad specificity chelator EDTA"4 (ethylene-diamine-
tetraacetic acid), but also more specific chelators EGTA and triethylenetetramine
(Cu2+ specific), dipicolinic acid and 1,10 phenanthroline (Zn2+ specific) or washing in
A-ethylmorpholine buffer alone, demonstrated the possibility of PrPsc with either
bound copper or zinc, to be responsible for PrPres conformation. This was proposed to
account for some of the variability in typing classification between groups.
It was thus decided to assess whether our isotyping classification could be
reconciled with other reported classifications by treating our standards with metal ion
chelators. Are differences in PrPres isotype due to differential metal ion binding?
Treatment of our isotype standard samples with EDTA, to obtain PrPres in a metal ion
unbound fonn, and comparison with the relative mobility of untreated standards was
the first priority. Further to this, cases with the anomalous intermediate mobility and
multiple isotypes were also investigated after EDTA treatment to investigate whether
they were experimentally induced artifacts. In addition iCJD and GSS cases were
investigated to assess whether the phenomenon was restricted to sCJD or was
aetiologically determined.
121
S1 PK1 1- S2A 2A 2A- S 2B 2B 2B EDTA M GM
Figure 41. The effect of chelation on PrPrcs mobility. EDTA treatment of standards.
Criterion precast 8-16% gradient gel, analysed with 3F4. Lane 1, postnuclear
supernatant from sCJD MM 1, lane 2, PK treated sCJD MM 1, lane 3, EDTA and PK
treated sCJD MM 1 (1-), lane 4, postnuclear supernatant from sCJD VV 2A, lane 5,
PK treated sCJD VV 2A, lane 6, EDTA and PK treated sCJD VV 2A (2A-), lane 7,
postnuclear supernatant from vCJD MM 2B, lane 8, PK treated vCJD MM 2B, lane 9,
EDTA and PK treated vCJD MM 2B (2B), lane 10, ECL markers (from top 46 kDa,
31 kDa, 20 kDa), lane 11, BFAV markers (second from top 21 kDa, 20 kDa, 19 kDa,
16 kDa).
EDTA is a divalent cation chelating agent that removes co-factor ions such as
copper or zinc. The use of different homogenisation buffers may account for some of
the variety in the results observed between research groups, such as the level of
EDTA incorporated. In order to determine whether bound divalent cations contribute
to the Mr of samples EDTA (500 mM) was added to the standard sCJD types 1 and
2A and vCJD standard 2B samples prior to PK treatment.
A small but clear increase in the mobility of the type 1 nonglycosylated
fragment occurs in PrPICS PK treated without bound metal ion (figures 41 and 42).
This results in an intermediate mobility that co-migrates with samples classified as
intermediate mobility (figure 42). The type 2 standards also display a slight increase
in Mr though less noticeable. The vCJD type 2B samples showed no such difference
in Mr and indicates possibly the lack of bound metal ions in vCJD derived PrPres or
the presence of the most open native conformation to PK cleavage. The lack of
change in the type 2B mobility in comparison to the type 2A may indicate a very
minor difference in conformation between the two PrPres types. However, due to the
small differences in molecular weights of the order of 0.5 to 1 kDa, SDS-PAGE lacks
the resolution required to provide uneqivocal determination of conformational
differences and an alternative technique is desirable. The changes in mobility
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between metal ion bound and unbound forms of PrPres are slight and do not appear to
account for the differences in mobility between type 1 and 2. The difference in codon
129 of the standards (VV type 1 and MM type 2) does not appear to influence the
metal ion bound PrPrcs conformation.
6.2 Intermediates and EDTA
Intermediate type PrPres is extracted in a cation bound form, shown by an
increase in relative mobility (figure 42). Type 1 and intermediate mobility cases have
a more prominent Mr shift, possibly due to having a conformation when bound to
cations more protective to PK NH3-terminal cleavage. The presence of bound cations
on the PrPres of intermediate mobility cases rules out the possibility that these samples
are a result of experimental artifact related to isolation in homogenisation buffers
causing chelation of the metal ions. This does not rule out the possibility that types
2A and 2B contain similar levels of bound cations without this leading to a more
protective conformation.
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Figure 42. Comparison of PK digested intermediates with and without EDTA
treatment and standards. Criterion precast 8-16% gradient gel analysed with 3F4.
Lane 1, sCJD MM 1, lane 2, sCJD MM 1 EDTA (1-), lane 3, sCJD MM INT, lane 4,
sCJD MM INT EDTA (INT-), lane 5, sCJD VV 2A, lane 6, sCJD VV 2A EDTA
(2A-), lane 7, sCJD MM INT, lane 8, sCJD MM INT EDTA (INT-), lane 9, vCJD
MM 2B, lane 10, vCJD MM 2B EDTA (2B), lane 11, ECL markers (from top 46 kDa,
31 kDa, 20 kDa).
The appearance of the glycoform ratios did not appear to differ after EDTA
treatment. Glycoform ratio analysis of the effects of EDTA treatment showed no
significant effects on the ratios (two tailed paired samples t test). This suggests that
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there are not differentially metal ion bound proportions of PrP,cs present within the
glycosylated bands that are masked by the relative heterogeneity of these bands.
6.3 Multiple isotypes and EDTA
It is possible that not all PrPres molecules in vivo have bound divalent cations.
Non-uniform divalent cation loading of PrPres might produce bands resembling the co¬
occurrence of type 1 and 2 PrPres. Removal of any bound divalent cations with EDTA
prior to PK digestion was therefore carried out on two of the cases identified during
the neuroanatomical investigations (RU#99/068 and RU#99/014). Both bands
remained in samples proteinase K treated in the presence of EDTA and displayed a
minor shift in increased Mr (figure 43), consistent with their extraction in a metal ion
bound form.
It is also feasible that type 2 PrP'e;> carrying a minor glycan chain, or even two
short glycan chains, results in the anomalous banding. Treatment with PNGaseF was
unable to resolve two bands within the nonglycosylated region due to the relatively
low levels of 1 band in relation to the overall PrPres and high signal.
2A + 1 2A + 1 2A 2A + 1 2A + 1
EDTA EDTA
Figure 43. Co-occurrence isotype cases treated with EDTA prior to PK digestion.
12% SDS-PAGE analysed with 3F4. Lane 1, case RU#99/068, lane 2, case
RU#99/068 treated with EDTA, lane 3, blank, lane 4, sCJD VV 2A standard, lane 5,
case RU#99/014, lane 6, case RU#99/014 treated with EDTA.
6.4 Metal ion binding of iatrogenic and familial prion disease
The influence of PrP primary structure on copper binding has been clearly
demonstrated with respect to the octapeptide repeat region, deletion of which or
mutation of histidines 68 and 76, can abrogate metal ion binding (Quaglio et al, 2001,
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Sumudhu et al, 2001). The influence of aetiology or pathological mutations in the
PrP sequence on metal ion binding and PrPres formation was investigated. For this
reason the study was extended to include iCJD due to DM or GHT infection (MV)
and GSS cases (MM and MV). In all these cases a similar increase in Mr was
observed (figures 44 and 45).
1 1 1- 2A
iCJD iCJD
Figure 44. Comparison of iCJD case treated with EDTA to sCJD standards. 12%
SDS-PAGE analysed with 3F4. Lane 1, sCJD MM 1 standard, lane 2, iCJD DM MM
type 1 case, lane 3, iCJD DM MM case treated with EDTA, lane 4, sCJD VV 2A
standard.
2A 1 T 1
GSS GSS
EDTA
Figure 45. Comparison ofGSS case treated with EDTA to sCJD standards. 12%
SDS-PAGE analysed with 3F4. Lane 1, sCJD VV 2A standard, lane 2, GSS type 1
case, lane 3, GSS case treated with EDTA, lane 4, sCJD MM 1 standard.
125
Summary
• PrPres from type 1 and INT cases are more susceptible to NHj-terminal PK
cleavage following EDTA treatment than samples from type 2 cases.
• PrPres from vCJD cases does not display a noticeable change in Mr when treated
with EDTA and PK. This indicates that either the PrPres is in an 'open'
conformation or does not have bound cations, which may be significant in the
disease process.
• In mixed isotype samples, the difference in Mr is not due to differential cation
binding.
• The presence of cation bound PrPres in GSS suggests that prevention ofmetal ion
binding to PrP is not responsible for the disease process.
The differences in Mr between isotypes is not due to metal ion binding. PrPies
accumulates in a metal ion bound form. The resolution ofWestern blotting is limited
in its' ability to determine minor differences in PrPies conformation arising from metal
ion binding. Variant CJD may bind metal ions forming a conformation that is as
susceptible to PK as the sCJD type 2 conformation i.e metal ion binding in the
octapeptide repeat region may not necessarily confer additional protection to PK
cleavage of the NEb-terminal.
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CHAPTER 7: Mouse Transmissions
7.1 Murine molecular strain typing
Is the PrPres isotype a marker of prion strain, is it reproduced upon
transmission and can it be used to distinguish the BSE strain? Do animal TSEs have
comparable PrPres isotypes to humans? To investigate the application of the human
typing classification system to non-human samples and determine the retention of the
strain type upon transmission, murine transmissions of CJD were investigated. Brain
tissue from three vCJD cases was used to transmit the disease to three strains of mice
(VM, RUT and C57 black) in conjunction with mock inoculations. Brain tissue from
euthanased mice following onset of prion disease or old age was subjected to the same
treatment protocol as human tissue and analysed by Western blotting. The samples
were analysed blind to the inoculum and strain of mouse, therefore initially
identification of PrPl0s positive samples was important to identify the inoculated and
control samples. The majority of murine samples contained PrPres, with many in
similar quantities to that found in human CNS tissue. Five samples clearly did not
appear to contain PrPres, despite 20-fold concentration. One sample displayed slight
non-specific staining in the region of the diglycosylated band when concentrated and
was most likely due to cross reactivity to PK. Some of the samples required 20-fold
concentration to detect PrPres and observe all three bands. The samples were all of the
type B glycoform (predominantly diglycosylated) with very low amounts and in some
cases undetectable levels of nonglycosylated PrP'es. The typing classification relies
on an observable level of nonglycosylated PrPres, for this reason many of the samples
were treated with PNGaseF to remove the glycan chains and produce a distinct
nonglycosylated band.
The majority of PrPres positive cases had an intermediate mobility (12 cases),
in stark contrast to human samples, which are predominantly type 1 or 2. Five cases
were classified as type 2B, the same classification applied to vCJD cases (table 13).
One case was type 1 mobility (case 15), yet appeared to have a subtly different
glycoform ratio to fCJD cases, more commonly classified as type 1B, and resembled
vCJD glycoform more closely. One case displayed a broad nonglycosylated band
making classification difficult and suggesting a preponderance of ragged NH3-
terminal ends (case 21). Of note in all the cases was the lower position/ greater
mobility of the monoglycosylated band (figure 46) and in a few also the
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diglycosylated band, irrespective of the position of the nonglycosylated band. This





2 VI / RIII 2B
3 C / C57BL Nil
4 V2 / RIII 2B
5 V3 / RIII INTB
6 V2 / C57BL INTB
7 V2 / RIII INTB
8 V3 / RIII INTB
9 C / RIII Nil
10 V2 / C57BL 2B
11 V3/VM INTB
12 C / RIII Nil
13 V3/VM 2B
14 V3 / C57BL 2B




19 VI / RIII INTB
20 V3 / C57BL INTB
21 VI / C57BL INT/2B
22 V2/VM 2B
23 VI/VM INTB
24 C / C57BL Nil
Table 13. Murine transmissions.
Original inoculating case (C = control, V = vCJD),
murine strain, resultant mouse isotype.
The Mr of case 21 could not be clearly defined and is discussed in the text.
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Type 1 Mouse Type 2A
Figure 46. Mouse sample example displaying type 1 vCJD transmission and lower
monoglycosylated band. Lane 1, sCJD MM standard type 1, Murine vCJD
transmission type 1B, sCJD VV standard type 2A.
After unmasking of the results it was indicated that only vCJD samples had
been inoculated, along with controls to three strains of mice (VM, RIII, C57 black).
None of the controls yielded PrPres and all the samples from mice inoculated with
vCJD did. The isotype of the samples was variable and did in fact represent a large
proportion of samples with an intermediate mobility. All of the samples fell within
the type B glycoform ratio nomenclature. The glycoform ratios were not within the
linear range of X-ray film for many of the samples and chemiluminescence scans
along with standards were analysed with the STORM 860 phosphoimager. Generally
less than 10% of the PrP'es is composed of nonglycosylated PrPrcs and over 50% is
diglycosylated (figure 47). Unexpectedly the vCJD patient or strain of mouse alone
did not influence the isotype and no correlation could be found between isoform and
inoculating PrPres or host PrPc. Similarly there was no correlation between the
presence of a monoglycosylated band with greater Mr and the strain of mouse as
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Figure 47. Scattergraph of mean glycoform ratios of PrPres from murine
transmissions, natural and experimental animal TSEs. The range of standard
deviations among the murine PrP1^ samples; diglycosylated 0.7-21.5,
monoglycosylated 0.3-18.8.
1 M 2A M 1 M 2B M 1
Figure 48. Mouse samples with low monoglycosylated band. Lane 1, sCJD MM type
1, lane 2, murine sample, lane 3, sCJD VV 2A, lane 4, murine sample, lane 5, fCJD
type 1B, lane 6, murine sample, lane 7, vCJD type 2B, lane 8, murine sample, lane 9,
sCJD MM type 1.
Both C57BL and RIII mice display shorter incubation periods and are
designated as Sine"7 or Prn-p" genotype that translates to leucine at mouse codon 108
(109 human methionine) and threonine at codon 189 (190 human threonine). VM
displays a longer incubation period and is designated Sine?7 or Prn-ph genotype that
translates to phenylalanine and valine at the respective codons 108 and 189 (Carlson
et al, 1986, Westaway et al, 1987, Bruce etal, 1997). The strains of mouse utilised in
this study carry methionine at the equivalent of human codon 129. The resultant
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PrPies detected in these mice will reflect the Pm-p sequence of the host and yet there
was no correlation between the mouse strain and isotype or glycoform ratio. Codon
108 resides at the position of the 3F4 epitope and thus a different antibody that detects
mouse PrP was employed (6H4). Glycoform ratio differences between 6H4 and 3F4
were not observed in human samples. The valine at 189 in VM mice is situated
between the two glycosylation sites yet no correlation with an influence on the
glycoform ratio could be identified. Glycoform ratios from at least three separate runs
were analysed. The range of values was roughly 50-80% diglycosylated, 20-40%
monoglycosylated and 2-16% nonglycosylated, however, due to the large levels of
diglycosylated PrP10" there was often less than 5% measurable nonglycosylated PrPres.
The large proportional differences between the bands complicated quantitation. The
diglycosylated band frequently measured AUC levels above the linear range while the
nonglycosylated band levels were below the linear range (examples can be seen in
lanes 4 and 6 of figure 48). Comparison with X-ray densitometry results indicated
that the greater linear range of the STORM analysis served to increase the relative
proportion of diglycosylated and decrease that of the monoglycosylated and
nonglycosylated bands. X-ray densitometry may therefore be exerting an artificial




Figure 49. Banding pattern of fCJD VI801 coupled to M. Lane 1, fCJD, lane 2,
vCJD type 2B frontal cortex.
To help elucidate the mechanism responsible for the phenomenon of different
monoglycosylated PrPres mobility in human cerebellar and murine tissue, a case of
fCJD that carries a mutation at codon 180 preventing addition of glycan chains to the
181 site was investigated (Nixon et al, 2000). The mutated allele is in conjunction
with a methionine at codon 129. This case was reported to lack the diglycosylated
band after PK treatment, indicating sole conversion of the mutated allele to PrPres, but
not the wt allele. The conversion of codon 180 from valine to isoleucing replaces one
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hydrophobic (non-polar) amino acid with another and does not directly alter the
consensus sequence for N-linked glycosylation, indicating a conformational change
that prevents addition of the glycan chain to the second alpha helix. There were low
levels of PrPres detected, however 20 fold concentration was able to resolve two
bands, representing monoglycosylated PrPres occupied at codon 197 and an
nonglycosylated band. This case lacked the diglycosylated band as would be
expected if disruption of the N-linked glycosylation occurred and had a
nonglycosylated band of type 1 mobility. The upper band was well resolved and in
line with the upper portion of the monoglycosylated band present in vCJD frontal
cortex (figure 49). This suggests that the 181 site is more occupied in the cerebellar
and murine samples. However, the type 1 mobility and low PrP'es levels may account
for the lack of a lower monoglycosylated band..
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7.2 Animal TSEs
Samples from four cases of animal TSE were investigated. One naturally
acquired, one acquired presumably through infected Meat and Bone Meal (MBM),
one acquired presumably through infected pet food and finally one experimentally
infected. Brain tissue from a sheep with naturally acquired scrapie, a terminal BSE
infected Fresian cow, a UK case of feline spongiform encephalopathy (FSE) and
cerebral tissue from a marmoset with experimentally transmitted BSE were available.
1 sheep 2A
scrapie
BSE FSE 2A marmoset 1
BSE
B
1 sheep 2A BSE 1
scrapie
FSE 2A Marmoset 1
BSE
Figure 50. Animal samples. A: PK treated samples. Lane 1, sCJD MM type 1
standard, lane 2, sheep scrapie, lane 3, sCJD VV type 2A standard, lane 4, BSE, lane
5, sCJD MM type 1 standard, lane 6, FSE, lane 7, sCJDW type 2A standard, lane 8,
BSE infected marmoset, lane 9, sCJD MM type 1 standard. B: PK and PNGaseF
treated samples. Lane 1, sCJD MM type 1 standard, lane 2, sheep scrapie, lane 3,
sCJD VV type 2A standard, lane 4, BSE, lane 5, sCJD MM type 1 standard, lane 6,
FSE, lane 7, sCJD VV type 2A standard, lane 8, BSE infected marmoset, lane 9, sCJD












IB 55.2 31.3 13.4
Cow brain
(BSE)
IB 75.2 23.9 1
Cat brain
(BSE)
2B 61.8 27 10.6
Marmoset
(experimental BSE)
2B 49.6 39.4 11.1
Table 14. Results of animal isotyping.
The typing of the animal samples, as with some of the fCJD regional samples
and the murine vCJD transmissions displayed a high proportion of diglycosylated
PrPrcs (figure 50A). Even after PNGaseF treatment some diglycosylated PrPres
remained (figure 50B). Repeated attempts to deglycosylate all the PrPres, were
unsuccessful but were most likely achievable on longer incubations with PNGaseF.
Despite the retention of some diglycosylated PrP1^, the deglycosylated band mobility
was accurately typed repeatedly and showed the same mobility. All the glycan chains
are removed intact by PNGaseF ruling out the potential for partial removal of glycan
chains accounting for the mobility of the samples. Previous studies have shown
scrapie isolates and mouse passaged scrapie strains to have a highly diglycosylated
PrPres. The mobility of scrapie cases has been reported in relation to molecular weight
with numerous different results (Hill et al, 1998, Kuczius and Groschup, 1999, Madec
et al, 2000a, Moudjou et al, 2001). In terms of the mobility relative to human
isotyping nomenclature there is very little data available on animal isolates and
inferences sometimes have to be made from published Western blots. The scrapie
samples typically shown appear to have type 1 mobility, as found here. The
glycoform ratio was type B (diglycosylated 55.2% ± 4.5: monoglycosylated 31.3 % ±
1.4: nonglycosylated 13.4% ± 3.4) as seen in all scrapie cases, natural and transmitted
and had a glycoform ratio similar to that of vCJD. However, the glycoform ratio was
significantly different (p<0.001 for di, mono and nonglycosylated bands, one sample
two tailed t test) from the vCJD cases.
The type IB finding in relation to the BSE sample was unexpected and goes
against numerous other studies that have repeatedly shown a type 2B pattern as seen
in vCJD, natural BSE infections and transmission studies. The glycoform ratio was
observed to be quite pronounced (diglycosylated 75.2% + 4: monoglycosylated 23.9%
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± 3.8: nonglycosylated 1% ± 0.3) making quantitation of nonglycosylated PrPres and
classification of isotype difficult. The glycoform ratio is significantly different from
that seen in vCJD (p<0.001 for di, mono and nonglycosylated bands, one sample t
test). Cattle carry a methionine at codon 129 as do all the vCJD cases diagnosed so
far ruling out the likelihood of a polymorphic effect. However, being an isolated
case, further conjecture on the implications of a type IB isotype is unsubstantiated
and is most likely an anomaly and does not dispute the retention of molecular typing
in BSE and vCJD.
The case of FSE had a 2B isotype (diglycosylated 61.8% ± 4.7:
monoglycosylated 26.9% ± 4.3: nonglycosylated 10.6% ± 2) comparison with the
vCJD cases found a significantly different glycoform ratio (p<0.001 for di, mono and
nonglycosylated bands, one sample t test). The marmoset sample was hard to resolve
in terms ofmobility, which may be due to low PrP,es levels, but was classified as type
2B. The glycoform ratio was similar to that in vCJD (diglycosylated 49.6% ± 0.6:
monoglycosylated 39.4% ± 0.1: nonglycosylated 11.1% ± 0.5). However, the
glycoform ratio differed significantly from that of the vCJD cases (p=0.0027
diglycosylated, p<0.001 monoglycosylated and nonglycosylated bands, one sample t
test). The differences in glycoform ratio between the animal samples and vCJD cases
was most likely due to the analysis of single cases and a larger number of cases is
required to confirm these findings. The glycoform ratio values of the marmoset
experimentally infected with BSE appeared similar to vCJD and was found in the
same area of the scattergraph plot as vCJD cases (figure 47). Analysing human and
animal samples together aimed to standardise the classifications. There were certain
differences that distinguished the animal samples from human PrPres samples; A:
increased Mr of monoglycosylated PrPICS in murine samples, B: consistently high
levels of diglycosylated PrPres. Despite this the samples could still be incorporated to
some degree into the human classification system.
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Summary
• Transmission of vCJD to mice does not result in retention of the 2B isotype in all
cases. An intermediate mobility was seen in the majority of cases.
• Neither the mouse strain, prn-p genotype or individual vCJD source correlated
with the resulting PrPres pattern.
• The glycoform ratios of the murine PrPres featured a greater proportion of
diglycosylated PrPres than vCJD cases.
• Murine PrPres has a prominent lower region in the monoglycosylated band.
• Sole conversion and accumulation of the mutant allele was observed in fCJD
VI801, indicating that the mutant allele does not convert the wild type allele to
PrPies. This may be due to the lack of diglycosylation or indicate that the presence
of PrPies is not sufficient to bring about conversion ofwild type PrP\
• Scrapie and BSE derived infections all resulted in predominantly diglycosylated
PrPres. FSE and experimental BSE displayed type 2 PrP'es while scrapie and BSE
displayed type 1.
• The glycofonn ratios of all the animal derived PrPres were significantly different
from vCJD.
The PrPres isotype is not consistently retained upon transmission. The
maintenance of the isotype upon repeated transmission within an inbred line of mice
does not apply to transmission from vCJD cases to mice. The PrPies pattern is
therefore not a strain marker and would not distinguish cases arising due to the BSE
strain. Classification of animal TSEs can be accomodated in the human typing






The initial investigation focused on single cortical samples and confirmed the
presence of two predominant PrPICS mobilities. The majority of sCJD cases were type
1 (21 kDa), the rest were type 2(19 kDa) with the exception of 3 cases with a relative
mobility intermediate between these two types. Comparison of molecular weights
and relative mobilities of the samples investigated with samples analysed by Collinge
et al, could not provide a consensus as to the mobilities.
The number of mobility types and their prevalence in the sCJD codon 129
subgroups differs greatly between Collinge et al, and the findings of Parchi et al, and
this study. Collinge et al, found 22% ofMM cases to be type 1, and 78% to be type 2
and none of type 3, Parchi et al, found 93% type 1 and 7% type 2, but in this study
84% ofMM cases were type 1 and 16% type 2. In the Collinge study all MV and VV
cases were type 2, but Parchi et al, found that in MV cases 42% were type 1 and 58%
type 2, similar to this study 44% type 1 and 56% type 2. The VV cases analysed by
Parchi et al, were 17% type 1 and 83% type 2 and in this study the prevalence
identical in this subgroup was identical. It was thus decided to adopt the classification
system of Parchi et al. Type 1 or type 2 PrPres was detected in the majority of sCJD
cases and showed that these two PrP isotypes occur in combination with each of the
three possible PRNP codon 129 genotypes as previously shown (Parchi et al, 1999c).
The frequencies of isotype / genotype combinations observed in sCJD, do not appear
random (Parchi et al, 1999c). In contrast to fCJD/FFI D178N, sCJD shows the
opposite effect of the polymorphisms. The type 1 mobility is most commonly
associated with methionine homozygosity while type 2 is most closely associated with
valine homozygosity. The effect of the codon 129 polymorphism is reflected in the
conversion of type 1 to type 2 when passaged into transgenic mice HuPrP+/+ Pm-p0 0
with a valine at codon 129 of the human PrP gene (Collinge et al, 1996, Telling et al,
1996b). Homozygote methionine patients made up the majority of sCJD cases,
however, when subdivided on the basis of the PrP'es type two rather distinct subgroups
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are observed. The two subgroups are significantly different when classified according
to the PrPres mobility. Likewise, the homozygous valine patients are significantly
different in terms of age at onset and disease duration. This suggests that the
conformation of the PrPres determines these clinical parameters, or that both PrPres
mobility and clinical features are determined by another factor. The age at onset and
disease duration of the MM 2A cases would suggest that these patients represent the
MM 2 thalamic variant subdivision described by Parchi et al. However, examination
of autopsy reports from these patients found significant cortical pathology, featuring
spongiform encephalopathy, perivacuolar PrPsc deposits in some cases and the
cerebellum showed little spongiform change but had focal PrP deposits around areas
of spongiform change. The majority of these cases would therefore be described as
the cortical subtype, though thalamic involvement was present in some and one
featured a prominent thalamic pathology. Further correlation of the clinical
phenotype and results of EEG, MRI and cerebrospinal fluid (CSF) findings with
Western blotting results would help to define the differences between sCJD
subgroups. The extended duration seen in heterozygote sCJD patients would be
expected if homodimerisation kinetics between the M and V allele determine the
length of clinical symptoms prior to death. However, the MM 2A and VV 1 patients
likewise have long durations (possibly due to the young age in the latter). The limited
number of heterozygote cases and the possibility of ascertainment bias in favour of
long duration cases may also explain the similarity of heterozygote disease duration to
vCJD. Classification of sCJD cases by PrPres isotype enables investigation of other
factors such as non PRNP ORF genotype (Mead et al, 2000, Stephenson et al, 2000,
Jackson et al, 2001, Lloyd et al, 2001, Mead et al, 2001, McCormack et al, 2002) in
detennining susceptibility, phenotype (Hauw et al, 2000) or pathological mechanisms.
It also enables better identification of the defining features of vCJD in contrast to
atypical cases of vCJD.
The correlation between isotype and codon 129 genotype was initially claimed
to restrict sCJD to the higher molecular weight isotypes (termed type 1 and 2) with
only MM patients fonning type 1 PrPres and the lower molecular weight isotype
(termed type 3) to iCJD patients (Collinge et al, 1996). Further studies by Collinge et
al, have found sCJD patients displaying all three molecular weight banding patterns,
though MM patients have not been identified with the type 3 pattern (Hill, 1998,
Wadsworth et al, 1999a, Wadsworth et al, 1999b, Jackson and Collinge, 2001). The
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findings here showed no codon 129 restriction. This may be due to the analysis of a
larger cohort and referral ofmore atypical cases.
Two sCJD cases showed clear intermediate mobility when sampled at
different times, other cases (iCJD, GSS, murine transmissions of vCJD) with
intermediate mobility were more prevalent in their respective aetiological subgroups.
Due to their low frequency in relation to the other two sCJD mobility types, their
common MM codon 129 polymorphism and a lack of outstanding phenotypic
features, it was concluded that alternative conformations of PrPres can occur without
being the cause or effect of pathological or genotypic features of the individual. The
presence of bound cations establishes that this difference in conformation is not due to
metal ion bound and unbound forms ofMM type 1 PrPres. The classification system
employed by Collinge et al, also described other sCJD banding patterns termed types
6 and 7. They reported one case of sCJD classified as type 6 and one as type 7 (Hill,
1998). Type 6 was observed in a sCJD MV case with a predominantly
nonglycosylated PrP'es band and mobility of the type 3 group, type 7 was observed in
an MM case with higher molecular mass than the type 1 group. In a few cases of
sCJD classified as MV 2A and 4 out of 8 MV 2A iCJD cases there was a prominent
nonglycosyated PrPres band. The appearance of this pattern is most obvious at shorter
X-ray exposures, however, glycoform ratio analysis of linear range PrPres did not
identify a greater proportion of the nonglycosylated band in the sCJD cases and it was
concluded that this banding pattern is not a true reflection of the PrP'es present in
sCJD. This emphasises the subjective nature of glycoform ratio typing when applied
without careful quantitation. It is therefore important to develop a quantitative and
non-subjective classification system. High levels of nonglycosylated PrPres may result
from ragged NH3-terminal cleavage as they often display a broad undefined band,
even after PNGaseF treatment, which can hamper mobility classification. This may
be due to partial copper bound forms of PrP. The possibility of both type 1 and type 2
nonglycosylated PrPres in samples could also be a factor in high levels of
nonglycosylated PrP'es. Thus their subgroup classification and any subsequent
subgroup comparisons would be fundamentally flawed. Only one sample with a
molecular weight similar to type 7 was observed, in the posterior thalamus of the
fCJD E200K MM case and suggests this result may represent a rare alternative
conformation or possibly an experimental artifact. A higher molecular weight in a
fCJD E200K case has been reported previously (Gambetti et al, 1995) and also in a
sCJD MM case (Aucouturier et al, 1999). The conformation of the DY and HY
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strains differs in relation to the (3-sheet content (Caughey et al, 1998) and eight
different strains have been differentiated by their conformation (Safar et al, 1998). It
is more likely that a range of different conformations occur, leading to a wide range of
cleavage points in PrPres from codon 74 to 103 (Parchi et al, 2000b). These cleavage
points are variable even within codon 129/isotype subgroups, however they do
confirm the PrPres banding pattern observed and classification system used in this
study identify two major PrPres species that correlate with the sites of NLh-terminal
cleavage. It has also been shown that pH influences the mobility of PrPres (Zanusso et
al, 2001) with low pH conditions generating type 1+. This may be related to the
association of copper with the octapeptide repeat region (Miura et al, 1999), but
would contradict the suggestion that removal of bound metal ions produces a more
susceptible conformation. The 1+ mobility maybe due to pH induced changes in the
P-sheet structure of the carboxyl-terminal as addition of metal ions did not increase
the MW of the type 1 samples (Wadsworth et al, 1999a). It has also been suggested
that nucleic acids or collagen fibres present in brain homogenates affect the molecular
weight of PrPlcs bands (Cardone et al, 1999). Thus a range of different variables
affect the banding patterns seen and need to be standardised to enable meaningful
comparisons ofmolecular weights and 'strains'.
8.1.2 Variant CJD
Sporadic CJD is the major differential diagnosis for vCJD. This is especially
important as sCJD occurs in each polymorphic population (MM, MV, VV), but so far
vCJD has only been detected in MM individuals. It may be that only individuals with
the MM genotype are susceptible to vCJD or that these individuals are more
susceptible and infected individuals in the other genotypes are still in the preclinical
phase of the disease. The evidence from iCJD and kuru epidemics suggest that all
genotypes are affected, but with differing susceptibility (heterozygotes presenting less
frequently and later) and incubation periods (Brown et al, 1994a, Huillard et al, 1999,
Lee et al, 2001). As with the occurrence in MM individuals, the 2B isotype has
remained constant and is a distinctive marker of the disease aetiology. The young age
at onset, prolonged disease duration, psychiatric signs and distinctive neuropathology
in differential diagnostic of vCJD has been extensively reported and these features
were not examined due to the lack of variability in PrPres. The consistent molecular
phenotype of the vCJD cases is in accordance with the hypothesis that it signifies the
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BSE 'strain' (Collinge et al, 1996, Bruce et al, 1997, Hill et al, 1997a) and showed no
difference in terms of age at onset. Mouse transgenic studies have indicated the
effect of human codon 129 variants (Prnp null background) for the neuropathological
feature, isotype and incubation times after species barrier transmission of bovine MM
2B PrPsc or vCJD MM 2B (Collinge et al, 1996, Bruce et al, 1997). The 2B isotype
was not consistently retained upon transmission to mice encoding methionine at the
equivalent codon to human 129. The 2B (type 4) isotype is retained upon
transmission to mice carrying human PrP with the methionine polymorphism (Hill,
personal communication). The conversion of the isotype on transmission to mice
expressing human PRNP encoding valine at codon 129 suggests that transmission of
BSE to humans with an MV or VV codon 129 genotype may accumulate PrPres with a
different relative mobility to MM vCJD cases.
8.1.3 Iatrogenic CJD
A relatively large number of iCJD cases were available, 2 were DM cases
while the other 16 were GH. Both the DM cases were MM type 1, while the GH
cases were VV, MV or unknown. This in accordance with earlier findings (Brown et
al, 1994a). Iatrogenic CJD cases provided the opportunity to look for differences in
isotyping, in relation to the route of entry. As previously described DM cases were
restricted to the type 1 mobility, however, the GHT cases could be either type 1 or 2.
Previously only small iCJD cohorts have been investigated and reported with Western
blotting, n = 4 (Deslys et al, 1994), 5 (Collinge et al, 1996), 1 (Antoine et al, 1997), 6
(Parchi et al, 1997), 1 (Cardone et al, 1999) and 5 (Parchi et al, 2000b). The first
study utilised a scrapie-associated fibrils protocol and did not distinguish between
isotypes or the codon 129 polymorphisms (Deslys et al, 1994). The other studies
identified both type 1 and 2 mobilities (Parchi et al, 2000b) and involvement of all
three codon 129 genotypes (Windl et al, 1996). The correlation of these isotypes to
the genotypes seems to correlate to sCJD, with type 1 occurring predominantly in
methionine homozygotes and type 2 occurring in MV and VV patients, though overall
susceptibility is greater in VV individuals in contrast to sCJD. The analysis of 18
cases allowed a greater sample size and the identification of the rare type 1 VV (1
case) and previously unreported type 1 MV (2 cases) individuals. The differences in
classification systems employed make it harder to compare the results, but taking type
1 and 2 ofCollinge et al, as the type 1 identified in this study and type 3 as the type 2,
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it appears that there is little restriction on PrPies isotype formation by either codon 129
or route of entry. There were no type 2 MM cases which may reflect the relative
rarity of this mobility in sCJD MM individuals. The lack of donor and recipient strain
typing correlations are due to the often undefined source of infection such as pooled
pituitary hormone and possibly scrapie infected DM which makes the identification of
codon 129 and retained passage variables such as lesion profile and isotype
impossible. In one study in which cranial surgery transmitted sCJD from an MM
individual to an MV individual, the clinical symptoms and neuropathology were
congruent, and interestingly PrP deposits were found in spinal cord and peripheral
nerve of the host. The source of the agent may be a greater influencing factor as
batches of DM were found to result in cases of iCJD with the MM genotype while
different sources have affected VV individuals (Brown et al, 1994a). Most cases of
iCJD are presumed to have arisen from sCJD cases and it has been seen that sCJD
retains molecular phenotype on transmission (Telling et al, 1996b). The identification
and molecular strain typing of both the donor and resulting iCJD infections should be
followed up wherever possible as it provides the only source of information
concerning human to human transmission of CJD, which is desperately needed to
assist in the identification of iatrogenic transmission of vCJD. The younger age at
onset and shorter disease duration in the heterozygote GHT cases supports the
contention that interaction of PrPSL and PrPc molecules and subsequent conversion is
aided by identical primary sequence. The additional finding that an iCJD case can
accumulate two types (conformations) of PrPres can be interpreted in one of three
ways; a) a pooled batch of growth hormone was infected by two different sCJD
patients, b) one sCJD patient with two PrP,es isotypes infected a single batch or c) the
different conformations arose in vivo. The substantial numbers of donors pooled in
growth hormone batches does not rule out the possibility of two sCJD infections,
despite the relative rarity of sCJD. If dilution of PrPres from one source leads to
individuals receiving different infectious PrPres conformations or two PrPres
conformations form in situ from one infecting strain, then the assumptions about
retention of conformation from donor to host on transmission must be reassessed.
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8.1.4 Familial TSEs
The majority of isotyping and glycoform ratio findings in familial TSEs were
reported during the course of this study, predominantly with respect to the D178N
mutation. Familial forms of prion disease, like the idiopathic form, can display both
the type 1 and type 2 mobility with differing glycoform ratios (Cardone et al, 1999).
Only one case with the D178N mutation, diagnosed as FFI, was analysed and
displayed low levels of PrPres in the frontal cortex and basal ganglia. This reflects the
findings of previous studies (Brown et al, 1995, Parchi et al, 1995b, Rossi et al,
1998). It was by no means an in depth study of regional distribution, as numerous
investigations of this type have been carried out on FFI patients with MM or MV
codon 129 polymorphisms and differing disease durations (Parchi et al, 1998c, Parchi
et al, 2000a). Unfortunately no cases of fCJD D178N were available for comparative
analysis, though once again many such studies have been performed and the findings
would likely contribute little to the well characterised differences in isotype (Monari
et al, 1994, Gambetti et al, 1995, Parchi et al, 1998c, Parchi et al, 1999b). However,
comparison of FFI, fCJD D178N and fCJD E200K have found PrPres of three
mobilities and a degree of different prominent diglycosylation, all of which could be
classed as the B type (Gambetti et al, 1995). Transmission studies of FFI MM and
MV or fCJD 178 VV, to TgMHu2M mice displayed retention of isotype and
neuropathological features (Telling et al, 1996b). If the codon 129 and isotype
determine clinical features in preference to the mutation, it may imply that the
mutation is a predisposing factor and that strains dominate, making a virus hypothesis
more likely.
Cases of fCJD with the E200K mutation co-segregated with methionine are
the most common familial prion disease and invariably display type 1 mobility with
prominent diglycosylation (Gambetti et al, 1995, Cardone et al, 1999). Investigation
of the three cases here found the same type IB pattern in both MM and MV
individuals. The clinical features are similar to sCJD, primarily featuring dementia
and commonly ataxic gait deficiencies (Simon et al, 2000). The codon 129
polymorphism of the unmutated allele is usually the same as the mutated allele due to
the preponderance of the methionine codon 129 polymorphism. However, the
relatively small numbers of cases do not make distinguishing between clinical signs
and neuropathology in all the homozygous and heterozygous subgroups easy. Cases
of the E200K mutation coupled with valine at codon 129 and type 2 mobility are a
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rare subgroup (Hainfellner et al, 1999, Puoti et al, 2000). These patients also have
prominent diglycosylation of PrPres. One patient studied had a long disease duration,
but rapidly progressive dementia (Hainfellner et al, 1999) which along with PRNP
sequencing can distinguish these cases from vCJD, that Western blotting alone would
not. These patients have phenotypic features in common with sCJD W 2A cases
including ataxia, dementia, plaque-like prion deposits in the cerebellum and the
Western blotting pattern (Kovacs et al, 2000) suggesting a strong codon 129-isotype
correlation with disease phenotype. Studies on cultured fibroblasts isolated from
fCJD patients and mice expressing transgenes with the corresponding mutations
suggest that, unlike sCJD, mutations at codons 178 or 200 cause aberrant
glycosylation due to their proximity to the glycosylation consensus sequences and
inhibit transport of the unglycosylated form to the cell surface (Capellari et al, 2000)
resulting in the prominent diglycosylation of the PrP,cs. Though other reports have
found a lack of glycosylated PrPres in human patients (Gabizon et al, 1994) and
mutant murine PrP expressing CHO cells (Wong et al, 2000b).
The GSS cases investigated displayed different mobilities, dependent upon the
codon 129 polymorphism, though the heterozygote case was from a different family
and may, be a result of other factors. Typical diglycosylated, monoglycosylated and
nonglycosylated bands, and smaller PrP'es fragments are detected in GSS (Kitamoto et
al, 1991, Tagliavini et al, 1991, Young et al, 1997, Parchi et al, 1998a, Piccardo et al,
1998, Tagliavini et al, 2000). As well as the typical PrPres banding pattern, cases of
GSS accumulate 7, 8, and 11 kDa fragments (Tagliavini et al, 1991, Parchi et al,
1998a). GSS P102L cases display the IB isotype as well as the low molecular weight
bands, however, cases with the F198S or D202N mutation display the 2B isotype.
PrP with a P102L mutation expressed in E.coli shows decreased a-helical content but
not increased protease resistance, suggesting the mutation affects the conformation
and hence cleavage site of the PrPres (Cappai et al, 1999). In this study the focus was
on the three 'typical' bands, as resolved by 12% acrylamide gels in the classical
P102L variant ofGSS and a 2B isotype was not detected. Most commonly P102L co-
segregates with methionine (Young et al, 1997) and cases are almost completely
restricted to the methionine homozygous population. Heterozygote cases have a more
even distribution of PrP plaques (Brown et al, 1995) though this is unlikely to account
for the difference in isotype identified in this study. The valine allele can co-
segregate with the mutation and has been detected as 11 kDa PrP'es fragments
(Tagliavini et al, 1991). The diversity of PrPies fragments seen in GSS cases and
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some sCJD cases (Chen et al, 1995, Cardone et al, 1999) highlights the limitations of
strain typing based upon the three typical PrPres bands and comparison with
neuropathological features such as PrP plaque formation.
Familial CJD patients with insertional mutations of four or five octapeptide
repeats have been studied and display type 1 mobility with MM codon 129 (Parchi et
al, 2000b). Insertional and even benign deletions of octarepeats do not directly affect
the PrPres isotype mobility as they are present in the region of PrP that is cleaved by
PK (Lehmann and Harris, 1996). They also do not appear to affect the cleavage point
via additional metal ion binding or alteration of the overall conformation of the mtPrP
as they co-migrate with sCJD MM 1 cases. Further studies into the effect ofmetal ion
chelators on the banding pattern may help elucidate the role of the additional
octapeptide repeats and their metal ion association in the development of the
pathology. Transgenic mice featuring deletions of the NH3-terminal up to codon 93
are phenotypically normal, susceptible to scrapie infection and produce protease-
resistant truncated PrP (Shmerling et al, 1998). This suggests that this region of PrPc
and metal ion binding are not essential for propagation of prions and that other
mechanisms can compensate to retain viability.
The codon 129 polymorphism, as already stated, correlates closely with
mobility, glycoform ratio, clinical symptoms and neuropathology of familial TSEs.
Similarities in phenotypic presentation between familial and sporadic CJD are all the
more important when codon 129 and isotype are the same, implying that these factors
have a greater influence than point mutations on the phenotype. The sCJD VV1
subgroup is rather similar to fCJD D178N VV type 1 cases with young age at onset,
long disease duration, a lack of PSWCs and cortical pathology featuring ballooned
neurons.
8.2 Glycoform ratio findings
8.2.1 Sporadic and variant CJD
Currently the improved classification of CJD phenotypes, in terms of clinical,
neuropathological and molecular features is the focus of a considerable amount of
research. The use of glycotypes to define molecular 'strains' of TSEs in humans has
been most succesfully applied to the differentiation of sCJD and vCJD, to support the
contention that vCJD is a result of BSE infection. The suggestion that similar
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'strains' can likewise be identified amongst the numerous sCJD phenotypic variants is
dependent on greater resolution of the glycoform ratio differences, in addition to the
Mr of the PrPres. Comparison of quantitative levels of PrPres glycoforms are hampered
by the extensive number of experimental variables and limit the assumptions that can
be made about the in vivo levels.
Cell specific differences in PrPc glycosylation have been proposed to account
for neuropathological targeting (DeArmond et al, 1997b), thus the location and degree
of tissue sampling may from the outset influence the levels of PrPres glycoforms
detected. The accumulation of one or other PrPres glycoform at less than 10% of the
total PrPres level may not be detectable. Despite this low levels of PrPc™ (<10% of
total PrP) have been proposed to be capable of causing disease (Hegde et al, 1998).
The homogenisation procedure may result in different solubilisation of PrP aggregates
and the resulting analysis of different pellet or supernatant fractions. Storage
conditions may lead to differential sample degradation and some subsequent loss of
detectable PrPies. The use of different Western blotting methods can influence the
glycoform ratios at a number of steps. Thickness of polyacrylamide gels and
subsequent transfer to membranes can influence the relative levels with the lower
molecular weights bands transferring more readily to membranes. Use of different
antibodies, with preferences for different glycoforms (Zanusso et al, 1998a) or
detection of different epitopes such as 6H4 and 3F4 influence the different forms of
PrPres detected.
These factors should be taken into account when comparing results from
different groups and drawing conclusions on the in vivo PrP,es levels. By analysis of a
large cohort of cases utilising the same technique the quantitative analysis could be
standardised and variables minimised.
Glycoform analysis of PrPres has use in distinguishing certain forms of human
TSE such as vCJD, FFI and fCJD. It can even identify the codon 129 genotype to
some extent in sCJD cases (i.e. VV 2A cases) and the codon 129 genotype could often
be accurately predicted from the appearance of the PrPres banding. The glycoform
ratio findings in the sCJD VV 2A subgroup are similar to those published by one
large study (Parchi et al, 1999c) though they also reported a similar ratio in the sCJD
MM 2A cortical subgroup that was not observed here. Confusingly, the glycoform
ratio of the sCJD MM 2A thalamic subgroup (Parchi et al, 1999c) and the analogous
sFl phenotype (Parchi et al, 1999a) featured a very different glycoform ratio to other
publications on the sFI phenotype (Mastrianni et al, 1999). Another study of six
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sCJD patients found a similar increased diglycosylated glycoform ratio in a VV type 1
patient and an MM type 1 patient, but a more typical sCJD glycoform ratio in the VV
type 2 patient and a VV patient with an intermediate mobility (Aucouturier et al,
1999). The rest of the sCJD codon 129 subgroups were indistinguishable by
glycoform analysis alone and the inclusion of this variable in sCJD 'strain typing'
does not aid classification. Differentiation of sCJD based on isotype mobility
represents the limit of the Western blotting technique. The small degree of glycoform
ratio difference seen between cases was most obvious in terms of variable
diglycosylated levels, due to higher levels of nonglycosylated PrPICS in some cases.
This may be due to NH3-terminal cleavage by PK producing nonglycosylated PrPres
with different cleavage sites (Parchi et al, 2000b). The greatest amount of glycoform
ratio variability was found in the nonglycosylated band of type 2 cases by Parchi et al,
(Parchi et al, 1996). Full sequencing of the PRNP gene is required to detect mutations
or rare polymorphisms that can produce glycoform ratios resembling vCJD. In
combination this data should, in almost all cases, differentiate between vCJD and
other forms of human TSE.
Glycoform ratios are distinct in vCJD and can be easily differentiated from
sCJD by eye, providing an important diagnostic marker that does not require
quantitation. The highly glycosylated PrPres found in vCJD appears to be a reliable
molecular marker for this form of CJD, confirming the original observation made in
10 cases by Collinge et al (Collinge et al, 1996) and extending it to 50 cases of known
genotype. The differentiation of sCJD VV 2A cases from other sCJD cases, due to a
more prominent glycosylation, can be seen by eye with experience, though
quantitation aides in the distinction. It remains to be seen whether the codon 129
polymorphism will differentiate the glycoform ratio in non-MM vCJD cases (if they
occur). It is not possible to predict the isotype in VV vCJD cases. They may have an
even more prominent hyperglycosylation based on the findings in sCJD VV cases, if
the type 2 mobility is retained. The glycoform ratio may be similar as seen between
fCJD E200K MM and VV cases. They may display a lower relative mobility and
similar glycoform ratio as seen in transmissions to transgenic mice carrying a valine
encoding 129 human transgene, or may display a relative lack of diglycosylation as
seen in sCJD VV 1 cases if the relative mobility is different. Thus the current
knowledge in this field does not allow for definitive prediction of glycoform ratios in
hypothetical genotypic-aetiological situations and rests on the contentious issue of
strain or host dominance in TSEs.
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Surprisingly a predominantly nonglycosylated pattern was uncommon, as cell
culture models have demonstrated that the nonglycosylated band is more prone to
conversion to a protease resistant form and lack of glycosylation enhances PrPres
formation (Taraboulos et al, 1990a, Lehmann and Harris, 1997, Ma and Lindquist,
1999, Korth et al, 2000). In fact the blockade of cell mediated glycosylation increases
the propensity for PrPsc formation (Caughey, 1999) and the generation of recombinant
glycosylated PrPsen inhibits cross species formation of PrPres (Priola and Lawson,
2001). However, it inhibits transport to the cell surface and subsequent internalisation
both of which play important roles in PrP conversion (Caughey et al, 1989). Studies
on the PrPc charge heterogeneity in Syrian hamster brains suggest that glycosylated
PrPc is not required for formation of PrPres. However, the common appearance of
predominant diglycosylation reflects the relative levels of this glycoform expressed in
uninfected brain tissue, thus accumulation of the other glycoforms may be indicative
of a specific pathological mechanism (DeArmond, 1999).
8.2.2 Sporadic CJD carrying an uncommon polymorphic
deletion
The influence of the codon 129 polymorphism and point mutations on PrPres
banding patterns are well documented, the influence of other polymorphisms has not
been documented. The other human polymorphisms 171, 219 and deletion of one of
the five octarepeats between codons 51 and 91 (Puckett et al, 1991) are present in
distinct ethnic groups and far smaller proportions of the population. The octapeptide
deletion has not been shown to be pathogenic or predisposing to the development of
CJD. The presence in only -1% of Caucasians (Bosque et al, 1992, Windl et al, 1996)
and low overall incidence of CJD makes epidemiological comparisons difficult. Due
to the proximity of the primers to the PRNP start and stop codons and the small but
significant presence of this polytmorphism in the general population, it was concluded
that the deletion seen in a sCJD MV case was most likely the R34 mutation between
the 4th and 5th octapeptide repeats. The distinct glycoform ratio of a sCJD
heterozygote case with an octapeptide deletion, type 1 mobility and increased levels
of diglycosylated PrPres, suggests that this non-pathogenic polymorphism influences
glycosylation of host PrPres either constitutively or in response to TSE infection. This
finding may acount for the glycoform ratio findings in the study by Acoutier et al,
(Aucouturier et al, 1999). The effect of this polymorphism on disease phenotype is
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dependent upon the assumption that the isotype observed was representative of the
patient as a whole, as one sCJD MV case was identified with neuroanatomically
varying isotypes and another with variable glycoform ratios, including increased
diglycosylation. Unfortunately the tissue available from this anomalous case was not
described and tissue for regional analysis of a sCJD MV 1 was not available,
precluding determination of regional influences on glycoform ratios in cases
diagnosed as sCJD MV type 1. The presumed impainnent of metal ion binding in
individuals with this polymorphism may also play a role in disease susceptibility or
PrP function and responses to the development of pathology. This may manifest itself
through an increased disease duration. Increased disease duration in all sCJD
subgroups also reduces the sensitivity of EEG and therefore some cases of sCJD with
24 bp deletions may not be identified, reducing their apparent prevalence. The
presence of this polymorphism may predispose to sCJD but this conjecture is not
supported by the similar prevalence of identified cases of sCJD with this
polymorphism and normal individuals with the polymorphism.
8.2.3 Iatrogenic CJD
So far there is little explicit description of the glycoform ratios seen in iCJD
cases, though a predominance of the monoglycosylated band has been observed and
quantified (Collinge et al, 1996, Cardone et al, 1999) and one case has been reported
with a glycoform ratio resembling vCJD. Type 1 cases have a greater degree of
nonglycosylated PrP,cs than type 2 cases who display equal levels of diglycosylated
and nonglycosylated, as seen in cases of kuru, which are also type 2 mobility
(Collinge et al, 1996). The degree of diglycosylation was less apparent than in some
sCJD cases but may still correlate with PrP amyloid plaque formation in these
patients.
8.2.4 Familial CJD
The glycoform ratios of the MM and MV cases featuring the E200K mutation
investigated were very similar to those previously reported in E200K MM patients
(Cardone et al, 1999) and to the sCJD VV 2A subgroup. The glycoform ratio in
fCJD E200K cases has been shown to differ to FFI and CJD 178 (Gambetti et al,
1995), in this case an E200K type 1 case was compared, though the codon 129
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genotype was not specified. E200K VV patients are reported to display the 2B
isotype and a glycoform ratio featuring more pronounced diglycosylation very similar
to that of vCJD (Hainfellner et al, 1999, Puoti et al, 2000). E200K cases co-
segregating with methionine at codon 129 analysed by Parchi, P. and Gambetti, P.
(1998, unpublished data) have a similar glycoform ratio to the type 2 E200K VV
cases according to Hainfellner et al, 1999. However, the published values of
Hainfellner et al, are more prominently diglycosylated than the published data of
Gambetti et al, 1995 and the findings are more readily interpreted merely as the type
B pattern. Therefore, it is of paramount importance in any cases of suspected non-
MM vCJD that the whole PRNP coding region is checked for mutations. It is also
important as the phenotype of fCJD E200K VV cases feature a prolonged disease
duration, unsteady gait and a neuropathology similar to sCJD VV 2A cases with
plaque-like PrP deposits. Features such as a rapidly progressive dementia, along with
diffuse PrP staining, as opposed to florid plaques, in the cerebral cortex, thalamus
basal ganglia, brain stem and cerebellum distinguish these cases from vCJD.
The glycoform ratio of the FFI case investigated was outwith the linear range
but displayed a high degree of diglycosylated PrP'es (--60%), similar to vCJD and
previous reports (Monari et al, 1994, Gambetti et al, 1995, Montagna et al, 1998,
Parchi et al, 1998c, Parchi et al, 1999b).
The GSS cases displayed two different glycosylation ratios, the MV case
diagnosed as intermediate mobility from the frontal cortex and the MM case classified
as 1B from the frontal cortex had glycoform ratios resembling the sCJD VV 2A cases,
fCJD E200K cases and previously published reports (Cardone et al, 1999). However,
the MM case diagnosed as type IB from thalamic tissue had a more pronounced
diglycosylation (like vCJD and FFI) than seen in a previous study (Parchi et al,
1998a).
The glycoform ratios of the insertional mutations were similar to sCJD cases
and the PrPres banding pattern resembled that seen in another study (Parchi et al,
2000b) though values were not stated to allow comparison. Unlike the sCJD case




Only one hemisphere was available in each study, the neuropathology of the
other hemisphere was assessed by immunohistochemistry and H&E staining. This
allows comparisons between Western blotting and neuropathological features
(generally similar features are seen in each hemisphere). However, inter-hemispheral
differences have been noted in sCJD MM cases (MacDonald et al, 1996) and it must
not be assumed that the pathology seen in one hemisphere is present to the same
degree in the other and is thus an indicator of a glycosylation state or isotype
conformation found in that corresponding region.
It has been suggested that neuropathological features of TSEs can be
correlated to banding patterns. The classical triad of neuropathological features may
correlate to the PrP,es isotype, such as plaque formation, specific perivacuolar or
diffuse staining patterns, correlating to type 1 or 2. Spongiform change or astrocytic
gliosis might be an indicator of the degree of glycosylation. The presence or absence
of PrPres as detected by Western blotting may not correlate with neuropathological
features and this may be related to levels of PrPres required to produce structural
lesions, which varies with brain region (Gambetti et al, 1995).
Correlation of isotypes with PrPres morphological deposits has been made
(Puoti et al, 1999) and this would support the nucleation-dependent polymerisation
model of prion protein conformational transmittance. Due to the differential spatial
distribution of neuropathological features in different patients according to aetiology
and genotype it may be possible to identify correlations with neuroanatomically
specific PrP'cs. The types of staining pattern and plaque fonnation observed differs
considerably. Immunocytochemistry enables the identification of different
morphological PrP deposition, including plaques. Many polyclonal and monoclonal
antibodies have been used as well as different pretreatment protocols, amplification
and detection systems and they can influence the sensitivity and specificity of PrP
visualisation (Hardt et al, 2000). Monoclonal antibodies to PrP are used, such as
KG9, which has very noticeable pericellular staining and 3F4 which has slightly
better synaptic staining sensitivity, to visualise the PrP deposits. Differences in the
staining specificities of monoclonal antibodies to PrP may relate to the accessibility of
the epitopes in different types of PrP aggregates, though some antibodies show
differences in glycofonn specific staining on Western blots (Zanusso et al, 1998a).
The banding patterns observed suggests a degree of correlation of PrP plaques or
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plaque-like structures with increased glycosylation and relative mobility. However,
this was not seen in a case displaying regional glycoform ratio and results suggest that
the increased glycosylation may correlate with spongiform change, neuronal loss or
astrocytosis. The overall levels of PrPres observed on Western blotting did not appear
to correlate with the levels of deposits observed on immunocytochemistry. The
reasons for this could be interhemispheral differences.
In an isotype-immunostain comparative study both type 1 and 2 isotypes have
been observed. In patients with only diffuse PrP staining, only type 1 PrPres was
found. In patients with both staining patterns (4 MM, 1 MV), type 1 PrPres was found
in areas of diffuse staining and type 2 PrPres was found in areas of focal staining. In
the 1 MV patient with both staining patterns there were both PrPres types, in the other
2 MV patients there was only type 2 PrP'es. Two VV patients had type 2 PrPres with
perineuronal and plaque-like deposits superimposed to diffuse staining (Puoti et al,
1999). So far no reports of differing glycosylation related to brain region have been
made, so the influence of this variable must be inferred from the different PrPres
deposition seen in sCJD, fCJD and FFI cases and their glycoform ratios.
8.3.1 Sporadic CJD
The assumption that single cortical samples display PrPres isotypes
representative of an individual as a whole was systematically investigated and found
both molecular weight differences and glycoform ratio variability in the PrPres
detected. The presence of multiple PrPies conformations within individuals was the
most frequent form of variability and a World Health Organisation study designed to
establish a consensual typing classification found both type 1 and 2 conformations.
This was attributed to the large amounts of tissue sampled and suggests that within
most individuals a degree of both isotypes are present. The proportion of sCJD cases
previously reported to contain both isotypes (3%) (Parchi et al, 1999c) suggested that
this was an uncommon occurrence. However a more detailed study found 3 out of 14
(24%) patients to have both isotypes (Puoti et al, 1999) and in another study of 32
cases of CJD, 2 were found to have both isotypes (6.3%) (Baron and Biacabe, 2001).
In contrast to the cases investigated here, the type 1 nonglycosylated band was more
prominent. The findings of 2 out of 6 (33%) sCJD cases with both isotypes in this
investigation supports a high prevalence of this phenomenon, though the prevalence
upon routine isotyping in sCJD cases was only 4.5%. The multiple isotypes found in
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routine analysis were not restricted by the codon 129 polymorphism but based on the
findings on small tissue samples in large cohorts of patients it seems likely that there
is a predisposition to formation of one isotype by the codon 129 polymorphism,
although not to the exclusion of the other isotype. It was reported that 4 MM cases
and an MV case featured both isotypes (Puoti et al, 1999), though it may be that MM
cases are more prone to formation of both isotypes. The results here represent the
first report of widespread PrPres glycoform heterogeneity within individual cases of
sCJD, iCJD and fCJD. The glycoform ratio findings were limited to a few individuals
but suggest the codon 129 polymorphism plays a role, with heterozygosity producing
a more varied pattern. The mechanism by which this variability arises may be
regional variation in PrPc glycosylation of the host as opposed to differential
conversion of the glycoforms. The finding of two very distinct mobilities and
glycoform ratios in one case (Head et al, 2001) highlighted the potential overlap of
sCJD and vCJD 'strain types'. Other regional studies on PrPres levels and banding
patterns have been carried out primarily focusing on the FFI phenotype (Parchi et al,
1995b, Mastrianni et al, 1999). The largest previous study involved sampling from
large portions of tissue (3-5 grams) in 8 regions (Brown et al, 1995) and focused on
establishing the relative levels of PrP'es. Differences in the PrPies banding patterns
were not identified by Brown et al, in this study, though heterozygotic sCJD cases
were not analysed. The investigations here involved the sampling of a greater degree
of subcortical and deep grey matter regions. Comparison of the relative mobilities
and glycoform ratios of these regions with the isotyping classifications, established
for a large cohort of sCJD and vCJD cases, identified the potential for
misclassification. Cases were chosen based on their codon 129 polymorphism and
cortical isotype classsification and included sCJD heterozygotes as well as including
the first neuroanatomical investigation of vCJD cases.
Differences in isotype have been correlated with the PrPres deposits seen on
immunohistochemistry (Puoti et al, 1999). PrP plaques have not been reported in the
sCJD MM 1 subgroup (Parchi et al, 1996, Tranchant et al, 1999). It has been
suggested that diffuse staining without the presence of plaques is indicative of type 1
mobility on Western blot (Puoti et al, 1999). The lack of any type 2 PrPres in the
sCJD MM 1 case investigated may represent the lack of PrP plaques. Overall PrPres
quantities in different brain regions were similar, in contrast to the findings of Brown
et al, who found the greatest levels in the occipital cortex while the cerebellum
displayed less and levels in the basal ganglia were barely detectable (Brown et al,
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1995). A different isolation procedure was adopted and this can lead to loss of PrPres
(Parchi et al, 2000a). Other ancilliary diagnostic investigations (e.g. CSF, MRI and
EEG) do not help to further differentiate cases in the MM 1 subgroup, neither do age
at onset or disease duration (Zerr et al, 2000) and it seems that this subgroup is fairly
homogenous.
The sCJD MM 2A case investigated conformed to the cortical subgroup
described by Parchi et al, (Parchi et al, 1999c) based on clinical and
neuropathological features. MM2 cortical cases have pathology resembling that of
the MM1 subgroup aside from a lack of cerebellar involvement. This is reflected in
their lack of ataxic symptoms (Parchi et al, 1999c). The PrP deposits are typically
strong coarse or perivacuolar in nature and affect the occipital lobe greatest (Worrall
et al, 1999) as well as there being thalamic lesions. The lack of PrP plaque-like
deposits, yet the presence of type 2 PrPres suggests that other morphological deposits
are composed of PrPies of the type 2 conformation.
Parchi et al, 1999 carried out a neuroanatomical Western blotting study of a
sFI case showing thalamic atrophy, especially the medial dorsal, anterior ventral and
inferior olive. A wide range of tissues were quantitatively assessed for PrP,es. The
amounts and distribution of PrPres was the same as in Familial Insomnia and the type
2 mobility was seen throughout (Parchi et al, 1999c). The PrPres levels and
distribution are quite different to sCJD. A sCJD MV 1 case was unavailable for
comparison with the MV 2A cases, though a previous study found that the glycoform
ratios appeared identical in temporal, parietal and occipital cortices of one patient
(Tranchant et al, 1999).
The two sCJD MV 2A cases investigated had greatly differing disease
durations (21 months in the first case and 8 months in the second case). The occipital
lobe is relatively spared in short disease duration cases, however, there was relatively
less PrPres in the occipital lobe of the long disease duration than the short disease
duration case. Sporadic MV 2A cases have pathological lesion involvement of the
basal ganglia along with thalamic, focal cortical involvement and presence of kuru-
plaques. There is strong synaptic staining that co-localises with spongiform change
and plaque-like focal deposits in the cerebral cortex as well as neuronal tract staining
(Parchi et al, 1999c). These neuropathological features may correlate with the PrPres
observed, plaque-like and kuru-plaques resulting in type 2 PrPres deposits and the
prominent basal ganglia and thalamic pathology resulting in increased PrPc
glycosylation as a protective mechanism prior to PrPres formation. Such a protective
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mechanism could operate through stearic hindrance of dimer formation (Zuegg and
Gready, 2000). However, in the regional study of a sCJD MV 2A case in which
glycoform variation was found, the other hemisphere displayed less PrP amyloid
plaques in these regions and a more prominent synaptic deposition. Studies on
transgenic mice with mutated PrP glycosylation consensus sequences has indicated
that PrPc location in the thalamus and amyloid-like PrP deposits are dependent on the
presence of glycosylated PrPc (DeArmond et al, 1997b). High intensity of the basal
ganglia in MRI (T2-weighted) is sensitive in all subgroups of sCJD but most reliable
with MV2 patients. Hyper intense signals on T2 and diffusion weighted MRI in the
cortex can also be prominent and correlate to spongiform degeneration, astrocytic
gliosis and neuronal loss (Samman et al, 1999). This may be related to the longer
disease duration as hyperintensities have been shown to become more pronounced
over time (Zerr et al, 2000). Therefore it is also possible that they correlate to
increased glycosylation, possibly as a protective response because it is also related to
a longer disease duration seen in the long disease duration MV 2A case and the sCJD
MV 1 case featuring a 24 bp deletion. A degree of glycoform ratio differentiation has
been noted in sCJD type 1 and 2 cases, in a limited number of regions. Type 1 sCJD
cases displayed a greater proportion of diglycosylated PrPICi in the cingulate gyrus,
monoglycosylated PrPres in the mesencephalon and nonglycosylated PrPres in the
hippocampus. In the type 2 cases the locus ceruleus displayed a greater proportion of
diglycosylated PrPres and the cerebellum displayed prominent nonglycosylated PrPres
(Parchi et al, 1996). Without codon 129 distinction and the values obtained for all the
regions tested it is difficult to compare these results with the differences in glycoform
ratio detected in this study. However, the increased diglycosylation in the locus
ceruleus was similar to that seen in the basal ganglia and thalamic regions of the first
sCJD MV 2A case investigated. The increased nonglycosylated PrPres in the
cerebellum may result from the presence of type 1 and 2 nonglycosylated bands that
are not clearly separate from each other.
The VV1 subgroup is the rarest and has a distinct clinicopathological
phenotype. A sCJD VV case with a young age at onset, long disease duration,
presenting with behavioural symptoms and featuring more dementia than cerebellar
deterioration, displayed type 1 mobility on biopsy and type 2 at autopsy (Head et al,
2001). Biopsy material did not show the presence of plaques but rather diffuse
granular "synaptic" staining. The autopsy displayed a similar histological appearance
in the cerebral cortex, though the caudate nucleus, putamen, thalamus and brain stem
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displayed small numbers of PrP-positive plaque-like structures upon PrP
immunocytochemistry. This does not account for the presence of the type 2 PrPres in
the frontal cortex at autopsy. The presence of PrPres type 1 throughout the brain of the
case neuroanatomically investigated and a lack of PrP plaques on
immunocytochemistry, also reported in patients of this subgroup (Parchi et al, 1999c,
Worrall et al, 1999), supports the contention that this correlates with diffuse PrPres
morphology. A lack of glycoform ratio differences in the case investigated was also
found in another study examining a wide range of tissues (Worrall et al, 1999). It was
reported that PrPres levels correlated directly with the degree of spongiform
degeneration (Worrall et al, 1999). In this study there was status spongiosis of the
cerebral cortex and spongiform change in the basal ganglia and cerebellum, all of
which showed significant PrPre> levels.
In a study of 12 valine homozygotes, five of which were identified as type 2A
there was a relatively uniform phenotype (Kovacs et al, 2000). The frontal and
parietal cortices displayed mild to severe spongiform change and PrP deposits of three
types (neuronal, diffuse/synaptic and plaque-like deposits). The occipital cortex
displayed spongiform change, diffuse PrP staining with a laminar accentuation and
plaque-like PrP deposits. The basal ganglia has severe confluent spongiform change
as well as diffuse PrP staining, perineuronal and plaque-like deposits. Plaque-like
structures and type 2 PrPres supports the hypothesis of Puoti et al, that the two are
related but the additional presence of diffuse deposits did not result in additional type
1 PrPres. In another study on 3 sCJD VV cases featuring only type 2 PrPres, similar
neuropathological features were seen, though only occasionally did the cerebral
cortex display PrP plaque-like structures, while punctate nonamyloid PrP and diffuse
staining was seen in the substantia nigra and granular cerebellar layer (Tranchant et
al, 1999).
There may be some correlation between the PrPres glycoform ratios and
clinical or neuropathological features in cases such as sCJD VV 2A, MV or vCJD.
The presence of spongiform change, PrP plaques, or plaque-like deposits and their
neuroanatomical location, high signal MRI findings and lack of characteristic EEG
PSWCs, may be related to prolonged disease duration and could result in the
increased degree of glycosylation seen in some cases.
The spatial distribution of M and V allele expression in heterozygotes and
their conversion into PrPres in different brain regions is currently unknown but would
greatly improve the understanding of the pathological mechanisms involved in
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conversion of PrPc to PrPsc and neuropathological targeting of prion strains. This
could be elucidated with cyanogen bromide cleavage (CNBr) or endoproteinase Lys-
C and Edman degradation of SDS-PAGE isolated PrPres. The cleavage sites have
been determined by Edman degradation (Parchi et al, 2000b), however, codon 129 is
too distal to the NH3-terminal for analysis without further cleavage. Tthe NH3-
terminal PK cleavage sites have been located between codon 78 and 103 in sCJD and
Edman degradation can only process up to 30 amino acids. Alternatively allele
specific antibodies, could differentiate between codon 129 polymorphic PrP, could be
used either on immunocytochemistry or Western blotting, depending on their
applicability. Allele specific monoclonal antibodies have been produced to the 219
polymorphism present in the japanese population (Matsunaga et al, 2001) and PrP
antisera that differentiated between wild type and mutant forms of PrP featuring the
E200K mutation have been produced (Gabizon et al, 1996).
8.3.2 Variant CJD
The relative consistency of the PrPies banding pattern throughout the CNS in
vCJD patients reflects the consistency of the neuropathological profile (Armstrong et
al, 2002). This suggests dominance of the BSE 'strain' over host PrPc, though the
restriction of this aetiology to the methionine homozygous population could also
account for the consistency. The banding pattern was not completely consistent and
the prominence of the lower portion of the monoglycosylated band in the cerebellum
suggested alternative occupancy at codon 181 of the N-linked glycan chains. The
banding pattern of a fCJD case carrying a V1801 mutation that prevents attachment of
oligosaccharide chains to the 181 site, elucidated the nature of this monoglycosylated
phenomenon. This case, as expected, lacked a band in the position normally occupied
by the diglycosylated band. This confirms that the uppermost PrPres band is in fact
diglycosylated. There was also a band present in the upper monoglycosylated region,
demonstrating that PrPres glycosylated solely at the 197 site can form PrPres of this Mr.
There was no detectable signal in the lower region of the monoglycosylated band.
Whether this is due to the low PrPres levels as a whole, or implies that PrPres is not
glycosylated at codon 181 and does not fonn a band in this region, is open to
conjecture. Studies comparing transgenic mice with mutations at either the codon
183 or 199 site that prevent glycosylation of PrPc demonstrated that the
oligosaccharide chains at the 181 residue are more abundant and variable in structure
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in the cerebellum than those at the 191 site (DeArmond et al, 1997b). The possibility
remains that the lower proportion of the monoglycosylated band represents PrP
glycosylated at codon 181. The low levels of PrPres in these patients may explain the
lack of transmissibility to mice (Tateishi et al, 1996) or may be due to hindrance of
homodimeric conversion of monoglycosylated CJD VI801 PrPies and murine PrPres.
Expression of Syrian hamster PrPc featuring a threonine to alanine mutation at codon
183 preventing glycosylation at the first consensus sequence in transgenic mice null
for mouse PrP, prevented transmission of scrapie strains (DeArmond et al, 1997b).
This was probably due to retention of the mutant PrP in the cell body (DeArmond,
1999). The transmission and molecular of strain typing of E200K and D178N
mutation individuals has been investigated however, neither of these mutations is
within the consensus sequences for N-linked glycosylation of PrPc. The availability
of patients with VI801, T183A or F198S PRNP mutations is more restricted, but their
potential application to molecular strain typing studies warrants further investigation
and may help elucidate the role of glycan chains in protein function. The T183A
mutation leads to severe spongiform change in the putamen and PrPlcs deposition in
the putamen and cerebellum (Nitrini et al, 1997). This suggests disruption of this
glycan attachment site leads to disturbance of PrPc specifically in these areas, possibly
due to perturbed cellular processing of the PrPc (Rogers et al, 1990, Lehmann and
Harris, 1997).
The glycoform ratios of non-CNS tissue have been shown to display differing
glycoform ratios. Lymphoreticular tissues (tonsil, spleen and lymph node) feature a
more prominent hyperglycosylation designated type 4t (Hill et al, 1999b, Wadsworth
et al, 2001). The same pattern has been detected in tonsil tissues using the same
technique applied in this study (Head, personal communication). In contrast,
investigation of ocular tissues displayed a less pronounced glycosylation, similar to
that seen in sCJD (Head et al, 2003). These findings provide additional evidence for
tissue specific differences in the glycosylation of PrPres accumulations. Recently a
progressive increase in nonglycosylated total PrP has been reported in the retina and
optic nerve in scrapie infected mice and hamsters, though the monoglycosylated PrPres
band was most abundant (Russelakis-Carneiro et al, 2002).
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8.3.3 Iatrogenic CJD
The regional analysis of an iCJD case heterozygotic at codon 129 resulting
from GHT infection showed a degree of glycoform variation, similar to that seen in a
sCJD MV case. This suggests that the codon 129 polymorphism of the individual is
more important in determining cell specific glycosylation than the aetiology of the
disease.
8.3.4 Familial CJD
The two fCJD E200K patients investigated proved harder to assess in terms of
both mobility and glycoform ratio, due to the low levels of nonglycosylated PrPres.
The most noticeable feature of this was that in some regions the nonglycosylated band
was clearly visible and not in others, suggesting by visual examination that the
glycoform ratios were heterogenous. These findings may be related to the overall
PrPres levels but differences in the relative mobility and hence conformation of the
PrPres were also noted. This is surprising as the primary sequence of the mutated form
of the PRNP is consistent and the PrPres is presumed to develop de novo according to
the prion hypothesis. The conclusion therefore is that neuroanatomically specific
differences in conformation and glycosylation of host PrPc results in the PrPICS pattern
observed. There is also a more diffuse monoglycosylated band in the cerebellum of
both patients and the MM patient appeared to have some prominence in the lower
portion of the band (figure 34 B), that is also seen in MM vCJD cases. During the
course of this study a similar pattern was reported in an E200K VV patient (Puoti et
al, 2000). The focal PrP deposits in the molecular layer of the cerebellum in the VV 2
case may account for the relative mobility of the PrPres (Puoti et al, 2000). Another
study of an E200K VV type 2 patient for PrPres found no difference between three
regions (frontal cortex, striatum and cerebellum) (Hainfellner et al, 1999). These
findings must be taken with caution as the normal or wild type allele in E200K cases
may display some of the features of the mutated PrPres partial insolubility and some
PK resistance, but in particular anomalous mobility (Capellari et al, 2000). This
could be in part due to abnormal glycosylation at the 197 site (Capellari et al, 2000).
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These studies demonstrate considerable molecular diversity within and
between cases of CJD. Both parameters of PrPres analysis (conformation and
glycosylation status) can vary within an individual. However, the molecular
phenotype as well as the clinical and neuropathological phenotype in vCJD is
consistent between cases. Despite the relative differences in neuropathological
features seen throughout vCJD brain regions, there appears to be no correlation with
the molecular phenotype. The prominent deposition of PrP in the occipital cortex,
spongiform change in the basal ganglia or thalamic gliosis do not appear to alter the
molecular phenotype and a consistent 2B pattern was observed irrespective of brain
region. The consistent increase in monoglycosylated cerebellar PrPres found across
aetiological subgroups suggests a degree of host dominance over PrPres formation.
8.4 Divalent cation determination of conformation
The three mobility types described in this study were all subject to increased
cleavage of the NH3-ten"ninal after chelation, most apparently in the type 1 and
intermediate type. The initial report by Wadsworth et al, 1999a described a minor
mobility shift of both types 1 and 2 to a smaller size designated 2". These experiments
found the type 1 and intermediate mobilities to remain distinct from each other after
EDTA treatment, however EDTA treated type 1 had mobility consistent with
intennediate cases. Similarly EDTA treated intennediate cases were consistent with
type 2 cases. The type 2A cases (analogous to types 3 and 4) displayed a discernable
shift in mobility however changes in type 2B cases could not be identified, though
other work suggests a very minor shift in mobility.
The influence of the codon 129 genotype on cation binding was assessed as
this has been shown to affect recombinant PrP structure (Wong et al, 2000a). The
levels of Cu, Zn and Mn binding to PrPc and overall levels in the brain of sCJD
patients showed some effect of codon 129 genotype and isotype (Wong et al, 2001a).
The patients classified as type 1 and 2 by Collinge et al, cover all the codon 129
permutations, however, only MM individuals were assessed (Wadsworth et al,
1999a). In our studies MM and VV sCJD cases, MM DM and MV GHT iCJD as well
as MM and MV GSS cases were assessed and the characteristic increase in Mr was
dependent upon the isotype and independent of codon 129 genotype or aetiology. The
glycoform ratios of EDTA untreated and treated samples were the same as expected.
This suggests that the presence of metal ion bound monoglycosylated PrPres co-
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migrating with unbound diglycosylated PrPres does not contribute to glycoform ratio
differences. The influence of metal ion binding and mobility in fCJD cases with
octapeptide repeat mutations or polymorphisms was not assessed but warrants
investigation.
It has been suggested that the presence of EDTA in homogenisation buffers
could account for the differences in the molecular weights of the banding patterns
observed. The procedure adopted in this study and by Collinge et al, did not involve
the use of EDTA (Collinge et al, 1996). The Parchi et al, methodology involves the
use of 10 mM EDTA, yet due to the consistency between these findings and theirs it
seems unlikely that this is the cause ofmolecular weight discrepancies. Use ofmetal
ion chelators produces artificial susceptibility to PK cleavage and may standardise the
PK cleavage site by opening up the NH3-terminal conformation to allow the
maximimum amount of the NEE-terminal to be hydrolysed i.e. the type 2
conformation. The 'open' confonnation of vCJD PrPres may be not be due to a lack of
metal ion binding. However, if there is a lack of bound metal ions this may have
significant implications for the pathological mechanism operating in this disease and
may even support the highly contentious hypothesis concerning the role of
environmental metal ions (Purdey, 2000, 2001). Exclusion of metal ion chelators
from homogenisation buffers and retention of the metal ions will assess the in vivo
conformation of PrPres and will be more relevant to the pathological conformation and
determination of conversion susceptibility. Differences in metal ion status in vivo
may be of relevence to neuropathological targeting in a comparable way to suggested
cell specific glycosylation. Neuroanatomical investigation of the metal ion bound
status of PrPres may identify such differences and could enable targeting of metal ion
homeostasis based therapeutics to maximise their effectiveness. The presence of two
isotypes in cases remain distinct on EDTA treatment and eliminate the possibility of
metal ion bound status as the cause of the different conformations.
Furthermore it has recently been shown that pH can also affect the isotype
generated (Zanusso et al, 2001), expanding the mitigating factors in pigeonholing
PrPres conformations. The findings in this study complicated the nature of PrPres
banding patterns but supported the classification of two predominant isotypes. The
codon 129 of cases in these two groups showed consistency with the findings of
Parchi et al, and the findings presented here, with type 1 containing MM and VV
individuals and type 2 containing MM, MV and VV individuals at pH 4-7.4 (Zanusso
et al, 2001). Type 1 VV cases analysed by Zanusso et al, were of increased relative
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mobility when homogenised at pH 8 prior to PK digestion, but not all the MM cases
were. This suggests that the classification system used by Collinge et al, could
artifactually separate the MM and VV individuals if minor increases in
homogenisation buffer pH occurred. The MM and VV cases susceptible to pH defined
PK cleavage were found to retain an intact NH3-terminus prior to experimental
proteolysis and were termed type 1FL. This also allows improved understanding of the
nature of the PrPres in relation to the disease phenotype and MM cases in the type 1FL
(Zanusso et al, 2001). This probably accounts for the large numbers of sCJD MM
cases classified as type 2 by Collinge et al. The intermediate mobility type (INT)
identified in a small number of cases (2 MM, 2 MV, 2VV) may represent this pH
dependent full length group, their increased relative mobility may thus be due to
anomalies in the pH of homogenisation buffer employed or endogenous proteolytic
digestion in vivo or ex vivo during sample preparation prior to PK treatment. This
increases the standardisation requirements between laboratories to ensure consensual
typing across the board and undermines the diagnostic significance of any particular
isotype in relation to strain of agent. However, it does emphasise the ability of
Western blotting to resolve different confonnations of PrPies and carefully define the
nature of the PrPrcs present in vivo resulting in different banding patterns, in terms of
the metal ion binding status and intact NHj-terminus. This requires clear definition of
the ex vivo experimental conditions and the employment of antibodies directed at
different epitopes (e.g. 5B2). The effects of pH, metal ion binding, codon 129
genotype and octapeptide repeat polymorphisms and mutations on the conformation
of PrPc and PrPlcs should be established to help elucidate the role in the pathogenesis
of TSEs. However, the use of 2D electrophoresis or mass spectrometry to investigate
this may be better able to determine the differences and would allow comparison of
nonglycosylated and glycosylated forms of PrP.
8.5 Animal TSEs and experimental transmissions
8.5.1 Murine transmissions of vCJD
Investigation of vCJD transmission to three mouse strains surprisingly found
differing isotypes and a degree of differing glycoform ratios. These differences could
not be attributed to different donor patients or the mouse strain that was inoculated.
Along with the findings in sCJD, iCJD and fCJD patients, this undermines the
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molecular strain hypothesis and contradicting previous investigations. However,
repeated passage in mice may lead to stabilisation of the isotype pattern as occurs
with incubation periods and neuropathological lesion profiles.
Transmission from BSE, vCJD, domestic cats with FSE, cheetahs,
experimental BSE in macaque and sheep, to wt (FVB, C57BL, RIII and VM) or
transgenic human and bovine PrPc expressing mice and the original inocula have all
displayed the type 2B isotype (Collinge et al, 1996, Hill et al, 1997a, Somerville et al,
1997, Hill, 1998, Hill et al, 1998, Kuczius et al, 1998, Baron et al, 1999, Demart et al,
1999, Kuczius and Groschup, 1999, Schaller et al, 1999, Scott et al, 1999, Baron et
al, 2000, Madec et al, 2000b, Baron and Biacabe, 2001, Hill and Collinge, 2001,
Stack et al, 2002). The glycoform ratio of vCJD and BSE have been reported to differ
yet both appear very similar upon transmission to FVB mice (Hill and Collinge,
2001). Studies on BSE transmission to cheviot sheep have detected an
unglycosylated PrPres band of 22 kDa quite different to the 19 kDa band reported in
other studies (Hope et al, 1999). The Mr of a BSE case in one paper was of greater
molecular weight than the sheep passaged BSE PrPres (Stack et al, 2002).
Interestingly a case of spongiform encephalopathy in a cheetah, implied to be the
result of BSE infection, displayed PrPres with a nonglycosylated molecular weight of
22 kDa (type 1). This case also displayed two very different glycotypes, one featuring
a prominent diglycosylated band and the other a prominent nonglycosylated band
(Baron et al, 1997) though a subsequent report of two cheetahs and their transmission
to C57B1 mice indicated the first glycoform ratio pattern to be correct (Baron et al,
1999). Co-infection ofmice with BSE and scrapie isolates that had type 2 and type 1
mobilities respectively, prevents the differentiation of the mobility of nonglycosylated
fragments and glycoform ratios. Mixing of the two separate isolates after
denaturation also prevents differentiation and results in an intermediate mobility
(Baron and Biacabe, 2001). An intermediate mobility was also seen when the DY and
HY strains co-exist (Bartz et al, 2000). These findings suggest that the intermediate
mobility sCJD cases could be a result of multiple isotypes, however, the mixing of
types 1 and 2 carried out in this study found a prominence of type 2 PrPies with a less
noticeable type 1 nonglycosylated band.
Comparison of the results in this study with previous studies on molecular
strain transmissions suggest that the codon 129 of the host PrPc does not determine
the resulting mobility. The three mice strains investigated all carry the methionine
genotype at the equivalent codon 129 position and in some cases formed a higher
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molecular weight PrPres than the donor, VM (n=4), RIII (n=4) and C57BL (n=3/4). In
transgenic mice carrying human PRNP with codon 129 valine that were infected with
vCJD a type 5 pattern was described that displayed high proportion of the
diglycosylated band and the type 2 mobility according to the nomenclature used in the
study (Collinge et al, 1996). This was attributed to the codon 129 valine
polymorphism and later studies on methionine encoding human PRNP transgenic
mice were reported to accumulate type 4 PrP'es (Hill, personal communication).
These differences may be attributable to species specific PrPres differences. Caution
should therefore be employed when predicting the potential banding pattern in vCJD
cases with a valine at one or both codon 129 alleles.
The presence of the lower portion of monoglycosylated PrPres in all the mice
analysed, in contrast to the majority of human tissues, suggests a species-specific
feature of PrPres formation that may be dependent upon PrPc glycosylation. This
phenomenon is similar to that seen in human PrPies isolated from the cerebellum. The
determination of PrP'es glycosylation seems to be both species and tissue specific.
This is probably as a result of differences in PrPL expression and post-translational
modification in diverse contexts. The presence of different truncated species cannot
be ruled out as the cause of the lower relative mobility of the monoglycosylated band
and may be more significant in murine tissue with the use of 6H4 possibly detecting
PK resistant glycosylated PrPII.
8.5.2 BSE, FSE, Marmoset BSE and Scrapie
Analysis of single cases of scrapie, BSE, FSE and transmitted BSE do not
allow wide-ranging extrapolations and emphasise species specificity. The scrapie
case was clearly distinguishable from vCJD and BSE. The BSE case had a type 1
mobility in comparison with human samples, but the FSE case had type 2 mobility
and the marmoset had a INT/2B isotype. The sequence of the host PRNP is unlikely
to determine the isotype, with 264 amino acids in cattle being longer than the shorter
sequences of ovine PrPc (256 amino acids) and marmoset PrPc (252 amino acids)
(Baker et al, 1993, Wopfner et al, 1999). The use ofWestern blotting in the diagnosis
of BSE has been evaluated in Swiss (Schaller et al, 1999) and French studies (Madec
et al, 2000b). In the former study the midbrain and medulla were identified as the
most reliable site for tissue sampling. While the latter showed the greatest levels of
PrP,es in the mesencephalon and cerebellum, and detectable levels in the frontal and
occipital cortices. The Western blots in each study displayed the 2B isotype. In the
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Swiss study the reliability was high as was the sensitivity and specificity, though the
authors added the caveat that the brain region and pretreatment protocol were
important (Schaller et al, 1999). Samples were taken from the midbrain, cerebellum,
rostral medulla and adjacent obex and PrPres was found to be most reliable when
positive cattle were sampled from the medulla oblongata adjacent to the obex of the
IV ventricle. This is in contrast to sheep scrapie that was most reliable when sampled
from the cerebellum and midbrain (Schaller et al, 1999). The type IB finding in this
study is likely to be an anomaly and unrepresentative of BSE based on the number of
findings that contradict this, however, the results in a few studies suggest that a degree
of variability may exist among BSE cases (Baron et al, 1997, Hope et al, 1999, Stack
et al, 2002). The assessment of glycoform ratios in BSE consistently finds values of
roughly 65 % diglycosylated, 25% monoglycosylated and 10% nonglycosylated (Hill
et al, 1997a, Kuczius et al, 1998, Baron et al, 1999, Sweeney et al, 2000, Hill and
Collinge, 2001, Stack et al, 2002). The values obtained in this study featured a more
pronounced diglycosylation (75% diglycosylated, 24% monoglycosylated, 1%
nonglycosylated) this may be a result of the limitations of the linear range. These
values overlap with those of the 87V scrapie strain (Somerville et al, 1997) but are
disparate to the values quoted by other studies, 50% diglycosylated, 40%
monoglycosylated and 10% nonglycosylated (Hope et al, 1999) and ~53%:34%:~13%
respectively (Kuczius et al, 1998).
The type 2B pattern in the FSE case supports previous conclusions that these
cases are a result of BSE infection (Pearson et al, 1991, Pearson et al, 1992, Fraser et
al, 1994, Wells and Wilesmith, 1997). The reported sequence of feline PrPc only
covered 126 amino acids preventing comparison (Wopfner et al, 1999). A marmoset
experimentally infected with BSE was investigated to determine the PrPres of BSE
following passage to a primate in comparison to vCJD transmission to mice. The
isotype was similar to that seen in some of the murine transmissions and vCJD cases
and supports the contention that BSE is the cause of vCJD. The PrPc of marmosets
has been demonstrated to have 96% homology with the human amino acid sequence,
they are not polymorphic at codon 129 and encode methionine as do all non-human
primates studied (Schatzl et al, 1995). Sequence variation from human PRNP is not
found at the 219 polymorphic codon, in the a-helices, sites of post-translational
modification or the signal peptide. Despite this, comparison between human and
marmoset BSE infection must take into account codon 112 (human M, marmoset V),
present in the proposed dimer interface of helix 1 (and the decreased preference for |3-
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sheet formation of adjacent heterologous a.a.s) as it is known to influence marmoset
susceptibility to human prions (Schatzl et al, 1995). Species specific differences in
PRNP prohibits cross species isotyping from being used as a marker of strains,
because unlike CJD deriving from a consistent PRNP sequence, the host sequence
may influence the mobility type. It also undermines the assumption of the BSE/vCJD
type 2B molecular pattern representing a strain of agent imposing conformational and
post-translational modifications upon the host that can be equated to a single
infectious agent strain.
The detection of a type 2B banding pattern in a single case of scrapie is
insignificant in terms of the large number of detailed investigations carried out on
natural scrapie isolates and murine passaged scrapie strains, however it does provide
evidence of a type 2B pattern in sheep when analysed alongside CJD cases. Scrapie
PrPres has previously been described as either type 1 or type 2 (Hill et al, 1998,
Kuczius and Groschup, 1999). Various tissues in sheep have been reported to display
different PrPc (Moudjou et al, 2001), PrP'es banding patterns (Madec et al, 2000a) and
glycoform ratios (Sweeney et al, 2000). PK cleavage in the presence or absence of
copper ions has not detected any change in relative mobilities in scrapie (Sweeney et
al, 2000). The scrapie glycoform has previously been reported to resemble BSE
glycoform ratio in both natural isolates (Madec et al, 1997, Madec et al, 2000a) an
experimental isolate of natural scrapie (Hope et al, 1999) and mouse passaged strains
22A, 87V and 263K (Somerville et al, 1997). The 87V strain also has the same
mobility as BSE and is predominantly present in the brainstem (Kuczius and
Groschup, 1999). The scrapie strains 22A (Somerville et al, 1997) and CHI641 (Hill
et al, 1998) have a mobility similar to that of type 1 CJD but show some similarities
to BSE. Three different mobilities of the nonglycosylated band have been reported
for scrapie isolates (-20 kDa, -24 kDa and -22 kDa) (Hope et al, 1999). In this study
CHI641 (isolated in 1970) was also classified as C (Hope et al, 1999). In another
study a large number of samples were found to have predominance of the
diglycosylated band, with varying degrees; 87V (61% diglycosylated : 27%
monoglycosylated : 12% nonglycosylated), 22A, ME7 mouse isolates and hessen 1
(-47% diglycosylated : -35% monoglycosylated : -18% nonglycosylated) (Kuczius
et al, 1998). The mobility was not stated but the glycoforms resemble the range
covered from FFI to vCJD tonsil.
No difference in PrPres was observed between cerebrum, cerebellum and
brainstem samples taken from mouse passaged BSE and natural sheep isolates
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(Kuczius et al, 1998). Neuroanatomical analysis of PrPies levels has found varying
levels, in the cerebellum (greatest levels), brain stem, mesencephalon and frontal
cortex (lowest levels) in cases of scrapie occurring in sheep of the PrPVRQ allele
(Madec et al, 2000a). The central nervous system samples all displayed the same
mobility (type 2 or 19 kDa nonglycosylated position) and prominent diglycosylation,
irrespective of brain region. These sheep also displayed PrPres in the spleen, lymph
nodes and tonsils, though of reportedly different mobility, the predominance of a band
in the lower region of the monoglycosylated band in spleen samples could be seen
(Madec et al, 2000a), as in E200K VV 2 and vCJD cerebellum. Another regional
comparative study has been carried out and found PrPres in the cortex, hippocampus,
mesencephalon, paraterminal body, cerebellum, medulla and thalamus with the
medulla showing consistently high levels (Manousis et al, 2000).
Strains could not be distinguished on the basis of glycoform ratio or mobility
in a large study of natural and experimental scrapie cases (n=42) including
experimental ovine CHI641, BSE or BSE transmissions, (Baron et al, 1999). It
seems apparent that PrPres isotyping is not sufficient on its own to establish or rule out
cases of BSE derived infection. The importance of differential diagnosis of scrapie
and BSE is particularly relevant to the identification of possible cases of BSE in the
sheep flock. The identification of a type 2B isoform in a natural sheep suspected of
having scrapie or even a mouse transmission of it would not necessarily indicate
infection by BSE as some type 2B PrPres has been reported in scrapie (Somerville et
al, 1997, Hope et al, 1999). Furthermore there are numerous polymorphisms in sheep
and along with the background genotype (i.e. breed) these can influence the
susceptibility to scrapie and the PrPres patterns.
8.6 Role of PrPres in diagnosis and molecular strain typing
The findings of this study present two problems in terms of the diagnostic use
of human molecular strain typing. The diagnosis and classification of CJD sub-types
with isotype / genotype combinations that define sCJD phenotypic variability (Parchi
et al, 1999c) is still broadly applicable due to the segregation of codon 129 genotypes
with mobility features. However, the co-existence of type 1 and 2 PrP'es in sCJD
cases, noted here and in other studies (Parchi et al, 1999c, Puoti et al, 2000, Baron
and Biacabe, 2001, Head et al, 2001, Kovacs et al, 2002), brings the classification
system into question. Regional variation in sCJD PrP'es isotype is not restricted to
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methionine homozygotes but can also occur in heterozygotes and valine
homozygotes, thus the classification could be re-interpreted merely as cases
displaying 'predominantly' type 1 or 2 PrPres. It should also restrict the further
differentiation between subgroups based on mobility. It is possible that small
amounts of one isotype, e.g. type 1 in a predominantly type 2 case could represent the
less dominant strain. The conformation of PrPres may change upon development of a
new strain by passage into a new species, along with the phenotype (Peretz et al,
2002). This could account for the distinct nature of the BSE strain in comparison to
scrapie. Development of a new strain upon cross-species transmission may thwart
molecular strain typing but supports the contention that PrPres conformation is a strain
marker and indicator of phenotypic features. Other features of the disease along with
the codon 129 polymorphism should be taken into account, as atypical features such
as young age at onset, long duration or psychological symptoms may be more
pertinent features of the phenotype than PrPres conformation. The presence of
different isotypes may be tissue specific due to differences in the PrPc expressed and
in mature human and bovine sperm a carboxyl-terminally truncated PrP isoform has
been detected (Shaked et al, 1999b).
Of particular concern is the finding of regional variation in glycoform ratio in
sCJD since this is the sole molecular feature that distinguishes the PrPres found in
vCJD (type 2B) from that found in a subset of sCJD cases (type 2A). The overlap of
PrPres glycoforms patterns as well as mobility is rare and most likely in either sCJD
MV or VV type 2 cases, fCJD or FFI, though careful quantitation of glycoform ratios
and experienced diagnosis can eliminate the risk of molecular misclassification. The
case of sCJD (RU#98/153) described here in a valine homozygote displaying a 2B
isotype suggests that age at onset, duration and PrPICS can indicate vCJD. Along with
a fCJD E200K heterozygote patient displaying type 2B PrPres and the reported case of
fCJD E200K 2B in a valine homozygote (Puoti et al, 2000), this argues for a cautious
integrated approach to the diagnosis of vCJD. The presence of neuroanatomically
differing glycoform ratios also contradicts the assumption that the glycoform ratio
represents a strain feature that can be transmitted as murine scrapie strains can be
transmitted from various brain regions yet retain their incubation periods and clinical
phenotype (Carp et al, 1997). Scrapie strains are also not dependent upon
glycosylation of host PrPc and can be transmitted in its absence (Korth et al, 2000).
Differences in glycosylation of PrPc and PrPsc in brain regions have been observed in
murine scrapie models (Somerville, 1999) and the glycosylation of host PrPc and
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infecting PrP60 have also been identified (Rudd et al, 1999). Analysis of small cohorts
of CJD by Western blotting does not allow definitive conclusions to be made as to the
aetiology of the disease without further epidemiological, clinical and neupathological
investigations and some such studies are of little benefit (Deslys et al, 1997, Hill et al,
1997b, Zanusso et al, 1998b, Beaudry et al, 2002). The absence of a type 2B pattern
would not rule out vCJD, as the phenotype in non-MM individuals is unknown,
though the presence of this pattern would warrant further investigations. Interestingly
in the study by Zanusso et al, the FSE pattern was unlike that in cases attributed to
BSE infection and may suggest some cases of FSE are sporadic and thus attributing
all cases of FSE in the UK to BSE infection would be unwarranted without strain
typing studies. In terms of incorporating molecular features into strain typing criteria
along with incubation periods and lesion profiling, differences in neuropathological
profiles with similar PrPres banding patterns suggest that the isotype does not represent
the neuropathology. Therefore, the PrPres banding pattern does not signify the strain
of agent when generated de novo in sCJD or fCJD individuals. There is also
considerable evidence to suggest the presence of multiple scrapie strains (Dickinson
et al, 1972, Dickinson et al, 1975, Kimberlin and Walker, 1978, Bartz et al, 2000).
The second problem is more conceptual and mechanistic in nature: A
considerable body of work has amassed to suggest that conformational change is the
basis of conversion from PrPc to PrPSc and that agent strain characteristics can be
enciphered in conformation variants of PrPSc. The occurrence of both type 1 and type
2 PrPlcs in individual cases of sCJD has three possible explanations; a) regional
factors can modify isotype in certain individuals, b) isotypes can spontaneously,
though rarely interconvert, or c) multiple different isotypes can arise de novo in
certain individuals.
The banding patterns of PrP are complex and dependent on a number of
factors. PrPc conformation can differ independently of the conformation determined
by PK cleavage (Aucouturier et al, 1999) and the primary sequence can differ in
familial forms including containing inserts or deletions. PrPc is post-translationally
modified to produce 3 glycoforms that have a wide range of possible glycan chains
(up to 400 different possible combinations) (Endo et al, 1989) and the full length wt
molecule can be truncated in varying degrees into two proteins PrP-I and PrP-II,
differentiated in part by their ability to bind 3F4 and 6H4. Levels of these two
endogenous cleavage products have also been found to differ in relative amounts
between subgroups (Jimenez-Huete et al, 1998). The brain homogenates consist of
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full length and truncated forms of the protein (Pan et al, 2001, Pan et al, 2002) that
differentially bind metal ions and are truncated in a pH dependent manner possibly
due to the affinity of metal binding (Zanusso et al, 2001). The degree of PK
resistance is also found to differ depending on the strain of agent. Relative PK
resistance assays carried out over a wide pH range (2-11) and incorporating GdnSCN
(0.25-3 M) have been used as an alternative measure of strain conformation (Madec et
al, 1997). Prolonged time taken to process samples can lead to degradation of PrPres
into a protease resistant PrPII which is not detected by 3F4 (Jimenez-Huete et al,
1998). Thus employing this antibody in a diagnostic method can not distinguish
differences in banding pattern ratios due to poor sample processing leading to further
truncation of the PrPres. Different antibodies produce different banding patterns and
immunohistochemistry staining patterns that may be glycoform specific (Zanusso et
al, 1998a, Liu et al, 2001). In addition to this there are numerous protocols, reviewed
in (Groschup et al, 2001), classification systems and nomenclature (types 1-7
Collinge et al, type 1, 2A and 2B Parchi et al, type IB Cardone et al, A, B and C
Hope et al, PrP-I, PrP-II, Pan et al, PrP-21, Hooper et al, C-l, C-2, Chen et al, FL
Zanusso et al). Differences in relative PK resistance has been applied to sheep
scrapie strains (Kuczius et al, 1998, Kuczius and Groschup, 1999, Horiuchi et al,
2002) and its application to CJD 'strains' may help to further elucidate the nature of
the phenotypic differences. Likewise the application of 2D gel electrophoresis to the
analysis of PrPres patterns should be a focus of future investigations (Pan et al, 2001,
Zanusso et al, 2002).
There are a number of host factors, including genotypic and tissue specific that
can modulate the presentation of TSE disease. The PRNP genotype correlates closely
with the PrPres formation and accumulation in individuals, however this is not
sufficient to conclude that prions are the causative agent. The retention of the
distinctive BSE/vCJD PrPres banding pattern suggests that a dominant strain of agent
causes vCJD and BSE, possibly through a prion related mechanism involving
conformational and glycosylation modulated conversion of host PrPc.
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Conclusions
Cases diagnosed with aetiologies other than TSEs did not display PK resistant
PrP.
The majority of cases displayed nonglycosylated PrPies bands with molecular
weights of either 21 or 19 kDa and were termed type 1 and type 2 respectively.
Two banding patterns were observed, either predominantly monoglycosylated or
predominantly diglycosylated.
The results confirm the presence of type 1 or type 2 PrPres in the majority of sCJD
cases and show that these two PrP isotypes occur in combination with each of the
three possible PRNP codon 129 genotypes.
The frequencies of isotype / genotype combinations that we have observed in
sCJD do not appear random. A small number of cases displayed a
nonglycosylated PrPres band intermediate between types 1 and 2. Neither
aetiology, codon 129 or phenotypic features distinguished these cases.
Type 1 MM sCJD cases were the most prevalent.
Type 2 sCJD cases were more frequently observed in conjunction with a valine
allele at codon 129.
DM iCJD cases were type 1 but the majority ofGHT iCJD cases were type 2.
Sporadic CJD and iatrogenic CJD cannot be differentiated on the basis of the
PrPres banding pattern. Iatrogenic CJD cases did not have significantly different
glycofonn ratios from sCJD cases. The route of entry or codon 129 did not
influence the glycofonn ratio.
The highly glycosylated PrPres found in vCJD appears to be a reliable molecular
marker for this form ofCJD, confirming the original observation made in 10 cases
by Collinge et al (1996) and extending it to 50 cases ofknown genotype.
The type 2B PrP'es banding pattern is consistent amongst all vCJD cases to date.
The type 2B PrPres banding pattern seen in vCJD cases is not restricted to this
aetiology. Some familial cases displayed a 1B isotype and the FFI case displayed
an isotype similar to vCJD. Familial CJD cases displayed glycoform ratios in the
range of vCJD, however, these two groups are distinguished by their isotype or
PRNP genotype.
Sole conversion and accumulation of the mutant allele was observed in fCJD
VI801, indicating that the mutant allele does not convert the wild type allele to
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Prpres may tQ ^gp. Qp digiycosyiation or indicate that the presence
of PrPies is not sufficient to bring about conversion ofwild type PrPc.
All sCJD cases had a predominantly monoglycosylated glycoform ratio. In all but
the VV 2A subgroup, the unglycosylated band was found in greater levels than the
diglycosylated ban.
Aside from sCJD VV 2A cases and a few MV 1 cases, sCJD subgroups could not
be distinguished by their glycoform ratio.
None of the sCJD glycoform ratios overlapped with vCJD.
A sCJD MV 1 case carrying an octapeptide repeat deletion had a different
glycoform ratio to the other sCJD MV 1 cases.
Biopsy and autopsy analysis can yield different PrPres isotypes.
Multiple isotypes were deteced in sCJD, iCJD and fCJD cases.
Glycoform ratio variation was seen in sCJD, iCJD and fCJD cases.
Variant CJD cases were consistent in isotype and glycoform ratio throughout the
brain.
PrPres of type 1 and type 2 can occur in the same brain and even in the same brain
region. The amounts of each type making up the total PrPres can vary.
The PrPres glycoform ratio can vary according to specific anatomical regions.
Cerebellum derived PrPres displays a more pronounced lower monoglycosylated
band.
PrPres from type 1 and INT cases are more susceptible to NH3-terminal PK
cleavage following EDTA treatment than samples from type 2 cases.
PrPres from vCJD cases does not display a noticeable change in Mr when treated
with EDTA and PK. This indicates that either the PrPres is in an 'open'
conformation or does not have bound cations, which may be significant in the
disease process.
In mixed isotype samples, the difference in Mr is not due to differential cation
binding.
The presence of cation bound PrP'es in GSS suggests that prevention of metal ion
binding to PrP is not responsible for the disease process.
Transmission of vCJD to mice does not result in retention of the 2B isotype in all
cases. An intermediate mobility was seen in the majority of cases.
Neither the mouse strain, pm-p genotype or individual vCJD source correlated
with the resulting PrPres pattern.
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• The glycoform ratios of the murine PrPres featured a greater proportion of
diglycosylated PrPres than vCJD cases.
• Murine PrPres has a prominent lower region in the monoglycosylated band.
• Scrapie and BSE derived infections all resulted in predominantly diglycosylated
PrP'es. FSE and experimental BSE displayed type 2 PrPres while scrapie and BSE
displayed type 1.
• The glycoform ratios of the animal derived PrP'cs was significantly different from
vCJD.
• A large number of discrepancies and caveats prevent the use of PrPres molecular
strain typing of TSEs and all available data should be taken into consideration
when diagnosing cases ofCJD.
The hypothesis that the different PrPres banding patterns observed in TSEs
correspond to different PrPies conformations that represent a molecular marker of
prion strains is not supported by the results of this study. The definition of a 'strain'
of prion disease does not extend to the PrPlcs isotype.
The hypothesis that this molecular marker can be used reliably and consistently to
determine TSE aetiology and differentiate between CJD subgroups has not held. The
PrPres banding pattern cannot distinguish between sCJD, iCJD and fCJD, or between
fCJD and vCJD. The isotype or glycoform ratio analysis could not clearly distinguish
sCJD codon 129 subgroups. The co-occurrence of both isotypes can lead to
misclassification of cases and undermines attempts to define 'strains' of sCJD based
on phenotypic features.
Furthermore correlates between the PrPies banding pattern and the clinico-
pathological phenotype could not be established but indicate that there is a
relationship between PrPres and the codon 129 polymorphism as well as PrP
accumulations, spongiform change and cell specific glycosylation.
The differentiation of sporadic and variant CJD based on the PrPres banding
pattern is reliable but does not allow predictions to be made in non-MM cases of
vCJD. The use of the distinctive type 2B banding pattern as a marker of the BSE
strain in sheep is not exclusive and would be misleading.
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A1 Autopsy protocol for frozen tissue sampling (Zeidler et al., 1999) page 43-44.
A2 Acrylamide gel concentration formula:




Power (watts) = Voltage x Current (amps)
Calculating electrophoretic run times is dependent on the concentration of a gel, it's
propensity to warm up, its' thickness, the size of the transfer membrane required etc,.
First dimension gel electrophoresis, should be run in as short a time as possible
without heating the glass plates at either constant current or constant voltage.
Semidry transfer run conditions are calculated depending on the size of the
membrane/gel with a current density of 2.5 mA/cm i.e. 250mA for a 10cm x 10cm
gel. Constant current is employed so that there is no need to make adjustments for
the numbers of blotting sheet or gel layers.
A4 Centrifugation speeds
The maximum relative centrifugal force (RCF) which is equivalent to the
gravitational force (g) can be calculated from the rotational speed (n) (measured in
revolutions per minute (rpm)) and the maximum radius of centrifugation (r)
(measured in (cm)) and differing dependent on the type ofmicro-test tube used.
RCF = 1.118 x 10 5xrxn2
l
A5 Densitometric analysis
Glycoform analysis was performed using a GS-700 imaging densitometer and
Quantity One 4.1 software (Bio-Rad Laboratories) or a Storm 860 (Molecular
Dynamics™) phosphoimager and ImageQuant software. A standard protocol was
established and applied to all the results. The majority of the data was collected on x-
ray film to ensure consistency between experiments and repeated analyses of samples,
STORM™ analysis was employed for murine samples and fCJD samples.
Bio-Rad Quantity One Protocol
Image acquisition
In Quantity One the default application is 'X-ray film', 'Gray film', 'Green'
filter colour and 'Transmissive' light. A practical level of resolution for X-ray film
was chosen (300 dpi) and the blot was cropped to include the relevant bands and
minimise the size of the resulting image file.
Image adjustment
Images were 'transformed' to scale the contrast of the image to provide the
optimal appearance without altering the densitometric data. Background signal was
subtracted by selecting an area of the gel which is representative of the general
background media. This automatically subtracts the average pixel density in the
selected region, from the whole image. Altering Minor 'noise' (such as 'salt and
pepper' type speckling) found uniformly across the X-ray film was filtered using the
'Filter Wizard'.
Band quantification
Lanes were defined manually by lines running down the centre of the lane.
Lane background was removed using 'Rolling Disk' calculation. This involves
calulation and removal of the baseline staining of the lane by comparison of the AUC
values of the bands to take into account signal between bands.
Bands were defined automatically by Quantity One and then adjusted
manually by referral to the lane intensity trace to take into account differences in band
n
width, 2/3rds of the actual lane width is optimal to prevent background and take into
account the curvature at the corners of bands. To ensure inclusion of the whole band
density. Bands were adjusted to encompass the entire lane to ensure 100% density
was measured and border at the lowest density regions or troughs as seen on the
density trace. The trace optical density (OD) x mm, provides the densitometric value
for the area under the curve (AUC). As determined by dilution series runs of each
standard, the linear range was defined as scans in which the 3 bands fell within 0.7-
7.0 or 0.8-8.0 relative units. The total lane density was 100% with each of the bands
making up a proportion of this.
Storm™ ImageQuant Densitometry Protocol
Image manipulation
Images were edited with ImageQuant Tools 2.2. The image display is
adjusted to enhance contrast and brightness, with the view being scaled to reduce
background and accentuate the signal. The appearance of the images was adjusted
with a brightness contrast autoscale sigmoidal curve to give an appearance akin to X-
ray film, however this does not affect the quantitative data of the images.
Area quantitation with peak finder
Quantitation is carried out with ImageQuant 5.2. A line graph of pixel
intensities generates a curve from which the area under the curve provides
quantitative glycoform data and removes background values. Lanes were defined
manually. The width of the lines were adjusted to 2/3rds of the width of the lane
(~1 Opixels). The AUC is automatically measured with the 'Peak Finder' according to
noise, sensitivity and kernel settings. Automatic quantification settings are optimised
to remove background, detect peaks and calculate area under the curve. The peaks
and baseline can then be adjusted for each line individually if required. Band width
was estimated at 2/3rds of the width of the lane (~1Opixels) as carried out with
Quantity One. The linear range of the storm scans was taken as AUC values of




Proteinase K treated samples used as positive controls were loaded onto 12%
gels following doubling (X-ray film) or linear (STORM) dilutions. X-ray film
quantitation utilised human sCJD and vCJD standards, whereas the vCJD standard
TM
and a murine transmission sample was used to assess the linear range of the STORM
phosphoimager system.
t» -«*#
Figure At. Western blot dilution curve of sCJD MM type 1 standard analysed with






































Figure A2. AUC values for sCJD MM type 1 standard shown in figure Al, loaded as
a doubling dilution. Each band plotted against the doubling dilutions, at different X-
ray film exposure periods.
IV
Figure A3. Western blot dilution curve of sCJD VV type 2A standard analysed with
3F4, 4 minute exposure shown.
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Figure A4. AUC values for sCJD VV type 2A standard shown in figure A3, loaded
as a doubling dilution. Each band plotted against the doubling dilutions, at different
x-ray film exposure periods.
Figure A5. Western blot dilution curve of vCJD MM type 2B standard analysed with
3F4, 8 minute exposure shown.
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Figure A6. AUC values for vCJD MM type 2B standard shown in figure A5, loaded
as a doubling dilution. Each band plotted against the doubling dilutions, at different
x-ray film exposure periods.
Dilution curves were carried out for the different isotypes standards (figure Al, sCJD
MM 1, figure A3, vCJD MM 2B, figure A5 sCJD VV 2A) with 3F4 primary
antibody. First of all the area under the curve (AUC) values for each band, across
numerous dilutions at different x-ray film exposure periods were measured. Overlap
of linear increases in AUC values demonstrated the possibility of measuring
quantitative band ratios from a single lane exposure. To determine the parameters of
the quantitative values the AUC values of numerous linear exposures were required.
The values from numerous exposures were overlaid to extend the range of density
readings (figures A2, A4 and A6). The graph displays a sigmoidal curve, representing
saturated levels of signal where all three bands' density ratio values are almost equal,
as well as incomplete quantitation, where one band is predominant. The linear range
of the bands is represented by the linear increase in density ratio seen in the mid-
portion of the graph. The linear values for each exposure time and the corresponding
AUC values for each band were compared. The AUC values ranged from a low value
of 0.845 to a high value of 7.704 in sCJD MM type 1, a low value of 0.897 and a high
value of 12.056 for sCJD VV 2A, low value of 1.101 and a high value of 9.472 for
vCJD MM 2B. The high value obtained with the sCJD VV 2A case was due to a
vi
closer relative amount of each band in this subgroup extending the linear range. A
conservative approach was adopted to eliminate erroneous readings, provide a range
applicable to all subgroups and be in keeping with the linear range of x-ray film of 1
log. It was decided that lanes displaying a band with AUC values above or below, 0.8
to 8 or 0.7 to 7 (i.e all three bands in a lane must fall within one of these two ranges),
were either underexposed or saturated respectively, and thus non-linear. Thus
readings for the bands in each lane were only reliably representative of the levels of
glycoforms in the samples when all three values are within these boundaries.
The STORM linearity was determined in a similar way. The samples were
loaded with between 10 and 2pl of a PK treated 10% brain homogenate from a mouse
infected with vCJD and a single high density scan performed as opposed to numerous
x-ray exposures. The dilution curve of the murine transmission sample (figure A7)
was analysed with monoclonal antibody 6H4. The lower range unglycosylated AUC
values were difficult to compare on the same scale as the other bands so a log curve of
the values were plotted on a separate graph. The high AUC value obtained was
99,067 and the low AUC value 738 (sample well loadings of between 7 and 4pl
appeared to be the most linear). The quantitative range of AUC values was thus
chosen as between 1000 and 100,000 pixel units representing the 10 log range of
linearity.












Figure A8. AUC values for murine transmission sample shown in figure A7. Each






















Figure A9. Log AUC values for murine transmission sample shown in figure A7.
Each band plotted against the sample loading.
viii
The variance that can arise due to repeated exposure times and repeated sampling of
the tissue (intra-assay error) has been quantified.
Comparison of 21 different exposure periods of the sCJD MM 1 standard, within the
linear range from the same PVDF Western blot found SDs of 3.1, 2.6 and 1.5 for di,
mono and nonglycosylated bands respectively and SEs of 0.6, 0.57, 0.32 for di, mono
and nonglycosylated bands respectively. Unpaired two tailed t tests comparing the
glycoform ratios of the di, mono and nonglycosylated bands measured in sCJD MM
1, sCJD VV 2A and vCJD MM 2B standards following extensive repeated analysis (n
= 29, 29 and 24 respectively) by x-ray film exposure was carried out. The SDs and
SEs are both low. Sporadic CJD MM 1 SDs (Di 3.3:Mono 4.9: Non 5.8), VV 2A (Di
3.6: Mono 2.6: Non 4.9) and vCJD SDs (Di 5.4: Mono 3.7: Non 5.3) sCJD MM1 SEs
(Di 0.73:Mono 1.06: Non 1.27), VV 2A (Di 0.74: Mono 0.53: Non 0.97) and vCJD
SEs (Di 1.1: Mono 0.74: Non 1.1). The t test showed a highly significant difference
between most of the bands for all three cases cases (sCJD MM 1 vs VV 2A p < 0.000
for the di and non glycosylated band, p = 0.06 for the monoglycosylated band, sCJD
MM 1 vs vCJD p < 0.000 for all three bands, sCJD VV 2A vs vCJD p < 0.000 for the
di and monoglycosylated band p = 0.085 for the nonglycosylated band). One way
ANOVA confirmed that the variation within the groups was less than that between the
groups (F test significance = 0.00) with p < 0.000 for all the band comparisons aside
from sCJD MM 1 vs VV 2A monoglycosylated p = 0.014 and sCJD VV 2A vs vCJD
nonglycosylated band p = 0.304). Analysis of multiple exposures for each
experimental analysis as well as multiple experiments of all the samples in this study
had SDs calculated and were very similar to the results obtained for the standards
here.
IX




Triplicate analysis >3 analyses
(%) (%)
sCJD MM 1 65.1 52.4 27
sCJD MM 2A 83.3 41.7 33.3
sCJD MV 1 33.3 16.7 16.7
sCJD MV 2A 38.5 30.8 23.1
sCJD VV 1 100 100 75
sCJD VV 2A 66.7 55.6 33.3
vCJD MM 2B 80.1 44.7 14.9
iCJD 80 53.3 40
fCJD 42.9 42.9 42.9
New cases were analysed up until the end of the study period and in some cases
limited tissue was available, reducing the number of experimental runs that could be
carried out.
A6 Histological findings
Kovacs et al, 2000
PrP immunocytochemistry
The results of PrP immunocytochemistry are classified as follows:
Vacuolar
Sparse granular positivity was observed around and between confluent vacuoles. In
areas of microcystic spongiform change this pattern was absent.
Diffuse/synaptic
Generalised staining of the neuropil with small dot-like granular deposits of
chromagen.
Neuronal
I. Intracellular punctate immunoreactivity.
II. Pericellular punctuate, or granular immunopositivity around unstained neuronal
perikarya.
x
Immunoreactive granular deposits andplaques
Dense positivity in a granular or plaque-like formation not visible in H&E sections,
occasionally surrounding a solid centre. Seen as fine granular deposits and unicentric
cored plaques. In some cases these were noticed in the perivascular space.
Kovacs et al, 2002
PrP IMMUNOSTAINING PATTERNS CHARACTERISTIC OF PRION DISEASE
CASES
The following immunostaining patterns were observed: (I) fine deposition
(diffuse/synaptic pattern); (II) coarser depositions (these include the granular, the
patchy/perivacuolar - including morula type - deposits); (III) plaques (with amyloid
characteristics, eg. kuru-type and florid plaques, or without amyloid characteristics, as
plaque-like deposits or so called focal deposits); (IV) pericellular deposits as dot-like
and/or coarse granular immunoractivity around unstained neuronal perikarya.
XI
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Clinicopathological phenotype of codon 129 valine homozygote sporadic Creutzfeldt-Jakob disease
The naturally occurring polymorphism at codon 129 of
the human prion protein gene (PRNP) influences
susceptibility to sporadic Creutzfeldt-Jakob Disease
(CJD); the majority of the patients are methionine
homozygotes at this locus, while valine homozygotes
represent only 10% of cases. The aim was to study the
clinical and neuropathological phenotype of sporadic
CJD in valine homozygotes, to estimate the reliability of
current clinical diagnostic criteria, and to identify any
consistent and distinct features. Twelve cases of
sporadic CJD with a codon 129 valine homozygote
genotype were identified at the National CJD
Surveillance Unit in Edinburgh. In addition to a
retrospective clinical analysis, tissue blocks were stained
by conventional techniques and by immunocytochem-
istry for prion protein. Frozen brain tissue was available
from five cases for Western blot analysis of PrPRls.
which in all cases showed a type 2 mobility. The cases
included four males and eight females, average age
63.6 years, with a mean duration of illness of
6 months. Eleven patients presented with ataxia, and
none had the characteristic EEG changes found in
sporadic CJD. The neuropathological phenotype com¬
prised spongiform change and prion protein immuno-
positivity most marked in the subcortical grey matter
and cerebellum, prion protein positive plaque-like
deposits in all regions, laminar deposition of prion
protein in the cerebral cortex, and hippocampal
involvement (which is seldom reported in sporadic
CJD). In conclusion, these cases exhibited a fairly
uniform phenotype. which is relatively distinct from
sporadic CJD in methionine homozygotes, and thus
diagnosis may be difficult using existing clinical criteria.
Keywords; codon 129, Creutzfeldt-Jakob disease, immunocytochemistry, prion protein, prion gene, valine, Western blot
Introduction
Creutzfeldt-Jakob Disease (CJD) is a rare and invariably
fatal neurodegenerative disorder, associated with accum¬
ulation in the central nervous system of the abnormal,
protease resistant form of the prion protein (PrP), which is
encoded on the short arm of the human chromosome 20
[reviewed in 21]. CJD is the most common form of the
human transmissible spongiform encephalopathies
Correspondence: Professor J. W. Ironside. CJD Surveillance Unit.
Western General Hospital. Edinburgh EH4 2XU. United Kingdom.
E-mail: j.w.ironside@ed.ac.uk
(TSE): TSEs can be acquired (kuru, iatrogenic and new
variant CJD), sporadic (CJD), or inherited (familial CJD,
Gerstmann-Straussler-Scheinker disease, fatal familial
insomnia) [21].
Clinically, sporadic CJD is characterized by progres¬
sive dementia, myoclonus and, in a high proportion of
cases, electroencephalogram (EEG) changes consisting
of periodic sharp wave complexes (PSWC) with
triphasic morphology [9,27]. Neuropathologically, the
diagnostic features are spongiform change, astrocytosis,
© 2000 Blackwell Science Ltd 463
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nerve cell loss, and prion protein amyloid plaques in a
minority of cases; accumulation of protease-resistant
PrP in the brain is best demonstrated by Western blot
analysis [12,14,18]. Clinical diagnostic criteria have
been developed for CJD [5,26], but some atypical
cases of sporadic CJD may be excluded by these
criteria, thus representing a potentially underdiagnosed
group. This clinical variability in sporadic CJD is
thought to be influenced by host genotype and the
agent 'strain' as identified on Western blot analysis of
prion protein [18,19,28]. Polymorphisms have been
identified at codon 129, 171, and 219 in the human
prion protein gene (PRNP) [19,23,28]; the methionine/
valine polymorphism at codon 129 is the most widely
examined amongst sporadic CJD cases. Studies in
Europe [26] have shown that 74% of sporadic cases
of CJD are methionine homozygotes at codon 129, thus
representing a predisposing factor for CJD in the
Caucasian population (in contrast to similar studies
from Japan) [10,23]. The codon 129 polymorphism
also influences susceptibility in some forms of iatro¬
genic CJD [6],
Diagnostic clinical criteria for CJD which allow
classification as definite, probable or possible CJD are
largely based on the predominant phenotype in
sporadic CJD associated with methionine homozygosity.
The aim of this study was to examine the clinico-
pathological phenotype in the homozygous valine
subgroup of sporadic CJD, and to determine whether
these cases exhibit atypical features that may compro¬
mise the application of current diagnostic criteria.
Materials and methods
Case selection and preparation of tissue
Cases of sporadic CJD of known valine/valine genotype
at the PRNP codon 129 locus were identified from the
brain bank at the National CJD Surveillance Unit in
Edinburgh.
After post-mortem the brains were fixed by immersion
in 15% formalin for a minimum of 3 weeks. Tissue
blocks were taken from the frontal, parietal, temporal
(including hippocampal formation) and occipital cortex,
basal gang-lia, thalamus, pons, cerebellum, hypothala¬
mus and if available, the spinal cord.
Blocks were decontaminated in 96% formic acid for
1 h prior to routine processing into paraffin wax. From
each block, 5 pm serial sections were floated on
Vectabond-coated slides and stained using haema-
toxylin and eosin (H&E) and with immunocyto-
chemistry using two anti-PrP antibodies (KG9-mono-
clonal, 1:200 dilution-Source: Dr C. Birkitt-Compton;
3F4-monoclonal, 1:2000 dilution-Source: R. Kascsak,
New York), using a consensus protocol [2], After
counterstaining with haematoxylin, sections were
dehydrated, cleared in xylene and mounted in Pertex.
PRNP coding sequence analysis
Genomic DNA was purified from peripheral blood
leuco-cytes and the PRNP coding region was amplified
by the polymerase chain reaction. Known disease
specific mutations were excluded by single strand
conformational analysis and a direct sequencing
protocol was used to identify the codon 129 genotype
[28],
Biochemical analysis of PrP
Western blot analysis of protease-resistant prion protein
(PrP ) in samples of frontal cortex was performed by
an established method [7]. Briefly, a 10% brain
homogenate was made from frozen tissue, cleared by
low speed centrifugation and the supernatant digested
with 50 pg/ml proteinase K. PrPRl:s isoforms were
separated by SDS-PAGE, transferred to nitrocellulose
and detected using the antibody 3F4, a horseradish
peroxidase conjugated secondary antibody and
enhanced chemiluminesccnce. The resultant isoform
patterns were classified on the basis electrophoretic
mobility as type 1 or type 2 [18].
Results
Twelve cases were identified, which will be referred to
subsequently as CJD1, CJD2 to CJD12. The clinical
features of these cases are summarized in Table 1.
Clinical findings
The age at death ranged from 49 to 80 years, with
an average age at death of 64 years. The mean
duration of illness was 6 months (range 4-17 months).
Eleven patients had unsteady gait as the presenting
symptom, seven had memory disturbance, and two
© 2000 Blackwcll Science Ltd, Neuropathology anil Applied Neurobiology, 26. 463-472
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complained of visual impairment. One patient (C]D9) had
itching as a presenting complaint, which has been
described recently in CJD [22], During the clinical
course all patients developed dementia, myoclonus
(and/or startle response) and developed akinetic
mutism before death.
Routine cerebrospinal fluid tests showed no relevant
abnormalities; 14-3-3 immunoassays were not per¬
formed in any of the cases. Characteristic periodic
triphasic complexes were not present in the 11 cases
with available EEC findings.
Histological findings
In routine sections the degree of spongiform change was
assessed and classified on a five-point scale from -
(absent) to + + + (severe microcystic and confluent
vacuoles); a summary of the neuropathological and
prion immunocytochemical findings is shown in Table 2.
In general, the grading of the spongiform change also
reflected the degree of neuronal loss.
PrP immunocytochemistry
Case CJD 3 showed only slight positivity after repeated
immunostaining with anti-PrP antibody KG9. In this
case the observations represent results with the 3F4 anti-
PrP antibody. The results of PrP immunocytochemistry
are classified as follows:
Vacuolar Sparse granular positivity was observed
around and between confluent vacuoles. In areas of
microcystic spongiform change this pattern was absent.
Diffuse/synaptic Generalized staining of the neuropil
with small dot-like granular deposits of chromagen.
Neuronal
1 Pericellular punctuate, or granular immunopositivity
around unstained neuronal perikarya.
2 Sparse intracellular punctate immunoreactivity.
Immunoreactive granular deposits and plaque-like
deposits Dense positivity in a granular or plaque-like
forma-tion not visible in II&E sections, occasionally
surrounding a solid centre. These formations resembled
those men-tioned by Miyazono et al. [16] as fine granular
deposits and unicentric cored plaques. In some cases these
were noticed in the perivascular space as described by
Watanabe et al. [25],
Anatomical mapping
The key neuropathological features are summarized in
relation to neuroanatomical structures in Figure 1.
Occipital cortex Seven cases showed mild to severe
spongiform change and eight had PrP plaques (in CJD1,
CJD8 and CJD9, plaques were also present in the
subcortical white matter). The diffuse/synaptic PrP
immunostaining had a laminar accentuation in CJD1,
CJD2, CJD6, CJD 7.
Table 1. Clinical findings in the examined cases
Age Duration of illness Clinical symptoms
Case number (years) Sex (months) (P: presenting T: terminal) EEG'
CJD1 49 Female 11 P: G-V T: D-M-AM-S _
CJD2 53 Male 6 P: G-MI T: D-M-AM -
CJD3 54 Male 17 P: MI-G T: D-M-AM -
CJD4 59 Female 4 P:G-MI T: D-V-M-AM -
CJD5 59 Female 6 P: G-MI T: D-M-AM -
CJD6 60 Male 4 P: G-MI-VGP T:D-V-S-AM -
CJD7 62 Female 7 P: G-MI T: D-M-AM -
CJD8 64 Female 5 P: G-DI T: D-S-AM -
CJD9 72 Male 7 P: G-I T: D-M-AM -
CJD10 75 Female 4 P: G T: D-M-AM -
CJD11 77 Female 4 P: MI-V T:D-M-AM
**
CJD12 80 Female 6 P: DI-G-UM T: D-M-AM -
'Characteristic PSWC and triphasic morphology. "Data not available. G, unsteady gait. D. dementia. M, myoclonus. S, startle. AM, akinetic
mutism. MI, memory impairment. DI, dizziness. V, visual disturbance. I. itching. UM, unvoluntary movements. VGP. vertical gaze paresis.
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Figure 1. Summary of the neuropathological features in the
anatomical regions examined. The presence of severe spongiform
change, diffuse/synaptic, neuronal and plaque-like prion immuno-
positivity was scored semiquantitatively (0-4) in each anatomical
region for every case. This allows a relative 'score' for each region to
be calculated that reflects the relative severity of pathological
involvement (the maximum score for any given region would be 48
(12 x 4). if each case contained severe spongiosis and the three
different prion immunostaining patterns in that anatomical region),
BG, basal ganglia. TH, thalamus, PG. parahippocampal gyrus
(entorhinal cortex). CE. cerebellum. SU, subicular cortex. HP,
hippocampus (including CA regions and dentate gyrus). PO, pons.
HY. hypothalamus. DN, dentate nucleus. OC, occipital cortex. TE,
inferior temporal cortex. PA, parietal cortex. FR. frontal cortex.
Frontal cortex Moderate to severe confluent spongiform
change (Figure 2a) was seen in all cases except CJD10,
plaque-like deposits were visible in seven (in three cases in
the subcortical white matter also). The synaptic/diffuse
PrP immunostaining in 10 cases and neuronal
(Figure 2c,d) in six cases showed laminar accentuation
(layer V-VI).
Parietal/parasagittal cortex Mild to severe spongiform
change was seen in all except CJD10. Plaque-like deposits
were visible in eight cases (in three cases in the
subcortical white matter also). Diffuse/synaptic PrP
deposition was present in 10 cases, perineuronal
deposition was identified in eight cases and laminar
accentuation in six.
Basal ganglia (caudate nucleus, putamen, globus palli-
dus) Every case showed severe, confluent spongiform
change and diffuse/synaptic PrP immunostaining.
Perineuronal positivity was noticed in nine cases, and
plaque-like deposits were present in all cases except CJD 3.
Plaques were also seen in the adjacent white matter in
five cases (Figure 2e).
Hippocampal formation In Ammon's horn, spongiform
change affected the CA1 region in all cases (Figure 2b),
predominantly in the pyramidal layer, whilst CA 2,3,4
were relatively spared. The usual PrP immunostaining
pattern was diffuse/synaptic and occasionally peri¬
neuronal, mainly in the CA1 and CA4 region.
Scanty plaque-like deposits were noticed in three cases.
In the dentate gyrus, the molecular layer showed
microcystic spongiform change from mild to severe
degree in seven cases with diffuse/synaptic PrP immu-
nopositivity in nine cases, whereas small plaque-like
deposits were visible in the granular layer in three cases.
The adjacent subiculum was affected by spongiform
change from a level ofmoderate to severe, confluent with
diffuse/synaptic PrP immunostaining in all cases and
perineuronal deposition in three cases. Plaque-like
deposits were noticed only in CJD12.
Inferior temporal cortex and parahippocampal gyrus
(entorhinal cortex) In two cases the inferior temporal
cortex was not available. In the remaining cases
spongiform change was found in the temporal cortex in
six cases and in the parahippocampal gyrus in seven
cases. PrP immunostaining of the inferior temporal
cortex showed diffuse/synaptic positivity in eight cases,
perincuronal deposition in four and perivacuolar
deposition in one. The immunostaining pattern had a
laminar accentuation (deeper lamina: V-VI) in four
cases. Plaque-like deposits were visible in seven cases,
of which five had plaques in the subcortical white
matter also. In the parahippocampal gyrus, 10 cases
showed diffuse/synaptic PrP staining, nine peri¬
neuronal staining, one vacuolar staining, with
laminar dominance in seven cases, and plaque-like
deposits in eight (live of which also showed plaque-like
deposits in the subcortical white matter).
Pons (mid level) Mild spongiform change in the
pontine nuclei was seen in four cases, while diffuse/
synaptic and intraneuronal PrP immunoreactivity was
noticed in 10 cases, but plaque-like deposits were not
visible.
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Figure 3. Western blot analysis ofPrPRES in homogenates of frontal
cortex from sporadic CJD case 2 (lane B) case 4 (lane C), case 7 (lane
D), case 10 (lane E), and case 12 (lane F). PrPRES isotype standards
are shown in lanes A and G (M/M type 1), lane H (V/V type 2A, case
2), and lane I (M/M type 2B, new variant CJD). Lanes are identified
by letter (top) and the PrPRES isotype (bottom).
Cerebellum Spongiform change affected the molecular
layer (10 cases) to a mild to severe (confluent) degree.
Purkinje cells were relatively spared but the number of
granular cells was variably reduced. Plaquc-Iike deposits
plaques were visible in the granular layer in all cases
except CJD 3, in the molecular layer in seven cases, and in
eight cases in the white matter. The main immuno-
staining pattern was diffuse punctuate with granular
deposits (Figure 2f). In the 10 cases where the dentate
nucleus was visible, five showed prion immunoreactivity
without obvious pathological changes.
Thalamus Spongiform change affected all three nuclei
(anterior, dorsomedial, ventrolateral) in a mild to severe
degree. The predominant immunostaining pattern was
diffuse/synaptic (11 cases) with neuronal pericellular
and occasionally intracellular reactivity in three cases.
Plaque-like deposits were observed in 10 cases, both in
the neuropil and the perivascular space.
Hypothalamus Ten cases were examined. Eight cases
showed mild to severe spongiform change and diffuse/
synaptic immunostaining, while plaque-like deposits
were visible in five cases.
Spinal cord Sections of the spinal cord were available in
only three cases (CJD2, CJD9, CJD10). Spongiform
change was not present in any case, but plaque-like
deposits were visible in two cases with diffuse/synaptic
PrP immunostaining most intense in the substantia
gelatinosa in all three cases.
PrP Typing
Frozen material was available in 5/12 cases examined
(CJD2, CJD4, CJD7, CJD10, and CJD12). Western blot
analysis on the frontal cortex (Figure 2) showed that in
each of these cases the PrPRl:s had a type 2 mobility. The
glycoform ratios were typical of sporadic CJD (type 2A)
and distinct from that associated with new variant CJD
(type 2B) (Figure 3).
Discussion
The present study has identified the clinical and
neuropathological features of 12 codon 129 valine
homozygote sporadic CJD cases in the archives of the
CJD Surveillance Unit in Edinburgh, UK. The polymorph¬
ism at this codon is thought to influence disease
susceptibility in sporadic and iatrogenic CJD, with
homozygosity as a predisposing factor [6,19]. Valine
homozygote cases are rare, and their disease phenotype
may lead to difficulties in clinical diagnosis and in the
application of current diagnostic criteria for CJD.
Clinical data was available in all 12 valine homozygote
cases of sporadic CJD. The average age at death in this
series was 64 years, in keeping with many series of
unselected sporadic CJD cases, but a recent multicentre
study of sporadic CJD has demonstrated an excess of
valine homozygotes in patients aged less than 50 years
[1], Unsteadiness of gait was a presenting symptom in the
majority of cases (11/12), in comparison to 20-30% of
cases with initial ataxia in sporadic CJD [4,27]. Similar
cases have been classified as the 'ataxic variant' of CJD,
and the results of lesion profiling of spongiform change in
such cases in one recent large study are similar to our
descriptive findings [19]. Early impairment of memory
Figure 2. (a) Spongiform change in the frontal neocortex (haematoxylin and eosin (H&E)) (left side of the picture represents the deeper
cortical layers), (b) Severe spongiform change in Amnion's horn (H&E) (dentate gyrus on the left, CA1 region on the right), (c) Intraneuronal
prion immunopositivity in the frontal neocortex, (d) Perineuronal prion immunostaining in the frontal neocortex, (e) Diffuse/synaptic and
plaque-like prion positivity in the putamen, with widespread spongiform change, (f) Plaque and diffuse-granular prion immunopositivity in the
cerebellum.
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was common (7/12) as in sporadic CJD. During the
clinical course dementia, myoclonus (often with a startle
response) and akinetic mutism were the dominant
features. All these features are characteristic of sporadic
CJD. In contrast the 'typical' EEG abnormalities found in
sporadic CJD were absent in all 11 cases in which EEG
data was available. The average age at death was similar
to that in larger series [4,9,26],
Current diagnostic criteria for CJD allow diagnostic
classification as 'definite', 'probable' or 'possible' CJD [5],
None of the valine homozygote cases in this report would
have been categorized clinically as 'probable' CJD and,
although all the cases would have fulfilled criteria for
'possible' CJD, these cases would not have been included
in analysis (or official statistics) in many studies without
neuropathological verification. There is a need for further
information on diagnostic tests such as CSF 14-3-3, CSF
immunoassay and magnetic resonance brain imaging in
valine homozygote cases of sporadic CJD in order to try
and improve clinical diagnosis.
Important neuropathological (immunocytochemical)
findings in these valine homozygote cases are involve¬
ment of the hippocampal formation, the presence ofPrP-
positive plaques, the laminar accentuation of PrP
immunostaining, and a significant trend to more severe
changes in the subcortical grey matter and cerebellum
(Table 3). Previous neuropathological reviews have
emphasized that the hippocampus is typically spared in
sporadic CJD [12,14], Misuzawa et al. [17] described the
involvement of the hippocampus in CJD, concluding that
the molecular-lacunosum layer was the area most
frequently affected, as in some descriptions of kuru. In
the present cases, the stratum pyramidale (predomi¬
nantly in CA1) was also affected and examination of this
region using prion immunocytochemistry revealed the
presence of abnormal prion protein. This feature, along
with the affection of subicular cortex, parahippocampal
gyrus and temporal isocortex resembled the distribution
of pathology in Alzheimer's disease [3]; it is of note that
the cases in the present series developed significant early
memory impairment.
Widespread loss of parvalbumin-positive neurones is
thought to be a distinctive feature of CJD [11], Guentchev
et al. [11] demonstrated that loss of parvalbumin-positive
neurones in the hippocampus is most commonly the only
pathological change in the hippocampus, suggesting,
that this could be an early event followed later by
spongiform change. Although parvalbumin immunos¬
taining was not used, the present results show that the
codon 129 valine homozygote cases have visible
neuropathological changes in the hippocampus, either
because of the longer duration of illness, or because of
different neuronal targeting, perhaps related to a distinct
form of disease-associated prion protein. The severe
pathology of the basal ganglia and cerebellum is also
distinct from previous studies of sporadic CJD (which
presumably included mainly methionine homozygote
cases) [12,14]; movement disorders and specifically gait
disorder occurred early in the clinical course in the
present cases. The thalamic pathology in the present
cases also differs from sporadic CJD in methionine
homozygotes and fatal familial insomnia, and shows
severe spongiform change and widespread prion protein
immunoreactivity [19], The occurrence of severe patho¬
logical changes in these subcortical structures was
unrelated to the duration of illness.
Western blotting studies showed that type 2 PrPRI!S
was present in all cases studied; the relative uniformity of
the clinical and pathological phenotype in this series
indicates that probably all the cases would have a type 2
PrPRR . Overall, the features of the 12 cases in this study
correspond to those of the VV2 subgroup reported in the
small series of Tranchant et al. [24] and the large
multicentre series of Parchi et al. [19], However, it has
not been possible to assess the clinical features in relation
to current diagnostic criteria and record the neuropatho¬
logical features (particularly the hippocampal pathology)
in much greater detail.
The significance of prion protein subtype in terms of
differential neuroanatomical targeting requires further
investigation: different prion immunostaining patterns
might indicate different stages of prion propogation in
susceptible neurones, thus influencing cell survival. The
significance of the laminar appearance of neuropatholo¬
gical features in the neocortical deeper layers is not clear,
although it may reflect distinct characteristics in
subgroups of cortical neurones, perhaps relating to
differences in PrPc expression [8], PrP-positive plaques
were found in every case examined except CJD3. This
case had a significantly longer duration of illness than the
other cases. It is of interest that it has previously been
suggested that plaque formation is predominantly
associated with prolonged illness duration [15], although
not in all series [20,25], The plaques identified on PrP
immunocytochemistry were morphologically distinct
from kuru plaques and may represent an immature
© 2000 Blackwell Science Ltd, Neuropathology and Applied Neurobiology. 26, 463-472
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form of amyloid plaque, as described in murine scrapie
models [13], The presence of a valine-associated isoform
of the abnormal prion protein appears to favour plaque
formation in sporadic CJD; kuru-type plaques (visible on
routinely stained sections) are associated with codon 129
heterozygosity and type 2 PrPRES in sporadic CJD [19].
In summary, cases of sporadic CJD with a valine
homozygous genotype at codon 129 in PRNP have a
clinicopathological phenotype that is relatively distinct
from the typical phenotype of sporadic CJD associated
with methionine homozygosity. Valine homozygote cases
may have a more prolonged duration of illness, do not
exhibit the 'typical' EEG, and often present with ataxia.
Neuropathologically, the characteristic features are
plaque-like deposits on PrP immunocytochemistry,
laminar perineuronal/synaptic deposition of PrP in the
cerebral cortex, spongiform change most marked in
subcortical grey matter structures, and involvement of
the hippocampus. These results, which include a detailed
neuropathological survey, support the findings of Parchi
et al. [19] suggesting that VV2 sporadic CJD is a distinct
entity. There is a clear need for further study of
determinants of phenotypic variability in sporadic CJD.
reinforcing the importance of neuropathological and
biochemical examination in this disorder [14,18].
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A case of sporadic Creutzfeldt-Jakob disease (sCJD) is de¬
scribed in a young Dutch protein prion gene (PRNP)
codon 129 valine homozygote. Certain clinical and mo¬
lecular features of this case overlap those of variant CJD.
The case highlights possible difficulties in the differential
diagnosis of vCJD and the more rare sCJD subtypes
based on molecular features alone.
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Creutzfeldt-Jakob disease (CJD) is a rare, rapidly pro¬
gressive, and invariably fatal neurodegenerative condi¬
tion characterised clinically by dementia and ataxia and
pathologically by neuronal loss, gliosis, and spongiform
change in the brain. It can be inherited (familial CJD),
acquired (iatrogenic CJD), or idiopathic (sporadic
CJD, sCJD). Irrespective of aetiology, CJD is charac¬
terised by the accumulation of an altered form (PrPSc)
of a host-encoded glycoprotein (PrP< ). Mutations in
the gene encoding PrP, termed PRNP, are closely as¬
sociated with the inherited forms of the disease,
whereas medical histories that include procedures such
as human growth hormone treatment or dura mater
grafting are strongly indicative of iatrogenic CJD. Sus¬
ceptibility and disease phenotype can be substantially
modified by the common methionine/valine polymor¬
phism at codon 129 of PRNP.
In 1996, a new form of the disease, variant CJD
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(vCJD), was described in the United Kingdom,1 which
appears to result from infection with the bovine spon¬
giform encephalopathy (BSE) agent.2'3 vCJD patients
are younger than sCJD patients and usually present
with psychiatric symptoms, followed by ataxia, move¬
ment disorders, and dementia during a protracted dis¬
ease course. The eventual size of the current epidemic
of vCJD is uncertain, but accurate long-term predic¬
tions necessitate ongoing surveillance and accurate di¬
agnosis. The phenotype described in the first 10 cases
has proved consistent, allowing formulation of clinical
diagnostic criteria for probable vCJD in living patients
with strong predictive value.4 The recent inclusion of a
postthalamic high magnetic resonance imaging (MRI)
signal (the pulvinar sign) has further strengthened the
criteria.4'5 Nevertheless, a definite diagnosis of vCJD
requires neuropathological examination of the brain.6
Another consistent finding in vCJD has been the pres¬
ence in the brain of a predominantly diglycosylated
form of the protease-resistant prion protein (PrPrcs).6-8
A further accentuation of this "glycosylation signature"
in PrPres was found in vCJD tonsil.9 Thus far, all pa¬
tients with a definite diagnosis of vCJD who have been
tested have been methionine homozygotes at codon
129 of PRNP. This has prompted speculation concern¬
ing the possibility and potentially novel phenotype(s)
of BSE infection in humans with valine at codon
129.3'10
In practice, sCJD is the major differential diagnosis
of vCJD.4 However, sCJD has a remarkably diverse
clinicopathological phenotype. A recent study of 300
sCJD cases identified six distinct subtypes.11 Each sub¬
type correlated with a particular combination of PrPrcs
isotype, defined by the molecular size of the nonglyco-
sylated, protease-resistant core fragment (type 1, 21
kDa, or type 2, 19 kDa) and PRNP codon 129 geno¬
type (methionine homozygosity, MM; heterozygosity,
MV; or valine homozygosity, W). Two of the least
frequent subtypes of sCJD require particular attention
in relation to vCJD. First, the PrPres in methionine
homozygous type 2 (MM2) cases differ only in glyco¬
sylation site occupancy from the PrPrcs found in vCJD.
Second, the valine homozygous type 1 (Wl) sCJD
subtype has a young age at onset and, in common with
MM2 cases, a prolonged disease course. These clinical
features alone may prompt neurologists to consider,
perhaps inappropriately, a diagnosis of vCJD.
This report describes a case of sCJD in a valine ho¬
mozygote, which brings several issues surrounding the
differential diagnoses of vCJD and sCJD into sharp fo¬
cus.
Case Presentation
A previously healthy 42-year-old woman was referred
to the outpatient memory clinic of the Vrije University
Medical Centre suffering from progressive memory
258 © 2001 Wiley-Liss, Inc.
loss, spatial disorientation, depression, and headache
over the previous 8-month period. Sensory and psychi¬
atric features were not evident. The patient had no
family history of dementia and no obvious iatrogenic
exposure to prions and had been continuously resident
in the Netherlands. On admission, neurological exam¬
ination revealed global memory impairment, visual ag¬
nosia, visuospatial disturbances, mild cerebellar ataxia,
and minor involuntary movements, best described as
"fidgety." Clinical tests showed 14-3-3 positive cere¬
brospinal fluid and an absence of periodic sharp wave
complexes on electroencephalography (EEC). MRI
showed signal increase in the grey matter on diffusion-
weighted images. No mutations were found in PRNP,
but the patient was homozygous for valine at codon
129. Given the early age at onset and the already pro¬
tracted disease course, a brain biopsy (right frontal cor¬
tex) was performed 2 months after admission, to con¬
firm the provisional diagnosis of CJD and discount a
diagnosis of vCJD. Neuropathological examination of
this material showed transcortical microvacuolar spon¬
giform change, variable neuronal loss, and gliosis (Fig
1A). No amyloid plaques were visible using Congo red
or periodic acid-Schiff stains. PrP immunohistochem-
istry showed a diffuse granular "synaptic" pattern, with
no plaques visible (Fig IB). Western blot analysis
showed easily detectable levels of PrPrcs, with a 21 kDa
nonglycosylated band (type 1) and an unremarkable
glycoform ratio (Fig 2). Immunohistochemical and
Western blotting studies were carried out exactly as de¬
scribed previously.6 Taken together, these findings sup¬
port a diagnosis of sCJD, the atypical clinical features
of the case being consistent with the rare W1 sCJD
subtype.
Over the following months, the patient became aki¬
netic and mute, with persistent mild ataxia (she was
still able to walk 14 months after the first symptoms)
and myoclonic jerks towards the end of the disease
course. She died 18 months after the onset of symp¬
toms. Permission for post-mortem examination was re¬
stricted to the brain. Flistopathological examination of
the left cerebral hemisphere, cerebellum, and brain
stem showed pathology similar to that seen at biopsy:
cerebral cortical spongiform change, more severe neu¬
ronal loss, and gliosis (Fig 1C), as well as a synaptic
PrP immunostaining pattern and absence of plaques
(Fig ID). This histological appearance was typical of
all cortical regions examined, with no laminar pattern
of PrP deposition. Spongiform change was also present
in the hippocampus. The caudate nucleus and puta-
men exhibited severe spongiform change, but this fea¬
ture was less marked in the thalamus and brain stem.
PrP immunocytochemistry showed granular synaptic
staining in all of these regions, along with small num¬
bers of PrP-positive plaque-like structures (which were
not evident on routine microscopy). Patchy spongi-
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Fig. 1. (A) The frontal cortex in the brain biopsy specimen
shows widespread microvacuolar spongiform change, with occa¬
sional areas ofconfluent vacuolation. No plaques are present.
Haematoxylin and eosin. (B) Immunocytochemistry for prion
protein shows widespread positivity in a reticular (synaptic)
pattern in the frontal cortex from the biopsy specimen. No
plaques are present. KG9 monoclonal antibody/haematoxylin
cotinterstain following proteinase K digestion. (C) 7be frontal
cortex in the autopsy specimen shows spongiform change, with
a coarse pattern of vacuolation. Neuronal loss and astrocytosis
are more evident than in the biopsy. Haematoxylin and eosin.
(D) Immunocytochemistry for PrP in the frontal cortex in the
autopsy specimen shows a widespread synaptic pattern of depo¬
sition. No plaques are visible, and there is no evidence ofa
laminar or perineuronal pattern ofPrP accumulation. KG9
monoclonal antibody/haematoxylin counterstain following pro¬
teinase K digestion. (A-D) Original magnification X175-
form change was present in the cerebellar molecular
layer, accompanied by Purkinje cell loss and gliosis.
PrP deposition occurred in a granular synaptic pattern,
with occasional small plaque-like structures in the mo¬
lecular layer and around the dentate nucleus.
Western blot analysis of a frozen autopsy sample of
the left frontal cortex (the only frozen tissue available)
contrasted starkly with that seen at biopsy. The nong¬
lycosylated PrPres was clearly of type 2 mobility (19
kDa); moreover, the glycoform ratio was not character¬
istic of sCJD and resembled that seen in vCJD (Fig 2).
Multiple sampling and analysis from different regions
of the available autopsy and biopsy frontal cortex sam¬
ples (n = 4 and 6, respectively) showed a reproducible
difference in the glycoform ratio between these 2 sam¬
ples (Fig 3).
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Discussion
All vCJD cases thus far described have been homozy¬
gous for methionine at codon 129 of the PRNP gene,4
although this genotype represents a minority of the
normal Caucasian population.11 Comparison with the
only other peripherally acquired forms of CJD cur¬
rently known (iatrogenic CJD and Kuru) suggests that
all three codon 129 genotypes might be susceptible to
vCJD but that the incubation times could differ.10,12
Although the codon 129 PRNP polymorphism has a
major influence in the neuropathology of sCJD, the
neuropathological changes in Kuru are modified only
to a minor degree by PRNP codon 129 polymor¬
phisms.10,13 Modelling of vCJD in human valine ho-
mozygotes using "humanized" mice has suggested that
the "glycoform signature" of vCJD will be conserved
on a valine background.9
The fundamental question posed by this case in the
first instance was whether it might represent vCJD in a
valine homozygote. These fears were raised by the early
onset, long duration, and behavioural symptoms early
in the illness without neurological signs. Brain biopsy
confirmed the clinical diagnosis of CJD and indicated
that the patient had a rare PrPres isotype/codon 129
genotype combination. The clinical features of this
case (early onset, long duration, progressive dementia)
and clinical test results (normal EEG, cortical abnor¬
malities on MRI) bear a strong resemblance to the four
W1 cases reported.11,14 The histological features in
the brain biopsy are similar to the W1 cases of
sCJD,11,14 but in the autopsy material there is a closer
resemblance to the neuropathology in W2 cases of
sCJD,11 although no laminar pattern of PrP deposition
was identified in any region of the cerebral cortex.
Fig. 2. Western blot analysis ofprotease-resistant prion protein
(PrPr") in frontal cortex from this case at biopsy (b, lane B)
and at autopsy (a, lane E). For comparison, the following
PrPr" types are shown: type 1 from an MM1 case ofsporadic
Creutzfeldt-Jakob disease (sCJD, lanes A and C), type 2A
from a W2 case ofsCJD (lane D), and type 2B from an
MM2 case of variant CJD (lane F). Markers are shown (lane
G) and their approximate molecular weights indicated in kilo-
daltons.
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Fig. 3. Histogram showing mean glycoform ratios (%) from
multiple samplings and analysis of biopsy (n = 6) and autopsy
(n = 4) frontal cortex. Error bars show the standard devia¬
tion of the mean.
We therefore believe this case to be sporadic in na¬
ture and not related to exposure to BSE. However, the
autopsy finding of a PrPrcs isotype (type 2) and glyco¬
form ratio distinct from that seen in the biopsy is dif¬
ficult to interpret. Two potential explanations present
themselves: (1) disease progression may involve changes
in PrP isotype, the single other biopsy/autopsy pair
available to us, from a case of vCJD, showing no such
difference (data not shown); (2) we may have inadver¬
tently sampled 2 different areas of this brain, which
displayed regional variation in PrPrcs isotype through¬
out the disease course. Parchi et al.11 commented that
around 3% of sCJD cases contain both type 1 and type
2 PrPres in the cortex. Other estimates are considerably
higher (5/14), and it has been further contended that
histological heterogeneity correlates with PrPrts isotypic
heterogeneity.15 Our own experience indicates that
both regional variation in PrPres isotype (1 or 2) and
glycoform ratio can occur in sCJD cases.
It is undoubtedly true that the cortical PrPres glyco¬
form ratio can distinguish between sCJD and vCJD in
the vast majority of cases.7,8 However, glycoform ratios
resembling those seen in vCJD have been reported pre¬
viously in fatal familial insomnia,16 P102L Gerstmann-
Straussler-Scheinker disease,17 and E200K familial
CJD.18'19 The finding of such a glycoform ratio in this
case of sCJD suggests that caution is required in the
diagnosis of vCJD on the basis of glycoform ratio in
the absence of any other confirmatory evidence.
1 b 1 2A a 2B M The UK Department of Health and the Scottish Executive fund the
National C1D Surveillance Unit (NCTDSU).
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Frameshift Mutation in the
Collagen VI Gene Causes
Ullrich's Disease
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Patients with Ullrich's disease have generalized muscle
weakness, multiple contractures of the proximal joints,
and hyperextensibility of the distal joints. Recently, we
found a deficiency of collagen VI protein in two patients
with Ullrich's disease. In this study, we detected a ho¬
mozygous 26 bp deletion in exon 14 of the collagen VI
alpha 2 gene (COL6A2) in one patient. This mutation
causes a frameshift and a premature termination codon,
and results in a truncated collagen VI alpha 2 chain. Our
data suggest that at least some cases of Ullrich's disease
result from recessive mutations in COL6A2.
Ann Neurol 2001;50:261-265
Ullrich's disease is a unique congenital disorder de¬
scribed as congenital hypotonic-sclerotic muscular dys¬
trophy by Ullrich in 1930.1 The major clinical findings
include generalized muscle weakness and wasting, strik¬
ing contractures of the proximal joints, hyperflexibility
of the distal joints from an early infantile stage, and a
progressive course. Muscle biopsies have revealed un¬
equivocal pathological changes of muscular dystro¬
phy.2,3 Although the gene locus has not been mapped
yet, this disease is considered to be a distinct entity of
multisystemic involvement inherited as an autosomal
recessive trait. '5 Recently, we found a complete defi¬
ciency of collagen VI in two patients with Ullrich's dis¬
ease.6 Our present molecular genetic study confirmed
the disease entity of Ullrich's disease, which was called
"a forgotten muscular dystrophy" in a previous report.
From the Third Department of Internal Medicine and depart¬
ment of Laboratory and Molecular Medicine, Faculty of Medicine,
Kagoshima University, Kagoshima; and 3National Okinawa Hospi¬
tal, Okinawa, Japan.
Received Feb 5, 2001, and in revised form May 7, 2001. Accepted
for publication May 9, 2001.
Address correspondence to Dr Higuchi, Third Department of In¬
ternal Medicine, Faculty of Medicine, Kagoshima University,
8-35-1 Sakuragaoka, Kagoshima 890-8520, Japan.
E-mail: ihiguchi@mcd6.kufm.kagoshima-u.ac.jp
© 2001 Wiley-Liss, Inc. 261
Brain Pathology 12: 1-11(2002)
RESEARCH ARTICLE
Immunohistochemistry for the prion protein:
comparison of different monoclonal antibodies in
human prion disease subtypes
Gabor G. Kovacs M.D.'2*, Mark W. Head Ph.D.3', Ivan
Hegyi M.D.4, Tristan J. Bunn3, Helga Flicker',
Johannes A. Hainfellner M.D.1, Linda McCardle3,
Lajos Laszlo Ph.D.', Christa Jarius M.D.', James W.
Ironside M.D. FRCPath3, and Herbert Budka M.D.'
1 Institute of Neurology, University of Vienna, and Austrian Ref¬
erence Centre for Human Prion Diseases, Vienna, Austria;
2 Department of Neurology, Semmelweis University, Budapest,
Hungary5;
3 National CJD Surveillance Unit and Department of Pathology,
University of Edinburgh, Western General Hospital, Edin¬
burgh, UK;
4 Institute of Neuropathology5, Department of Pathology, Zurich,
Switzerland;




Demonstration of the abnormal form of the prion
protein (PrP) in the brain confirms the diagnosis of
human prion disease (PrD). Using immunohisto¬
chemistry, we have compared ten monoclonal anti¬
bodies in PrD subtypes including sporadic and vari¬
ant Creutzfeldt-Jakob disease (CJD), fatal familial
insomnia, Alzheimer's disease (AD), and control
brains. CJD subgroups were determined using
Western blot analysis for the protease-resistant PrP
type in combination with sequencing to determine
the genotype at the methionine/valine polymorphism
at codon 129 of the prion protein gene. None of the
antibodies labeled given subgroups exclusively, but
the intensity of immunoreactivity varied among mor¬
phologically distinct types of deposit. Fine granular
or synaptic PrP deposits stained weakly or not at all
with antibodies against the N-terminus of PrP, and
were visible in one case only with 12F10 and SAF54.
Coarser and plaque type deposits were immunola-
beled with all antibodies. The immunostaining pat¬
terns appear characteristic for the disease sub¬
groups. Labeling of certain neurons in all cases irre¬
spective of disease, and staining at the periphery
and/or throughout the senile plaques of AD patients
were also noted. Antibodies such as 6H4 and 12F10
failed to give this type of labeling and are therefore
less likely to recognise non-pathological PrP materi¬
al in immunohistochemistry.
Introduction
A common feature of sporadic, acquired, and inherit¬
ed prion diseases is the accumulation of an abnormal
conformer of the host encoded prion protein (PrPSc) in
the brain (20). Visualisation of PrP by immunohisto¬
chemistry in formalin fixed tissue serves to confirm the
diagnosis; specific pretreatment of paraffin sections is
necessary to abolish or diminish the immunoreactivity
of the normal cellular PrP (PrPc) (4). Detection of pro¬
tease resistant prion protein (PrPR") by Western blotting
has proven to be a useful additional test.
New monoclonal antibodies, including one specific
for the abnormal form of PrP have been developed (3,
12), and several antigen retrieval procedures have been
used, and new ones suggested (2, 19, 25). In a recent
ring trial including seven neuropathological centers
(Edinburgh, Fukuoka, Helsinki, Milan, Paris, Vienna,
and Zurich), formic acid, hydrated or hydrolytic auto-
claving, guanidine thiocyanate, and combined protocols
with different monoclonal and polyclonal antibodies
were compared (9). This study has shown that the qual¬
ity of staining depends both on the primary antibody and
the tissue pretreatment. Using brain tissue of
Alzheimer's disease (AD) and control cases with non-
dementing illness, it was also demonstrated that nonspe¬
cific labeling can occur in the absence of prion disease
(9). Although the post mortem diagnostic possibilities
constantly widen (7, 23), there is still a need for a high¬
ly reliable neuropathological method demonstrating PrP
in the most readily available formalin fixed, paraffin
embedded material. This need is further reinforced by
the discovery of variant Creutzfeldt-Jakob disease
(vCJD), related to bovine spongiform encephalopathy
(24, 27).
In addition to point mutations and insertions within
the prion protein gene (PRNP), polymorphisms, such as
Corresponding author:
Professor Herbert Budka, Institute of Neurology, AKH 4J, Wahringer Gurtel 18-20, POB 48, A-1097 Vienna, Austria; Tel.: +43-1-
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Antibody Epitope Isotype Supplier Dilution Immunogen
FH11 23-85 lgG2b TSE Resource Centre, Birkett CR, Compton, U.K. 1:1000 Sheep recPrP
BG4 23-85 lgG2b TSE Resource Centre, Birkett CR, Compton, U.K. 1:1000 Cow recPrP
8G8 95-110 lgG2a CEA, Service de Pharmacologie et d'lmmunologie, Saclay, France 1:500 Human recPrP
3F4 109-112 lgG2a SENETEK, Maryland Heights, MO, USA 1:300 Hamster SAF
6H4 144-152 lgG1 Prionics, Zurich, Switzerland 1:500 Cow recPrP
12F10 142-160 lgG2a CEA, Service de Pharmacologie et d'lmmunologie, Saclay, France 1:1000 Human recPrP
SAF54 142-160 lgG2b CEA, Service de Pharmacologie et d'lmmunologie, Saclay, France 1:1000 Hamster SAF
L42 141-159 lgG1 FRC for Virus Diseases of Animals, Dr. M.H. Groschup, Tubingen, Germany 1:300 Sheep recPrP
KG9 140-180 IgGl TSE Resource Centre, Birkett CR, Compton, U.K. 1:1000 Cow recPrP
DF7 140-180 lgG2b TSE Resource Centre, Birkett CR, Compton, U.K. 1:2000 Cow recPrP
(rec: recombinant)
Table 1. Characteristics of the ten monoclonal antibodies used in this study.
that at codon 129 (methionine/valine; MV), influence
the clinicopathological presentation of the disease (20).
Recently a molecular classification of sporadic
Creutzfeldt-Jakob disease (sCJD) suggested two major
types of protease-resistant PrP (PrPR"), type-1 and type-
2 (15, 16), although others report additional types seen
on Western blots (5). Some prion disease subtypes are
extremely difficult to confirm by PrP immunohisto-
chemistry (e.g. fatal familial insomnia, FFI; sCJD codon
129 VV homozygote, type-1 prion protein). In this
study, our aim was to compare different monoclonal
antibodies in relation to human prion disease subtypes,
including FFI, and to assess the reliability of their appli¬
cation in respect of definitive diagnosis.
Materials and methods
Twenty cases of human prion disease, five cases of
neuropathologically verified (CERAD criteria)
Alzheimer's disease (staged according to Braak and
Braak), and three cases of control brains with no neu¬
rodegenerative disorder were selected from the tissue
banks of the Institute ofNeurology, University of Vien¬
na, Austria, and the National CJD Surveillance Unit,
Edinburgh, UK. Fourteen cases were sporadic, and three
were variant CJD. Three were from the Austrian FFI
family, reported previously (1). Formalin fixed, paraf¬
fin-embedded tissue blocks from cortex (frontal and/or
temporal) and cerebellum were obtained. In the FFI
cases, thalamus was also included. Blocks from thirteen
CJD cases were pretreated with formic acid for one hour
prior to processing to paraffin wax, while four sCJD
cases (sCJDl, 2, 5 and 8; see following text), the FFI
cases, the AD and control cases were not.
PrP immunohistochemistry. In accordance with the
ring trial, we employed an extensively used 3 tiered tis¬
sue pretreatment protocol, including 10 minutes hydrat-
ed autoclaving at 121°C, 5 minutes 96% formic acid,
and 2 hours 4M guanidine thiocyanate at 4°C prior to
anti-PrP antibody incubation (2, 9), referred to as proto¬
col A. In each subtype, we selected one case for com¬
parison using the recently suggested pretreatment proto¬
col (25), which includes 10 mM citric acid 121°C auto¬
clave 10 min, 88% Formic acid for 5 minutes and 4 M
Guanidine thyocyanate 2 hours at 4°C, referred to as
protocol B. In selected sections, we also compared our
results using 30 minutes hydrated autoclaving at 121 °C,
and 5 minutes 96% formic acid without further treat¬
ments, referred to as protocol C.
The characteristics of the ten monoclonal antibodies
used are summarized in Table 1. Applying the pretreat-
ments of protocol A prior to performing the study, we
tested different dilutions of the antibodies using two dif¬
ferent blocks showing patchy/perivacuolar and dif-
fuse/synaptic PrP immunoreactivity. The dilution of
antibodies used in our study reflect the best results in
respect of background and specific immunolabeling.
Negative controls were included with the primary anti¬
bodies being substituted with irrelevant, isotype-
matched control antibodies.
The immunolabeling of sections was visualised using
the avidin-biotin-complex method (Amersham Life Sci¬
ence, UK and SIGMA, Germany) and diaminobenzidine
(DAB, Fluka Chemie AG, Switzerland) in an automated
immunostaining machine (Shandon, SequenzaT™; Ast-
moor, Runcorn, Cheshire, England, UK). The intensity
of labeling was evaluated by a scoring system: W =
weak specific immunolabeling; M = distinct, moderate¬
ly strong specific immunolabeling, clearly distinguish¬
able from background; S = strong specific immunola¬
beling.
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PrP type* Age at death Duration
Case Cortex Cerebellum (years) (months) Sex Remark
sCJD1 1 1 45 12 M 129 codon Met/Met
sCJD2 NA 1 65 2 M 129 codon Met/Met
sCJD3 1 1 61 3 F 129 codon Met/Met
SCJD4 1 1 78 8 M 129 codon Met/Val
SCJD5 2A Neg 72 8 F 129 codon Met/Met
sCJD6 2A (+1) 1 72 8 M 129 codon Met/Met
sCJD7 2A (+1) 2A (+1) 62 11 M 129 codon Met/Met
SCJD8 2A 2A 58 7 M 129 codon Val/Val
SCJD9 2A 2A 72 2 F 129 codon Val/Val
SCJD10 2A 2A 65 6 F 129 codon Val/Val
SCJD11 1 1 42 11 M 129 codon ValA/al
SCJD12 2A NA 70 10 F 129 codon Met/Val
SCJD13 2A 2A 64 21 F 129 codon Met/Val
SCJD14 2A NA 62 8 F 129 codon Met/Val
vCJD15 2B 2B 33 18 M 129 codon Met/Met
vCJD16 2B 2B 25 14 M 129 codon Met/Met
VCJD17 NA NA 28 16 F 129 codon Met/Met
FFI 1 2B NA 25 13 M 129 codon Met/Met
FFI 2 NA NA 58 8 F 129 codon Met/Met
FFI 3 NA NA 37 11 M 129 codon Met/Met
AD1 Neg NA 80 - M Braak V
AD2 Neg NA 79 - M Braak V
AD3 Neg NA 77 - F Braak IV
AD4 NA NA 78 - F Braak IV
AD5 NA NA 80 - F Braak V
C01 Neg NA 67 - M COPD; Pneumonia
C02 Neg NA 66 - M Myocardial infarct
C03 Neg NA 55 - F Pulmonary embolism
Table 2. Patient data on the 28 cases in this study; the CJD and FFI cases include PrP type and PRNP codon 129 genotype, the
Alzheimer cases include Braak staging, and the cause of death is included for the control cases. NA: Not available; Neg: negative;
sCJD: sporadic, vCJD: variant Creutzfeldt-Jakob disease; FFI: fatal familial insomnia; AD: Alzheimer's disease; CO: control; M: male;
F: female; COPD: chronic obstructive pulmonary disease. *According to Western blotting.
Case numbers
Pattern sCJD sCJD sCJD sCJD sCJD sCJD vCJD FFI
1-3 4 5-7 8-10 11 12-14 15-17 1-3
Cerebral cortex
Diffuse/synaptic 3/3-D 0/1 1/3-F 3/3-F 1/1-F 2/3-D 0/3 1/3-F
Patchy/perivacuolar 1/3-F 1/1 -F 3/3-D 0/3 0/1 1/3-D 3/3-F 0/3
Plaque-like or plaque 1/3-F 1/1 -F 0/3 3/3-F 0/1 2/3-D 3/3-D 0/3
Pericellular 1/3-F 0/1 0/3 3/3-D 0/1 2/3-D 3/3-D 0/3
Cerebellar cortex
Fine deposit 3/3-D 0/1 1/3-F 2/3-D 1/1-F 3/3-F 0/3 1/3-F
Coarse deposit 3/3-D 1/1-D 1/3-F 3/3-D 0/1 3/3-D 3/3-D 0/3
Plaque-like or plaque 1/3-F 1/1 -D 3/3-F 3/3-D 0/1 3/3-D 3/3-D 0/3
Pericellular 0/3 0/3 0/3 0/3 0/1 0/3 3/3-D 0/3
Table 3. Number of cases showing a particular PrP immunostaining pattern and distribution of immunoreactivity (F-focal or D-diffuse,
widespread) in the cerebral and cerebellar cortex in different prion disease case groups. (sCJD: sporadic, vCJD: variant Creutzfeldt-
Jakob disease; FFI: fatal familial insomnia).
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Figure 1. A. Western blot analysis of proteinase K treated samples of frontal cortex (FC), from cases sCJD3 (3), sCJD8 (8), and
vCJD15 (15). sCJD3 shows type-1 (21 kDa nonglycosylated, lowest band), and sCJD8 and vCJD15 show type-2 PrPR" (19 kDa
nonglycosylated, lowest band). Type-2 PrPR<* can be further subclassified as those samples where the monoglycosylated, middle
band predominates, termed type 2A (sCJD8), or those where the diglycosylated, top band predominates, termed type 2B (vCJD15).
B. Western blot analysis of proteinase K treated samples from frontal cortex (FC) from cases sCJD3, 7, 6, 14, 13, and 11. sCJD3
and CJD11 show type-1 PrPR" whereas sCJD7, 14, and 13 show type-2 PrPR". sCJD6 shows a mixture of predominantly type-2 with
a minority type-1 visible in the non-glycosylated lowest band. C. Western blot analysis of proteinase K treated samples from frontal
cortex (FC) and cerebellum (CB) of cases sCJD6, and sCJD9. The frontal cortex of sCJD6 shows a mixture of type-1 and -2 nong¬
lycosylated, lowest bands whereas the corresponding cerebellum sample appears to contain type-1 only. sCJD9 frontal cortex and
cerebellum contains only type-2 PrPR™ nonglycosyiated bands.
Prion protein gene analysis. Genomic DNA was
prepared from peripheral blood leukocytes and the
PRNP coding region was amplified by the polymerase
chain reaction. Known disease specific mutations were
excluded by single strand conformational analysis, and
a direct sequencing protocol was used to identify the
codon 129 genotype (28).
Biochemical analysis of PrP. Western blot analysis
of PrPRcs in samples of frontal and/or temporal cortex
and/or cerebellar cortex was performed. Briefly, a 10%
brain homogenate was made from frozen tissue, cleared
by low speed centrifugation, and the supernatant digest¬
ed with 50 p.g/ml proteinase K. Protease resistant PRP
(PrP7?&y) isoforms were separated by SDS-PAGE, trans¬
ferred to nitrocellulose or PVDF membranes, and
detected using the antibody 3F4, a horseradish peroxi¬
dase conjugated secondary antibody and enhanced
chemiluminescence system (10).
Results
Data of age at death, sex, duration of illness, PrPR''
isotype, and codon 129 polymorphism of the investigat¬
ed prion disease, Alzheimer's disease and control cases
are summarized in Table 2.
Western Blotting bantling patterns and isotyping.
Different PrP isotypes can co-exist. The Western blot
isoform patterns were classified on the basis of elec-
trophoretic mobility as type-1 (non-glycosylated PrPR",
21 kDa) and type-2 (non-glycosylated PrPR", 19 kDa)
(Figure 1A). Further differences in glycoform ratio were
observed between type-2 cases of sCJD (type-2A) and
vCJD (type-2B) (Figure 1 A). According to this classifi¬
cation system, we selected three cases each of sCJD
MM type-1, MM type-2A, VV type-2A, MV type-2A,
and vCJD (MM type-2B), and one case each of sCJD
VV type-1 and MV type-1, in addition to the three FFI
cases (MM type-2B). In sCJD5, the sample of the cere¬
bellum contained no detectable PrPR" by Western blot.
Further Western blot analysis confirmed the original
PrPR" isotype classifications in the majority of cases;
however, re-examination of sCJD6 and sCJD7 provided
clear demonstration of the existence of both type-1 and
type-2 PrPRes in both of these two cases. In sCJD6, the
cortex showed both type-1 and type-2A PrPR" in the
Figure 2. (Opposing page) Average intensity of PrP immunoreactivity (S: strong; M: moderate; W: weak) in the cerebral (A-F) and
cerebellar (G-J) cortex in different prion disease case groups. The applied monoclonal antibodies are labeled with different colours
and the amino acid number of the recognized epitope on the prion protein is indicated below in the map. (sCJD: sporadic, vCJD: vari¬
ant Creutzfeldt-Jakob disease; FFI: fatal familial insomnia). A: Diffuse/synaptic (picture taken from sCJD1); B: Patchy/perivacuolar
(sCJD5); C (sCJD1) and D (vCJD16): Plaque-like deposit and plaque; E (sCJD8) and F (vCJD16): Pericellular. G: Fine granular
deposits (sCJD1); H: Coarse deposits (sCJD8); I: Plaque-like deposit and plaque (sCJD12); J: Pericellular (vCJD16); (all with 3F4
antibody, all x450, except I: x600).
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Figure 3. Cumulative number of cases with strong (S), moder¬
ate (M) and weak (W) PrP immunoreactivity of each antibody.
The result for each case was entered both for cerebral and
cerebellar cortices as well as for the four major patterns of
immunohistochemistry according to Figures 2. Thus, more than
one result could enter the number of cases on the y-axis.
same sample (Figure IB), whereas only type-1 was
detectable in the corresponding cerebellar sample (Fig¬
ure 1C). Similarly, both types-1 and -2 were seen in
sCJD7 cortex and were also detectable in the cerebel¬
lum. Multiple sampling of the cerebellum from this case
showed type-2 was present in each area sampled, but the
co-occurrence of type-1 was variable, as was the amount
of PrPR" in toto (data not shown). No frozen tissue was
available for vCJD17 and Western blot analysis was not
performed. The diagnosis of vCJD in this case was
made according to the established clinical and neu-
ropathological criteria only.
Immunostaining patterns and differences between
antibodies. PrP immunostaining patterns characteristic
ofprion disease cases. The following immunostaining
patterns were observed: (I) fine deposition
(diffuse/synaptic pattern); (II) coarser depositions (these
include the granular, the patchy/perivacuolar - including
morula-type deposits); (III) plaques (with amyloid char¬
acteristic, e.g. kuru-type and florid plaques, or without
amyloid characteristic, as plaque-like deposits or so
called focal deposits); and (IV) pericellular deposits as
dot-like and/or coarse granular immunoreactivity
around unstained neuronal perikarya. Average scoring
of the signal (weak; moderate; strong) using different
antibodies in distinct disease subtypes is shown in Fig¬
ure 2; the occurrence of different PrP immunostaining
patterns in each case group is summarized in Table 3.
Strong immunoreactivity was observed in the major¬
ity of patterns and subtypes with antibodies to the mid
region of the prion protein (3F4, 6H4, 12F10, SAF54,
KG9, DF7), while those against the N-terminus or adja¬
cent region (FH11, BG4, 8G8) rarely showed this. In
spite ofhaving an epitope in the mid portion, immunore¬
activity with L42 was somewhat weaker although still
clearly distinguishable (Figure 3). Fine depositions were
particularly weak or unlabeled with FH11, BG4, 8G8
antibodies (Figure 4A and B). In sCJD VV type-1, the
faint diffuse/synaptic staining of the cerebral cortex was
only visible with 12F10 and SAF54. The coarser and
plaque type deposits of both cerebral and cerebellar cor¬
tex were clearly immunolabeled with all antibodies.
In the cerebral cortex of sCJD subtypes,
diffuse/synaptic PrP immunoreactivity was noted pre¬
dominantly in MM type-1 and MV type-2A cases and
focally in others, including the VV type-1 case.
Patchy/perivacuolar deposits were observed in all MM
type-2A cases, while only one MM type-1 and MV type-
2A, and the MV type-1 case exhibited this staining pat¬
tern. Amyloid plaques were abundant in MV type-2A
and vCJD, while plaque-like deposits were observed in
all VV type-2A cases, and scantily in one MM type-1
case. Pericellular PrP immunoreactivity characterized
VV type-2A and vCJD, but only rarely was it observed
in MV type 2A and focally in one MM type-1 case. In
the latter, this was coarse and the majority of antibodies
strongly immunolabeled it, in contrast to the more wide-
Figure 4. (Opposing page) A. Strongly immunolabeled fine deposits in the molecular, coarser deposits in the granular layer and
plaques in both layers of the cerebellum (sCJD13; 12F10 antibody; x600). B. Weakly immunoreactive fine deposits, strongly
immunolabeled coarse deposits and plaques in the corresponding region as figure 4A of the cerebellum (sCJD13; 8G8 antibody;
x600). C. Coarse immunoreactivity forming focal aggregates in the molecular layer of the cerebellum (sCJD6; 3F4 antibody; x750)
D. Neuronal immunopositivity in the frontal cortex of a control case (C02; DF7 antibody; x600) E. Senile plaques show immunore¬
activity using antibodies against the N-terminus of the PrP in Alzheimer's disease (AD4; FH11 antibody; x600) F. Senile plaques
(arrows) show no immunopositivity using 6H4 antibody (AD4, corresponding region as figure 4E; x600) G. Immunohistochemistry
for PrP using pretreatments of protocol A (see text) in the frontal cortex: pericellular immunoreactivity in the deeper layers (to the
right) (sCJD8; 3F4 antibody; x300). H. Immunohistochemistry for PrP using pretreatments of protocol B (see text) in the frontal cor¬
tex: pericellular immunoreactivity, neuronal immunolabeling and stronger background (sCJD8, corresponding region as in Figure 4G;
3F4 antibody; x300).
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Figure 5. Presence of intraneuronal immunoreactivity (cerebral
and/or cerebellar neurons) for the prion protein. The black rep¬
resents many, while grey indicates few immunoreactive cells.
Blank fields indicate no labeling. "Observed only with SAF54
antibody.
spread but finer pericellular deposits of all sCJD VV
type-2A cases which were less prominently immunola-
beled with antibodies against the N-terminus of PrP.
In the cerebellum, fine granular deposits in the
molecular and somewhat coarser deposits in the granu¬
lar layer were seen in nearly all subtypes. Amyloid
plaques and/or plaque-like deposits were abundant in
the vCJD, MV type-2A, VV type-2A cases, and the MV
type-1 case, while only one MM type-1 case exhibited
sparse plaque-like deposits in the cerebellar white mat¬
ter. All three MM cases that exhibited type-2A PrPR" in
at least one of the investigated samples (sCJD5,6,7) dis¬
played peculiar coarse PrP immunoreactivity forming
focal plaque-like aggregates in the molecular layer (Fig¬
ure 4C). This was also noted in sCJD5, where Western
blot failed to detect PrPR". Interestingly, sCJD6 and 7
showed both fine and coarse PrP deposits; this was
clearly and spatially distinguishable in the cerebellum.
Pericellular immunolabeling was observed only in
vCJD, this was surrounding molecular layer neurons.
In FFI, the cortex exhibited weak diffuse/synaptic
deposits in one case only; the cerebellum contained a
coarser deposition in the molecular layer. In spite of
severe gliosis and loss of neurons, the thalamus lacked
PrP immunoreactivity.
The KG9 antibody proved to be especially strong in
vCJD cases. Otherwise, we did not observe any correla¬
tion between the presence of immunoreactivity, the
immunogen and/or the isotype of the antibody applied.
In Alzheimer's disease and control cases, no staining
patterns similar to the above were seen.
PrP immunostaining patterns common to prion dis¬
ease and control cases. (I) Intraneuronal punctuate and
diffuse type of PrP immunoreactivity was observed pre¬
dominantly in the cortex ofVV type-2A and FFI cases.
Notable was the lack or only occasional presence of
intraneuronal immunoreactivity in MM-1, MV-1, MV-
2A, MM-2A and MM-2A+1 (in the latter predominant¬
ly in Purkinje cells) and vCJD cases. This type of
immunoreactivity was not observed with antibodies
against the N-terminus. In FFI, neurons of the cerebral
cortex and Purkinje cells were immunopositive, while
none were in the thalamus, except for some rare neurons
labeled with the 3F4 antibody. Interestingly,
immunopositivity was not seen in Purkinje cells of the
only FFI case with marked PrP deposition in the molec¬
ular layer. In Alzheimer's disease and control cases, all
antibodies except 6H4 and 12F10 (and L42 in controls)
immunostained cortical neurons to some degree (Figure
4D); the immunolabeling with N-terminal antibodies
was less prominent than with others (summarized in
Figure 5). Intraneuronal PrP immunoreactivity was less
pronounced in controls than in Alzheimer's and prion
disease brains.
(II) Glial and (III) vessel wall immunolabeling was
variable, but seen in at least one of every type with each
antibody. (IV) Neurofibrillary tangles of Alzheimer's
disease were free of PrP immunoreactivity, but PrP colo-
calization with senile plaques and dystrophic neurites
was evident. The latter were labeled with all antibodies,
though to a different degree. Antibodies against the N-
terminus of PrP labeled most consistently and strongly
the core of senile plaques, while other antibodies
showed only occasional and weak immunostaining of
the core of the plaques; 6H4 and 12F10 stained the
fewest plaques (Figure 4E and F).
Comparison ofpretreatment protocols. Protocol B
resulted in a high background in nearly all of the cases
(Figure 4G and H). Intraneuronal, glial, and senile
plaque-associated deposits were stronger, or appeared
also in cases and/or with antibodies not immunopositive
using protocol A and C. In contrast, the diffuse/synaptic
immunoreactivity was more intense in MM type-1, VV
type-1, and in FFI applying protocol B. In our hands,
protocols A and C did not exhibit significant difference,
nor could we demonstrate any difference between cases
with formic acid pretreated blocks and those left
untreated.
Discussion
Detection of the abnormal form of PrP in tissue is the
gold standard for the definitive diagnosis of human
prion diseases (4). The abundance of available antibod-
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ies and pretreatment protocols requires urgent harmo¬
nization of anti-PrP immunohistochemistry. With one
exception (L42; for description see ref. 26), using com¬
mercially available monoclonal antibodies, we have
compared the immunostaining patterns in different sub¬
types ofhuman prion disease and evaluated Alzheimer's
disease and control cases.
Our results confirm that prion disease subtypes as
defined by PRNP codon 129 genotype exhibit charac¬
teristic PrP deposition patterns; this is most distinctive
in the cerebellum (22). The extension of such subclassi-
fication to include PrPR" isotype is subject to a number
of complications. A recent study suggested that individ¬
ual brains might contain different PrPR" types (21), and
that the regional PrP immunostaining pattern correlates
with the particular PrPR" type found in that region. This
study confirms the former observation by detecting the
presence of type-1 PrPR" as a minor component along
with type-2A PrPRcs in a frontal cortex sample from a
case of sporadic CJD in a methionine homozygote
(sCJD6) previously classified as having type-2A PrPR".
Interestingly, the corresponding cerebellar sample
showed type-1 PrPRcs in the absence of detectable type-
2A. Another MM case with both type-1 and -2 in the
cortex (sCJD7) also showed variable overall levels and
a mixture of both types of PrPR" in the cerebellum. The
cerebellum in this case also showed spatially and mor¬
phologically distinct patterns of PrP immunoreactivity.
Furthermore, this particular pattern of coarse aggregat¬
ed deposits (Figure 4C) was noted in all MM homozy¬
gote cases that had detectable type-2A PrPR" in at least
one sample. These observations are consistant with an
association between the presence of mixed PrPR" iso-
types, as determined by Western blotting, and the mixed
morphological appearance of PrP aggregates, as deter¬
mined by immunohistochemistry. However, in order to
establish the exact nature of this correlation, fine map¬
ping of affected areas by immunohistochemistry and
Western blot will be required.
Antibodies directed against N-terminal epitopes react
differently with both fine extra- and intracellular
deposits and senile plaques, when compared to antibod¬
ies directed to other regions. The NMR solution struc¬
ture of the human prion protein contains a flexibly
extended N-terminal tail, a globular domain, and a short
flexible chain end of residues 229-230 (29). According
to differential proteinase K cleavage sites, type-1 and 2
PrPRcs fragments differ in the extent of the truncated N-
terminal region (17). In our hands, the fine deposits
were not consistently immunolabeled with the N-termi¬
nal antibodies, while the coarser deposits and plaques
were clearly immunoreactive. This might reflect a high¬
er accessibility of the flexible N-terminal end in the
amyloid and preamyloid states (e.g. patchy/perivacuolar
or plaque-like deposits) (14).
We confirm previous studies showing that PrP
immunoreactivity localized to neurons is frequently
observed also in non-prion disease cases (6, 18). West¬
ern blot analysis confirms the absence of PrPR" in the
brains of the investigated control and AD cases, further
supporting the proposition that these deposits represent
the cellular form of PrP. In control and AD cases all anti¬
bodies, except 6H4 and 12F10, gave this pattern of
staining.
The amount of intraneuronal staining was clearly dif¬
ferent between sCJD subtypes, with VV type-2A cases
containing the most. This is in accordance with our
observation that areas containing fewer PrP deposits
exhibit more intraneuronal staining. It should be noted
that 6H4 and 12F10 immunolabeled intraneuronal
deposits only in sCJD VV type-2A. This might mean
that this form of immunoreactivity in this sCJD subtype
(which showed similarity with FFI) reflects a different
stage of prion protein processing that might be relevant
to the pathogenesis ofVV type-2A cases (13).
Formic acid treatment enhances amyloid antigenici¬
ty, presumably by limited proteolysis or denaturation of
amyloid protein aggregates (11). Application of lower
concentrations of formic acid and the addition of citrate
buffer in the pretreatment protocol labeled more intra¬
neuronal (also with antibodies not labeling immunore¬
activity in the original pretreatment) and fine
(diffuse/synaptic) deposits, thus buried epitopes became
uncovered. This also suggests, that at least some of the
intraneuronal PrP immunoreactivity might reflect a dif¬
ferent conformational stage of the prion protein in prion
diseases versus controls. Accordingly, though it might
be useful to apply protocol B in diagnosing prion dis¬
ease cases with weak or no staining of fine deposits (e.g.
sCJD VV type-1 or FFI), care must be taken using this
protocol because of the frequent occurrence of nonspe¬
cific labeling and higher levels of background staining.
PrP accumulates mainly at the periphery but also
throughout the p A4 plaques of Alzheimer's disease
patients (6, 8). This is most clearly seen with the use of
N-terminal antibodies. We could not demonstrate PrPR"
in the Western blots ofAD patients, and the substitution
of the primary PrP antibodies by nonspecific, isotype-
matched antibodies did not show similar labeling to that
observed with PrP immunostaining. Furthermore, anti¬
bodies against different epitopes of PrP exhibited
immunoreactivity in the same manner. As a result, we
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think that this immunoreactivity is specific and might
reflect co-aggregation of the non-pathological form of
PrP.
Conclusions
None of the tested antibodies proved to be specific
for any prion disease group, but the intensity of labeling
is related to the morphological type ofPrP deposits pres¬
ent. Fine granular or synaptic PrP deposits stained
weakly or not at all with antibodies against the N-termi-
nus of PrP, and were visible in one case only with 12F10
and SAF54. Coarser and plaque type deposits were
immunolabeled with all antibodies. The PrP deposition
patterns are characteristic for the subtypes, especially
those found in the cerebellum. Immunolabeling of cer¬
tain neurons in all brains examined presumably results
from the detection of remaining or aggregated, non-
pathological form of PrP, and its detection is influenced
by the pretreatments used. Some antibodies exhibit
immunoreactivity restricted to cases of prion disease
(6H4, 12F10) and thus are more reliable tools for the
specific immunolabeling of the abnormal form of PrP .
However, it is important to emphasize that any positive
signal in immunohistochemistry for disease-associated
PrP needs to be interpreted with caution and experience.
Finally, in at least some cases, the same brain and the
same anatomical region contain a mixture of PrPR"
types; this may correlate with the morphology of PrP
accumulation.
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Prion Protein Accumulation in Eyes of Patients with
Sporadic and Variant Creutzfeldt-Jakob Disease
Mark W. Head,1 Victoria Northcott,1 Kathleen Rennison,1 Diane Ritchie,1 Linda McCardle,1
Tristan J. R. Burin,1 Neil F. McLennan,1 James W. Ironside,1 Andrew B. Tullo2
and Richard E. Bonshek2
Purpose. Creutzfeldt-Jakob disease (CJD) primarily affects the
brain. This study was conducted to assess the possible involve¬
ment of the eye in sporadic and variant CJD by testing for the
presence of the disease-associated, protease-resistant isoform
of the prion protein (PrPSc) in ocular tissue.
Methods. Human eyes from donors with CJD and non-prion
neurodegenerative disease control eyes were studied. In situ
hybridization and Western blot analysis were used to deter¬
mine the normal pattern of cellular prion protein (PrPc) ex¬
pression. Western blot analysis and immunohistochemistry
were then used to determine the localization, abundance, and
isotype of PrPSc in eyes in CJD.
Results. PrP( was expressed in the nuclear layers of the retina.
In both the sporadic and variant forms of CJD, PrPSc accumu¬
lated throughout the synaptic layers of the retina. The levels of
prpSc foun(j jn the retina were comparable with those found in
the brain. Lower levels of PrP"* could be found in the optic
nerve, but no PrP'Sc was detectable in other ocular tissues. The
glycoform ratio of PrPSt in the retina did not correspond to that
found in the brain.
Conclusions. Presumptive centrifugal spread of PrPSc from the
brain through the optic nerve occurs in two major types of
CJD. PrP'Sc is a marker of CJD infectivity. Given that routine
decontamination may not remove PrPSc from surgical instru¬
ments, a careful risk assessment should be made of possible
iatrogenic spread of sporadic and variant CJD after surgery to
the retina or optic nerve. (Invest Ophthalmol Vis Sci. 2003,44:
342-346) DOI: 10.Il67/iovs.01-1273
Creutzfeldt-Jakob disease (CJD) is a rare fatal neurodegen-eration ch racterized by neuronal loss, gliosis, and spon¬
giform change in the brain. According to the prion hypothesis,
the agent responsible for CJD is an altered form (PrPSc) of a
host-encoded glycoprotein (PrP°) which is highly aggregated
and partially resistant to proteolysis.1 CJD occurs in idiopathic,
familial, and acquired forms. The most common of these is the
idiopathic form, sporadic Creutzfeldt-Jakob disease (sCJD)
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which occurs worldwide at a rate of one per million persons
per annum and primarily affects the elderly.1 The acquired
forms include Kuru and iatrogenic Creutzfeldt-Jakob disease
(iCJD). Most cases of iCJD result from medical exposure to
either growth hormone extracted from human cadaveric pitu¬
itary glands or from human dura mater grafting during neuro¬
surgical operations.2 Nevertheless, one definite and two prob¬
able cases of iCJD have been attributed to corneal grafting,
including the first ever reported case of iCJD.3"5 Iatrogenic
exposure can result in very long incubation periods, measured
in years in growth hormone recipients, although the incuba¬
tion periods after exposure through corneal grafting were
short in two cases.2 These data imply that CJD infectivity
resides in ocular tissue and that transplantation of infected
ocular tissue offers a direct route for entry of the agent into the
brain. Direct confirmation of the former comes from the trans¬
mission to primates of disease from pooled CJD eye tissue.
The appearance of a new variant of Creutzfeldt-Jakob dis¬
ease (vCJD) in the United Kingdom7 has refocused clinical
interest in CJD. vCJD differs from sCJD in a number of impor¬
tant respects, including earlier age at onset, longer disease
duration, and presence of peripheral disease and infectivity in
elements of the lymphoreticular system.8"10 This has necessi¬
tated a reappraisal of the potential for iatrogenic spread of CJD,
including those risks posed by the transplantation of ocular
tissues.11"13 Unfortunately, there is a dearth of primary inves¬
tigative studies of ocular disease in CJD, even though neuro-
ophthalmic features are common1'4 and retinal degeneration
has been described in an animal model of CJD.13
We have taken advantage of a rare opportunity to examine
histologically and biochemically eyes of patients with variant
and sporadic CJD for the accumulation of the disease-associ¬
ated form of PrP to better understand the pathogenesis of CJD
and provide data for risk assessment of iatrogenic transmission.
Materials and Methods
Pairs of eyes from three autopsy-proven cases of CJD, one sCJD (S) and
two vCJD, were examined (VI and V2). Two pairs of eyes from
neurologic control cases were also analyzed. One was an autopsy-
proven case of Alzheimer disease (CI) and the other a case of corti-
cobasal ganglionic degeneration (C2). Full permission was obtained for
research, and the study protocol conformed with the provisions of the
Declaration of Helsinki, in all five cases, frozen and fixed eye and
frozen cerebral cortex (CC) was available for study. After enucleation,
the left eye of each pair was dissected into the following components;
cornea, lens, vitreous body, neural retina, choroid and retinal pig¬
mented epithelium, sclera, and optic nerve. Due to the nature of the
eye after death, complete separation was not possible. This was par¬
ticularly true for the posterior segment tissues, and it is certain that
cross contamination occurred between neural retina and the overlying
vitreous body and the underlying pigmented epithelium. The right eye
of each pair was fixed whole. Two additional control eyes, which had
not been decontaminated with formic acid, were used for the in situ
hybridization analysis. Both were enucleations, one due to a recur¬
rence of melanoma of the iris (C3) and the other due to optic pain
resulting from rubeotic glaucoma (C4).
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In situ hybridization to localize PrP mRNA was performed with
digoxigenin-labeled, PCR-generated, single-stranded sense and anti-
sense RNA probes, visualized with alkaline phosphatase and an ni-
troblue tetrazolium/5-bromo-4-chloro-3-indoyl phosphate (NBT/BCIP)
chromogen as previously described.16
The protease-resistant core fragment (PrPrcs) of disease-associated
prpSc was detected by Western blot analysis with the monoclonal
antibody 3F4, as previously described.9 Initially, all eye samples were
prepared and analyzed as protease-treated 10% (wt/vol) tissue homog-
enates. In samples in which PrPrcs was initially found to be low or
undetectable, it was concentrated (X20) by centrifugation at 21,00Qg
for 1 hour at 4°C and redissolved in SDS-PAGE loading buffer for
analysis. Glycoform analysis was performed with a scanning densitom¬
eter (model GS700, with Quantity One software; Bio-Rad Laboratories,
Herts, UK). The normal cellular protease-sensitive prion protein PrPscns
was detected in non-CJD tissues by use of the same Western blot
protocol with the omission of the proteinase K digestion and concen¬
tration steps.
PrP was localized in sections of formalin-fixed, formic acid-treated
eye tissue by immunohistochemistry. The anti PrP monoclonal anti¬
bodies KG9, 3F4, and 6H4 were used with a protocol that distinguishes
PrPSc from the normal cellular form of PrP, as previously described.9
Before immunolabeling, sections were taken to water and formalin
pigment removed with saturated picric acid. Sections were washed
and then autoclaved at 121°C in distilled water for 10 minutes before
immersing in 96% formic acid for 3 minutes at room temperature.
Sections were then immunolabeled by overnight incubation in the
primary anti-PrP antibodies KG9 diluted 1/250 (Institute for Animal
Health, Compton, UK), 6H4 diluted 1/2000 (Prionics AG, Zurich,
Switzerland), and 3F4 diluted 1/50 (Dako, High Wycombe, UK), in
combination with an avidin-biotin (ABC) kit (Vectastain Elite; Vector
Laboratories, Burlingame, CA). Labeling was visualized with diamino-
benzidine (DAB), and sections were lightly counterstained with hema¬
toxylin. Selected sections were double immunolabeled for PrP and
astrocytes. PrP immunolabeling was performed with the anti PrP anti¬
body KG9, as outlined earlier. After visualization with DAB, sections
were thoroughly washed and blocked in normal goat serum (1:5) for
20 minutes. Sections were then incubated with glial fibrillary acidic
protein (GFAP) antibody (Dako), washed, and then incubated with a
diluted biotinylated secondary antibody. An alkaline phosphatase ABC
kit (Dako) was used to complete the immunolabeling with red stain
(Vector red; Vector Laboratories) used to visualize the astrocytes. The
sections were counterstained with hematoxylin.
Results
In situ hybridization of the non-CJD control eyes (C3 and C4)
with the antisense probe showed labeling of the retina around
the entire retinal curvature and labeling of nonneural struc¬
tures, such as cornea and sclera. The labeling of sclera and
cornea were particularly intense, but labeling was also seen
with the control sense probe, indicating that it resulted from
nonspecific binding. The control sense probe showed only
background labeling of the retina, confirming the specificity of
the signal with the antisense probe and therefore the presence
of PrP mRNA in the retina. Specific labeling of cells was seen
within the ganglion cell layer (GCL), inner nuclear layer (INL),
and outer nuclear layer (ONL; Figs. IB, ID). Labeling in the
ONL was not uniform and included an intense band of labeling
at its outer limit. The corresponding sense probe is shown for
comparison (Fig. 1C). The labeling of the nerve fiber layer
(NFL) or inner limiting membrane (ILM) appeared to be spe¬
cific, in that it was absent with the sense probe. However,
because of the resolution provided by this technique we could
not determine whether it represents specific labeling of gan¬
glion cell axons or artifactual binding to basement membrane
structures, as we have reported previously.16 The poor mor¬
phology of the lens in all preparations precluded determination












Figure 1. In situ hybridization for PrP RNA in the retina of the
non-CJD eye. Antisense (b) and sense (Q probes are shown hybridized
to sections of eyes from case C3. The sections were not counter¬
stained, and positive labeling was seen in all nuclear layers (b). A
hematoxylin and eosin-stained section is shown (A) for orientation
with the retinal pigmented epithelium at the top and the vitreal surface
at the bottom. A region of (b) is shown at higher magnification in (d),
and the retinal layers are indicated, rpe, retinal pigmented epithelium;
prs, photoreceptor segments; onl, outer nuclear layer; opl, outer plex-
iform layer; inl, inner nuclear layer; ipl, inner plexiform layer; gel,
ganglion cell layer; nfl/ilm, nerve fiber layer/inner limiting membrane.
Scale bar, 50 |iim.
Western blot analysis of non-CJD control eyes (CI and C2)
shows the presence of PrP in the neural retina (Fig. 2). The PrP
detected in the neural retina was of a mobility similar to that
seen in the corresponding brain sample (Fig. 2A). Signals were
also seen in lens samples but these were of lower molecular
weight. We noted that the concentration of soluble protein in
the vertebrate lens far exceeded that in any other organ,
including the brain, and that most of these lens proteins are the
crystallins, which cluster in the 16- to 30-kDa mass range.
Given that our Western blot analyses were loaded with an
equal tissue weight equivalent, it seems likely that 3F4 binds to
extremely abundant crystallins in the lens lanes. The signals in
retina and brain were lost entirely by treatment of the samples
with proteinase K, indicating that the PrP detected in the
retina, similar to that of the brain, was the protease-sensitive
normal cellular form of the protein PrPc (see Fig. 5).
Immunohistochemical staining for PrP by a protocol opti¬
mized for PrPSc detection did not produce a positive reaction
in the control non-CJD eye (Fig. 3A). In contrast, immunostain-
ing of the sCJD and vCJD eyes all showed strong positive
staining for PrPSc (Figs. 3B-E). The staining in each case was
largely restricted to the inner plexiform layer (IPL) and outer
plexiform layer (OPL), in a uniform distribution around the
retina. The staining in the OPL was of a coarse granular pattern,
whereas the INL staining tended to be of a finer "synaptic" type
(Fig. 3C). No positive staining was seen in the photoreceptor
cells (PRS) or other neuronal cell bodies. Doubling labeling for
f JWI
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Figure 2. Western blot analysis of PrP in cornea (Co), lens (Le),
vitreous body (Vi), neural retina (NR), retinal pigmented epithelium
and choroid (PE), sclera (Sc), and optic nerve (ON) in the non-CJD eye.
(B) Case CI; (A) case C2. Cerebral cortex (CC) from case C2 was
included as a positive control for PrP (A). Because of the abundance of
PrP in the cerebral cortex, one fifth of this sample was analyzed,
compared with the eye sample. Optic nerve was not available for CI.
GFAP and PrPSc showed GFAP-positive astrocytic end feet in
the vCJD retina (Fig. 3D). The cornea, iris, lens, ciliary body,
choroid, sclera, and optic nerve sheath all showed a negative
reaction. Positive staining was seen in sections of the optic
nerve of donors with sCJD and vCJD (Fig. 3F) and in one of the
vCJD donor eyes was in an obvious quadrantic distribution.
The positive staining seemed to be associated with astrocytic
cell bodies, as confirmed by immunocytochemistry for GFAP in
the areas where axon loss and secondary myelin loss was
accompanied by astrocytosis (data not shown). No evidence of
spongiform change or formation of amyloid plaque was ob¬
served in the retina or optic nerve on routine stains or on
immunohistochemistry for PrP. However, individual neuronal
processes showed vacuolation. The retina in sCJD and vGJD
showed variable loss of ganglion cells and photoreceptors,
some of which may be age-related in the donor with sCJD. No
other specific morphologic features were identified in the
retina or in the optic nerve.
Western blot analysis for PrP" s confirmed the results of the
immunohistochemical analysis. PrP" s was detectable in the
retina from the case of sCJD and in both cases of vCJD. The
level of PrP1" in the vCJD retina was similar to that seen in the
corresponding sample of brain, with lower levels present in
optic nerve (Fig 4A). Longer exposure of the Western blot
showed all three glycoforms (di-. mono-, and non-glycosylated
PrPrcs) present in the brain, neural retina, and optic nerve (Fig.
4B). Low molecular weight, presumptive crystallin, and degra¬
dation products were seen in the lens sample. Weak reactions
to a protein of approximately the same mobility as diglycosy-
lated PrPres were also seen in otherwise negative lanes. We
observed this band in all heavily exposedWestern blot analyses
of proteinase K-treated samples and when proteinase K (mo¬
lecular weight, ~29 kDa) was analyzed in the absence of tissue
extracts. Our working assumption is that this band represents
weak cross-reactivity between the primary or secondary anti¬
body and proteinase K.
Concentration of any PrPSc in the samples by a factor of 20




Figure 3. Immunohistochemical lo¬
calization of PrPSc in retina (A-E) and
optic nerve (F) from control, CI (A);
sCJD (B, C); and vCJD, VI (D) and V2
(E, F). Sections were immunostained
for PrP with monoclonal antibody
KG9 and diaminobenzidine (brown)
and counterstained with hematoxy¬
lin (blue). Double labeling for GFAP
with red stain is shown for the retina
of VI (D). Scale bars, SO /am.
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Figure 4. Western blot analysis of PrPr<:s in cornea (Co), lens (Le),
vitreous body (Vi), neural retina (NR), retinal pigmented epithelium
and choroid (PE), sclera (Sc), and optic nerve (ON) in the vCJD eye
(V2). An equivalent amount of sample from the cerebral cortex (CC) of
the same case is shown as a positive control for the presence of PrPrLs.
Results of a (A) short and a (b) long exposure of the same Western blot
are shown. The same ocular samples were also concentrated by cen-
trifugation before Western blot analysis (C). Positive signals from
aggregated and protease-resistant PrP were present only in the neural
retina, pigmented epithelium, and optic nerve eye samples (C).
neural retina and optic nerve, but a weaker signal also became
evident in retinal pigmented epithelium (RPE; Fig. 4C). The
centrifugal concentration step clearly indicates the dramatic
difference in the level of PrP""'s between positive tissues (retina
and optic nerve) and negative tissues (cornea, lens, vitreous
body, and sclera). It also serves to confirm that the positive
signals in retina and optic nerve are in fact PrPSc, in that they
are insoluble in nondenaturing buffers in addition to being
protease resistant, reacting with the antibody 3F4, and having
the expected molecular weight of di-, mono-, and non-glyco-
sylated PrPr' \ The tissue distribution of PrPres in the sCJD eye
resembled that found in the vCJD eyes (i.e., restricted to the
retina), although frozen optic nerve was not available for study
in this case. The level of PrPrts in the retina in the case of sCJD
was similarly high and exceeded that found in the correspond¬
ing brain sample (Fig. 5). Analysis of control (CI) brain and
retina in parallel shows that the abundant PrP in these tissues
was completely sensitive to proteolytic degradation (PrPscns),
and therefore it corresponds to the normal cellular form PrP*
(Fig 5). Glycoform ratios of PrPres in the sCJD and vCJD eyes
were not identical with those in the corresponding brain sam¬
ples. Instead, each exhibited a strong shift toward increased
abundance of the monoglycosylated form in retina. This was
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Figure 5- Western blot analysis of PrP in the cerebral cortex (CC) and
retina (r) from control (CI) and sCJD (S) eyes. The samples are shown
with (+ PK) and without (-PK) proteinase K digestion before analysis.
Similar amounts of PrPrcs were seen in retina and cerebral cortex in
sCJD, but PrPrcs was absent from the same tissues of the Alzheimer
disease control (CI).
particularly noticeable in the cases of vCJD in which the retinal
glycoform ratio was no longer typical of vCJD, but more closely
resembled that usually associated with sCJD (Fig. 6).
Discussion
The presence of PrPSc remains the sole, although possibly a
surrogate, marker of CJD infectivity currently available. Al¬
though this study was not designed to directly address ques¬
tions of relative infectivity in CJD eye tissues, the finding of
PrPres in the eyes of three individuals who died of CJD, though
not unexpected, is clearly a cause for concern. Transmission of
CJD by intracerebral inoculation of nonhuman primates with
CJD eye tissue has been shown previously,6 but the material
used was pooled, and it was therefore not possible to say
which ocular components harbored the infectivity. Our results
using both immunohistochemistry and Western blot analysis
clearly implicate the retina. Although CJD has been transmitted
inadvertently by corneal transplantation,2 PrPSc was not detect¬
able in the cornea in any of the eyes examined in this study. It
is well known that bioassay, even across a species barrier has
a greater sensitivity than any currently available assay for PrPSc.
From this we infer that our inability to detect PrPrcs in the
cornea, sclera, and lens cannot be taken as evidence for the
70
60
Figure 6. Histogram showing the relative abundance of diglycosy-
lated (■), monoglycosylated (P), and nonglycosylated (□) PrPres in
samples of cerebral cortex (CC), retina (R), and optic nerve (ON) from
cases of sCJD (S) and vCJD (VI and V2). All samples of retina showed
an increased relative abundance of the monoglycosylated form com¬
pared with their respective cerebral cortex samples.
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absence of infectlvity in these tissues. Although the level of
infectivity found in the retina is very much greater than that
found in the cornea in a rodent model of scrapie,17 corneal
transplantation failed to transmit disease in monkeys.18 The
issues surrounding the relative levels of CJD infectivity and
how this relates to the relative levels of PrPSc in human ocular
tissues can be resolved only by transmission studies using
primary human diseased eye tissue.
The agent(s) that cause CJD and related transmissible spon¬
giform encephalopathies are notoriously difficult to decontam¬
inate.19 Therefore the presence of readily detectable levels of
PrPSc in the retina is clearly pertinent to the current debate
over the reuse of surgical instruments in high-risk procedures.
The detection of PrPres in the retina at levels equivalent to
those found in the brain suggest that retinal surgery may
present the same risk and therefore necessitates the same
precautions as are taken in neurosurgery. The finding of PrPSc
in the sCJD eye, however, indicates that this risk is not new and
predates the appearance of vCJD. To date, there is no evidence
that any form of CJD has been transmitted by intraocular
surgery, although surgical manipulation of the retina has been
undertaken in a significant number of cases only in the past 25
years.
Our data are in agreement in many respects with a recent
publication reporting use of Western blot analysis to detect
PrPrcs in the retina and optic nerve of single case of vCJD.2"
This brings the total number of reported cases of vCJD in
which retinal positivity has been demonstrated to three, and
we would anticipate this to be a general phenomenon. Our
estimations of the relative levels of PrPrcs in retina and optic
nerve are different from the report that the optic nerve con¬
tains 10 times more PrPrcs than in retina.20 The two cases of
vCJD reported in this study were investigated by Western blot
analysis and immunohistochemistry, are internally consistent
and show a greater presence of PrP""' in the retina than in the
optic nerve, where staining was less intense and less consis¬
tent. A further discrepancy is the absence of PrP"s from any
eye tissue in the case of sCJD analyzed20 and the abundant
PrPrcs detected in the case of sCJD in this report. Given that our
methods appear to be of equivalent sensitivity, it may be that
sCJD is heterogeneous in retinal involvement. It may be pre¬
mature to speculate on the basis of two cases, but there is
convincing evidence that the scrapie agent strain and mouse
host genotype are known to determine whether ocular involve¬
ment occurs in experimental rodent models of scrapie.21 In
this light, it is of interest to note that the sCJD case reported2"
and the sCJD case we report herein differ in both PRNP codon
129 genotype and PrPrcs isotype.
The finding that PrPSc can be detected in the CJD optic
nerve and accumulates in the retina in both sCJD and vCJD is
consistent with centrifugal spread from the brain, presumably
through the optic nerve. Although other factors may be in¬
volved, the accumulation of PrP'Sc in the plexiform layers is
consistent with the pattern of expression of PrP' in the neural
retina (this report) and the known synaptic location of PrP' in
neurons.22
Lastly, glycosylation site occupancy has been proposed as a
marker of the vCJD agent strain, and this appears to be a
consistent feature in the vCJD brain.23 However, PrP""' glyco¬
sylation occupancy is consistently higher in vCJD lymphore-
ticular tissues than in brain.24 In this study, we report the first
examples of vCJD PrP"s glycoform ratios (found in the retina
of both cases of vCJD) that resemble the PrPres glycotype that
characterizes sCJD rather than vCJD. The tendency toward
monoglycosylation was also evident in the retina from the case
of sCJD. This indicates that tissue differentiation, even within
the central nervous system can dominate over agent strain in
specifying the PrP"s glycotype.
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